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SUMMARY
This work involved the investigation of three different molecular cytogenetic approaches, 
Fluorescence In Situ Hybridisation (FISH), Comparative Genomic Hybridisation (CGH) 
and Primed In Situ (PRINS) labelling, and their utilisation in chromosomal localisation of 
DNA sequences, breakpoint definition and the detection of cryptic abnormalities.
As a development of earlier mapping in this department using non-fluorescent ISH, simple 
and reliable localisation, by FISH, of unique cloned sequences in a range of vectors was 
optimised and applied. Among the sequences localised were myotonic dystrophy protein 
kinase-related Cdc42-binding kinase p {MRCK0) and telomerase reverse transcriptase 
(hTERT), to 14q32.31~q32.32 and 5p15.33 respectively.
Probes were sourced, and their map localisations confirmed or refined, for application to 
two cases of chomosomal abnormality which required breakpoint definition. The first was 
a patient with der(12)(12qter-^12p13.3::21q22.3-^21q11.2::21q11.2->21qter).
Breakpoint mapping with 21q-specific clones showed that the 21 q region monosomie in 
this individual was proximal to BAC sequence 268F23, which lies at 16.03Mb from 21 pter, 
and included marker D21S1911 at 15.06Mb from 21 pter. The breakpoint of at least one 
of the two chromosome 21 components of the derivative chromosome 12 lies between 
these two loci. This has provided a focussed region for further biochemical and molecular 
study.
The second case was a rare proximal duplication of 8p with a mild phenotype. The 
duplication was confirmed to be direct, rather than inverted, and the breakpoints defined 
as dup(8)(p11.1 p21.1 -p21.2). This abnormality had not previously been reported. 
Concurrently, FISH probes were sourced, extracted and optimised for use in diagnostic 
investigation of cryptic segmental aneusomy in DiGeorge/velocardiofacial (DGA/CF), 
Rubinstein-Taybi and Wolf-Hirschhorn syndrome patients, and in potential carriers of 
Duchenne and Becker muscular dystrophy.
Chromosome 22q 11.2-specific cosmids were used to investigate 161 patients with 
features of DiGeorge/velocardiofacial syndrome, detecting 34 deletions. Following 
reports of hemizygosity at 22q11.2 in patients with non-syndromic conotruncal defects, a 
series of 24 patients with tetralogy of Fallot were examined for microdeletion at this locus 
and 4 deletions were disclosed.
Plasmid probes for 4p16.3 and 11p15.5 were used to determine a cryptic t(4;11) 
rearrangement in a child for whom there was clinical suspicion of Wolf-Hirschhorn 
syndrome. This provided a means to carrier determination and prenatal diagnosis for her 
large, extended family.
VIII
Cosmids specific for 16p13 were used for FISH assessment of a group of 15 patients with 
suspected Rubinstein-Taybi syndrome. No microdeletions were found with the original 
RT1 cosmid probe, but work now continues with 4 additional cosmids which span the 
Rubinstein-Taybi syndrome critical region.
Prior to and during the introduction of a quantitative PCR method in this department a 
range of 20 exon-specific dystrophin probes was used to provide an unequivocal, simple 
method of carrier determination in families with inherited microdeletion at Xp21. Ninety 
seven female carriers were diagnosed in a total of 83 families using this FISH approach. 
Following the report that ~6% of cases of idiopathic mental retardation might be 
associated with a cryptic subtelomeric rearrangement (Flint et al 1995), the novel 
commercial Multiprobe-T device was initially appraised then used to screen a series of 
100 patients. This disclosed three cryptic chromosomal abnormalities, namely a 
der(9)t(3;9), der(9)t(9;16) and der(18)t(10;18).
Successful clinical application by Bryndorf et al (1995) prompted optimisation and 
assessment of CGH in the investigation of a selection of patients with apparent or 
suspected constitutional chromosomal aberrations. Abnormalities detected included a 
subtle deletion at 17p11.2, and a deletion involving 1q25-q31 in an individual with an 
apparently balanced translocation of chromosomes 5 and 6 but abnormal phenotype. In 
combination with FISH, CGH refined characterisation of an apparent but unresolvable 
abnormality of chromosome 3, demonstrating duplication of 3p24.2-p25 and deletion of 
the 3p subtelomeric region.
This study also involved the introduction of PRINS technology to this department and 
evaluation of its potential for robust detection of unique target sequences. Technical 
modifications assessed included, proteinase K and ligase pretreatments and use of 
Tyramide Signal Amplification (TSA). Slide pretreatment in Carnoy’s fixative then 2xSSC, 
and use of an alternative, relatively inexpensive, enzyme not previously reported in 
PRINS (Dynazyme), were identified as beneficial.
PRINS with commercial repetitive PRINS kits and ‘in house’ repetitive sequence primers 
was successful, but no satisfactory results were obtained with primers for unique or very 
low copy sequences.
The future role of these methods in mapping and investigation of segmental aneusomy is 
discussed and array CGH, a high resolution refinement of CGH, reviewed.
IX
1. INTRODUCTION
1.1 General Introduction
Historically genetic diseases have been diagnosed by biochemical analysis of gene 
products, cytogenetic study of visible chromosomal changes and, most recently, 
molecular study of DNA itself. Within cytogenetics one aim has been to improve 
resolution of subtle aberrations and to define breakpoints. Molecular cytogenetics, 
combining cytogenetic and molecular techniques, has, though initially employed in 
sequence localisation, come to provide major advances in the scope and utility of 
diagnostic chromosome investigation.
1.2 DNA and the Chromosome
Genetic information is carried in DNA, as triplets of nitrogenous bases adenine (A), 
guanine (G), thymine (T) and cytosine (C) in two nucleotide chains. These form a double 
helix joined by hydrogen bonds between the inwardly projecting bases.
DNA is packaged in eukaryotic chromosomes as chromatin, a mix of DNA, protein and 
associated RNA organised on four basic levels. The elementary DNA fibre, iOnm in 
diameter, consists of repeating nucleosome units constructed from histone molecules 
(two each of H2A, H2B, H3 and H4) around which 200 base pairs (bp) of DNA is coiled 
1.75 times. This is coiled into a chromatin fibre, 30nm in diameter, and loops of fibre 
(Laemli loops), each about 200 kilobase pairs (kb), radiate to form the 0.6um diameter 
body of the chromatid. Further chromatid coiling produces the quaternary structure of the 
chromosome.
Humans have 24 types of nuclear chromosomes: 22 autosomes (as two copies in somatic 
cells but one in gametes) an X chromosome (two in female but one in male somatic cells) 
and a Y (in males). In late prophase or metaphase stages of cell division, mitosis, cells 
spread on glass slides and visualised by light microscopy have condensed chromosomes 
with differential morphologies. The ‘karyotype’ is the collective features of a cell’s 
chromosomes or an image of these stained, paired and ordered numerically. 
Chromosomes are constructed of two broad classes of DNA - heterochromatin and 
euchromatin, and within the chromosome there are recognisable substructures including 
centromeres and telomeres.
Heterochromatin and Euchromatin
Heterochromatin is highly contracted, tends to be transcriptionally inactive, and replicates 
late. Facultative heterochromatin is formed on condensation and inactivation of 
euchromatin (as with one X chromosome in female mammalian cells). Constititutive 
heterochromatin generally flanks centromeres and telomeres, though its amount and 
distribution varies between individuais, and is enriched with repetitive sequences. 
Euchromatin contains the unique or low-copy sequence structural genes and related 
regulatory sequences, and is assumed to be genetically active and less contracted than 
heterochromatin.
The proportions of repetitive and unique sequence DNA in a genome can be determined 
from a cot' curve (Fig. 1-1).
Centromeres
The centromere is generally the site of the primary chromosomal constriction, the location 
of the kinetochore (the anchor point for microtubule proteins of the mitotic spindle) and 
the last point of sister chromatid pairing at anaphase, the penultimate stage in mitosis. It 
is composed of satellite DNA, predominantly alphoid, and associated proteins (CENPs). 
Alphoid repeats, though not necessarily the only essential component, appear pivotal to 
centromere function.
Telomeres
Telomeres are the structures which protect chromosome ends from exonucieolytic 
degradation, end to end fusion and irregular recombination. The highly conserved 
teiomeric repeat sequence (TTAGGG)n, represents 4-6kb in the somatic cells of human 
neonates. Telomere repeats minimise the effect of the ‘end replication problem’ (Watson 
1972) which results in shortening of the chromosome at each cell division. This is caused 
by the inability of the DNA replication system to copy the 5’ terminus of DNA, resulting in 
one strand being fully synthesised while the other has an unsynthesised section at the 
end on which the DNA polymerase is primed. The terminal positioning of non-coding 
repeats means it is these, rather than the rest of the chromosome, which shorten, by an 
average of 31 bp per year (Slagboom et al 1994).
Telomeres are maintained by the riboproteln telomerase. This acts as a reverse 
transcriptase, using the 3’ end of the G-rich strand as a primer to synthesise teiomeric 
DNA repeat units from its integral RNA template (Morin 1989). Human telomerase activity 
is high in most tumour, germ-line and stem cells (which are capable of infinite or 
prolonged proliferation) but low in somatic tissues, suggesting that telomere instability 
may contribute to senescence (Counter et al 1992).
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Fig. 1-1 A ‘cot’ curve displaying the renaturation kinetics of sheared, denatured human 
DNA. Dashed lines indicate approximate Coti/2 values for highly repetitive, moderately 
repetitive and single copy DNA classes. Adapted from McConkey (1993).
The proportion of repetitive DNA in a genome can be assessed by tracking the rate at which 
denatured DNA becomes double-stranded under standard conditions: the more copies of a given 
sequence, the faster they reassociate. The fraction of DNA still single-stranded is measured after 
different incubation periods. Results are then graphed as a plot of C/Co against the logarithm of Cot 
where C is the concentration of single stranded DNA remaining after t seconds of incubation and Co 
its concentration at time zero. The human DNA ‘cot’ curve comprises the sum of the individual cot 
curves of various kinetic classes of DNA that renature at different rates, and the estimated plateaus 
of the individual curves gives the percentage of each class in the total DNA.
1.3 Cell and Chromosome Division
1.3.1 Meiosis and Mitosis
Chromosome division takes two forms. In meiosis, which occurs during gametogenesis, 
there are two divisions (1 and II) with only one replication (prior to meiosis I), so the 
haploid number of chromosomes (23) passes to each of four daughter cells. 
Recombination between maternally and paternally derived chromosomes and 
Independent assortment of chromosomes into gametes takes place. In mitosis the 
genetic material of a cell replicates then is divided equally between two daughter cells.
1.3.2 The Mitotic Cycle
The mitotic cycle in humans takes 24 hours. For most of the cycle the cell is in 
interphase, the Gapi (Gi) interphase stage, immediately after telophase, lasting longest. 
Each chromosome exists at that time as a single thread of double-stranded DNA, or 
chromatid. Chromosome replication subsequently occurs during the S phase (which lasts 
6-8 hours). By G2 chromosomes have two chromatids.
The remaining mitotic stages, i.e. prophase and metaphase (when chromatin coiling 
produces visible chromosomes), then anaphase and telophase, take 20 to 60 minutes.
1.4 Human Cytogenetics
1.4.1 A Brief History
Walter Flemming, who introduced the term ‘mitosis’ in 1882, was reputedly the first to 
observe chromosomes. Wilhelm Waldeyer-Hartz named them ‘chromosomes’ (coloured 
bodies) in 1888.
Modern human cytogenetics began in 1956, when tissue culture and squash techniques, 
colchicine mitotic arrest and chromosome spreading with hypotonic salt solutions were 
simultaneously available and allowed determination of the human chromosome number 
as 46 (Tjio and Levan 1956). Drying of fixed chromosomes on microscope slides 
provided further improvement in metaphase quality (Rothfels and Siminovitch 1958). 
However, diagnostic cytogenetics only became relatively routine when the use of 
phytohaemagglutinin (PHA) to stimulate T lymphocyte mitosis allowed chromosomes to 
be obtained from cultures of easily accessible peripheral blood (Moorhead et al 1960).
The first chromosomal disease to be demonstrated was trisomy of a small chromosome, 
later called 21, in Down Syndrome (Lejeune et al 1959). Absence of an X chromosome, 
and no Y, was soon reported in females with Turner syndrome (Ford et al 1959) and the 
first successful prenatal diagnosis (PND), for trisomy 21. was performed in 1965 (Steele 
and Breg 1966).
Although such numerical, and also gross structural, chromosome disorders could be 
recognised, precise pairing and identification of all chromosomes only became possible 
on the introduction of staining techniques which produced a series of light and dark 
bands. Fluorescent staining with quinacrine was the first (Caspersson et al 1970) 
followed by many alternative methods, including G-banding (Drets and Shaw 1971, 
Seabright 1971). Synchronised culture techniques were used to obtain prometaphase 
chromosomes and their banding made it possible to determine chromosome segments 
and breakpoints even more accurately by greatly increasing, to 1000-2000, the number of 
visible bands (Yunis 1976).
1.4.2 Chromosome Banding Techniques
Chromosome banding techniques can be considered in two categories, those designed 
for differential identification of all chromosomes and those which highlight specific 
chromosome features (references and full methods in Verma and Babu 1995).
Techniques used in human cytogenetics for differential identification of all chromosomes 
include fluorescent, Giemsa and reverse banding.
Fluorescent banding
Here fluorochromes intercalate DNA and produce banding visualised by fluorescence 
microscopy with appropriate optical filters. Q-banding involves quinacrine 
dihydrochloride. Alternative stains such as DAPI (4,6“diamidino~2-phenylindole),
Hoeschst 33258 and acridine orange have been used alone or in combination to produce 
different banding profiles, but fluorescent banding is disadvantaged by relatively low 
resolution and fluorophore fading.
Giemsa (G- or GTG-) banding
This produces permanent bands which are highly suitable for diagnostic work. 
Chromosome pretreatment is with salt solution at 60°C or protease, usually trypsin (Drets 
and Shaw 1971, Seabright 1971) and staining is with Giemsa, Leishman or Wrights stain. 
Brightly fluorescent Q-bands appear dark and dull Q-bands light with this method. G-light 
bands replicate earlier than G-dark bands, which are 3.2% richer in A and T sequences. 
Depending on chromosome length, 300-2000 bands can be produced (per haploid set) 
with this method though the band number is usually 400-800 in routine work. 
Chromosomes and their G-bands are described and numbered in an international 
nomenclature system (ISCN 1995). Chromosomes are, mainly, numbered by size (the 
largest being 1) and categorised as metacentric, acrocentric or submetacentric according 
to centromere position (Fig. 1-2). The shorter and longer arms of a chromosome are 
called petit (p) and queue (q). Bands on each arm are numbered distaliy from the 
centromere.
Reverse (R-) banding
Pretreatment with alkali at 80-90°C and staining with Giemsa (RHG bands) or fluor such 
as acridine orange (RFA bands) produces banding that is the reverse (dark bands 
become light and vice versa) of G- or Q-banding respectively. This method, and a 
modification, T-banding, can stain chromosome ends darkly, assisting their resolution.
Techniques which identify specific chromosome features include 5-bromodeoxyuridlne 
(BrdU) staining, which is used in order-of-replication and sister chromatid exchange 
studies, centric (C-) banding which highlights heterochromatic regions around the 
centromeres and on chromosome Y, and staining, involving acid treatment, of the 
nucleolar organising regions (NORs) on the short arms of acrocentric chromosomes 13, 
14, 15, 21, and 22 (Fig. 1-2). Active NORs are stained using silver nitrate.
TELOMERE ^  T-for R-j banding
pARM
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STALKSNOR/Silver stain 
CENTROMERE Q  ^ -----  C-banding
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TELOMERE •  4"T- (or R-) banding -►
SUBMETACENTRIC ACROCENTRIC
Fig. 1-2 Position of C-,T-for bands and NOR stain on submetacentric and acrocentric 
chromosomes. In submetacentric chromosomes the p arm is shorter than the q arm.
1.4,3 Types of Chromosomal Aberrations
Chromosome aberrations affect at least 7.5% of conceptions and 0.6% of live births. 
These can be numerical (varying from the diploid number) or structural and occur either 
as a result of a germ cell mutation in an ancestor or due to somatic mutation, in which 
case only a proportion of cells will be affected (mosaicism). Detailed discussion of human 
chromosome abnormalities is provided in Gardner and Sutherland (1996).
Numerical Aberrations
Aneuploidy is any chromosome number which is not an exact multiple of the haploid 
number. It usually arises from the failure of paired chromosomes or sister chromatids to 
disjoin at anaphase (non-disjunction) or delayed chromosomal movement at anaphase 
(anaphase lag) and can occur during mitosis or meiosis I or II. Non-disjunction during 
mitosis may cause mosaicism - the presence, in an individual derived from a single 
zygote, of two or more cell lines with differing chromosomal complements. The only 
autosomal aneuploldies occurring at appreciable frequencies in live births are trisomy 13, 
trisomy 18 and most commonly trisomy 21 (1 in -700 births). The only known autosomal
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monosomy is the rare monosomy 21. Sex chromosome aneupioidies with appreciable 
incidence include 45,XO, 47,XXX, 47.XXY and 47,XYY.
Polyploidy is an abnormal number of complete haploid sets (i.e. more than two). Triploidy 
(three times the haploid number, n) may arise by various processes including fertilisation 
of the egg by two sperm. Triploids represent around 17% of spontaneous abortions and 
rare cases which survive the perinatal period are usually mosaic, having a diploid cell line. 
Tetraploidy (4n), is found in around 6% of spontaneous abortions.
Structural Aberrations
The variety of structural aberrations, caused by random re-joining of broken chromosome 
ends, is limited only by the possible lethal effect of any rearrangement. Rates of 
breakage vary according to genetic make-up and age, and are increased by exposure to 
various radiations, mutagenic chemicals, viruses, and in individuals with chromosome 
instability syndromes (e.g. Fanconi anaemia). Partial trisomy and/or monosomy can be 
caused by translocations, deletions, duplications, ring chromosomes, inversions, 
isochromosomes and centric fragments (Table 1-1, Fig.1-3). Of particular relevance to 
this study are reciprocal translocations, deletions and duplications.
Translocations
Here transfer of material between chromosomes is caused by breakage of more than one 
chromosome followed by incorrect repair, or by erroneous meiotic recombination between 
non-homologous chromosomes. Where no genetic material is lost, and no critical locus 
disturbed, the affected individual may be clinically normal but have a risk of chromosomal 
imbalance in any progeny.
Simple reciprocal translocations arise when a two-way exchange of material occurs 
between two non-homologous chromosomes. The rearranged, or derivative, 
chromosomes are named according to the centromere carried. Around 1 in 625 
individuals is a carrier of a familial or de novo reciprocal translocation. The risk to a 
carrier of abnormal offspring and/or miscarriage depends on the chromosome segments 
translocated (Jalbert et al 1980).
Deletions
Deletions arise from loss of a chromosome segment distal to a single break (terminal), 
between two breakpoints (interstitial), as a consequence of unequal cross-over, or by 
inheritance of an unbalanced form of a parental translocation. The smallest 
cytogenetically visible deletion, 4Mb (Connor and Ferguson-Smith 1993), represents loss
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Fig. 1-3 Chromosome breaks and rearrangements.
Adapted from Therman and Susman (1993).
Result of Gi breaks In one chromosome (A), two chromosomes (B), and, forming Robertsonian 
translocations, breaks in two acrocentric chromosomes (0):
(A1) broken chromosome; (A2) centric ring and acentric fragment; (A3) acentric ring and centric 
fragment; (A4) pericentric Inversion
(81) dicentric chromosome and acentric fragment; (82) balanced reciprocal translocation 
(C1) breaks on the short arms forming a dicentric and acentric chromosome; break through the 
centromeres (C2) or one break on a short arm, one on long arm (C4) forming two monocentric 
chromosomes.
of large numbers of genes, therefore autosomal deletion usually results in multiple 
congenital abnormalities and mental retardation (MR).
Duplications
The presence of two copies of a chromosomal segment might arise through unequal 
cross-over in meiosis (the reciprocal product being deleted) or meiotic events in a parent 
with a translocation, inversion or isochromosome.
Duplications are generally less harmful than deletions (Connor and Ferguson-Smith 
1993).
CHROMOSOME ABERRATION CAUSE
Reciprocal Translocation
Robertsonian Translocation 
(centric fusion)
Insertional Translocation
Deletion
Ring Chromosome
Duplication
Inversion
Isochromosome
Centric Fragment
Two-way exchange of material between two non-homologous 
chromosomes
Breaks at or near the centromere in acrocentric chromosomes 
with translocation of the products usually forming a dicentric (with 
no NOR) and a non-viable acentric chromosome. Chromosome 
21 involvement can cause familial translocation Down Syndrome.
Three breaks in one or two chromosomes. If two involved, an 
interstitial deletion results in one with the deleted segment 
inserted in the gap of the other.
Loss of a chromosome segment distal to a single breakpoint 
(terminal) or between two breaks (interstitial). See ‘duplication’.
Breaks in both arms of a chromosome and fusion of the resultant 
chromosome ends.
Unequal cross-over in meiosis (reciprocal product being deleted) 
or meiotic events in a parent with a translocation, inversion or 
isochromosome.
Two breaks in a single chromosome and, before re-joining, the 
intervening segment is reversed. Peri- or paracentric depending 
on whether the inverted segment does or does not involve the 
centromere. Generally of no phenotypic significance but the risk of 
unbalanced gametes increased.
Deletion of one arm with duplication of the other, resulting either 
from transverse centromeric fission during cell division or from an 
isochromatid break and fusion above the centromere (with 
inactivation of one centromere in the resultant dicentric).
Centric fusion translocation between satellited chromosomes 
during meiosis. May have no clinical significance unless 
transcribed genes involved.
Table 1-1 Structural chromosome aberrations and their origins.
1.4.4 Limitation of Chromosome Banding Techniques
Many clinically significant chromosomal aberrations, such as microdeletions, are beyond 
the resolution of conventional banding, and its monochromatic nature can render 
interpretation, especially of complex rearrangements or small centric fragments, uncertain 
or impossible. In addition, identification of chromosome anomalies by banding techniques 
is not always appropriate or feasible. Crucially, the abnormality may not be present in 
dividing cells or high quality metaphase spreads may not be available (a particular 
problem in cancer cytogenetics). Another practical consideration is the time and skill level 
required for interpretation of high resolution banding.
These limitations prompted, during the 1990s, the evolution of in situ hybridisation 
techniques as an adjunct to classical diagnostic cytogenetics.
1.5 Development of Fluorescence In Situ Hybridisation
In situ hybridisation (ISH) is a method for the detection of specific nucleic acid sequences 
in specimens fixed to microscope slides, allowing determination of the presence and 
localisation of these sequences within a morphological context. The technique, when 
applied to chromosomes, represents a convergence of molecular genetics and 
cytogenetics thus the term molecular cytogenetics was adopted for the scientific field.
1.5.1 Isotopic ISH
Hybridisation of a nucleic acid sequence to the DNA of a cytological preparation was first 
described in 1969 (Gall and Pardue, John et al), when tritium-labelled ribosomal RNA was 
localised in Xenopus oocytes. Following acid fixation of the preparation to remove basic 
proteins which can interfere with ISH, the technique involved denaturating chromosomal 
DNA while retaining cytological integrity, then incubation with a single stranded probe 
sequence under conditions enabling specific pairing. A significant excess of silver grains 
in an autoradiographic emulsion overlay localised the site of hybridisation. The principles 
of this approach remain the basis of molecular cytogenetics today (Fig. 1-4).
From the early 1970s this procedure was increasingly used to localise repetitive 
sequences, since RNA or DNA probes for these could be readily isolated (Saunders et al 
1972, Jones et al 1973, Evans et al 1974). The parallel development of DNA recombinant 
technology made pure, single copy, sequences available and improvements in the 
efficiency of labelling, hybridisation and quality of chromosome banding eventually made 
ISH sufficiently sensitive to permit the localisation of such single copy sequence DNA 
(Gerhard et al 1981, Harper and Saunders 1981, Malcolm et al 1981). High specific 
activity tritiated probes could detect as little as 0.5kb of target sequence on pachytene 
chromosomes (Jhanwar et al 1983).
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Fig. 1-4 Stages of the FISH process. Adapted from LIchter and Cremer (1992).
1.5.2 Non-isotopic ISH
1.5.2.1 Labels and Labelling Methods
Isotopic ISH had, however, serious disadvantages. These included prolonged 
autoradiographic exposure of up to several weeks, poor resolution due to scattered 
radioactive disintegrations around the hybridisation region, probe instability caused by 
radioactive decay, the necessity for statistical analysis of a large number of metaphases 
to establish statistically significant counts above background level, and the risk to 
personnel involved in the use of radioisotopes.
The quest for faster, safer, more specific ISH effected, in the late 1970s to mid 1980s, 
development of several methods using non-lsotopic probe labels, also known as reporter
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molecules. Probe incorporation of these labels was either chemical or enzymatic. Some 
of these approaches, their limitations, and the detection and visualisation methods they 
employed are described in Table 1-2 with the relevant references.
Biotin, a B vitamin, is a particularly useful label as it forms high affinity complexes with 
avidin in addition to being immunocytochemically detectable. The first biotin labelling of 
nucleic acid sequences was by cross-linking. More general use of biotin as a probe label 
became possible with the preparation of biotinylated derivatives of DTP and dUTP.
These substrates for nucleic acid polymerases could easily be incorporated enzymatically 
by means of, for example, a nick translation reaction (Fig. 1-5). Though a plethora of 
indirect probe labelling systems were introduced in the 1980s, enzymatic incorporation of 
biotin and subsequently of dUTP-conjugated digoxygenin (DIG), a steroid derivative of 
Digitalis purpurea, was the simplest and most enduring (Fig. 1-6).
Fluorescent dyes were amongst the first non-isotopic labels utilised, initially 
thiosemicarbazide derivatives of FITC (fluorescein isothiocyanate) or TRITC (tetramethyl 
rhodamine isothiocyanate) incorporated by 3’ end labelling of nucleic acid sequences. 
Immunocytochemical amplification improved the weak signal provided by the single 
fluorescent molecule on each probe fragment. More efficient fluorescent labelling was 
later provided by enzymatic incorporation of FITC derivatives of dUTP (Fig. 1-6).
1.5.2.2 Detection Methods
These non-isotopic labels were variously detected indirectly by antibody-associated 
chromogenic enzyme reactions, colloidal gold with silver amplification, or fluorescence.
As mentioned above, biotin could be detected immunocytochemically or by avidin 
conjugated to an enzyme or fluorochrome. Fluorescent labels were either visualised 
directly where probes were large, complex or repetitive target sequences so producing 
signals of adequate strength, or amplified using immunofluorescence. Direct detection 
reduces processing time and immunocytochemically-derived background signals, and 
removes potential for cross-reactivity of antibodies in different layers. Also, as the 
stoichiometry of indirect detection is more complex, direct detection represents a more 
appropriate approach for sequence copy number quantitation.
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Fig. 1-5 The nick translation reaction. Adapted from Le itch et a! (1994).
1 and 2. Deoxyribonuclease 1 (DNase I) introduces single strand breaks (‘nicks’) to expose free 3’- 
OH groups.
3. The 5’ to 3’ exonuclease activity of DNA polymerase I removes nucleotides at the 5’-phosphate 
side of the nick.
4 and 5. DNA Polymerase I simultaneously synthesises DNA complementary to the intact strand in 
the 5’ to 3’ direction using the 3’-OH termini of the nicks as primer. Labelled and unlabelled 
nucleotides in the solution are incorporated in the newly synthesised strand.
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Fig. 1-6 Chemical structures of the modified nucleotides most commonly used in non­
isotopic ISH.
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1.5.2.3 The Limit of Sensitivity of Non-isotopic Methods
The sensitivity of an ISH process is defined as the smallest target detectable. Non­
isotopic methods were initially found to be less sensitive than isotopic ISH and restricted 
to the detection of repetitive sequences (Manuelidis et al 1982) and relatively large single 
copy sequences of around 20-40kb. A collection of short cosmid-derived subclones of 
the target sequence, total length 22.3kb, was employed to localise the human 
thyroglobulin gene (Landegent et al 1985b), and a cosmid probe (insert 35-45kb), 
because it had few cross-hybridising repeats, was able to be used in mapping to 4p16 a 
sequence closely linked to the Huntington disease locus (Landegent et al 1986).
It was the use of whole plasmid (exploiting vector sequence cross hybridisation) and three 
layer detection for signal amplification which allowed the sensitivity of avidin-conjugated 
alkaline phosphatase detection of biotinylated probes to match that of isotopic ISH 
(Garson et al 1987, Morrison et al 1990). Sensitivity to probes of around 1kb was also 
demonstrated for amplified immunofluorescent detection of biotinylated probes (Cherif et 
al 1989, Murphy et al 1993). Non-isotopic ISH using biotin label and immunofluorescence 
was even claimed to be more efficient than isotopic ISH on comparison of mapping 
results with chromosome 11 q-specific plasmid probes of size range 1.0-3.2kb (Fan et al
1990), although different plasmids were used in the isotopic and non-isotopic studies.
Radiolabelled signals were detected in only 20% of cells, whereas fluorescent signals 
were present in 70% and against much lower background.
1.5.2.4 Factors Affecting the Sensitivity of Non-isotopic ISH
The ‘stringency’ of hybridisation and post-hybridisation wash conditions determines 
whether a probe binds specifically to its complementary sequence or nonspecifically, and 
whether it remains annealed once bound. Stringency is a result of the temperature of 
incubation and the concentrations of salt and helix-destabilising molecules (e.g. 
formamide) in hybridisation buffer and wash solutions. Lower incubation temperatures, 
lower formamide and higher salt concentrations reduce stringency, increasing probe 
binding and therefore sensitivity while possibly decreasing specificity. Other variables 
affecting ISH sensitivity are listed below.
• The efficiency of probe labelling. Methods, such as random priming, which can effect 
higher incorporation of label may provide improved signal intensity (Cherif et al 1989).
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• As mentioned above, the presence of vector sequences in the probe may result in 
signal amplification (Garson et al 1987), though this effect has been questioned (Cherif et 
al 1989).
• Use of multi-layer detection. Amplification by applying multiple layers of fluorophore 
immunoiogically is a controllable feature of fluorescence ISH (FISH) which can optimise 
signal to background ratio. Signal intensity can be multiplied six times at each 
amplification (Pinkel et al 1986).
• Use of tyramide amplification (TSA). Increase in sensitivity can follow the use of biotin 
or fluor labelled tyramides in the indirect fluorescence detection of biotin or DIG labelled 
probes (Raap et al 1995). In this process, peroxidase is bound to the hybridised probe 
then tyramide conjugates, which are peroxidase substrates, generate many biotin or fluor 
molecules at the ISH site. TSA does, however, reduce signal resolution.
• The microscope must be adequately and homogeneously illuminated. FISH requires 
the appropriate optical filter combinations and use of a high numerical aperture (NA) 
objective specified for fluorescence e.g. x100, NA 1.4.
• The use of digital imaging (discussed in section 1.5.2.6).
• The amount of repetitive sequence in the probe can affect the apparent sensitivity of a 
hybridisation as these sequences may require to be blocked (in chromosomal in situ 
suppression, see section 1.5.2.8), reducing the hybridisation efficiency relative to a 
similarly-sized probe with less repetitive content (Landegent et al 1986).
• Chromosome preparation critically affects penetrance therefore a wide variety of slide 
pretreatments have been recommended, e.g. pepsin, proteinase K, collagenase, RNase 
(Leitch et al 1994). Pretreatment is particularly critical with histological sections, 
uncultured amniocytes or tissue imprints.
• Presence or absence of non-competitive carrier DNA (such as sonicated salmon 
sperm DNA) and/or dextran sulphate in hybridisation buffer (Harper and Saunders 1981, 
Manuelidis 1985, discussed in Malcolm et al 1986).
• Hybridisation time and probe concentration. Optimal concentration varies between 
probes and probe types as does hybridisation time, which is usually 2-24 hours. Raising 
concentration 5-10 fold may considerably reduce this period (Ward et al 1995).
• Concentration of competitor DNA (Ward et a! 1995, section 1.5.2.8).
• Size of hybridised probe fragments. 200-400bp is optimal for ISH (Trask 1991).
As hybridisation efficiency tends to relate to target size, the increasing availability of larger 
cloned sequences for many applications made ISH sensitivity somewhat less critical.
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1.5.2.5 Hybridisation Efficiency Improvement with Larger Probes and CISS
Probes containing 2kb of single copy sequence generally detected a maximum of 40-50% 
of all target sites and the discrimination of weak specific signals against background 
required statistical evaluation following the lengthy analysis of many metaphases (Lichter 
and Cremer 1992).
The availability of larger cloned sequences and, crucially, the chromosomal in situ 
suppression (CISS) method (as described in section 1.5.2.8) for blocking cross- 
hybridising repetitive sequences in these probes enabled production of larger, more 
reliable signals (Landegent et al 1987, Lichter et al 1988, Cremer et al 1988, Pinkel et al
1988). A signal is usually produced in at least 80% of the complementary chromosome 
sites when cosmid (40kb) or YAC clones (1 OOkb-1 Mb) are used as probes, and 
contiguous probe sequences can further improve signal intensity (Landegent et al 1987). 
This allowed the examination of fewer metaphases, obviated statistical analysis, and 
further simplified and accelerated the process of ISH.
Through optimising hybridisation efficiency and sensitivity direct visualisation of directly 
fluorophore-labelled probe, with the concomitant benefit of reduction in processing time 
and background signal, became increasingly feasible.
1.5.2.6 Visualisation - Microscopy and Recording
Non-isotopic ISH methods have employed a range of visualisation methods (examples in 
Table 1-2). Visualisation of fluorescent ISH sites is generally by epifluorescence (most 
frequently using mercury vapour lamps) with appropriate objectives and filter sets for 
each fluor (Fig.1-7, Table 2-1).
The impermanent nature of FISH preparations made recording of the result essential. 
However the long exposure times required by conventional cameras to photograph the 
low light intensity fluorescent signal using colour film often resulted in poor image quality 
and signal fading. This was overcome with the adoption of electronic imaging systems. 
The most sensitive, capable of photon counting over long integration times, was the 
cooled charge coupled device (CCD) camera (described in Aikens et al 1989). This 
allowed detection of signals invisible to the microscopist’s eye and further facilitated the 
use of directly-labelled fluorescent probes, improving signal;noise ratio (Weigant et al 
1991). Cooling of the chip suppressed background noise from dark current (thermal 
generation of electrons during long exposures).
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LIGHT SOURCE
FLUORESCENCE LIGHT 
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Fig. 1-7 The key features of the optics of an epifluorescence microscope.
Adapted from Notes on Fluorescence Microscopy (Vysis Inc).
The mercury vapour light source emits a range of light wavelengths, together appearing white, 
which pass through the condenser (collector) lenses. The excitation filter then blocks all 
wavelengths except those that excite the fluor to be visualised. The dichroic beam splitter or mirror 
reflects some shorter wavelengths (those that excite the fluor) on to the specimen and transmits 
longer wavelengths (emitted by the fluor) returning from the specimen. A barrier filter then blocks 
transmission of all wavelengths except those emitted by the fluor, and removes stray reflected light 
from autofluorescence, t)efore the light reaches the eyepiece lens or camera.
Fig, 1-8 Digital imaging system (Digital Scientific, Cambridge).
1 ; Zeiss Axioskop Microscope
2; Fluorescence light source (a) and control box (b)
3; Photometries cooled charged coupled device camera (a) and control box (b) 
4: LudI filter wheel
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In addition to high sensitivity (digital imaging could result in 30 fold improvement, Weigant 
et al 1991), CCD cameras also provided high spacial resolution and linearity with wide 
dynamic range, ideal for low light level FISH and quantitation.
Colour CCD cameras initially had lower sensitivity and resolution and were disadvantaged 
for advanced applications of ratio imaging (section 1.5.2.7) and quantitative fluorescence 
microscopy, so black and white cameras became standard. These generate grey scale 
images separately for each fluor (e.g. signal and chromosome counterstain) which are 
then pseudocoloured and electronically overlayed. Moving between different filters, just 
as when using multiple exposures of colour film in conventional photomicrography, could 
however cause a change in the optical axis leading to incorrect registration of 
superimposed images. This problem was solved by using a fixed dichroic mirror with a 
fixed newly developed multiple bandpass emission filter (to allow the simultaneous 
emission of signals of two or more wavelengths) in combination with selectable excitation 
filters on a separate motorised wheel which could be computer-controlled (Fig. 1-8).
Digital imaging also simplifies storage of FISH data and allows image processing, 
including enhancement of signal and of DAPI bands to aid chromosome identification.
1.5.2.7 Multiple Target FISH
Simultaneous detection of more than one target sequence saves time and material. 
Fluorescence detection, directly or indirectly, has the advantage that multiple, differently- 
labelled probes may easily be used together, each detected by a different fluorochrome 
concurrently (Nederlof et al 1989, Wiegant et al 1991). It was primarily this feature, and 
the recognition that fluorescent signal offered the best prospect for automated 
chromosome analysis, that led to the expansion in use of fluorescence detection.
Mixtures of probe labels (combinatorial labelling) can be used to provide more detection 
colours than there are available fluors, thereby extending the number of simultaneously 
detectable FISH targets (Nederlof et al 1990). The number of targets which can be 
distinguished by combinatorial labelling Is 2"-1 where n is the number of fluorochromes. 
Hence a digital imaging system, with its ability to pseudocolour and merge images, could 
be used to distinguish up to seven probes using only three labels (e.g. biotin, DIG, DNP- 
dUTP) and fluors (Reid et al 1992, Fig. 1-9). Conventional photography, requiring multiple 
exposures of colour film, could not adequately display and resolve images from these 
combinatorially labelled probes.
dUTP derivatives of biotin, DIG, DNP and FITC were the most practical labels to combine 
because of the identical labelling formats and ISH conditions. By simply mixing
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haptenised dUTPs in the nick translation it is possible to label one probe with multiple 
reporters (and detect it with multiple fluors). Technological improvements enabled 
differential labelling, and hence colour karyotyping, of all 24 human chromosomes by 
approaches known as SKY (spectral karyotyping, Schrock et al 1996) and M-FISH 
(multiplex FISH, Speicher et al 1996).
Ratio-labelling, the use of different proportions of reporters on probes, further extended 
the multiplicity of combinatorial labelling, initially allowing twelve colours to be determined 
using 3 labels (Dauwerse et al 1992). Fluorescence ratio imaging of double-labelled 
probes in multiple ISH was shown to be feasible (Nederlof et al 1992) but ratio-labelling 
failed to become widely applied due to the demanding technical aspects associated with 
accurate determination of the relative amounts of each label staining each target.
Fig. 1-9 Schematic representation of 7-colour FISH using probes combinatorially labelled 
with three reporter molecules. Adapted from an image kindly supplied by Vysis Inc.
1.5.2.8 Probe Types and Generation
Probes used for ISH can be categorised as repetitive target sequence probes, unique 
target sequence probes and composite probes, which allow specific painting' of individual 
chromosomes or chromosome regions.
Repetitive Target Sequence Probes
Unique or low copy sequences, which include structural genes with their related 
regulatory sequences, represent around 50-70% of total human DNA (Clark and Wall 
1996). The remainder is repetitive DNA. This is classed as moderately repetitive DNA, 
which has several hundred sequence copies and includes the genes encoding transfer 
RNA, ribosomal RNA and histones, and highly repetitive DNA, in tens of thousands to one 
million copies, which comprises -20% of the genome and may have a role in 
chromosome pairing, alignment and recombination. Highly repetitive sequences can be 
arranged as tandem repeats or interspersed throughout the genome as Long or Short 
Interspersed Elements (LINEs or SINEs). The most abundant SINE is the Alu family.
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consisting of several hundred thousand copies of a 280bp sequence which is flanked by 
recognition sites for the enzyme Alu I. The average frequency is one copy per 3kb.
LINEs are over SOObp long. The L1 (LINE 1) or Kpn family consists of 50,000-100,000 
copies found on average every 8kb. Alu sequences predominate in Giemsa-light and L1 
in Giemsa-dark bands.
Highly reiterated tandem repeats are known as satellite DNA from the minor bands 
produced, separate to bulk DNA, by satellite I, II and III DNA on equilibrium centrifugation 
in a caesium chloride density gradient. Depending on the average size of the repeat unit 
arrays, this non-coding DNA is sub-grouped as satellite (lOOkb-several Mb), mainly found 
at centromeres, minisatellite (0.15-20kb) which includes telomeric and hypervariable 
families, and microsatellite (under 150bp) which is dispersed throughout chromosomes. 
Alpha satellite DNA is, like ALU sequences, primate-specific. It constitutes the bulk of the 
centromeric heterochromatin (a few hundred kb-several Mb), and accounts for -3-5% of 
the DNA of each chromosome. Its basic unit is a 171 bp monomer. Divergence in higher 
order organisation has resulted in alpha satellite repeats on most human chromosomes 
being chromosome-specific (reviewed in Willard and Waye 1987, Choo et al 1991).
Probes recognising alphoid sequences have strong but discrete signal which makes them 
useful for chromosome copy number determination in metaphase and interphase cells. 
Other repetitive sequences used for ISH analysis include satellite II and III probes from 
proximal Yp and Yq, 1, 9, and 16 heterochromatic regions, beta satellite sequences from 
the heterochromatic regions of 1, 9, Y and acrocentric chromosomes, and satellite ill 
heterochromatin from the short arm of 15. Usually a repetitive probe consists of cloned 
DNA containing one or a few of the repeat elements (often in a plasmid vector) but they 
can be generated from genomic DNA by polymerase chain reaction (PCR) amplification 
(Dunham et al 1992).
Unique Target Sequence Probes
These detect specific sequences present in only one copy in the genome. As previously 
discussed, ISH with unique sequences was initially confined to the use of short stretches 
of DNA, often in plasmid or bacteriophage lambda vectors (incorporating inserts of up to 
15kb, Harper and Saunders 1981), or to cDNA sequences (Malcolm et al 1981). Vectors 
with larger insert sizes, such as cosmids ( -  40kb, Collins and Hohn 1978), potentially 
offered increased target size and reliability of ISH, but their longer inserts contained 
LINES and SINES which cross-hybridised causing high background signal. They became 
usable as ISH probes with the crucial introduction of chromosomal in situ suppression 
(CISS) hybridisation (Landegent et al 1987), an approach earlier Investigated during the 
first mapping of a single copy gene (Harper and Saunders 1981). It involved co-
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hybridisation of unlabelled competitor DNA (total genomic DNA or the Cot1 fraction 
enriched for highly repetitive sequences) to saturate the repetitive probe elements leaving 
the unique sequences free to hybridise to the target loci (Fig 1-10).
Even longer probe inserts (up to 2Mb) became available with the introduction of yeast and 
bacterial artificial chromosomes (YACs, BACs), bacteriophage PI clones and P1-derived 
vectors (PACs), as reviewed in Monaco and Larin (1994).
GENOMIC PROBE
LABELLED AND DENATURED PROBE + EXCESS DENATURED COM!PETITOR DNA 
CED g]
^  GO
PREANNEALUNG
(37‘C  F O R -I HOUR)
ra  m arm . cu
HYBRIDIZATION
X E CHROMOSOMAL DNA
TARGET REGION
SINGLE COPY OR LOW COPY REPETITIVE DNA 
MODERATELY AND HIGHLY REPETITIVE DNA
Fig. 1-10 Chromosomal in situ suppression (CISS) hybridisation. 
Adapted from Lichter and Cremer (1992).
Chromosome Paint Probes
Chromosome paints are collections of sequences spanning the length or a specific 
section of a target chromosome. Chromosome painting was developed at Lawrence 
Livermore National Laboratories (Pinkel et al 1988) and Yale University (Cremer et al 
1988, Lichter et al 1988) using cloned DNA libraries derived from flow-sorted human 
chromosomes. As with large insert probes, cross-hybridising elements were blocked with 
CISS hybridisation. These early bacteriophage libraries had high proportions of vector 
DNA but re-cloning in plasmid increased insert to vector ratio (to 0.5 from 0.1 in phage), 
reducing background hybridisation (Fuscoe et al 1989, Collins et al 1991).
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Paints were also produced without cloning from human-rodent hybrids containing single 
human chromosomes (Kievits et al 1990) and made more sensitive by differentially 
amplifying the human sequences by interspersed repetitive sequence (1RS) PCR with Alu 
or LI primers (Lengauer et al 1990). PCR with degenerate oligonucleotide primers 
(OOP), which theoretically prime every 4kb, was used on either small numbers of flow- 
sorted or microdissected chromosomes to rapidly generate paints with further improved 
signal to noise ratio and target coverage (Telenius et al 1992, Meltzer et al 1992). Labels 
such as biotin can conveniently be incorporated during such PCR. With microdissection, 
specific chromosome arm or band probes could also be produced (Guan et al 1996). 
Depending on degree of coverage, background noise and target chromosome 
condensation, paints can resolve approximately 5Mb of DNA (Rosenberg et al 1992).
1.6 The role of ISH in Human Gene Mapping
ISH has become a versatile tool in many research disciplines including radiation biology 
(Cremer et al 1990), evolutionary cytogenetics (Weinberg et al 1990), meiotic studies 
(Goldman and Hulten 1992), nuclear topography (Manuelidis 1985, Lichter et al 1988) 
and the organisation and replication of human DNA (Korenberg and Rykowski 1988, 
Rosenberg et al 1995). The first application of ISH, however, was in sequence mapping. 
The major reason for mapping human genes is to improve our basic understanding of the 
human genome and, through this, the role of particular genes in health and disease. The 
two main strategies in sequence localisation are linkage and physical mapping.
1.6.1 Linkage Analysis and Early Mapping Studies
In family linkage studies the chromosomal location of one trait is known and the frequency 
of rearrangement between this and a second sequence or trait is a measure of the 
linkage between these (0%=tight linkage, 50%=none). Tight linkage suggests two 
sequences co-localise to the same chromosomal region.
Prior to the cloning era protein variants, such as blood groups and serum protein markers, 
and chromosomal heteromorphisms (e.g. 1qh+, 9ph) were used as polymorphic marker 
traits for such studies. Other early mapping approaches involved the correlation of gene 
product with the presence of a chromosomal region by exploiting gross chromosomal 
duplications and deficiencies (gene dosage and exclusion mapping studies) and 
translocations in somatic cell hybrids (reviewed in Ferguson-Smith and Aitken 1982).
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Recombinant DNA technology initially provided hybridisation, both in situ and to Southern 
blots following restriction enzyme digestion (reviewed in Davies 1981), then, in the late 
1980s, PCR methods for dosage and somatic cell hybrid studies (example in Abbott et al
1989). More highly polymorphic markers for linkage analysis became available, in the 
form of restriction fragment length polymorphisms (RFLPs) and variable number tandem 
repeats (VNTRs, comprising minisatellite and microsatellite repeats). Microsatellite 
markers (short tandem repeat polymorphisms, STRPs, of di, tri or tetranucleotides) have 
been particularly useful, being abundant, evenly dispersed in the genome, highly 
informative and easy to type (discussed in McConkey 1993).
In 1989 the international research community established the Human Genome 
Organization (HUGO) to promote collaboration and coordinate human genome mapping. 
The same reference families were used by different research groups for all linkage 
studies and their data combined to produce integrated maps. This effort was expedited 
by adoption of a ‘factory’ approach, only possible in dedicated laboratories, using large 
scale automation and computerised statistical linkage analysis on polymorphic repeat 
markers.
By 1994 a map of 5840 loci provided a marker density of one per 0.7cM (Murray et al 
1994). Marker locations were submitted to databases, primarily the Genome Database 
(http://www.gdb.org), making this information widely available electronically. The 
expanding linkage map was to provide the framework for construction of a physical map, 
allowing sequences to be mapped to intervals between the PCR-based markers.
1.6.2 Physical Mapping
Physical mapping aims at the isolation, chromosome localisation, ordering and 
sequencing of contiguous cloned pieces of human DNA, ultimately covering all areas of 
all chromosomes. The ordering of sets of sequences requires a hierarchy of stages at 
different levels of resolution.
Physical mapping using recombinant DNA technology began in the 1970s in a sporadic 
fashion, with both restriction mapping of DNA in somatic cell hybrids and isotopic ISH to 
chromosomes of repetitive, and later unique, sequences as these were isolated by 
independent investigators and ISH sensitivity improved (Davies 1981).
Systematic physical mapping was made feasible by the introduction of pulsed-fleld gel 
electrophoresis (PFGE, Schwartz et al 1983) followed by the crucial development of 
YACs (Burke et al 1987). PFGE allowed differential separation, and therefore analysis by
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molecular hybridisation and construction of long-range restriction maps, of large (50kb- 
1Mb) DNA molecules. YACs provided a means of cloning such large sequences.
Isolation and characterisation of clones from genomic YAC libraries allowed production of 
coarse contig maps of individual human chromosomes (Cohen et al 1993). Smaller insert 
vectors could then be used to assemble high-resolution contig maps, a prerequisite for 
sequencing of whole chromosomes. Partial sequencing of clones reveals unique STS 
(sequence tagged sites) and ESTs (expressed sequence tags, 200-300bp), and STS/EST 
maps can be used to help localise other clones according to their STS and EST content. 
ISH has been involved at different stages of this physical mapping process. For example:
• Confirming the human chromosome content of somatic cell hybrids prior to production 
of single chromosome YAC libraries from these, and confirming the chromosomal 
localisation of cloned sequences (Montanaro et al 1991).
• Checking the chromosome-specificity of YACs selected from a genomic library for the 
preparation of a single chromosome library (Ross et al 1992).
• Ascertaining YAC inserts do not contain artefactually-linked sequences from non­
contiguous genomic regions (YAC libraries have a high frequency of chimaeric clones).
• Band localisation of STRPs in YAC clones (Murray et al 1994).
• Ordering clones, as an alternative to PFGE (Lebo et al 1992).
• The localisation of ESTs (in human cDNA clones) as an alternative to PCR screening 
of somatic cell and radiation hybrids (Korenberg et al 1995).
In summary, ISH complements other mapping approaches and is often involved in initial 
localisation, confirmation, ordering and (as described below) orientation of clones 
because it offers some advantages over other techniques. It is direct, rapid, gives 
excellent regional localisation and does not require production and maintenance of 
regional mapping panels of somatic cell hybrids or flow-sorted chromosomes for dot-blot 
production. Nor does it depend on availability of polymorphic markers or large pedigrees. 
Eventually, by integrating linkage and physical maps produced by the Human Genome 
Mapping Project, it will be possible to find the genes for all diseases and biological 
functions. However, while awaiting this achievement, it remains useful to map, as they 
are isolated, sequences that could be candidate genes.
Such specific sequences can be isolated by functional cloning (where the gene product is 
known so its sequence can be inferred) or positional cloning. In positional cloning a gene 
must first be mapped, for example through association of a specific chromosomal 
aberration with abnormal gene function (as in the case of the dystrophin gene, Kunkel et 
al 1985). The DNA at that locus is then screened for genes by, for example, identification 
of hypomethylated CpG islands. That the gene of interest has been isolated is confirmed
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by finding mutations in patients with the disease or from the distribution and function of 
the predicted protein.
ISH to chromosomes prepared from cultured lymphocytes, an approach particularly 
accessible to cytogenetic laboratories, is often the method of choice for mapping 
functionally cloned sequences or confirming the localisation of sequences obtained by 
positional cloning.
1.6.3 Mapping DNA Sequences to Chromosomes using ISH
1.6.3.1 Use of Standard Banding Techniques
For mapping data obtained by ISH to chromosomes to be expressed in cytogenetic terms, 
a banding method must be combined with the hybridisation protocols. Banding can be 
induced by essentially standard techniques before or following ISH (reviewed in Lichter 
and Cremer 1992). Early applications often involved pre-, rather than post-1 SH G~ 
banding (with Lipsol or trypsin treatment) to avoid interference of heat dénaturation with 
banding quality (Malcolm et al 1986, Garson et al 1987, Klever et al 1991). There was no 
risk of banding failing following ISH and, when statistical analysis of signal distribution 
was necessary, it removed bias in post-ISH metaphase selection. However It required 
photography of banded chromosomes, destaining, then re-location of previously 
photographed metaphases post hybridisation for signal placement on bands.
Banding after ISH, e.g. with Quinacrine, Hoechst 33258 or DAPI, was more convenient 
and less time consuming, but the band quality was variable (Lichter and Cremer 1992). 
R-banding could be obtained post-ISH by a rather complex process involving BrdU 
incorporation during cell culture then, usually, Hoechst staining and UV irradiation (Cherif 
et al 1990). Counterstaining was with propidium iodide (PI), PI plus DAPI, or, for 
permanent replication banding following chromogenic enzymatic detection, by Giemsa. 
Photography was simplified and the ease and precision of mapping probes to bands 
improved if banding could be viewed together with probe signal without a change of 
optical filter. To detect FISH signals and bands simultaneously, counterstain and probe 
label had to produce distinct colours with the same excitation filter (PI stain and FITC 
label both excite at 450-490nm but emit in red and green respectively). Double, triple and 
even quad bandpass optical filters now allow simultaneous visualisation of multiple fluors.
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1.6.3.2 Chromosome and Regional Identification Without an Orthodox Banding Protocol
Specific chromosomes are easily identified without banding by simultaneously hybridising 
a marker probe for the chromosome of interest (e.g. an alphoid sequence). Though co­
hybridisation to chromosome-specific ‘bar codes’ (combinations of probes which generate 
staining patterns for regional identification) was proposed as a way to increase resolution 
(Lengauer et al 1993) this was not routinely adopted. Incomplete suppression of Alu 
sequences can provide an R-banded background hybridisation pattern (Francke 1995), 
and FISH with Alu or LINE sequences produces R- or G-bands respectively (Korenberg 
and Rykowski 1988, Lichter et al 1990, Baldini and Ward 1991).
The most convenient alternative banding approach is provided by digital imaging software 
which enables enhancement and contrast reversal of DAPI counterstain Q-banding, 
resulting in a low-resolution G-banding.
Accurate mapping without bands can be achieved by mapping with respect to a reference 
point on the chromosome. The short arm telomere has been used as reference and 
distance to the probe signal expressed as a fraction of the chromosome length (the 
FLpter value, Lichter et al 1990). This approach can be useful for mapping the relative 
localisation of multiple probes but chromosome length polymorphisms and differential 
homologue condensation may affect FLpter values. Also ISCN banding ideograms are 
not normalised relative to the fractional length so it is not appropriate to use this measure 
to indirectly assign a signal to a band. Other reference points potentially useful for 
mapping and ordering sequences include fragile sites and regions of structural 
abnormality such as translocation breakpoints (Ferguson-Smith and Aitken, 1982).
1.6.4 High Resolution Mapping and Ordering of Sequences
As larger signals are more likely to co-hybridise, higher resolution ISH mapping and the 
ordering of more tightly linked markers is more readily achieved with smaller sequences, 
e.g. bacteriophage X rather than YAC probes (Knoll et al 1993). The fluorescent signal 
produced by a cosmid probe on metaphase chromosomes is usually < 0.3um in diameter. 
The other factor affecting resolution is chromatin condensation. Banded metaphase 
chromosomes provide the coarsest ISH mapping targets, variable condensation of bands 
and slight variations in size and position of ISH sites limiting resolution to 5Mb (Trask 
1991), or 3Mb when mapping relative to the telomere (Lichter et al 1990). Resolution can 
be improved to -1Mb by co-localisation with a differently-labelled probe of known location.
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Chromosome packaging may distort the linear order of adjacent sequences - correct 
orientation was seen in only 59-70% of chromatids hybridised to two cosmids even with 2- 
3Mb separation (Trask et al 1991). This can necessitate scoring of multiple chromatids to 
derive probe order with statistical confidence. Ordering may be particularly problematic at 
the telomeres (Trask et al 1991).
For increased ISH mapping resolution, less condensed chromatin preparations must be 
targeted (Table 1-3). To this end, cytogenetic preparations can be enriched for prophase 
or prometaphase chromosome spreads by synchronised cell culture (Yunis 1976), meiotic 
chromosomes can be used (Jhanwar et al 1983, Bello et al 1989) or nuclei can be fused 
with mitotic cells leading to ‘premature chromosome condensation’ (Sperling and Rao 
1974). Cytocentrifugation of unfixed, hypotonically-treated metaphase preparations 
produces stretched chromosomes which allow rapid ordering of clones > 200kb apart, 
though variable regional stretching permits only estimation of sequence distance (Haaf 
and Ward 1994).
Even higher resolution is achieved using Gi nuclei (Lawrence et al 1988, Trask et al 1989,
1991). Interphase mapping has at least ten times the sequence ordering resolution of 
dual colour FISH to metaphase chromosomes (25 or 50-1 OOkb versus 1Mb). A set of 
probes is ordered by comparing the distances between differentially labelled pairs of 
probes (Trask et al 1989). Within 25-2000kb there is a linear relationship between the 
genetic interval and mean square of the distance between two signals (Yokota et al 
1995a). As an alternative to distance measurements, multiple probes labelled 
differentially can be hybridised and ordering performed by determining which probe order 
occurs with highest frequency (Trask et al 1991).
Above 1-2Mb distance, packaging of the interphase chromatin begins to affect signal 
distance and probe order, though alkaline borate treatment can expand the range of 
interphase FISH mapping to 4Mb (Yokota et al 1995b). Extension of mapping resolution, 
to 20kb, was achievable by FISH to decondensed chromatin of sperm pronuclei (Brandriff 
et al 1991) but the method was laborious and required specialised expertise.
Fortunately more direct means of obtaining decondensed DNA were developed. The 
term fiber FISH came to be applied to several methods involving FISH to extended DNA 
stretched on a glass slide, including free chromatin, halo preparations, DIRVISH, and 
molecular combing (references in Table 1-3). Chromatin organisation is loosened by 
alkali, DNA relaxation reagents such as topoisomerase II inhibitor m-AMSA (both Heng et 
al 1992), high salt (Weigant et al 1992) or detergent (Para and Windle 1993) treatment of 
cell preparations. Fibres can also be prepared from DNA fragments in agarose blocks 
following PFGE (Heiskanen et al 1994). In molecular combing, DNA in solution is
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linearised by allowing one end of the DNA molecule to bind to a slide, then the solution is 
coverslipped and DNA stretched by the hydrodynamic action of the receding meniscus. 
This yields high fibre density with minimal shearing and an average fibre condensation of 
2.3kb/um (Weier et al 1995). Relaxed duplex DNA has 2.9kb/um.
Fiber FISH is applicable to the determination of physical distances between signals by 
comparison to the known length of one probe (Para and Windle 1993) though direct 
conversion of measurement to kilobases is possible if stretching is uniform, as in 
molecular combing (Weier et al 1995). Fibres are generally used for resolution of 
overlapping and adjacent clones 1 -500kb apart (Florijn et al 1995, Weier et al 1995) 
though longer ISM distances have been reported (700kb, Para and Windle 1993).
ISM to genomic DNA fibres allows sequence ordering and structural analysis (Haaf and 
Ward 1994), ordering of contig elements (Florijn et al 1995), and study of rearrangements 
in disease genes such as the detection and measurement of micro-rearrangement or 
deletion (Florijn et al 1995, Heiskanen et al 1995a, Weber-Hall et al 1996). The 
alternative, PFGE, can be problematic and lengthy. With probes from the 5’ and 3’ ends, 
sequence transcriptional orientation is determinable with respect to flanking regions 
(Heiskanen et al 1995b, NIshio et al 1996). FISH to fibres from large DNA clones, e.g. 
YACs, provides high resolution information on insert integrity and stability, positioning of 
smaller clones within the YACs, and replication origin data (Weier et al 1995, Rosenberg 
et al 1995).
TARGET MATERIAL RESOLUTION ADVANTAGES(+) REFERENCES
(kb) /DISADVANTAGES(-)
metaphase >1000 +tel-cen orientation Weigant et ai
chromosomes +mapping to specific band 
-Low resolution
1991
mechanically-stretched >200 +tel-cen orientation Haaf and Ward
chromosomes (x5-x20) -distance not determinable 1994
interphase nuclei 25/50 to ^distance determinable Trask e ta l
1000/2000 -no tel-cen orientation 1989, 1991
sperm pronuclei 20 - 800 +dlstance determinable 
-no tel-cen orientation 
-specialised technique
Brandriff 
et ai 1991
free chromatin 20 -> 35 0 +accurate distance determination 
-no tei-cen orientation
Heng et al 
1992
halo-DNA 1 0 - 2 0 0 as above Weigant et al 
1992
DIRVISH fibres <5 ->700 as above Para and Windle 
1993
molecular combing as above as above, with straight. Bensimon et ai
fibres homogeneously stretched, fibres 1994
Table 1-3 Mapping resolution obtainable with different ISH targets. 
Adapted from Buckle and Kearney (1993) and Heiskanen et al (1996).
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1.7 Diagnostic Application of Fluorescence In Situ Hybridisation
With the introduction of CISS hybridisation and increasing availability of clinically relevant 
probes, some from convenient commercial sources, FISH began to be exploited as a 
diagnostic technique and found application in many areas of clinical cytogenetics. 
Visualisation and localisation of specific DNA sequences by FISH is possible in a wide 
variety of diagnostic material. Apart from the commonly studied metaphase spreads and 
Interphase nuclei of standard cytogenetic preparations, other probed preparations include 
uncultured amniocytes (Klinger et al 1992), tissue sections (Leong et al 1993, Afify et al 
1996), tumour touch imprints (Taylor et al 1994), blood smears (Anastasi et al 1992) 
marrow smears and core biopsy sections (Taylor et al 1994, Miranda et al 1994) and 
blastomeres (Delhanty et al 1993). FISH can also be performed on specimens which 
have already undergone cytogenetic analysis (Klever et al 1991).
In postnatal constitutional cytogenetics, accurate identification of chromosome 
aberrations by FISH is important for prognosis assessment and, where relevant, 
facilitating future rapid PND of familial rearrangements. It may also allow eventual 
identification of clinically significant genes at rearrangement breakpoints. Interphase 
FISH can provide rapid testing on uncultured lymphocytes, or where culture has failed.
In PND, apart from metaphase FISH for the identification or confirmation of abnormalities 
detected during conventional cytogenetics, interphase FISH has enabled rapid aneuploidy 
detection. Maternal anxiety and the limited time available for any intervention makes 
speed essential in PND, and FISH on uncultured amniocytes gives a result in 2 days, 
instead of the 7-10 days for culture and conventional cytogenetics (Guyot et al 1988, 
Klinger et al 1992). Multicolour ISH can further expedite analysis (Reid et al 1992, Divane 
et al 1994).
FISH has also been used in association with developmental techniques designed to 
achieve non-invasive PND, such as screening foetal cells from maternal blood (reviewed 
by Steele et al 1996) and transcervical cell sampling (Adinolfl et al 1995). Preimplantation 
genetic diagnosis (PGD) has involved FISH in sex determination for couples at risk for X- 
linked disease (Delhanty et al 1993, Griffin et al 1994) and in aneuploidy testing (Munne 
and Weier 1996).
FISH, in addition to other molecular techniques, is extensively used to address difficulties 
in cancer cytogenetics. Specifically, cytogenetic preparations from neoplastic material 
may be highly aneuploid with complex chromosomal abnormalities which FISH can clarify. 
Alternately, they may not yield analysable meta phases or may have very low mitotic 
index. Further, some clinically significant abnormalities, such as trisomy 12 in B-CLL, are 
only present in non-dividing cells (Anastasi et al 1992). Interphase FISH facilitates
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analysis of high numbers of dividing and non-dividing cells and detection of abnormalities 
present in only a small proportion. Its use can avoid the risk of bacterial contamination or 
overgrowth of sub-populations or stromal cells associated with tumour culture, and ISH 
identification of chromosome abnormalities in focal, tumour cell areas of tissue sections 
allows genetic testing to be related to specific tumour histology.
Diagnostic Use of Chromosome Paints
Paints, applied singly or in combination, have a wide range of uses in clinical diagnosis. 
They are frequently employed, in constitutional as well as malignant cells, in determining 
the chromosomal origin(s) of structural abnormalities, known as ‘markers’, which are 
unidentifiable by banding. Probe choice is often guided by clinical phenotype or marker 
banding pattern, and multiple hybridisations might be required to fully characterise the 
abnormality. Used in conjunction with banding, painting can also improve 
interchromosoma! rearrangement breakpoint definition (Cremer et al 1988).
Generation of paint from a flow sorted or microdissected marker for ISH to normal 
metaphase spreads, reverse painting, has successfully resolved structural chromosomal 
abnormalities and can reveal unsuspected complexity (Carter et al 1992, Blennow et al
1992). This is one way of removing the need to identify a suitable probe or use a series 
of probes for any investigation, but it requires specialised expertise and equipment.
Small marker chromosomes may contain no, or very small amounts of, euchromatin so 
may not be identifiable by painting. Other factors affecting the utility of paints include 
their limited resolution (5-10Mb) and inability to detect small interstitial rearrangements - 
deletions, duplications or inversions (Rosenberg et al 1992), Also, while translocations 
have been detected in nuclei using paints (Pinkel et al 1988, Cremer et al 1988), their 
diagnostic application is generally confined to metaphase analysis, as interphase paint 
signals are diffuse and difficult to quantitate.
Diagnostic Use of Repetitive Target Sequence Probes
Centromere-specific repetitive target sequence probes singly, or in a systematic series of 
multicolour combinations, are extremely useful for the identification of small marker 
chromosomes (Callen et al 1992). They are also widely used as control probes, 
highlighting target chromosomes to which diagnostic probes are hybridised.
Their reliable, discrete signal has made them ideal for a wide range of interphase FISH 
cancer studies (for example Anastasi et al 1991, 1992, Chen et al 1992, Macoska et al 
1993, Micale et al 1993, Wessman et al 1993, Murphy et al 1995, Afify et al 1996) and, 
particularly because they require only a few hours hybridisation and so provide rapid
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chromosome enumeration, PND and PGD. Here chromosome X, Y and 18 scoring 
usually employs repetitive sequences (Divane et al 1994, Cacheux et al 1994, Munne and 
Weier 1996). However, centromeric alphoid sequences are heteromorphic and this 
(Verma and Luke 1992) as well as Robertsonian translocation (Spathas et al 1994) and 
somatic pairing of centromeric regions, may, rarely, lead to misinterpretation.
The closely homologous alphoid sequences on chromosomes 13 and 21, as well as 14 
and 22, can not be differentiated by alpha satellite probes, rendering their use for 
interphase chromosome scoring unreliable (Cacheux et al 1994).
Diagnostic Use of Unique Target Sequence Probes
These also can be used as chromosome identifiers. For example, as no chromosome 21- 
specific alphoid probe is available, collections of chromosome 21-specific plasmids were 
used to diagnose trisomy 21 in nuclei (Lichter et al 1988). Later use of cosmids and 
YACs improved reliability (Klinger et al 1992, Romana et al 1993). A unique sequence 
probe is also used for chromosome 13 enumeration (Klinger et al 1992).
A particular asset of unique sequence, locus specific probes is the refinement they bring 
to FISH study of structurally-rearranged chromosomes, including interstitial abnormalities. 
They allow more accurate definition of breakpoints, especially when fiber FISH is 
employed (Florijn et al 1995, Weber-Hall et al 1996).
FISH with unique probes can diagnose deletions of clinically significant sequences in 
tumours, for example retinoblastoma (Kallioniemi et al 1992a), the amplification of 
oncogenes, such as erbB2 In breast cancer (Murphy et al 1995) and N-myc In 
neuroblastoma (Leong et al 1993), and determine ploidy (Taylor et al 1994).
Several unique probe combinations have been designed for visualisation of specific 
clinically significant rearrangements in metaphase and Interphase cells from neoplastic 
lines. One approach is use of locus specific probes on the two chromosomes involved in 
a rearrangement, the signals from which appear fused if translocation occurs. Targeted 
rearrangements include PML/RARA fusion in the t(15;17)(q22;q11~21) diagnostic for 
AML M3 (Mancini et al 1995), AML/ETO fusion on the derived 8 in the t(8;21)(q22;q22) 
associated with AML M2 (Sacchi et al 1995), and BCR/ABL fusion due to t(9;22)(q34;q11) 
in a variety of leukaemias (Tkachuk et al 1990). As with all interphase FISH, careful 
design of controls, as well as result evaluation, is crucial, especially if these procedures 
are used for minimal residual disease determination.
The application of unique sequence probes to detection of the subtle chromosome 
abnormalities associated with microdeletion syndromes and idiopathic mental retardation 
is discussed in detail in the next section.
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1.7.1 Detection of Submlcroscopic Chromosomal Rearrangements
A particularly valuable attribute of unique sequence probes Is their ability to visualise 
chromosome aberrations which are beyond the resolution of conventional banding 
techniques and light microscopy. Such aberrations are termed ‘cryptic’.
1.7.1.1 Microdeletion and Microduplication Syndromes
In clinical genetics, the term ‘syndrome’ is used to denote a recognisable pattern of signs 
or malformations that characterise a particular condition. The resolving power of unique 
sequence probes is exploited for FISH testing in a variety of syndromes known to be 
associated with deletion or duplication of specific, often submlcroscopic, chromosomal 
segments (Table 1-4). As not all the features of a syndrome may be manifest in every 
patient it is often difficult to establish or exclude the diagnosis beyond doubt. Detection of 
the appropriate segmental aneusomy confirms the diagnosis of these conditions, and may 
allow earlier diagnosis and Institution of appropriate medical management.
SYNDROME SEGMENTAL ANEUSOMY REFERENCE MIM#
Charcot-Marie-T ooth 
Type1A
dup(17)(p11.2p11.2) Lupski et al 1992 
Lebo etal 1993
118220
Miller-Dieker del(17)(p13.3) Kuwano et al 1991 247200
Prader Willi del(16) Kuwano et al 1992 176270
and Angelman (q11-q13q11~q13) 105830
Smith-Magenis del(17)(p11.2p11.2) Juyal etal 1995 182290
Rubinstein-Taybi del(16)(p13.3) Breuning et al 1993 180849
Williams del(7)(q11.23q11.23) Ewart et al 1993 194050
Cri du Chat del(5)(p15.2~p15.3) Pettenati et al 1994 5pi5.2 
Gersh et al 1995 5pi5.3
123450
Wolf-Hirschhorn del(4)(p16.3) Gandelman et al 1992 194190
DiGeorge/ del(22)(q11.2q11.2) Lindsay et al 1993 188400
Velocardiofacial/ Scambler etal 1992 192430Conotruncal anomaly face ___ Burn etal 1993 217096
Table 1-4 Some microdeletlon and microduplication disorders detectable by FISH. 
MIM #: Mendelian Inheritance in Man database number
FISH to cytogenetic preparations is an efficient method of detecting such segmental 
aneusomy as it can be informative more often than polymorphic PCR analysis, faster than 
PFGE, and faster, more informative and reliable than restriction analysis (Lebo et al 
1993). The resolution of interphase FISH is required for microduplication detection 
whereas microdeletions are commonly detected by FISH to metaphase chromosomes.
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DiGeorge/velocardiofacial, Wolf-Hirschhorn and Rubinstein-Taybi syndromes were 
investigated in this study.
1.7.1.1.1 DIGeorgeA/eiocardiofacial Syndrome
DiGeorge presented his observations on patients with hypoparathyroidism, aplastic 
thymus and defective cellular immunity to a Society for Pediatric Research meeting in 
1965, though thymic aplasia was first noted in association with congenital 
hypoparathyroidism in 1959 (Lobdell 1959, DiGeorge 1965).
A wide spectrum of clinical features have now come to be associated with DiGeorge 
syndrome (DGS, MIM 188400), but the predominant components of the classically 
defined syndrome are cardiac outflow tract defects, aplastic or hypoplastic thymic and 
parathyroid glands (presenting as deficient cell-mediated immunity and hypocalcaemia) 
and dysmorphic facial features (Conley et al 1979). The dysmorphism includes 
hypertelorism with short palpebral fissures, small mouth with short philtrum, broad-based 
nose with bulbous tip, unusually shaped auricles and micrognathia. Heart defects include 
type B interrupted aortic arch, persistent truncus arteriosus, right-sided aortic arch and 
tetralogy of Fallot (TOF).
The conotruncus, thymus and parathyroids are derived from the 3^  ^and 4‘^  pharyngeal 
pouches and branchial arch. DGS is believed to be a consequence of a defect in the 
interaction of these embryonic structures and the cephalic neural crest at 4-6 weeks 
gestation (Lammer and Opitz 1986) and appears aetiologically heterogeneous. Exposure 
to teratogens including alcohol (Lammer and Opitz 1986) and to maternal diabetes 
(Wilson et al 1993) were noted in patients with DGS. The phenotype was also reported in 
individuals with a variety of cytogenetically detectable chromosomal defects, notably 
monosomy of 22pter-q11 in cases of unbalanced translocation involving 22 and interstitial 
deletion of 22q11 (de la Chapelle et al 1981, Greenberg et al 1988).
Molecular, including FISH, investigations demonstrated that 22q11.2 deletion (often 
submicroscopic) was actually present in the majority of DGS cases (in 33/35 individuals in 
one study) and provided a map of the commonly deleted region (Carey et al 1990, 1992, 
Scambler et al 1991, Halford et al 1993a, Lindsay et al 1993).
Deletion of lOp is the only cytogenetic aberration, other than 22q11.2 deletion, repeatedly 
associated with DGS and related phenotypes (Goodship et al 1994, Daw et al 1996, 
review and other references in Greenberg et ai 1988, Lipson et al 1996). The other 
chromosome abnormalities reported in patients with DGS features have been isolated 
cases (Wullich et al 1991, Fukushima et al 1992, van Essen 1993, Lindgren et al 1994,
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Siu et al 1996, others reviewed in Greenberg et al 1988) and, as most had no molecular 
testing, could also have had cryptic deletion at 22q11. All exhibited additional multiple 
congenital abnormalities but so too do many 22q11 deletion cases.
Shprintzen or velocardiofacial syndrome (VCFS, MIM 192430) is a syndrome of palatal 
insufficiency, conotruncal cardiac anomalies, minor facial dysmorphology and mild 
learning difficulties (Shprintzen et al 1978, 1981), first described by Dr Eva Sedlackova 
(Sedlackova 1955). The degree of clinical overlap with DGS led to the molecular 
Investigation of VCFS patients (using RFLPs, dosage analysis, and some FISH) and 
demonstration of 22q11 deletion in the majority of cases (Scambler et al 1992 5/5 cases, 
Driscoll et al 1992 14/15 cases, 1993 41/55 cases, Lindsay et al 1995 44/54 cases). 
Deletion at 22q11.2 was also reported in patients with conotruncal anomaly face 
syndrome (CAF or CTHM, MIM 217095), a condition comprising dysmorphic facies, 
cardiac outflow tract defects and delayed development (Kinouchi et al 1976, Burn et al
1993). This led to realisation that these syndromes have a common aetiology and that 
assignment of patients to these three syndromic groups may have resulted from 
ascertainment bias through clinical expertise in either Immunology (DGS), craniofacial 
malformations (VCFS), or cardiology (CAF, VCFS).
Patients initially assigned other diagnoses such as CHARGE association (MIM 214800), 
Opitz syndrome (MIM 145410) and Cayler syndrome (MIM 125520) have been found to 
have 22q11 microdeletion (references in Dallapiccola et al 1996), as have patients with 
isolated features of DGS such as hypoparathyroidism (Scire et al 1994) and cardiac 
abnormalities. These included individuals in five out of nine tested families with recurrent 
outflow tract defects. Although two of these families contained individuals with 
hypocalcaemia, one child was developmentally delayed and, in retrospect, several 
individuals were assessed as subtly dysmorphic, these results prompted a preliminary 
study of 40 clinically normal individuals and 40 individuals with isolated TOF, the most 
common cyanotic congenital heart malformation. With a prevalence of 2.5 to 3.5 per 
1000 live births, classic anatomic findings in TOF are large, non-restrictive, anterior, 
malaligned, ventricular septal defect (VSD) with pulmonic stenosis or atresia and 
overriding aorta. Chromosome 22q11 microdeletion was found in 2 (5%) of the TOF 
group and none of the controls (Wilson et al 1992a).
Microdeletion at 22q11 appears to be the most frequent segmental aneusomy. One in 
9700 births has 22q11 deletion associated with a typical DG/VCFS phenotype, but the 
overall prevalence of the deletion is estimated at 1:4000 when including those deletions 
found in approximately 5% of individuals with non-syndromic congenital heart defects 
(Tezenas du Montcei et al 1996).
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Detection and Definition of DGA/CF Syndrome 22q11 Deletion 
Even high resolution banding (at least 850 bands/haploid set) allowed cytogenetic 
identification of deletion in only 9/30 cases with hemizygosity at 22q11 (Wilson et al 
1992b). More sensitive, molecular, detection initially employed RFLP analysis or 
quantitative Southern blotting. These techniques are time consuming and subject to 
variability and, by 1993, FISH was emerging as a particularly useful approach which 
allowed a more qualitative detection of deletion than Southern analysis and the relative 
ordering of markers (Lindsay et al 1993, Halford et al 1993a).
At the time of this study it was known that most patients with DG/VCFS pathology had a 
large deletion detected by scl 1.1, a probe which detects two loci (scl 1.1a proximally and 
scl 1.1b distally) approximately 2Mb apart (Halford et al 1993a, Lindsay et al 1993, 1995). 
Haplotype analysis of VCFS patients had suggested deletions shared the same proximal 
breakpoint (between D22S427 proximally and D22S941) and one of two distal deletion 
breakpoints (between D22S944 and D22S264 or D22S311 and D22S306/308, Morrow et 
al 1995) but the precise extent of deletions was unknown. FISH analysis found one in 
forty four deleted VCFS patients with deletion which included E0472 but not sc11.1b 
(Lindsay et al 1995).
Breakpoint analysis of unique smaller deletions allowed attempts to define a shortest 
region of overlap (Fig. 1-11). The critical region was initially estimated as 300-575kb 
(Lindsay et al 1993, Halford et at 1993a). An unbalanced t(15;22) translocation then 
defined the minimal DiGeorge critical region (MDGCR, Li et al 1994, Gong et al 1996) as 
250kb in the proximal part of the commonly deleted region which included the t(2;22) 
balanced translocation breakpoint found in DGS patient ADD, a prime candidate gene 
region (Lindsay et al 1993). However the atypical proximal deletion boundary in 
interstitially deleted DGS patient ‘G’ was positioned lOOkb telomeric to this breakpoint, 
excluding it from the critical region (Levy et al 1995). If other factors are not the cause of 
DGS in this patient, the phenotypic effect of the ADU breakpoint could be due to its 
position effect on genes in the critical region (Levy et al 1995, Bedell et al 1996).
The identification of potentially causal genes was further complicated by the presence of 
another non-overlapping region, located distally in the commonly deleted region 
(Kurahashi et al 1996). Thus all the other transcription units in the commonly deleted 
region remained candidate causes. Among these, apparently lying just distal to the 
250kb MDGCR (Gong et al 1996), is the TUPLE 1 sequence (Halford et al 1993a) which, 
like N25, became a commonly used diagnostic FISH probe.
TUPLE 1 is also known as HIRA, the major splice variant of the same gene (Llevadot et al 
1996). The HIRA protein product was Implicated in transcriptional regulation based on its
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similarity to other WD40-containing proteins which form multimeric complexes that 
function as transcription regulators, and because of its homology to Hir1p, Hir2p and 
Tup1p histone regulating transcriptional co-repressors in yeast (Halford et al 1993a, 
Lamour et al 1995). Homology to Hirip and Hir2p indicated a possible role in histone 
synthesis regulation, and the fact that Tupl bound to histones H3 and H4 suggested 
HIRA involvement in the regulation of chromatin structure and through this gene 
expression (Edmondson et al 1996). As HIRA protein was predicted to be a component 
of multi-protein complexes involved in transcriptional regulation, it was thought that its 
reduced level secondary to hemizygosity at 22q11 might alter the stoichiometric 
relationship with other subunits in the complex, which could conceivably disrupt function 
(Halford et al 1993a).
These features led to the proposal that haploinsufficiency for TUPLE 1 was at least in part 
responsible for the DGA/CFS phenotype (Halford et al 1993a).
DGA/CF Syndrome Phenotype/Genotype Correlation
DG/VCFS is not a straightforward contiguous gene syndrome. The complexity of the 
phenotype does not correlate with deletion size (Scambler et al 1991). However, as 
almost all DG/VCFS deletions at 22q11 involve at least 250-300kb, non-overlapping 
regions can generate the phenotype, and, when this study began, no point mutations had 
been found in any gene in the commonly deleted region, it was suggested that it was not 
caused by a single transcription unit (Dallapiccola et al 1996).
As genes in the commonly deleted region have a similar expression pattern in 
embryogenesis it was further proposed that the entire region may behave as a functional 
unit so that the phenotype results from disruption of any of the genes or of some common 
regulatory element (Dallapiccola et al 1996). Position effects, such as the possible 
silencing effect of heterochromatin on proximally moved genes, might be involved. 
However, this concept of a functionally-related chromosome region did not preclude the 
existence of a major gene related to a specific phenotypic aspect.
1.7.1.1.2 Wolf-Hirschhorn Syndrome
Wolf-Hirschhorn syndrome (WHS, MIM 194190), which has an incidence of 1/50,000 live 
births, was first described in patients with cytogenetically visible deletion of 4p16-pter by 
Wolf et al and Hirschhorn et al (1965). Characteristic clinical features are severe growth 
retardation, severe mental retardation (MR), seizures, distinct facies (hypertelorism, highly 
arched eyebrows, sagging lower eyelids, short philtrum, carp-shaped mouth and most
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notably a prominent glabella giving a characteristic Greek helmet profile), and a number 
of other anomalies including microcephaly, congenital cardiac defects, genital and renal 
abnormalities, simple ears, cleft lip and palate and ocular colobomata.
The chromosome 4p deletion arises as a de novo event in around 90% of cases, whereas 
in the remainder it is derived from a familial balanced translocation (Tranebjaerg et al 
1984). At the start of this investigation, several WHS cases associated with a subtle or 
cryptic chromosome abnormality had been described (Altherr et al 1991, Gandelman et al 
1992, Goodship et al 1992, Johnson et al 1994, Hagg et al 1992).
1.7.1.1.3 Rubinstein-Taybi Syndrome
Rubinstein-Taybi syndrome (RTS or RSTS, MIM 180849) is a multiple congenital anomaly 
syndrome characterised by mental and growth retardation, short broad thumbs and/or 
halluces, and typical facial features including downward-slanting palpebral fissures, 
abundant dark scalp hair and prominent columella (Michail et al 1957, Rubinstein and 
Taybi 1963). The existence of patients with an RTS phenotype and translocations 
involving chromosome region 16p13.3 identified disruption at this locus as one cause of 
the syndrome.
When this study began, a chromosome 16p 13.3-specific cosmid sequence, RT1, had 
been found to be deleted in 25% (6/24) of RTS patients tested (Breuning et ai 1993). The 
gene encoding the human CREB (cyclic AMP response element-binding) binding protein 
(CREBBP or GBP), located at 16p13.3, was subsequently cloned and it was shown that 
mutations in this gene are also associated with RTS (Petrij et al 1995).
1.7.1.2 Microdeletion Detection at the Dystrophin Locus in Duchenne and Becker 
Muscular Dystrophy Carriers
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder with a 
progressive, muscle-wasting course and fatal outcome before the age of 30 (reviewed in 
Emery 1993). Affecting 1 in 3500 live-born males, it is the most frequent neuromuscular 
disease, with one third of cases being due to new mutations. DMD is allelic with the 
milder and rarer Becker muscular dystrophy (BMD). The DMD/BMD gene encodes a 
membrane protein called dystrophin of approximately 400kDa (Hoffman et al 1987) and 
maps to chromosome band Xp21 (Francke et al 1985).
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With 79 exons spanning 2.4Mb it is the largest recognised gene (Roberts et al 1993). In 
60-70% of cases, DMD or BMD results from deletion (usually but not invariably 
cytogenetically cryptic) involving one or more exons. Duplications cause a further 6%. 
Breakpoints occurring in a major hotspot in the central part of the gene (intron 44-45) and 
a minor hotspot in the 5’ part of the gene (around intron 7) account for 75% of all detected 
dystrophin gene deletions and duplications (Blonden et al 1991). Approximately 60% of 
deletions were believed to include exon 45, and occur in the region defined by the probe 
P2Ü (DXS269, Waapenar et al 1988, Reid et al 1990).
Causal deletions are inherited in 60-70% of patients. Familial deletion is therefore 
implicated in -40% of all cases, representing a high carrier risk for female relatives. 
Deletion detection by multiplex PCR Is straightforward in affected males (Abbs et al 1991) 
but, when this present study commenced, the molecular approaches available for carrier 
detection in asymptomatic female relatives were limited and complicated by the presence 
of the normal X masking the result from the defective chromosome.
Identification of the chromosome segregating with the mutation by linkage analysis based 
on RFLPs required several intragenic and flanking probes due to the high frequency of 
intragenic recombination within the large dystrophin gene (12%). Highly polymorphic 
markers for linkage analysis were provided by PCR-amplified (CA)n repeats (Clemens et 
al 1991, Bunyan et al 1994).
A definite carrier diagnosis could be achieved if size-altered ‘junction’ fragments 
(restriction fragments of altered mobility detected by cDNA probes on Southern blot) were 
demonstrable in an affected individual, but small rearrangements (e.g. one exon) could be 
missed (den Dunnen et al 1989). The use of PFGE or whole cosmid probes rather than 
short cDNA sequences (Blonden et al 1991) could increase the frequency of fragment 
identification. Junction fragments could also be detected with reverse transcription and 
nested PCR amplification (RT-PCR) of mRNA (Roberts et al 1990, Bunyan et al 1994).
In cases with a defined deletion, investigators could employ gene dosage analysis in 
Southern blots (Darras and Franke 1988), in which the intensity of specific bands in test 
and control samples were compared by densitometry. However as band intensity is 
dependent on various experimental factors this carried a degree of uncertainty which 
many clinical laboratories considered unacceptable.
Demonstrating raised creatinine kinase (CK) levels could be diagnostic, but only 70% of 
adult carriers have raised CK so a normal level does not exclude carrier status (Sibert et 
al 1979). Immunostaining of muscle tissue by dystrophin antibodies was successful, but 
only for the detection of DMD, rather than BMD, carriers with elevated CK levels (Reid et 
al 1993).
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In contrast to these often time-consuming, complex and potentially inconclusive 
approaches, and while a new approach, quantitative PCR, was in the early stages of 
introduction as a diagnostic tool (Mansfield et al 1993), a technically simple solution was 
offered by metaphase FISH with cosmid probes that are specific for commonly deleted 
regions of the dystrophin gene. This allowed direct and unequivocal determination of 
DMD/BMD carrier status in female relatives of known carriers or affected individuals, even 
when the CK or RFLP analysis was not informative (Reid et al 1990).
1.7.1.3 Detection of Subtelomeric Chromosomal Rearrangement
Apart from RTS and WHS, other genetic conditions including a thalassaemia with 
learning disability (ATR-16), cri du chat and Miller-Dieker syndromes have been 
associated with subtelomeric rearrangements (Lamb et al 1989, Overhauser et al 1989, 
Kuwano et al 1991). These rearrangements, including de novo subtelomeric deletions 
and unbalanced familial translocations, can be cytogenetically cryptic, and their detection 
initially required clinical suspicion to direct molecular or ISH testing of appropriate 
subtelomeric regions.
1.7.1.3.1 Screening for Cryptic Subtelomeric Rearrangements
As the recognised cause of much abnormality, gene-rich (Saccone et al 1992) and 
believed to be particularly prone to rearrangement, subtelomeric regions came to be 
considered appropriate loci for a focussed search for cryptic chromosomal 
rearrangements in the absence of a practical method of whole genome screening. These 
regions are G-band negative therefore rearrangements can be missed by conventional 
cytogenetics. Also the majority of chromosome translocations involve ends of 
chromosomes and subtelomere screening would detect all of these, regardless of size. 
When this study commenced, molecular methods, examining inheritance of VNTRs using 
Southern blotting, had allowed estimation that 6% of all cases of idiopathic MR were due 
to subtelomeric microdeletion (Flint et al 1995). This promised considerable diagnostic 
impact as MR, which affects approximately 3% of the population, is of unknown aetiology 
in around 40% of moderately to severely affected individuals (IQ<50) and 70% of people 
with mild learning disability (IQ 50-75) (Flint and Wilkie 1996).
A molecular screening test based on GA repeats would have facilitated such investigation, 
but primer development initially proved problematic. This, and the fact that FISH would
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identify balanced rearrangements in carriers, led researchers to commence development 
of a FISH-based approach.
1.8 Comparative Genomic Hybridisation
Molecular genetic methods in the early 1990s were generally highly focussed, targeting 
one or at most a small group of chromosome region(s) at a time and leaving the majority 
of the genome unexamined. Studies were additionally restricted by, for example, 
polymorphic probe availability and informativeness, design of compatible sets of primers 
and differentiation of their product fragments. Conventional karyotyping does provide 
global (if low-resolution) analysis of the genome, but solid tumour analysis, in particular, is 
impeded by low quantity and quality of metaphase spreads, the complexity of genetic 
changes and the fact that some clinically significant chromosome abnormalities in 
cancers are not present in dividing cells. Identification of cytogenetic aberrations by FISH 
again needs to be guided by suspicion of the nature of the abnormality, depends on the 
availability of appropriate probes, and may require sequential hybridisations.
To circumvent these problems and, following some successful reverse painting with 
interspecies hybrid DNA (Boyle et al 1990, Kievits et al 1990), total genomic tumour DNA 
was used as a probe for CISS hybridisation to normal metaphases, identifying highly 
amplified sequences in some tumours (Joos et al 1993). Comparative genomic 
hybridisation (CGH), the first molecular cytogenetic technique to allow comprehensive 
analysis of the entire genome (Kallioniemi et al 1992b, du Manoir et al 1993), arose as a 
refinement of this approach (Fig. 1-12).
CGH is a ‘one-step’ method for quantitative genetic change determination and involves 
use of differentially labelled test and normal control DNA simultaneously as paints in CISS 
hybridisation to normal metaphase spreads. The test DNA (usually labelled or detected 
with a green fluor) and control DNA (labelled or detected with a red or orange fluor) 
hybridise in a concentration-dependent manner to chromosomal target sequences. 
Software integrates fluorescence from each label and calculates the ratio of green to red 
along each chromosome thereby identifying regions of DNA gain or loss. Ratio profiles 
can then be produced for each chromosome. The co-hybridisation of normal reference 
DNA improves sensitivity by providing a control for local variations in hybridisation 
efficiency possibly caused by differential dénaturation of regions with different base 
composition and packaging or differing target accessibility (Bentz et al 1994).
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Advantages of Comparative Genomic Hybridisation
As CGH is a global analysis which uses isolated genomic DNA the need for metaphase 
spreads is removed, obviating tissue culture which is time-consuming, may result in clonal 
loss and is not advisable with high-risk specimens. Abnormalities which are not present 
in PHA stimulated cells may be detected, and archived tissue studied (Speicher et al 
1993). CGH can also assist interpretation in cases where chromosome preparations are 
available, but karyotypes are highly complex and difficult to analyse.
At the time of its introduction CGH was also faster than the molecular genetic approaches 
used to screen for genetic imbalance (e.g. loss of heterozygosity studies, quantitative 
Southern blot for amplification).
Critical Stages in CGH Procedure
i) Preparation of target metaphase chromosome spreads
The properties of the target metaphase preparations dramatically influence CGH results, 
possibly because each element of the probe is present at very low concentration so that 
accessibility of the target to the probe is critical (Kallioniemi et al 1994). Normal 
metaphase spreads for CGH targets are prepared from synchronised peripheral blood 
cultures from karyotypically normal donors (Wheater and Roberts 1987). On phase 
contrast microscopy, chromosome preparations should have a fairly high mitotic index 
with low cell density, little residual cytoplasm (which can cause high background and 
prevent optimal dénaturation), be of adequate length (400-550 bands) and with minimal 
overlap (as CGH analysis excludes overlapped chromosomes). Longer chromosomes 
increase resolution but are more likely to intersect. Chromosomes should not have 
separated chromatids and, for good banding, should appear dark and not réfringent. 
However, even preparations with apparently acceptable morphology may not produce 
acceptable CGH results. Researchers therefore may prepare several large batches of 
slides at once, ascertaining their suitability with CGH of two control DNAs. Suitable 
batches yield uniform, intense, painting of all euchromatic chromosome regions.
ii) Isolation of DNA
CGH is applicable to DNA from clinical samples such as blood, bone marrow or tissue, 
from cultured cells, or from histological sections. DOP-PCR can be used to amplify DNA 
from tissue sections (Speicher et al 1993) although the DNA fragments obtained may be 
of sub-optimal length for CGH.
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iii) Probe labelling
Nick translation is the most widely used method of labelling DNA for CGH, allowing simple 
adjustment of fragment size by variation of reaction time or DNase:Polymerase I ratio. 
Originally, labelling was indirect, involving biotin and DIG-conjugated dUTPs visualised 
fluorescently via immunocytochemistry (Kallioniemi et al 1992b, 1994). Direct labelling 
subsequently expedited the process and minimised locus-specific hybridisation problems 
at 1p32-pter, 16p, 19 and 22 caused by differential ISH properties of DIG and biotin- 
labelled probes (Kallioniemi et al 1994, Bryndorf et al 1995).
The optimal genomic probe fragment length after nick translation (a smear from 600 to 
around 2000bp in an agarose gel) is longer than that for conventional FISH probes. This 
improves hybridisation intensity and uniformity.
iv) Hybridisation
Dénaturation, incubation, post-ISH wash and slide mounting protocols essentially follow 
those used in basic FISH (Kallioniemi et al 1994). Target metaphases are denatured in 
70% formamide at 72-74°C for ~^3 minutes, though optimal time and temperature may 
vary between slide batches. The aim is maximal dénaturation and penetrance while 
retaining chomosome structural integrity and good DAPI banding potential. Proteinase K 
slide treatment has been used to improve probe penetrance (du Manoir et al 1993, 
Kallioniemi et al 1994) but over-digestion may damage chromosome structure therefore 
proteolysis was increasingly omitted (as in the 1996 CGH procedure recommended by 
Vysis Inc, Downer’s Grove, IL, USA).
Probes are generally equal mixtures of test and control DNA. The amount of each in lOul 
hybridisation mix has ranged from 60ng (Kallioniemi et al 1992b) to lug (du Manoir et al 
1993). Between 0.5 and 30ug/ul Cotl DNA has been used in CISS CGH to block binding 
of labelled repetitive sequences to target metaphases. Hybridisation is carried out under 
a sealed coverslip in a moist chamber at 37-39°C for two to four days.
v) Fluorescence microscopy and Image acquisition
The technical requirements for CGH three colour fluorescence microscopy are similar to 
those described for FISH analysis. High copy gene amplifications (of more than ten to 
twenty fold, Kallioniemi et al 1994) as well as changes involving large regions (e.g. entire 
chromosome arms) are visually detectable in homogeneous cell lines. More detailed 
evaluation is only possible using digital imaging.
Image acquisition follows selection of each of five to ten highest quality metaphases from 
each CGH area. Cooled monochrome CCD cameras offer high sensitivity, spatial
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resolution and dynamic range with low noise, but cheaper video-rated cameras can 
provide adequate images for CGH analysis (du Manoir et al 1995).
CGH quality depends on illumination uniformity and accuracy of overlay of CCD images 
obtained with different filters. Signal visualisation was initially via a double bandpass 
(FITC/rhodamine) filter set or single bandpass filters aligned to minimize image shifts 
(Kallioniemi et al 1992b, du Manoir et al 1993). Fortunately, shortly after the introduction 
of CGH, the technology became available to optimise image registration by placing the 
excitation filter for each fluor in a computer-controlled filter wheel and viewing emitted 
light via a stationary triple bandpass filter. Grey-level images are obtained as Texas 
red/rhodamine, FITC and DAPI are sequentially excited, and exposure times are adjusted 
to obtain high intensity without saturation (Kallioniemi et al 1994).
Prior to analysis the image quality of captured metaphases is critically evaluated 
(Kallioniemi et al 1996). They should show uniform, smooth, intense, balanced green and 
red fluorescence. Background fluorescence around chromosomes should be low and 
uniform, and both chromatids of each chromosome and both chromosome homologues in 
each cell should show the same changes. Hybridisation to centromeres and 
heterochromatic regions must be minimal and chromosomes should show good software 
enhanced reverse DAPI bands. Images with nonspecific fluorescent spots on 
chromosomes are excluded from analysis, as are any showing inadequate dénaturation 
as signified by fluorescence intensity variations which follow the DAPI banding pattern.
vi) Quantitative analysis
Quantitative analysis of green to red fluorescence ratios along chromosomes (described 
in Kallioniemi et al 1996) is performed using dedicated software, versions of which have 
been available since the mid 1990s from a number of commercial sources, e.g. Applied 
Imaging (Newcastle-upon-Tyne, UK) or Vysis.
Chromosomes are first segmented by adaptive thresholding (du Manoir et al 1993), 
providing a chromosome outline from which the medial axis is determined. Fluorescence 
intensities are then measured for the green and red images at one pixel intervals along 
the axes of individual chromosomes, each value representing the mean of the values 
from a strip perpendicular to the axis. Background fluorescence intensity surrounding the 
individual segmented chromosomes is determined and subtracted from the chromosome 
fluorescence. Fluorescence ratios are normalised so that the average green:red ratio for 
the entire metaphase spread is 1.0. The ratio of the fluorescence intensities (green to 
red) on individual chromosomes is calculated and chromosomal ratio profiles generated. 
With some, particularly earlier, software, the ratio values can be transformed into a three- 
colour lookup table, where different colours are assigned to deleted, amplified or
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balanced chromosomal sequences depending on chosen thresholds (du Manoir et al 
1993). This approach has been termed ‘global’ analysis (Digital Scientific, Cambridge, 
UK). In all systems, chromosomes are identified, for imbalance localisation, by software 
enhancement of the DAPI bands. Regions that show an increased green:red ratio have 
elevated copy number in the test DNA whereas those with a decreased ratio are deleted.
vii) Profile averaging
Slight differences in hybridisation quality between metaphase spreads and the presence 
of nonspecific signal limits the sensitivity of CGH analysis. It was recognised from the 
earliest use of CGH (Kallioniemi et al 1992b) that interpretation should be based on 
average ratio profiles for all homologous chromosomes from several cells in order to 
reliably detect smaller imbalances, but basic software for this task was not reported for 
another two years (Kallioniemi et al 1994). initially, commercial CGH systems performed 
only rudimentary quantitative functions (e.g. Smartcapture, Digital Scientific) but it was 
apparent that automation of CGH processing would facilitate objective interpretation of 
CGH and its routine application, and systems evolved to perform most functions 
necessary for full CGH analysis. This includes interactive karyotyping and generation of a 
‘copy number karyotype’ - a set of mean fluorescence profiles displayed to the side of the 
relevant chromosomal ideogram. At least four homologous chromosome profiles are 
included, after length normalisation, in an average profile (Kallioniemi et al 1994).
viii) Interpretation of CGH experiments
CGH result interpretation is based on whether the mean ratio value for a chromosomal 
region is outside a threshold (fixed or statistical). A fluorescence ratio of 0.5 corresponds 
theoretically to monosomy and 1.5 to trisomy, however in practice fixed thresholds are 
generally set between 1 +/- 0.1 and 1 +/- 0.25. A range wider than 0.75-1.25 may be too 
insensitive to identify imbalances that are present in only a proportion of cells. A narrow 
range (e.g. 1+/- 0.1) might produce too many false positives. The first use of statistical 
thresholding involved tabulated comparison of average ratio values for each chromosome 
type against the limits of the 95% confidence interval (Cl) calculated for the same 
chromosome type in a normal versus normal control CGH (du Manoir et al 1993).
Initially ratio profile interpretation was not automated (Kallioniemi et al 1994). Software 
which displays apparently under- or over-represented regions (according to selected 
thresholds) as green or red bars against a karyotype ideogram was later developed, 
although interpretation was not standardised.
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Sensitivity of CGH
Amplifications can be detected when the product of the copy number and size of the 
amplicon is at least 2Mb (Joos et ai 1993). Under ideal conditions, the theoretical deletion 
detection limit is also 2Mb (Piper et al 1996), however several factors impair CGH 
resolution, particularly chromosome length variability. Lengths are normalised for each 
chromosome type before average ratio profiles are calculated, which results in slightly 
distorted map positions of identical regions on chromosomes of different lengths. In 
practice, therefore, 10Mb deletions are detectable (Kallioniemi et al 1992b, 1994). 
Sensitivity does depend largely on the threshold criteria selected to separate balanced 
from unbalanced regions in the test genome, and is affected by the degree of any 
mosaicism. Though theoretical ratios for monosomy and trisomy are 0.5 and 1.5, if only 
50% of cells carry imbalance the ratios are 0.75 and 1.25. If less than 50% contain the 
imbalance, the ratio profiles are unlikely to reach the gain or loss thresholds.
A compromise has to be made between sensitivity and specificity, depending on the 
experimental aims and availability of alternative methods of result confirmation. To detect 
imbalances present in only a proportion of cells a more permissive threshold may be 
required, with subsequent exclusion of false positives by, e.g., use of FISH probes.
Limitations of CGH
In addition to limitations imposed by mosaicism, CGH only detects aberrations involving 
loss or gain of DNA regions, not balanced translocations or inversions. It provides no 
information on the structural changes involved in gains and losses and, as the standard 
approach detects DNA sequence copy number changes relative to the average copy 
number in the entire specimen, it can not show alterations in total genome ploidy.
Some regions are excluded from CGH analysis or, as 1p32-pter, 16p,19 and 22, 
evaluated with particular caution. The repetitive DNA at heterochromatic regions, 
centromeres, and the short arms of acrocentric chromosomes is, due to polymorphisms, 
suppressed by Cotl DNA to different extents in different Individuals, and fluorescence 
intensity naturally declines at telomeres (Kallioniemi et al 1994).
Quality Assurance and Validation
Controlling hybridisation quality is more important in CGH than in other ISH techniques, 
because the result is analysed quantitatively. CGH quality is dependent on all steps of 
the procedure, the most difficult variable to control being the hybridisability of the target 
chromosomes. Variation in hybridisability affects CGH results by producing false positive 
findings (such as on Ip, 19 and 22) or by decreasing the dynamic range of the ratio
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profiles (the amplitude of gains and losses). Only high quality images of high quality 
hybridisations, rigorously selected, should therefore be evaluated (Kallioniemi et al 1994, 
1996).
Visual assessment of the images should show concordance with ratio profiles and green 
to red ratio should be consistent between metaphases. An estimation of the variation 
(e.g. standard deviation, SO) of the fluorescence ratios from one metaphase to another 
provides a measure of the result consistency and reliability. Ratio changes that clearly 
exceed the background ratio variation in a negative control CGH can be interpreted as 
evidence of real copy number differences, in a successful CGH the normal variation (+/- 
1 SD) should not exceed ratios of 0.85 to 1.15 (Kallioniemi et al 1994, 1996).
Since most imbalances affect only a minority of the chromosomes, the normal range of 
ratio values can be deduced empirically from a number of chromosome types showing 
values close to that expected for balanced chromosomes (du Manoir et al 1993).
A positive control cell line with known imbalances of differing size can be used to evaluate 
the CGH sensitivity (Kallioniemi et al 1994).
Validation of CGH results can be achieved by re-examination of G-banding or by FISH (as 
in Bryndorf et al 1995) or conceivably, in the absence of cytogenetic preparations, by 
targeted molecular study. Repeat CGH, reversing the labels on test and control DNA, can 
also provide confirmation of true gain or loss (Kallioniemi et al 1994).
Application of CGH
CGH was primarily developed for and most widely applied in the study of solid tumours, 
providing characterisation of unbalanced rearrangements, implication of novel genes in 
cancer development or progression, analysis of clonal evolution and subclassification and 
prognostic evaluation of cancer (later reviewed in Forozan et al 1997). The technique 
was subsequently shown to be a powerful adjunct to conventional cytogenetics and FISH 
for characterisation of constitutional karyotypes with numerical aberrations or complex 
structural rearrangements unresolvable by G-banding (Bryndorf et al 1995). This group 
took six months to successfully establish CGH in their laboratory. Production of target 
metaphases of adequate quality for CGH was a particular problem, and they recognised 
that further technical development of CGH would be necessary for its routine clinical 
application. The present study concerned the introduction and application of CGH to the 
diagnostic service in this laboratory.
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Fig. 1-13 Diagram of PRINS (a) and Cycling PRINS (b). Primers are extended from 
their 3’ ends. From A Guide to In Situ (1994), Hybaid Limited, Teddington, Middlesex.
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1.9 Primed In Situ Labelling
PRimed IN Situ labelling (PRINS, Koch et al 1989, Gosden et al 1991) combines features 
of in situ hybridisation and the polymerase chain reaction.
1.9.1 The Polymerase Chain Reaction
The polymerase chain reaction (PCR) is a process for copying a specific DNA or cDNA 
target sequence (Saiki et al 1985,1988, reviewed by Innis et al 1990). PCR is so 
sensitive that a single DNA molecule has been amplified, and single-copy genes are 
routinely derived from total genomic DNA then visualised as distinct bands on 
electrophoresis.
During the PCR the target DNA sequence is cycled through a series of incubation steps 
at different temperatures in a buffered solution containing thermostable DNA polymerase, 
MgCb, dNTPs and primers (a pair of oligonucleotides complementary to the 3’ boundaries 
of the target sequence). This can be performed manually in preset water baths or 
automatically with a thermal cycler. In the first step, the double-stranded DNA target is 
heat denatured. In the second, the temperature is lowered to allow hybridisation of the 
primers to the single-stranded DNA and initiation of polymerisation. Raising the 
temperature slightly in the third step allows the enzyme to complete the copy initiated 
during this annealing. The annealing and extension steps can often be combined, giving 
a two-temperature cycle. Primers hybridise to opposite strands of the target sequence 
and are orientated so that DNA synthesis proceeds across the region between them, 
copying both target strands with each cycle. The thermal stability of the polymerase 
allows repetition of the cycle, with exponential accumulation of target DNA, as the copies 
subsequently act as templates.
PCR Reaction Mix
The most important chemical variable to optimise in a PCR is the free magnesium ion 
concentration in the reaction buffer. High concentrations enhance mispriming, causing 
production of nonspecific amplicons. At very low concentrations extension is impaired 
and yield reduced as Mg ions are a co-factor for DNA polymerase activity. The optimum 
Mg ion concentration must be determined by titration but is generally 1 5-3.5mM. 
Nucleotide concentrations of 20-200uM produce the optimal balance of yield, specificity 
and fidelity in solution PCR, and use of equivalent concentrations of the four dNTPs 
minimises misincorporation errors.
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Up to 50mM KCI can be included in the reaction to facilitate primer annealing, but KC! 
above 50mM or NaCI at 50mM (as in stop buffer) inhibits the polymerase.
Inclusion of gelatin or bovine serum albumin (BSA) and nonionic detergents such as 
Tween 20 (0.05-1%) may improve enzyme thermostability.
PCR Enzymes
Thermus aquaticus (Taq) DNA polymerase, the most widely used PCR enzyme, has, at 
its optimum thermal range of 70-80°C, an extension rate of 35-100 nucleotides per 
second depending on the buffer, pH, salt concentration and nature of the DNA template.
It has a 5'- 3' exonuclease, which removes nucleotides ahead of the growing chain, but no 
proofreading 3’-5’ exonuclease so its fidelity is low (2x10'^  errors per bp per duplication). 
Its optimal concentration is about 2 units (2U) per lOOul reaction. Use of over 4U can 
result in accumulation of nonspecific amplification products, whereas amounts less than 
1U usually reduce specific product yield.
AmpliTaq (Roche Molecular Systems Inc, Branchburg, New Jersey, USA), encoded by a 
modified form of the Taq DNA polymerase gene, is recombinant, therefore the purity and 
reproducibility of this thermostable 94kDa enzyme is higher than Taq polymerase. 
Dynazyme DNA polymerases (Finnzymes, Espoo, Finland), from Thermus brockianus, 
are less expensive than AmpliTaq and have increased thermal stability (150 minute half 
life at 96°C compared with Taq half life of 40 minutes at 95°C).
PCR Primers
Although selection of efficient, specific primers is fairly empiric, there are guidelines for 
their design and computer software, such as Primer 3 (frodo.wi.mit.edu/cgi-bin/primer3/ 
primer3_www.cgi), to facilitate it. Primers should be 18-28 nucleotides long with an 
average G+C content of around 50% and random base distribution. Sequences with 
significant secondary structure and stretches of polypurines, polypyrimidines or other 
unusual sequences, such as palindromic sequences, should be avoided. Three or more 
Cs or Gs at 3’ ends may promote mispriming at G+G-rich sequences, and 
complementarity at the 3' ends of primer pairs promotes formation of artefacts termed 
primer dimers and reduces yield of specific product.
Melting temperatures (T^s) for a given primer pair should lie between 55°C and 80°C 
(calculated using 2°C for A or T and 4°G for G or G) and be balanced.
Primer concentrations between 0.1 and 0.5 uM are generally suitable. Higher 
concentrations may promote mispriming and accumulation of nonspecific product and 
increase the probability of primer dimer generation. Nonspecific products and primer
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dimers are also PCR substrates and compete with the target sequence for reactants, 
lowering specific product yield.
PCR Dénaturation Time and Temperature
The temperature is usually monitored inside one reaction tube with a thermocouple probe. 
Typical dénaturation conditions are 95°C for 30 seconds or 97°C for 15 seconds, however 
higher temperatures may be appropriate, especially for G+C-rich targets. The most likely 
cause of PCR failure is incomplete dénaturation of the target template and/or PCR 
product. This allows DNA strands to reanneal, reducing yield. Preceding the first cycle 
with an initial 3 minute dénaturation at 93°C may be beneficial, however dénaturation 
steps that are too high or long reduce enzyme activity. Taq polymerase half life is >120, 
40 and 5 minutes at 92.5°C, 95°C and 97.5°C respectively.
Primer Annealing
The temperature and time required for primer annealing depends on primer length, base 
composition and concentration. An applicable annealing temperature is 5°C below the 
primer Tm, with temperatures in the 55-72°C range generally giving optimal results. At 
typical primer concentrations (0.2uM), annealing requires only a few seconds.
As Taq polymerase is active over a wide temperature range, primer extension will occur 
at lower temperatures, including the annealing step. Increasing annealing temperature 
aids discrimination against incorrectly annealed primers and reduces misextension of 
incorrect nucleotides at primer 3’ ends thereby promoting specificity. Specificity can also 
be Improved in the initial cycle by adding the enzyme to the reaction mix at a temperature 
above that of primer annealing.
Primer Extension
Extension time depends on the length of the target being amplified. One minute at 72°C 
is sufficient for products of up to 2kb. Low extension temperatures and high dNTP 
concentrations favour primer misextension and extension of misincorporated dNTPs.
The extension step can be omitted if the target is 150bp or less. During the thermal 
transition from annealing to dénaturation, the sample will be in the 70~75°C range for the 
few seconds required to completely extend the annealed primers.
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Cycle Number
When other parameters are optimised the optimum number of cycles primarily depends 
on the starting concentration of target DNA. Too many can increase the amount of 
nonspecific products (see below) and too few reduce product yield.
Plateau Effect
This is the attenuation in the exponential rate of product accumulation that occurs during 
late PCR cycles with the build-up of 0.3-1 pmol of specific product. Depending on reaction 
conditions, the factors influencing the plateau effect’ include substrate utilisation, dNTP or 
enzyme stability, end-product inhibition, competition for reactants by nonspecific products 
or primer dimer, reannealing of specific product at concentrations over 1Q“®M and 
incomplete denaturation/strand separation of product at high product concentration. An 
outcome of the plateau, averted by optimising cycle number, is that an initially low 
concentration of nonspecific products may continue to amplify preferentially.
Contamination in PCR
As PCR produces highly amplified product from a small amount of DNA it is particularly 
affected by DNA contamination. Experiments should therefore be set up in a laminar flow 
cabinet or separate laboratory and dedicated PCR equipment and reagents used. 
Disposable gloves and lab coat must be worn. Where appropriate, reagents should be 
sterilised in an autoclave. Reaction tubes and reactants (excluding sample DNA, primer 
and enzyme), should be irradiated with UV light (Newton and Graham 1994).
1.9.2 The PRINS Procedure
Amplification in situ in non-disrupted cells allowing subsequent detection of the amplicon 
at the site of origin has been proposed since the earliest descriptions of PCR. In PRINS, 
sequence-specific primers are annealed to DNA in slide-bound chromosomes or nuclei 
then extension, incorporating labelled dNTPs, is catalysed by thermostable polymerase 
using chromosomal DNA as a template (Koch et al 1989, Fig. 1-13).
Both oligonucleotide and double stranded DNA fragments have been used as primers in 
PRINS. Synthesised oligonucleotides (used singly or, if this improves specificity, paired, 
Gosden and Lawson 1994) are generally 15-30bp (Gosden et al 1991). Double stranded 
PRINS primers are usually a few hundred base pairs long (Koch et al 1991).
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PRINS with alpha satellite-specific primers was made more convenient with the 
introduction, in 1995-96, of commercial oligonucleotides and labelling kits (Boehringer- 
Mannheim (Roche), Advanced Biotechnologies).
Sample Preparation for PRINS
Sample preparation must protect against loss of target morphology during the extreme 
temperatures used in PRINS. Alcohol and acid/alcohol fixatives, and hence standard 
cytogenetic slide preparations, can be utilised. Slides are generally used within one week 
of preparation. Prior to PRINS, dehydration of such fresh preparations in an alcohol 
series is crucial for maintenance of sample morphology.
PRINS Reaction Mix
As with solution phase PGR, the optimal reaction mix composition must be empirically 
determined for each PRINS target. Higher concentrations of MgClg (up to 4.5mM), primer 
or enzyme may be needed for PRINS than solution PGR (according to Roche/Perkin 
Elmer).
A typical reaction mix contains 100-200uM dATP, dGTP and dGTP and 100-250uM 
labelled dUTP (as in Gosden and Han ratty 1993, Koch 1996). Biotin, DIG, or FITG label 
can be employed. Use of FITG-dUTP may produce weaker signal than hapten-labelled 
nucleotides, but associated background signal reduction can maintain signal to noise ratio 
(Koch et al 1992).
Solution PGR primers can be successfully employed in PRINS and generally lOOng-lug 
oligonucleotide or 1-3ug of cloned probe is used per 50ul reaction mix (Koch 1996).
One unit of DNA polymerase per 50ul reaction is usually adequate. Reaction buffer which 
provides optimal pH and ionic strength for PGR is often supplied with the enzyme. 
Inclusion of BSA or gelatin may enhance PGR efficiency, probably by blocking nonspecific 
binding sites in the sample or on the slide that could sequester reactants, but such carrier 
protein can denature and interfere with amplification.
AmpliTaq DNA Polymerase IS
Successful PRINS often requires a higher concentration of enzyme than solution PGR. 
AmpliTaq DNA Polymerase IS (Roche), a component of the GeneAmp Kit (Perkin Elmer, 
Foster Gity, GA, USA) is supplied at 20U/ul in a low detergent buffer and is optimised 
specifically for PGR in situ. It can be used at up to 10U/50ul without introducing 
significant concentrations of detergent from the buffer into the reaction, minimising 
sample damage caused by detergent during prolonged exposure in cycling (see below).
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PRINS Dénaturation, Annealing and Extension Temperatures and Times 
Slides may undergo preliminary dénaturation in 70% formamide solution at 70°C for 2 
minutes followed by 70% (-20°C), 90% and 100% (room temperature) ethanol and air 
drying (Gosden and Lawson 1994). Reaction mix is then applied and slides placed at the 
annealing temperature. Alternatively dénaturation is performed on a thermal cycler block. 
The slides either have reaction mix applied prior to placing on the hot block (Advanced 
Biotechnologies Print Kits) or the slide is placed on the hot block to preheat to 
dénaturation temperature before the mix is added and the reaction begins (Koch 1996).
As in solution PCR, when reactants are added to the target DNA at temperatures below 
the optimal annealing temperature, mispriming and primer-dimerisation can occur, 
reducing specific signal and contributing to background. Dénaturation is at 93-94°C for 
up to 5 minutes. Temperature is then lowered (to a level depending on the probe used 
and stringency required) to allow probe annealing. If a programmable hotplate is not 
used the slide must be rapidly transferred between hotplates to avoid temperature 
dropping below annealing temperature. Annealing is for 2-60 minutes (according to probe 
amount, size and complexity) but 15-30 minutes is often suitable. The temperature may 
be raised for a separate extension stage, if required. In single cycle PRINS, the reaction 
is stopped on completion of extension.
PRINS is terminated by immersion in stop buffer containing EDTA at or just above 
annealing temperature. Following washing, the slide is ready for mounting in counterstain 
and microscopy if a fluorescent nucleotide was incorporated. Detection with antibodies or 
(strept)avidin is necessary for hapten labels.
Detection of Labelled Products
When DIG- or biotin-labelled dUTP has been incorporated into the amplified target 
sequence the slides are treated with blocking buffer then the appropriate reporter applied 
(see DIG and biotin detection in Methods). Slides are then mounted in counterstain and 
visualised using fluorescence microscopy.
Optimisation and Control of PRINS Reactions (Koch 1996, Hybaid Workshop, Edinburgh, 
1996)
To assure PRINS specificity and sensitivity it is essential to stringently maintain reaction 
temperature on the slide during dénaturation, annealing/extension and incubation in stop 
buffer, and a programmable slide thermal cycler improves result reproducibility. 
Optimisation of the dénaturation and labelling temperature may be required, adjusting 
temperatures only by small increments in each test. Absent or weak signals may be
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caused by a dénaturation temperature which is too low. This can be elevated, to a 
maximum of or the duration of the step increased, to a maximum of 5 minutes, 
however excessive dénaturation will destroy chromosome morphology. Overly high 
temperature during annealing/extension leads to inefficient priming, also resulting in poor 
signal, and even brief exposure of denatured target DNA to temperatures below the 
stringent annealing/extension temperature before and during extension and between 
extension and stop buffer can cause nonspecific priming and background signals.
In addition to these temperature effects, DNA repair, mispriming and detection system 
artefacts can contribute to false positive results and failure of reactants can give false 
negatives. Thus appropriate controls should be employed, such as inclusion of known 
positive and negative samples, especially for interphase analysis or for metaphase 
studies (e.g. of sex chromosomes) where there is no internal positive control.
Appropriate control investigations may identify the cause of sub-optimal results. Where 
there is nonspecific signal only on chromosomes, primer omission will reveal any 
‘endogenous priming’ (label incorporation in damaged or nicked DNA via nick translation 
in situ by the polymerase’s DNA repair mechanism), if found, slides freshly prepared 
from well-fixed material should be used to minimise damage. Exposure of the preparation 
to nucleases during fixation and pretreatment can be reduced by using high-quality sterile 
reagents. Alternatively, nicks in chromosomal DNA can be inactivated by incubation with 
a termination solution (DNA polymerase and dideoxynucleotides) or closed with T4 DNA 
ligase prior to dénaturation (as in Gosden and Lawson 1994).
Where there is nonspecific signal throughout the slide, controls could include detection 
without prior PRINS, which demonstrates nonspecific binding of detection agents, and 
omitting enzyme and primer to show nonspecific binding of label. If either test is positive, 
blocking and washing can be intensified, but repeating the chromosome preparation may 
be required to remove the excess cellular proteins and matrix responsible.
If specific signals are large but minor additional signals are visible, increasing the dTTP 
concentration can conveniently reduce reaction sensitivity. If specific signal is weak it 
may be enhanced by further layers of detection, but this may also increase background.
Advantages of PRINS
PRINS is rapid, detection of highly repetitive DNAs on chromosomes taking only 2 hours 
(Gosden and Lawson 1994). It is highly specific, so that a single nucleotide mismatch 
with the genomic sequence at the 3’ primer end prevents amplification, potentially 
allowing discrimination between two target sequences that differ by only one base 
(Pellestor et al 1994). It is also very efficient, the small size of the primers maximising
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sample penetration and target hybridisation (Pellestor et al 1995a), and the short PRINS 
incubation steps may preserve chromosome morphology (Koch et al 1992).
As they are unlabelled, excessive amounts of primers can be used in PRINS to optimise 
reaction kinetics without increasing background. Unincorporated labelled dNTPs do not 
produce visible signal and, in good quality preparations, should only be incorporated at 
the primer annealing site so rarely cause nonspecific fluorescence. Non-hybridised or 
poorly-hybridised FISH probes, however, can generate background.
The preparation of oligonucleotide primer using an automatic DNA synthesiser is fast and 
relatively inexpensive whereas FISH probe production is laborious and involves 
procedures which are not accessible for ail labs. Also, FISH probes then require to be 
labelled before use, and commercial probes are expensive and the selection limited.
Limitations of PRINS
When first introduced, PRINS had limited application because it was only reliable for 
detection of moderate to high copy repeats e.g. alphoid sequences, as the product had to 
be greater than 1 kb. Also, only one locus could be detected.
Modifications of PRINS
PRINS has undergone development to improve its sensitivity and versatility. The process 
was extended to low copy repeat sequences with ‘cycling PRINS’, also termed in situ 
PCR, where multiple amplification rounds are performed by denaturing the initial product 
from its target, annealing of more primer and further extension, generating more product 
(Gosden and Hanratty 1993). An example of such a reaction would be annealing at 60°C 
for 3 minutes, extension at 70°C for 10 minutes, then up to 30 cycles with dénaturation at 
95*13 for 1 minute, annealing at 60*0 for 1 minute, and extension at 70*0 for 3 minutes. 
‘Instant’ and ‘flash’ modifications allowed further acceleration of PRINS, producing 
visualisation of high copy repeats in 15-20 and 2-3 minutes respectively (Gosden and 
Lawson 1995). This was achieved by incorporating fluor-labelled dUTP in the product 
during synthesis, obviating hapten detection, and removing Initial formamide dénaturation, 
using only heat dénaturation on a thermal cycler. The ‘instant’ program was then 95*0 for 
1 minute, 60*0 for 1 minute, and 70*0 for 5 minutes. ‘Flash’ PRINS had even shorter 
dénaturation, annealing and extension (30, 30, and 60 seconds).
Multi-PRINS (detection of several chromosomes simultaneously) required multiple 
sequential primer reactions, each time using a different labelled nucleotide, blocking nicks 
and free 3’ ends of previously synthesised DNA with dideoxynucleotides (ddNTPs) to 
prevent their use as initiation sites (Gosden and Lawson 1994, Speel et al 1995).
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Applications of PRINS and Cycling PRINS
In addition to metaphase chromosomes and nuclei, PRINS and in situ PCR has been 
used on a variety of preparations including uncultured blood cells (Gosden and Scopes 
1996), spermatozoa and blastomeres (Pellestor et al 1995a, 1996a,b), tissue sections 
(Speel et al 1996), cells in suspension and cytospins (Komminoth et al 1992).
An obvious application is mapping and investigation of repeat sequence organisation 
within chromosomes (Gosden et al 1991). Multi-PRINS involving Alu primers can provide 
simultaneous R-banding for such mapping (Gosden et al 1991, Speel et al 1995) and 
PRINS with consecutive chromosome painting can be performed as a single procedure 
(Hindkjaer et al 1995a).
Centromere and telomere-specific PRINS has been used to assist characterisation of 
acquired and constitutional structural chromosome abnormalities (Hindkjaer et al 1995b, 
Brandt et al 1993, Hertz et al 1995, Friedrich et al 1996), in supernumerary marker 
chromosome identification (Koch et al 1993), and in studying the frequency and 
distribution of aneusomy in human sperm (Pellestor et al 1995a, 1996a).
PRINS could potentially provide the speed and accuracy required by PND (Pellestor et al 
1995b,c) and PGD (Pellestor et al 1996b) of sex or aneuploidy. The design of primers 
capable of 13 and 21 alpha satellite discrimination appeared to enhance PRINS suitability 
for this purpose (Pellestor et al 1994, 1995b).
The ultimate aim of PRINS development has been the detection of unique sequences. 
This would offer a means of chromosomal localisation for sequences defined only by 
pairs of primers (e.g. STSs and ESTs), obviating inter-lab clone exchange and long-term 
storage with the accompanying risks of mutation or inactivation. Most significantly,
PRINS specificity would provide detection of small deletions (outwith FISH resolution) or 
even mutations. By the start of this study unique sequence PRINS had been reported, 
but only in a limited number of publications (Cinti et al 1993, Troyer et al 1994a,b), Only 
one of these reports involved human chromosomes and fluorescence, rather than 
chromogenic, detection (Cinti et al 1993).
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1.10 Aims of the Study
Fundamental to this work was the development and application in this department of 
reliable chromosomal localisation, by FISH, of unique DNA sequences in a range of 
different vectors. This expertise could then be directed to the institution of a departmental 
facility which could validate and utilise non-commercial FISH probes for chromosomal 
breakpoint investigation. It could also, in the absence of appropriate commercial probes, 
be applied in the establishment and provision of a diagnostic microdeletion detection 
service.
A particular clinical need was identified for microdeletion determination in patients with 
DGA/CFS, because of the high incidence of this disorder, and in potential carriers of DMD 
or BMD, because FISH could offer the most direct and unequivocal diagnosis in cases 
with recognised familial microdeletions. Probes for these conditions, in addition to RTS, 
were fortunately available from other research groups.
Detection of cryptic chromosomal abnormalities acquired heightened clinical relevance 
with the report that ~6% of cases of idiopathic MR were caused by subtelomeric 
segmental aneusomy (Flint et al 1995). This study therefore incorporated 
the introduction of a novel multiple subtelomeric probe system and appraisal of this 
approach in the investigation of patients with idiopathic MR.
Although CGH had been used as a research tool in this department, the work reported 
here was intended to optimise CGH for reliable and convenient investigation, in a routine 
diagnostic environment, of apparent or suspected unbalanced constitutional chromosome 
abnormalities.
The study also aimed to introduce PRINS to this laboratory, and, in particular, investigate 
its potential use for the detection of single copy sequences.
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2. MATERIALS AND METHODS
2.1 Safety
Protective coat and gloves were worn during all laboratory work. Handling of all unfixed 
biological material was carried out in a Class II safety cabinet. Work with toxic and 
carcinogenic agents was performed with care in a fume hood according to departmental 
safety guidelines.
2.2 Samples
The cytogenetics laboratories at the Department of Medical Genetics, Yorkhill NHS Trust 
supplied fixed metaphase preparations remaining after diagnostic analysis and also the 
results of these analyses. The molecular genetics laboratory provided DNA for CGH 
studies. Patient sample details are provided in Results and Appendix II.
2.3 Commonly Used Solutions
TE Buffer (10mM Tris-HCl, pH8.0, 1mM EDTA pHB.O).
A commercial version (x100, Sigma T-9285) was also used.
Phosphate Buffered Saline (PBS)
Dissolve ten PBS tablets (Dulbecco) in 1L water. Adjust pH to 7.4 prior to sterilisation by 
autoclaving.
pH6.8 buffer
Dissolve one pH6.8 buffer tablet (Gurr, BDH) in 1L purified water.
20xSSC (3M Sodium chloride, 0.3M Trisodium citrate)
Dissolve 175.3g of Sodium chloride and 88.2g of Trisodium citrate in 800ml purified 
water. Adjust the pH to 7 with a few drops of 10M Sodium hydroxide. Adjust the volume 
to 1L with purified water. Sterilise by autoclaving. Store at room temperature.
A commercial 20xSSC solution (GibcoBRL 15557-036) was also used.
2xSSC
Add 50ml 20xSSC to 450ml purified water.
0.4xSSC
Add 10ml 2xSSC to 40ml purified water in a Coplin jar.
0.4xSSCT (0.4xSSC, 0.15% Tween 20)
Add 10ml 2xSSC to 40ml purified water, 75ul Tween 20 (Sigma P-1379) in a Coplin jar.
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4XT (4xSSC, 0.05% Tween 20)
Add 250ul Tween 20 to 500ml 4xSSC (100ml 20xSSC, 400ml purified water).
70% formamide solution (toxic)
Add 35ml formamide (Fluka 47670) to 5m! 20xSSC and 10ml purified water in a Coplin 
jar.
50% formamide solution (toxic)
Add 25ml formamide (Fluka 47670) to 5mI 20xSSC and 20ml purified water in a Coplin 
jar.
DAPl (4',6-diamidino-2-phenylindole dihydrochloride)
Prepare 40ug/ml stock by diluting 1ul DAPl 1 mg/ml (Sigma D-1388) in 24ul sterilised 
distilled water. Store, covered to protect from light, at 4*C.
DAPl counterstain
Dilute stock, e.g. 1/50 to 1/25 (0.4ul DAPl 40ug/ml, 9.6ul mountant), in Citifluor AF1 
mountant (Citifluor Ltd). This gives a final concentration of 0.8-1.6ug/ml.
DAPl + Propidium iodide (PI, toxic) counterstain
1/50 dilution of 40ug/ml DAPl plus 1/50 dilution of 20ug/ml Propidium iodide (Sigma P- 
4170) in Citifluor AF1.
Carnoy’s fixative (1:3 glacial acetic acid:methanol)
2.4 Probes
Probes for these studies were provided, together with associated information, by many 
different sources. These are detailed in Results and Appendix I.
2.5 Plasmid, Cosmid, BAG and PAG Probe Culture
Materials
LB (Luria-Bertani) Culture Medium
Bacto-tryptone (Difco 0123-17-3) 5.0g
Bacto-yeast extract (Difco 0127-17-9) 2.5g
NaCI 5.0g
Instead, for convenience and as Difco is no longer trading, LB tablets (Sigma L-7276,
1 tablet makes 50ml medium) were used for BAC and PAC clone culture.
Add purified water to 500ml, autoclave to sterilise. Cool and add appropriate antibiotic, 
either:
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1ml of 50mg/mi ampicillin (Sigma A-9518), prepared by adding 1g to 20ml purified water 
and filter sterilisation (0.22p Millex filter unit, Millipore, Cork, Ireland). Final concentration 
in medium 0.1 mg/ml.
1ml of 7.5mg/ml kanamycin (Sigma K-4000). Final concentration 0.015 mg/ml.
500ul of 20mg/ml chloramphenicol (Sigma C-7795), prepared by adding 1ml filtered 
ethanol (0.45p Millex filter unit) to 20mg in supplied vial. Final concentration 0.02mg/ml.
LB Agar Plate Preparation
Add 7.5g (1.5%) Bacto-agar (Difco) to 500ml LB medium. Alternatively add ten LB Agar 
tablets (Sigma L-7025) to 500ml purified water. Autoclave to sterilise.
Add antibiotic when bottle is just cool enough to hold (ampicillin to 0.1 mg/ml, kanamycin 
to 0.015mg/ml, chloramphenicol to 0.02mg/ml). Makes about 20 x 100mm plates.
Procedure
1. Streak out stab culture on agar plates containing appropriate antibiotic. Incubate 
overnight at 37°C.
2. Prepare starter cultures by transferring individual colonies to 5ml selective LB medium 
in 30ml Universal containers (Sterilin). Incubate 8-16 hours, 37°C, shaking (-300rpm) in 
an orbital incubator (e.g. S150, Bibby, Stuart Scientific, UK).
3. Set up glycerol stocks (50:50 culture:steri!e glycerol (Sigma G5516)) In 2ml freezing 
vials (Sarstedt) for storage at -20 to -70°C.
2.6 Plasmid, Cosmid, BAC and PAC Extraction and isolation
Probe extraction and isolation initially used the Circleprep kit (almost all DMD probes were 
isolated by this method) but this product was discontinued, leading to trial of the Hybaid 
midiprep system. This was compared with Circleprep for extraction of cosmid cYD4.66. 
Probe signal was weaker, with more background. Four subclones of DGA/CFS probe 
H1012 were then used for comparison of Circleprep with the Qiagen midiprep kit. Though 
slightly more background occured using Qiagen, the quality was acceptable and this kit 
adopted for subsequent probe extractions.
2.6.1 Isolation of Cosmid DNA with the Circieprep II Kit (Bio 101 Inc. CP200)
Materials (*stored at room temperature to avoid precipitation)
Isopropanol (Sigma 19516)
Kit contents:
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Pre-lysis buffer (Tris/EDTA/glucose solution)
Alkaline lysis reagent (0.2N NaOH and 1% SDS)*
Neutralizing solution (3M potassium acetate)
Lithium chloride (LiCI) solution*
Circleprep Glassmilk
Binding buffer (KBr/Nal/Tris mix, promotes binding of DNA to Glassmilk)
Wash solution (30ml of salt solution, 30ml of 100% ethanol added before use)
RNase MiXX xIO 
Sieve material
Procedure (essentially according to manufacturer’s protocol)
1. Inoculate lOOmIs selective LB broth in a sterile bottle (e.g. 280ml tissue culture flask) 
with 100ul starter culture or 200ul glycerol stock and grow 8-16 hours, shaking at 37°C.
2. Centrifuge (Sorvall RC-5B Refrigerated Superspeed Centrifuge, HB4 rotor) in closed 
50ml tubes (Oakridge (Natgene) Nalge Company, Rochester, New York) at 6000rpm for 
15min to pellet cells. Discard supernatant, drain tube for 1-2min.
3. Resuspend pellet with 4ml pre-lysis buffer and vortex to mix.
4. Add 4ml alkaline lysis reagent, mix immediately and incubate at 45-65*C, 5min.
5. Add 4ml neutralizing solution. Invert by hand until white flakes appear homogeneous. 
Centrifuge, 12,OOOrpm (~20,000g) for 5min at 4*C to pellet precipitate.
6. Transfer supernatant through sieve material provided to a clean 50ml tube.
7. Add 12ml isopropanol. Mix. Centrifuge 12,OOOrpm, 10min, 4*C. Decant supernatant. 
Centrifuge. Remove last of supernatant with a micropipette. Invert tube and wipe inside 
walls with tissue. Resuspend pellet in 0.5ml water, transfer to a microfuge tube.
8. Puncture tube lid, place in hotblock at 100*C, boil 3min to denature linear cellular DNA 
without nicking vector.
9. Cool on ice 30 seconds.
10. Add 300ul LiCI. Mix and let stand, room temperature, 5min. Centrifuge in a 
microfuge at 13,OOOrpm, 30 seconds. Transfer supernatant to a clean tube.
11. Add 600ul isopropanol to supernatant, mix. Microfuge Imin, resuspend pellet in 0.5ml 
water. Add 20ul RNase MiXX, incubate 37*C, 5min.
12. Add 300ul LiCI and 75ul vortexed Circleprep Glassmilk. Incubate 5min at room 
temperature with occasional mixing. Microfuge 5 seconds to pellet Glassmilk. Remove 
supernatant.
13. Wash pellet twice with 1ml wash solution and remove the residue of this solution.
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14. To elute plasmid from Glassmilk resuspend pellet in lOOul sterile purified water, 
incubate in a 45-65*C waterbath for 5min. Microfuge for 1 min and transfer supernatant 
containing vector DNA to a clean tube.
2.6.2 Isolation of Cosmid DNA with the Qiagen Midiprep Kit
Materials
Supplied Buffers (all stored at room temperature except PI with RNase A):
Buffer PI (Resuspension Buffer, store at 2-8°C after addition of RNase A) - 
50mM Tris-HCl pH8, 10mM EDTA, 100ug/ml RNase A
Buffer P2 (Lysis Buffer) - 
200mM NaOH, 1% SDS
Buffer P3 (Neutralisation Buffer) - 
3M Potassium acetate, pH5.5
Buffer QBT (Equilibration Buffer) -
750mM NaCI, 50mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton X-100
Buffer QC (Wash Buffer) -
1.0M NaCI, 50mM MOPS pH 7.0, 15% isopropanol
Buffer OF (Elution Buffer) -
1.25M NaCI, 50mM MOPS, pH 7.0, 15% isopropanol
Procedure (essentially according to manufacturer’s protocol)
Before starting;
• Add RNase A vial (briefly centrifuged) to the P I. Gives a concentration of 100ug/ml.
• Check P2 for SDS precipitation. If necessary, dissolve the SDS by warming to 37°C.
• Pre-chill P3 to 4°C.
1. Follow Circleprep Method steps 1 and 2.
2. Completely resuspend the bacterial pellet by vortexing in 4ml PI.
3. Add 4ml P2, mix gently but thoroughly by inverting 4-6 times. Incubate at room 
temperature for 5min, no longer. The lysate should appear viscous.
4. Add 4ml chilled P3, gently mix immediately by inverting 4-6 times, and incubate on ice 
for 15min. A white precipitate, containing genomic DNA, proteins, cell debris and SDS, 
forms and the lysate becomes less viscous.
5. Centrifuge, immediately after mixing again, in polypropylene tubes at 12,OOOrpm in a 
Sorvall RC-5B HB4 rotor (~20,000g) for 30min at 4°C. Remove supernatant, which 
should be clear, promptly.
6. Re-centrifuge supernatant at 12,OOOrpm, 15min, 4*C. Remove supernatant promptly.
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7. Equilibrate a Qiagen-tip 100 by applying 4ml QBT, and allow column to drain.
8. Without delay apply the supernatant from step 6 to the Qiagen-tip.
9. Wash the Qiagen-tip with 2x10ml QC.
10.Elute DNA with 5ml QF. Collect eiuate in an Oakridge tube (polycarbonate tubes are 
not resistant to alcohol). This may be stored overnight at 4°C.
11.Precipitate DNA by adding 3.5ml room-temperature isopropanol to the eluted DNA.
Mix, centrifuge immediately at 12,OOOrpm for 30min at 4*C. Carefully decant supernatant.
12.Wash pellet with 2ml 70% ethanol, and centrifuge at 12,OOOrpm for lOmin. Carefully 
decant the supernatant.
13.Air dry the pellet for 5-10 min and re-dissolve the DNA in lOOul TE buffer, pH8.0.
2.6.3 DNA Isolation From BAC and PAC Clones
Adapted from Children’s Hospital Oakland Research Institute method, a modification of 
the standard Qiagen procedure that uses no organic extractions or columns 
(http://bacpac.chori.org/bacpacmini.htm).
Solutions
P I, P2, P3 as in Qiagen Midiprep Kit 
Method
1. Using a disposable loop, inoculate a single bacterial colony into 5ml LB media plus 
appropriate antibiotic. Incubate at 37°C for 8-16 hours, shaking at 225-300rpm.
2. Prepare glycerol stock as described above (section 2.5) then transfer 2ml of culture to 
a 2ml Apex tube (Alpha Laboratories). Microfuge this 2ml aliquot at 13,OOOrpm for 3min.
3. Discard supernatants. Drain tube. Resuspend (vortex) pellet in 0.3ml PI. Add 0.3ml 
P2 and gently shake to mix. Let sit at room temperature for at least 5min. The 
appearance of the suspension should change from very turbid to almost translucent.
4. Slowly add 0.3ml P3 and gently shake during addition. A thick white precipitate of 
protein and E. coli DNA forms. Place the tubes on ice for at least 5min.
5. Microfuge at 13,OOOrpm for lOmin at 4°C.
6. Remove from centrifuge and place on ice. Transfer supernatant, avoiding white 
precipitate, to a 1.5ml microfuge tube using a micropipette. Add 0.8ml ice-cold 
isopropanol. Mix by inverting tube a few times and place on ice for at least 5min. Can be 
left at -20*0 overnight.
7. Microfuge at 13,000rpm for 15min at 4*0.
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8. Remove supernatant and add 0.5ml of 70% ethanol. Invert several times to wash the 
pellet. Microfuge 13,OOOrpm for 5min at 4°C.
9. Repeat step 8. Remove as much of the supernatant as possible.
10. Air dry pellet at room temperature. When pellet becomes translucent, i.e. when most 
of the ethanol has evaporated, add 40ul TE. Occasionally tap the bottom of the tube to 
gently resuspend. Resuspension may take over 1 hour.
2.7 Calculation of DNA Concentration
1 unit of absorbance at 260nm = 50ug double stranded DNA/ml.
The spectrophotometer (Gene Quant II RNA/DNA Calculator, Pharmacia Biotech) was set 
to read absorbance at 260nm. A 1ml, 1/200 dilution of DNA in ultrapure water was 
prepared. A blank of ultrapure water in a quartz cuvette was used to set the background 
absorbance to zero. Absorbance of the test DNA in a matched cuvette was then read 
and concentration (ug/ml) calculated as absorbance at 260nm x 50 x dilution factor (200). 
For example: 0.034 x 50 x 200 = 340ug/ml = 0.34ug/ul.
2.8 Probe Labelling
Nick Translation with Gibco BRL Kit (Catalogue number 8160-010)
Procedure (essentially according to manufacturer’s protocol)
1. Add sequentially to a microfuge tube:
• 5ul kit solution A4 (0.2mM nucleotides C, G and A in 500mM Tris-HCl (pH7.8), 50mM 
Magnesium chloride, 100 mM 2-mercaptoethanoI, 10Oug/ml bovine serum albumin
• lug DNA to be labelled
• 3.5ul 0.3mM Biotin-11-dUTP (Sigma B6780)
• Solution E (water) to make final volume 50ul
• 5ul solution C (0.5U/ul DNA Polymerase I, 0.4mU/ul DNase I, 50 mM Tris-HCl (pH 
7.5), 5mM Magnesium acetate, 0.1 mM phenylmethylsulphonyl fluoride, 50% glycerol, 
100ug/ml bovine serum albumin
2. Mix well then incubate for 90min at 15°C.
3. To stop the reaction add 5ul solution D (300mM diSodium EDTA, pH8).
4. To precipitate the probe DNA add:
• 4.6ul 3M Sodium acetate pH5.2 (filter sterilised. Sigma S-7899)
• 1 ul 20mg/ml glycogen (Roche 901393)
• 122ul iced ethanol
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5. Vortex to mix, centrifuge for 30min, 14.OOOrpm.
6. Remove supernatant and dry pellet (e.g. using the Speed Vac Concentrator (Savant)).
7. Add lOul TE buffer (gives a concentration of iOOng/ul). Vortex and centrifuge briefly.
8. Leave at room temperature or 37°C for 2 hours with occasional vortexing and 
centrifugation to fully dissolve precipitate prior to storing at -20"C.
For Digoxygenin labelling, Biotin-11-dUTP and solution A4 were replaced with 5ul of 
Digoxygenin DNA labelling mix (Boehringer Mannheim, now Roche, 1277 065 (ImM 
dATP, dCTP, dGTP, 0.65mM dTTP, 0.35mM Dig-11-dUTP).
For direct labelling, Biotin-11-dUTP was replaced with lul of either fluorogreen or 
fluorored (Amersham).
If a probe was to be used frequently e.g. DGA/CFS and DMD cosmids, 10Qul labelling 
mixes were prepared. Appropriate volumes of competitor and salmon sperm DNA were 
added after step 3, the DNA ethanol precipitated with 1/10 volume Sodium acetate pH5.2 
and 2-3 volumes ethanol as above, and the pellet resuspended in hybridisation buffer 
rather than TE. The probe was then ready to aliquot and denature as required.
2.9 Oligonucleotide Primers
All non-commercial primers used in this study were prepared by the primer service in this 
department using an ABI 319 oligonucleotide synthesiser according to manufacturer’s 
instructions.
2.9.1 Primer De-protection
All primers were supplied in a column and required to be de-protected before use. 
Procedure
1. Collect 1ml of ammonium hydroxide (NH3OH, Aldrich) in a 1 ml polypropylene syringe 
and connect to one end of the column. Attach an empty syringe to the other end.
2. Gently push through the column, displacing the barrel of the second syringe. Ensure 
that the column is filled with liquid.
3. Push the NH3OH back and forth through the column three times over a two to three 
hour period, ensuring the column is always liquid filled. Avoid formation of ‘bubbles’ in the 
column. The column should decolourise from yellow to white.
4. Withdraw the NH3OH and expel into round-bottomed, screw-capped vials (Nunc).
5. Make up volume to ~2.0mls (full vial) by passing more NH3OH through the column 
using a fresh syringe.
6. Tightly cap vial and incubate floating in a 55*C water bath overnight.
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7. Store at -70*C till required.
2.9.2 Oligonucleotide Evaporation or Precipitation
De-protected oligonucleotides had to be removed from NH3OH before use. This was 
achieved by one of two methods:
• A volume of primer (e.g. 0.45ml, leaving enough for three subsequent evaporations or 
precipitations) was precipitated with 1/10 3M Sodium acetate pH5.2 and 2-3 volumes of 
cold ethanol, centrifuged at 13,OOOrpm for 30min, vacuum dried and 500ul of sterile 
purified water added.
• A volume of primer (e.g. 0.45ml) in an open vial was left overnight in a fume hood to 
evaporate, then 500ul of sterile purified water added.
2.9.3 Assessment of Oligonucleotide Concentration
The absorbance of the primer DNA was obtained using a Gene Quant II RNA/DNA 
Calculator as described above. DNA concentration (ug/ml) was calculated by the 
spectrophotometer, using single-stranded DNA conversion factor 33 (1 unit of absorbance 
at 260nm = 33ug single stranded DNA/ml).
The numbers of A, G, C and T bases in the primer were determined and the molar 
extinction coefficient of the primer calculated as:
The no. of A bases (16,000) + no. of G (12,000) + no. of C (7000) + no. of T (9,600).
The molar concentration of the primer stock (uM = pmoles/ul) was then calculated as: 
(absorbance at 260nm x dilution factor) divided by the molar extinction coefficient.
2.9.4 Calculation of Primer Annealing Temperature
This uses the formula 4(C+G)+2(A+T) (range + or - 5*0). For example:
Factor IX 3’G (Cinti et al 1993 X I) C+G=11, A+T=9 so annealing temperature should be 
62*0 +/ - 5*0
Factor IX 3 0  (Ointi et al 1993 X2) C+G=10, A+T=11 so annealing temperature should be 
62*0 +/- 5*0
2.10 Preparation of Slide-Bound Target Material
Chromosome culture and harvest
Slide-bound metaphase chromosome spreads were made from fixed cell suspensions 
provided by the cytogenetics department of this institute. On receipt, cell suspensions 
were transferred to 1.5ml microfuge tubes (Sarstedt) and stored at -20*0 till required.
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Slide preparation
1. Clean microscope slides by overnight soaking in Decon (Decon Laboratories, Hove, 
Sussex) and rinse with running tap water, first warm (for 30min) then cold (90min). The 
washed slides can be stored at 4*0 in purified water for one week.
2. Centrifuge the vial of cell suspension at 1200rpm for 7min, remove the supernatant 
and discard. Re-suspend the pellet in enough fresh Oarnoy’s fixative (usually 200 to 
500ul) to provide a slightly milky suspension.
3. Tilt a cold, clean wet slide on its long side and, using a Pasteur pipette, place two 
drops of cell suspension side by side near the slide edge. Allow the drops to run 
downwards before levelling the slide and air drying. The area of slide-bound material 
produced is easily enclosed by a 22mm^ coverslip for FISH.
4. Before use evaluate the mitotic index and metaphase quality of the slide preparation by 
phase contrast light microscopy with a x10 objective lens.
2.11 Lipsol Banding (Malcolm et al 1981)
Staining solution
Add 3g Leishman powder to 2L methanol. Stir to dissolve then filter. For use, dilute 1 
part stain in 3 parts buffer (pH6.8).
Procedure
1% Lipsol detergent (LIP Equipment and Services Ltd, Yorkshire), freshly made in purified 
water, was applied to 1 day-old slides for 20-25 seconds (or as required) then rinsed with 
saline. The slide was then flooded with Leishman stain for 2-3 minutes, rinsed with pH6.8 
buffer and mounted in pH6.8 buffer using a 22 x 64mm coverslip.
2.12 Pre-Hybridisation Photography
(used prior to the availability of software-enhanced reverse DAPl banding)
2.12.1 Locating, Photographing and De-staining Slides
1. Locate complete, well spread and adequately banded metaphases within 20 Vernier 
units on the slide (representing ~2 cm )^ and photograph them (Kodak Technical Pan 2415 
film). Avoid spreads at slide edge. Note Vernier reading for each cell to allow re-location.
2. Wipe off excess immersion oil, remove coverslip by soaking in pH6.8 buffer, mark the 
area to be probed with a diamond pen and de-stain slide in an ethanol series.
3. Air-dry and use for ISH within 48 hours or store frozen in a box with dessicant.
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4. Develop the film (to check photography has been successful) before ISH.
2.12.2 Developing Films
Solutions (Prepared fresh as required):
Developer -1 part Kodak Dektol in 3 parts water
Stop buffer - 3% (48ml) glacial acetic acid in 1600ml water
Fixer -1 part Ilford Hypam Fixer in 3 parts water
Procedure
1. In dark, remove film from camera, wind on to developing reel and place in developing 
tank.
2. Add in succession:
• Developer, agitate every 30 seconds for 4.5 minutes then pour off.
• Stop Buffer, agitate for 30 seconds then pour off.
• Fixer, agitate every minute for 3.5 minutes then pour off.
3. Wash, under running cold tap water for at least ten minutes. Remove film from reel 
and hang to dry. Examine to ascertain negative image quality.
2.12.3 Printing Films
Following hybridisation, if signal appeared to be present, negatives were printed. 
Procedure
1. Prepare trays containing:
• Ilford paper developer, 1 part in 9 parts water.
• Running cold water.
• Ilford paper fixer, 1 part in 9 parts water.
2. For every negative, determine exposure time, expose paper and pass through 
developer, running water, fix and water again prior to drying.
2.13 Fluorescence In Situ Hybridisation and Detection of Liquid DNA Probes
2.13.1 FISH with Indirectly Labelled Non-Commercial DNA Probe
Adapted from Carter et al (1992).
Materials
50% Dextran sulphate (Sigma D-8906)
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Add 2.5g Dextran sulphate to 3ml purified water. Allow time to wet' and mix frequently. 
Adjust volume to 5ml with purified water.
Hybridisation Buffer
• 5ml formamide (Fluka 47670) 50%
• 2ml 50% dextran sulphate 10%
• 0.5ml 20xSSC 1xSSC
• 2.5ml sterile water
Aliquot and store in microtubes at -20*C.
Sonicated salmon sperm DNA (10.4mg/ml Salmon Testes DNA Sigma D9156)
• Switch on sonicator (Soniprep 150, MSE) and allow to warm for 15min.
• Place DNA, on ice, under the sonicator probe. Close sonicator door. Wearing ear 
protection, sonicate at high power for four periods of 15 seconds.
• Boil vial for 10min.
• Check fragment size is 100-500bp by agarose gel electrophoresis.
• Store at 4*C.
Blocking solution and diluent for detection agents
15% human AB serum (Sigma 8-7148, now discontinued) in 4XT. The amount required 
depends on the number of ISH areas to be detected but 5ml is usual. Alternatively, use 
5% low fat milk powder in 4XT. Prepare 100ml, aliquot 5ml volumes, and store at -20*C.
Detection solutions
Volumes in brackets represent the amount of detection agent in each 100ul detection 
solution prepared. One ISH area requires lOOul of each appropriate solution per layer.
• FITC- or Texas red-avidin: FITC-avidin (Vector Labs A-2011) or Texas red-avidin 
(Jackson Immunoresearch 003-070-083) 5ug/ml in blocking solution (i.e. 0.25ul
of 2mg/ml stock FITC- or Texas red-avidin in 99.75ul).
• Biotinylated anti-avidin; As FITC-avidin solution but replacing FITC-avidin with 
biotinylated anti-avidin (Vector Labs BA-0300).
• Mouse anti-digoxygenin FITC; Mouse anti-digoxygenin FITC (Sigma F3523) 0.3% in 
blocking solution (i.e. 0.3ul of mouse anti-digoxygenin FITC in 99.7ul).
• FITC anti-mouse: FITC anti-mouse (Sigma F3008) 0.5% in blocking solution (i.e. O.Sul 
of anti-mouse FITC in 99.5ul).
• Mouse anti-digoxygenin FITC + biotinylated anti-avidin: Mouse anti-digoxygenin FITC
0.3%, biotinylated anti-avidin 5ug/mi in blocking solution (i.e. 0.3ul mouse anti- 
digoxygenin FITC and 0.25ul 2mg/ml biotinylated anti-avidin in 99.45ul).
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• FITC anti-mouse + Texas red-avidin: FITC anti-mouse 0.5%, Texas red-avidin 
(Jackson Immunoresearch 003-070-083) 5ug/ml in blocking solution (i.e. 0.5ul FITC anti­
mouse and 0.25ul 2mg/ml Texas red-avidin in 99.25ul).
Procedure 
Slide preparation
If banding was not performed, slide preparations were checked for mitotic index and 
quality using phase contrast microscopy. Suitable slide areas were marked with a 
diamond pencil and generally used for ISH within a few days of preparation. Prior to ISH, 
slides were dehydrated in an ethanol series (70%, 85%, 100%, 2min in each).
Slide dénaturation
Slides were placed in a Coplin jar containing 70% formamide at 70-72*C for 2min. 
Transfer to ice-cold 70% ethanol for 2min arrested dénaturation. Slides were again 
dehydrated in an ethanol series, and allowed to air dry.
Probe preparation and dénaturation
A. If the probe was to be pre-annealed with competitor DNA (YACs, BACs, cosmids, 
larger plasmids of > ~6kb) the following volumes were added to a microfuge tube for each 
22mm2 slide area to be hybridised with lOOng of labelled probe:
• 1ul 100ng/ul labelled probe stock
• lul lOug/ul total human genomic DNA (Cambio CA97205) or 2ul 1 ug/ul Cot1
DNA (Gibco BRL 15279-011)
(concentration might be varied according to the amount of CISS required)
• 0.4ul 10ug/ul sonicated salmon sperm DNA (optional)
If probes were to be co-hybridised, an appropriate volume of the additional probe was 
also added.
Hybridisation buffer was added to make the volume lOul unless the total DNA volume 
would comprise more than 30% of the hybridisation mix volume. In that case the DNAs 
were re-precipitated, as in nick translation, and the pellet dried before adding lOul 
hybridisation buffer. Doubling the concentration of labelled probe prepared in TE (to 
200ng/ul) could remove the need for this extra step. With the most frequently used 
probes, the entire labelling product was precipitated with competitor DNA immediately 
after nick translation and stored ready-to-use in hybridisation buffer.
The probe mix was denatured by 5 minute incubation at 70*C, then transferred to 37°C 
for 30-60 minutes to allow blocking of nonspecific, highly repetitive sequences.
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B. If probe was not to be pre-annealed (plasmid probes phins310 and pK082 only):
0.5.1 ul of 10Ong/ul labelled probe and hybridisation buffer (to a 10ul volume) were added 
to a microfuge tube. This was denatured at 70°C for 5 minutes immediately before ISH.
Hybridisation
Probe mix was applied to marked slide area, covered with a glass coverslip and sealed 
with rubber solution. Slides were incubated on a metal tray floating in a water bath at 37- 
43*C (depending on probe) overnight (16 hours).
Post-hybridisation washing and detection
Subdued lighting was used and all washes were performed in Coplin jars.
1. Gum and coverslips were carefully removed and slides soaked for 5min (or less if 
reduced stringency required for smaller probes) at 42*C in each of two jars of pre-warmed 
50% formamide. Alternatively, slides were washed in salt solution (usually 0.4xSSC,
72*C, 2min) and step 2 omitted.
2. Following 50% formamide, slides were washed twice in 2xSSC at 42°C (usually 5min 
each wash).
3. Appropriate detection solutions were prepared, incubated for 10min at room 
temperature then centrifuged for 10min at 14,OOOrpm to pellet any precipitate.
4. Slides were briefly soaked in 4XT. Blocking solution (lOOul) was added to each ISH 
area then covered with Parafilm ‘M’ laboratory film (American National Can, Chicago). 
Slides were incubated at 37°C for lOmin, by floating in a water bath on a metal tray.
5. If detecting biotinylated probe with FITC: lOOul FITC-avidin was added to the ISH area, 
covered with Parafilm and incubated for 15min at 37*C as before.
Detection agents for this first detection layer were varied as required:
If detecting DIG-labelled probe with FITC then mouse anti-digoxygenin FITC solution 
was substituted for FITC-avidin solution.
If performing dual hybridisation detecting DIG and biotin labelled probes then Texas 
red-avidin was used alone for the first layer.
6. Parafilm was removed and slides washed twice for 5min in 4XT at room temperature.
7. If detecting only a biotinylated probe, lOOul biotinylated anti-avidin solution was added 
to the ISH area, covered with Parafilm and incubated at 37*C for 15min, as before.
If detecting only a DIG-labelled probe then FITC anti-mouse solution was substituted 
and stages 9 to 11 omitted.
If performing dual hybridisation then mouse anti-digoxygenin FITC+biotinylated anti- 
avidin solution was used.
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8. Parafilm was removed and slides washed twice for 5min in 4XT at room temperature.
9. If detecting biotinylated probe then slides were incubated again with 100ul FITC-avidin 
solution at 37*C for 15min as before.
If performing dual hybridisation, anti-mouse FITC+Texas red-avidin solution was used.
10.Parafilm was removed and slides washed twice for 5min in 4XT at room temperature.
11.If using a biotinylated probe requiring further amplification of signal, stages 7-9 were 
repeated.
12.Excess 4XT was drained and each slide mounted in 30ul of counterstain (DAPl or 
DAPl + PI as appropriate) overlayed with a 64x22mm glass coverslip. Slides were stored 
in the dark below 4*C.
2.13.2 FISH with Commercial DNA Probe
Biotinylated chromosome paint (Cambio) was prepared (5ul + 4.5ul hybridisation buffer +
0.5.l Cotl DNA per lOul hybridisation area) then denatured, pre-annealed, hybridised 
and detected as detailed in section 2.13.1.
Digoxygenin-labelled satellite DNA probes (ONCOR/Qbiogene) were prepared (O.Sul + 
9.5ui hybridisation buffer) and also processed as above, but without pre-annealing. 
Directly labelled probes were prepared and processed according to the manufacturer’s 
instructions.
2.14 Fluorescence In Situ Hybridisation with Slide-Bound Cytocell Probes
2.14.1 Chromoprobe-T Procedure (adapted from the manufacturer’s protocol)
1. Pre-heat 70% formamide in a Coplin jar to 72°C in a covered water bath.
2. Wash slide in 2xSSC for 2min at room temperature.
3. Dehydrate slide in an ethanol series (70%, 85%, 100%, Imin in each). Air dry.
4. Denature slide by immersing in 70% formamide for 2min at 72*C.
5. Quench In ice cold 70% ethanol for 2min and dehydrate in an ethanol series as above. 
Air dry.
6. Mix the provided hybridisation solution and pre-warm to 37°C for a minimum of 2min.
7. Working in subdued light, pre-warm to 37*C the slides for ISH and Chromoprobe-T 
coverslips (Teflon-coated side upwards) by placing on a hotplate for 2min.
8. Apply 10-15ul of pre-warmed hybridisation solution to each hybridisation area.
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9. Place the Chromoprobe-T coverslip (Teflon side down) on the ISH area. Allow 
hybridisation solution to spread to the coverslip edges by applying gentle pressure. 
lO.Seal the coverslip edges with rubber solution (applied with a plastic syringe).
11 .Leave on the 37*C hotplate for at least 5min.
12.Check, using the liquid crystal thermometer supplied with the kit, that the temperature 
of the denaturing hotplate is 74-75*C.
13.Ensuring slide is in good contact with the hotplate, denature for 2.5min (Cytocell 
recommend 2min) at 74-75°C.
14.Cool for 30 seconds on the bench at room temperature, place slide/Chromoprobe-T 
combination on a metal tray, and float tray in a covered 37*C water bath overnight.
15.Prepare 0.4xSSC in a Coplin jar and heat to 72*C in a covered water bath.
16. Remove the Chromoprobe-T (and gum) carefully from the slide and place slide in pre­
heated 0.4XSSC for 2mln, 72*C.
17.Place the slide in 4XT, room temperature, for 30 seconds. Drain off excess solution by 
placing slide briefly on its edge.
IS.Apply 30ul DAPI/mountant then a glass coverslip (22x64mm) to slide.
2.14.2 Multiprobe-T Procedure (adapted from manufacturer’s protocol)
1. Pre-heat 70% formamide in a Coplin jar to 72-74*C in a covered water bath.
2. Template slide spotting:
• Soak template slide 2min in 100% methanol. Polish dry with a clean soft tissue.
• Add ~150ul Carnoy’s fixative to the pelleted metaphase preparation. Pipette 2ul of the 
cell suspension on to one slide area and allow to dry. Examine using phase contrast 
microscopy. If cell density Is too high, dilute the suspension with more fix. If too low 
(require at least 5 metaphases in each template square) centrifuge it and add less fix 
(minimum 60ul). Placing an extra drop of fix on the 2ul spot during spreading or 
warming the slide over a 65*C water bath may reduce cytoplasm around metaphases.
• Pipette 2ul on to all areas in the following order to prevent drops of suspension 
interfering with the spreading of adjacent drops -
1®^ row odd numbers, 2"^  row even numbers, 3"^  row odd numbers then, after drying,
1®^ row even numbers, 2"^  row odd numbers, 3^  ^row even numbers.
3. As Chromoprobe-T steps 2 -6 .
4. Float a lidded plastic box (supplied) in a 37°C water bath.
5. In subdued light, warm Multiprobe device to 37°C (label side down) on a hotplate.
6. Apply lul of warmed hybridisation solution to each of the raised bosses of the device.
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7. Carefully invert the template slide so that square 1 is located over the top right hand 
area of the device, marked in yellow. Lower the slide over the device, ensuring slide and 
device are properly aligned. Apply gentle pressure to ensure hybridisation buffer is 
spread to the edges of each Multiprobe area.
8. Lift the slide/Multiprobe-T device combination and invert so that the slide is underneath.
9. Leave at 37°C for 20min.
10.Check, using the liquid crystal thermometer supplied, that the temperature of the 
denaturing hotplate is 74-75*C.
11 .Transfer the slide/Multiprobe-T to the 74-75*C hotplate taking care to hold it level. 
Ensure the slide is in good contact with the hotplate. Denature for 2-3min.
1 2 .C0 0 I for 30 seconds at room temperature on the bench. Place in the warmed plastic 
box, replace lid and float at 37*C overnight in a water bath with no lid.
13. Prepare wash solution (Q.4xSSC) in a Coplin jar and heat to 72*C in a water bath.
14. Remove the device from the slide and place in pre-heated 0.4xSSC for 2min, 72°C.
15. As Chromoprobe-T steps 17-18.
2.15 Visualisation
Most slides were examined by epifluorescence using a Zeiss Axioskop microscope with 
appropriate optical filters (Table 2-1) and initially a 50W, then latterly a 100W, mercury 
vapour light source. Images were captured by a digital imaging system attached to this 
microscope (Fig. 1-8). Rhodamine, FITC, and DAPl excitation filters were present on a 
LudI filter wheel, and triple bandpass emission filter on a slider bar. A cooled CCD 
camera (Photometries, Tucson, AZ, USA, Kodak KAF 1400 chip (1317x1035 pixels)) 
was controlled by a Macintosh computer (initially Quadra then Powermac) with image 
manipulation and analysis software (Smartcapture V2.1, Digital Scientific).
Breakpoint mapping experiments involving BAC and PAC clones were examined using a 
Zeiss Axtoplan imaging microscope attached to a Cohu camera and Applied Imaging 
workstation with Cytovision software.
Prior to the availability of digital imaging, colour photomicrographs were taken using 
Kodak Ektachrome film (ASA 400) which was processed commercially.
2.16 Analysis Procedure
2.16.1 Using a Conventional Fluorescence Microscope
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Early FISH Investigation of t(4;11) Family Members Using Plasmid Probes 
Pre-banded and photographed, DAPl-stained hybridised cells were re-located using Zeiss 
filter combination 1. FITC signals on these post-1 SH metaphases, appearing as yellow- 
green spots against the red PI counterstain using filter set 9, were marked on the relevant 
photographs. A record of signal distribution was prepared by marking on an ideogram the 
positions of all signals in all examined cells, and Chi square ) testing performed to 
determine the significance of any signal peaks (as in Malcolm et al 1981).
Early Work with DGA/CFS and DMD Cosmids
The required number of metaphases were examined (see appropriate Results sections) 
and the presence or absence of probe signals recorded. Target chromosomes were 
identified by control probes (as In DMD/BMD studies) or morphology.
2.16.2 Using Digital imaging
Software enhanced reverse DAPl banding was used to identify the chromosomal 
localisation of signals in mapping studies. These could then be recorded directly on an 
ideogram and, if necessary, testing performed to determine the significance of any 
signal peaks.
PI had previously been included in counterstain so that, with conventional fluorescence 
microscopy, the use of Zeiss filter 9 could allow green FITC signal to be viewed together 
with red chromosomes. However when imaging such preparations an interference filter 
had to be inserted on capturing the FITC signal in order to block simultaneous PI 
emission, and this movement during the capture process could introduce an image 
registration shift. PI was therefore omitted from the counterstain.
For microdeletion studies, the required number of metaphases were scored, recording the 
presence or absence of probe signals. Chromosomes were identified by control probes 
or software enhanced reverse DAPl banding. At least two typical metaphases from each 
case were archived. Images were stored on 940MB optical disks (Panasonic).
FLUOR EXCITATION A, EMISSION 1 FILTER SET
FITC 490 525 Zeiss 9,10
Rhodamine 540-660 580 Zeiss 15
DAPl 345 425 Zeiss 1, 2
PI 520 610 Zeiss 9
Spectrum Green 505 535 Vysis Spectrum Green
Spectrum Orange 545-555 585 Vysis Spectrum Orange, Zeiss 15
Table 2-1 Optical filters.
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2.17 Amplification of Max-Planck Institute 21-Specific YACs
Adapted from the supplied Max-Planck Institute (MPI) protocol.
To avoid artefacts caused by DNA contamination only autoclaved reagents were used.
Procedure
1. Add to a 0.5ml microfuge tube:
•5.0ul lOxbuffer (Promega, magnesium free)
•5.0ul 2.5mM dNTPs (Pharmacia, a 1/10 dilution of 25mM)
•2.Oui 20pmol/ul DOP primer (a 1/10 dilution of 200pmol/ul stock,
Telenius et al (1992))
•5.0ul 25mM MgCl2 (Promega)
•30.6ul sterile ultrapure water
2. Leave microfuge cap open, UV-irradiate (Amplirad), lOmin,
3. Add:
•2ul (100ng/ul) VAC template (1®^ re-DOP reaction, supplied by MPI)
•0.4ul (2U) Tag DNA Polymerase (Promega 5U/ul)
•50ul mineral oil overlay
4. Close cap, transfer to thermal cycler (Perkin Elmer), and run PCR;
Dénaturation at 94*C for Imin, followed by 94*C, Imin; 40°C, 1min; 72*C for 4min (35 
cycles) then 72*C for lOmin. Soak at 15*C.
5. After carefully removing 45ul through the oil, the product was either precipitated 
immediately or first stored at 4°C overnight.
6. To precipitate PCR product, add to 45ul of product in a 1 ml microfuge tube and mix:
•4.5ul 3M Sodium acetate pH5.2 
•lul glycogen
•125ul (2-3 volumes) ethanol (-20*C)
7. Place at -40*C, 15min.
8. Centrifuge at 13,000rpm (Eppendorf microfuge), 30min.
9. Vacuum dry (Speed Vac Concentrator).
10.Add 30ul TE buffer, pH8
11 .Float In water bath at 37°C, 90min.
12.Measure absorbance at 260nm (section 2.7). One PCR amplification should yield 5- 
10ug/50ul according to MPI.
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2.18 Agarose Gel Electrophoresis
Materials
Electrophoresis grade agarose (Gibco BRL 15510-027)
TBE buffer xIO (0.90M Tris, 0.9M Boric acid, 20mM EDTA):
108g Tris base 
55g boric acid 
40ml 0.5M EDTA
Make up to 1L in distilled water and dilute 1:10 for use.
Also available from National Diagnostics, Hull, England.
Loading mix:
0 .2 5 . Bromophenol blue (Sigma) in a 30% glycerol/70% water solution 
1 kb ladder mix:
lOul Ikb ladder (lug/ul Gibco BRL 15615-016)
20ul loading mix 
80ul TBE (or H20)
Store at 4'^ C or -20°C.
Procedure
1. Assemble electrophoresis system (EMBITECH RunOne).
2. Prepare a 1.3% agarose gel in a 250ml beaker:
• 0.65g agarose
• 50ml IxTBE buffer
3. Heat to boiling in a microwave (about Imin).
4. When cooled to 60°C, add 3ul Ethidium bromide (lOmg/ml aqueous solution. Sigma 
El 510, carcinogenic) in a fume hood.
5. Pour into gel tray with ends in place. Add comb and allow to cool for 20min.
6. Prepare samples: 5ul DMA plus 2ui loading mix.
7. Remove comb and ends from gel, cover with IxTBE buffer.
8. Load samples. Load a size ladder (7ul) in one well.
9. Run at 100V (-45mA) until loading mix halfway down gel, remove gel and check using 
a UV light source (UV transilluminator) and gel documentation system (UVP).
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2.19 Comparative Genomic Hybridisation Adapted from Kallioniemi et al (1994).
2.19.1 Siide Preparation
Only well spread, high mitotic index, low debris slide preparations of synchronised 
peripheral blood cultures from karyotypically normal male donors were selected for use as 
target chromosomes. Slides were generally prepared 1-3 days prior to CGH and stored 
at room temperature but could be frozen in a Parafilm-sealed box containing silica gel 
crystals (2-3 crystals In a small box with 2-3 slides) till required. Slides were not returned 
to freezer once removed.
Procedure
Target metaphase slides made from previously tested and stored fixed cell suspensions 
were examined prior to dénaturation by phase contrast microscopy using a xIO objective, 
x10 eyepiece and x1.6 Optovar which provided the extra magnification to confirm the 
absence of unevenly-stained chromatids and damage on chromosomes (which could be 
frequent on Vysis slides). Dark, non-refractile chromosomes were preferred.
If, on checking slides after dénaturation, chromosomes appeared pate and ‘grey’, 
another, less stringently denaturated slide would be examined prior to use in CGH. This 
effect was seldom apparent when metaphases of appropriate quality were selected for 
CGH.
Test DNA was generally hybridised to target metaphase preparations from more than one 
individual, increasing the chance of high quality signal being obtained in at least some of 
the hybridisation areas in an experiment.
2.19.2 Slide Dehydration and Dénaturation
Procedure
1. Dehydrate in an ethanol series (70, 86,100%, 2min each).
2. Denature in 70% formamide for 3min at 73-74°C.
3. Quench in ice cold 70% ethanol, 2min.
4. Dehydrate in an ethanol series (70, 85,100%, 2min each).
2.19.3 Probe Labelling and Hybridisation
Most CGH investigations were performed using DNA extracted by the molecular genetics 
division of this Institute. Labelling was by nick translation, a modification of the method 
described for use of the Gibco BRL kit (18160-010).
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Procedure
1. in 1ml microfuge tubes on ice prepare labelling mixes as below, using dUTP 
conjugated to a green fluor (Fluorescein-12-dUTP, NEN NEL413, or SpectrumGreen 
dUTP, Vysis 30-803200) for test DNA, and dUTP conjugated to a red fluor (Texas Red-5- 
dUTP, NEN NEL417, or Spectrum Red dUTP, Vysis 30-803400) for the control DNA. Mix 
after each addition.
Kit dNTP mix (minus dTTP) 5ul
DNA 1 ug
fluorophore labelled dUTP (green or red) ImM 1ul
DNA Polymerase lOU/ul (Promega M205A) lul
Kit DNA Polymerase/DNAse I (Gibco BRL 18162-016) 5ul
H2O to bring final volume to 50u! Xu I
2. Incubate 15°C, 55min to obtain 500-2000bp fragments.
3. Place at 65°C, lOmin to stop reaction.
4. Remove 10ul from each tube for later electrophoresis (to confirm fragment size). Store 
at -20°C.
5. To the test DNA tube add:
• 40ul (800ng) control DNA labelled as above or 2ul (200ng) Vysis labelled control DNA 
(female 32-804023 or male 32-804024).
• 30-40ul (40ug) Cot1 DNA. Use 20ul if employing Vysis labelled control DNA.
• 12ui 3M Sodium acetate pH5.2 (filter sterilised, Sigma S-7899) or 6.3ul if using Vysis
labelled control DNA.
• 300ul iced ethanol or 170ul if using Vysis labelled control DNA.
• Mix, place at -70 °C, 15min.
6. Microfuge 14000rpm, 30min.
7. Remove supernatant and vacuum-dry pellet for 20min. The dry pellet must not be left 
standing, as fluorophores may decay faster when dry.
8. Add lOul hybridisation buffer. Mix gently.
9. Denature in a water bath at 70°C, 5min.
10.Apply probe to marked hybridisation area on slide.
11 Hybridise at 39°C for 72 hours.
12.Perform the following washes In very subdued light:
• 50% formamide, 7.5min, 45°G (twice)
• 2xSSG, 5min, 45*G (twice)
• 4XT, 5min, room temperature
13.Dehydrate in an ethanol series as before.
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14.Mount in 30u! Citifluor AF1 containing 1.6ug/ml DAPI.
2.19.4 Slide Examination and Image Processing
Procedure
1. Select for analysis metaphase spreads with fairly bright and even signals, bright DAPI 
counterstain and ‘blocked’ centromeres (no signal).
2. Record digital fluorescent images of all 3 colours with the CCD camera and 
Smartcapture software using automatic setting, gain 4. Ensure lamp is centred and 
focussed to achieve homogeneous illumination of the optical field.
3. Save and (following reverse-DAP! banding with Smartcapture software if necessary) 
process at least 5-10 of the highest quality images according to Quips CGH Karyotyper 
and Interpreter software by following the manufacturer's instructions (Vysis). Ignore 
signals on acrocentric short arms, centromeric and heterochromatic regions. Particularly 
note any signal which is visible on two apparently homologous chromosomes.
Early CGH experiments were alternatively, or additionally, software processed using 
Smartcapture global’ analysis according to manufacturer’s instructions.
2.19.5 CGH Quality Assessment
• Ascertain even paint coverage, bright signal and blocked’ centromeric regions.
• Examine images by eye - it may be possible to visualise an apparent imbalance on 
both chromosome homologues, helping to confirm its significance.
• Check for detection of the pseudoautosomal region on Xp (-2.6Mb) with relaxed 
threshold.
• A normal male versus normal female control CGH can be included. This should show 
a loss of entire X and gain of entire Y at thresholds 0.8 /1.2 without introducing false 
positive gains or losses (Kallioniemi et al 1994).
• Use test and control DNAs of differing gender to provide an internal control via the sex 
chromosomes (Weiss et al 1999). With female test and reference male DNA, gain should 
be visible on chromosome X unless threshold set to > 2.0. With male test/female 
reference, apparent loss should be visible unless threshold set to < 0.5.
• If the limits of 95% or 99% Cl of test versus reference CGH ratio profiles are used as 
thresholds, gains or losses are identified when the 95% or 99% Cl at the site of a 
suspected Imbalance does not contain 1.0 (Weiss et al 1999).
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• Repeat or duplicate CGH using a different control DNA. Ascertain that any apparent 
gains/losses are consistent.
• Repeat CGH with inverse labelling of test and reference DNA can be used to check 
that any apparent gains/losses are consistent (Kallioniemi et al 1994).
• Use FISH, if appropriate probes available, to confirm apparent imbalances and provide 
increased resolution.
2.20 Primed In Situ Labelling
2.20.1 Commercial Repetitive Target Sequence Primers and Kits
2.20.1.1 The PRINS Reaction Set
Initial experiments employed the PRINS Reaction Set (Boehringer Mannheim 1695932) 
with a human chromosome 12 alpha satellite-specific primer (1696009). The contents of 
the reaction mix and recommended dénaturation and annealing/extension temperatures 
used were identical to those in test 1, Table 3-28.
Materials
Contents of PRINS Reaction Set, stored at -20°C:
PRINS labelling mix x10 (500uM of each of dATP, dCTP, dGTP, 50uM DIG-11-dUTP in 
50% glycerol)
dTTP solution (450uM dTTP)
PRINS reaction buffer xIO
Anti-digoxygenin-fluorescein Fab fragments (200ug/ml). Aliquot and store ‘in use’ vial for 
up to 2 months at 4°C. To prepare detection solution dilute 1:1000 in PBS containing 1% 
blocking solution (10% blocking reagent - available separately from Boehringer Mannheim 
- w/v in buffer comprising lOOmM maleic acid, 150mM NaCI, pH7.5).
Additional reagents not provided in kit:
Taq DNA Polymerase lU/ul (Boehringer Mannheim)
PRINS oligonucleotide primer (chromosome 12-specific, Boehringer Mannheim 1696009) 
Wash buffer (0.2% Tween 20 in PBS)
PRINS stop buffer (0.05M NaCI, 0.05M Na2 EDTA, pH8, Gosden and Hanratty 1993) -
0.5ml 5M NaCI 
5ml 0.5M NazEDTA 
40ml purified water
84
Procedure (essentially, apart from counterstaining, as in manufacturer’s instructions)
1. For each PRINS area add the following reagents to a sterile microfuge tube on ice;
• sterile ultrapure water 13.5ul
• PRINS reaction buffer x10 3.Oui
• PRINS labelling mix x10 3.0ul
• dTTP solution S.Oul
• oligonucleotide primer S.Oul
• Taq DNA polymerase (1U/ul) 2.Sul
2. Mark 22x22cm reaction areas on dry slides with fixed chromosomes. Place on a 
heating block and incubate at 94°C for 1min.
3. Add 25ul of the reaction mix and cover with a 22x22cm coverslip.
4. Incubate at 91-94°C for 3min to denature the chromosomal DNA (set the heating block 
to 95°C to obtain this temperature on the slide).
5. Adjust the heating block to 60°C and incubate the slides for 30min at 60°C.
6. Remove the slides from the block and stop the reaction by washing slides immediately 
for Smin at 60°C in pre-warmed stop buffer in a Coplin jar.
7. Wash three times for Smin at 37°C in wash buffer and once for 1min in PBS.
8. Incubate the slides in detection solution for 30min at 37*^ 0 in the dark.
9. Repeat step 7.
10.Mount and counterstain in DAPI or DAPI + PI in Citifluor AF1.
2.20.1.2 The Chromosome Print Kit
The Chromosome Print Kit (a commercial PRINS system available from Advanced 
Biotechnologies, Surrey) was later assessed. A programmable heat block (Omnigene, 
Hybaid), which compensated for the temperature difference between the block and the 
surface of the slide, was available for use by that time (Fig.3-25). Omnigene hot blocks 
also have an internal lid and reservoir which can provide a humid environment.
Materials
Contents of Print Kit:
Chromosome Print labelling mix, stored at -20°C 
Chromosome Print oligonucleotide, stored at ~20°C
Chromosome Print stop solution, stored at 4‘^ C. Pre-warm 50ml to 65°C in a Coplin jar 
before use.
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Chromosome Print wash solution x5, stored at 4°C. Add contents to 400ml sterile purified 
water and mix. Pre-warm to 45°C before use.
Blocking reagent, stored at 4°C. To prepare blocking buffer, add 1ml of pre-warmed 
wash solution and dissolve by vortex mixing.
Additional reagents not provided in kit:
CP-CPP Chromosome Print Polymerase 5U/ul
(Alternative: AmpliTaq IS Polymerase 20U/ul and MgCL 25mlVI (Perkin Elmer))
Biotin-16-dUTP ImM (Boehringer Mannheim 1093070)
(Alternatives: Digoxygenin label mix 1mM dATP/dCTP/dGTP, 0.65mM dTTP, 0.35mM 
dUTP-DIG (Boehringer Mannheim) or DIG-11-dUTP ImM (Boehringer Mannheim)) 
Fluorescein Avidin DCS (Vector Laboratories, A-2001) diluted 1:500 in blocking buffer for 
use (0.25ul in 125ul blocking buffer)
Procedure (see Table 3-27)
1. For each PRINS area add the following reagents to a sterile microfuge tube on ice. 
Either:
Chromosome Print labelling mix 43.Oui
Chromosome-specific primer 5.0ul
Chromosome Print polymerase 1 .Oui
1 mM Biotin-16-dUTP/digoxygenin-11 -dUTP 1 Oui 
Or:
Chromosome-specific primer S.Oul
Digoxygenin label mixxlO S.Oul
PCR Buffer xIO (Perkin Elmer) S.Oul
MgCL (25mM, Perkin Elmer) 2.0ul
Sterile ultrapure water 32.8ul
AmpliTaq IS Polymerase 20U/ul 0.25ul
For experiment 4 the total volume of the reaction mix was adjusted to 30 rather than 50ul 
and the AmpliTaq IS concentration increased to 0.13U/ul (0.2ul/30ul). The concentrations 
of the other components were as above.
2. Mark 22x32cm reaction areas on 1 day-old slide-bound chromosome preparations. 
Dehydrate in an ethanol series (70%, 85%, 100%, 2min each). Air dry. Add reaction mix 
and cover with a 22x32cm coverslip. Seal coverslip with rubber solution and allow to dry.
3. Place on a heating block pre-heated to 93°C and run program:
93°C for Imin, 60°C for 10min and 72°C for 15min.
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4. Quickly remove coverslip and place slide in a Coplin jar containing pre-warmed stop 
solution. Incubate at 65°C, 1min.
5. For biotin detection:
• Place slide in wash solution.
• Prepare 40ul avidin-FITC detection solution for each slide reaction area.
• Remove the slide from wash solution, blot the slide edges to drain. Add 40ul of 
blocking buffer, cover with Parafilm and incubate for 5min at room temperature.
• Remove Parafilm, blot slide edges to drain buffer and add 40ul of diluted avidin-FITC. 
Incubate at 37°C, 30min, floating on a metal tray in a covered water bath.
• Remove Parafilm and wash three times for 2min at 45°C in wash solution.
Alternatively, for digoxygenin detection:
• Place slide in 4XT at room temperature.
• Block in 4XT + 15% human AB serum for lOmin and detect DIG label as for FISH.
6. Mount and counterstain in DAPI or DAPI + PI in Citifluor AF1.
2.20.2 PRINS and Cycling PRINS Using In-House' Primers
Slides were processed using, as detailed in Tables 3-28, 30, 32, 35, 37, 38, 39, variations 
of the procedures and reagents described above. Reaction mixes were 30 or 50ul 
volumes, generally applied under 22x22mm or 22x32mm coverslips. Slides which were 
denatured in 70% formamide (for 2min at 70°C, unless otherwise stated) were (as in 
FISH) dehydrated in an ethanol series before and after dénaturation. Label detection, 
generally following incubation in stop buffer (0.05M NaCI, 0.05M NaaEDTA, pH8) for 5min 
at 60°C, was as described for FISH.
2.20.3 Ligase Pretreatment
Some slides were treated with T4 DNA Ligase to attempt to reduce background arising 
from nonspecific initiation at single strand nicks in the chromosomal DNA.
Materials
Ligase mix:
0.5ul T4 DNA Ligase (lU/ul, Gibco BRL)
2ul Ligase buffer (x5, Gibco BRL)
7.5ul sterile purified water
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Ligase stop solution (0.5M NaCI, 0.05M N32EDTA, Gosden and Hanratty 1993):
5ml 5M NaCI 
5ml 0.5M NagEDTA 
40ml purified water
Procedure
1. Prepare ligase mix. Require 0.5U ligase in 10ul for each 22x22mm reaction area.
2. Place lOul ligase mix on each reaction area, cover with a 22x22mm coverslip.
3. Place on a thermal cycler block in a humid chamber at room temperature for 1 hour.
4. Terminate the ligase reaction by soaking for Smin in stop solution.
5. Dehydrate slides in an ethanol series and air dry.
2.20.4 Fix Pretreatment
Place slide in Coplin jar containing Carnoy’s fix for 45-60min. Remove and air dry. 
Incubate in 2xSSC for 30min at 37°C. Dehydrate in an ethanol series.
2.20.5 Tyramide Signal Amplification
Materials
Contents of TSA-lndirect Kit (NEL730A, DuPont NEN), stored at 4°C:
Streptavidin-HRP (horseradish peroxidase) Conjugate 100ml
DuPont Blocking Reagent 3g
Biotinyl Tyramide sufficient for 50 slides
Reconstitute with 0.5ml of 100% ethanol. Close immediately after use to avoid volatility of
ethanol affecting tyramide concentration.
Amplification Diluent (2x) 20ml
Diluted 1:1 with purified water for use.
Purchased separately:
Anti-Digoxygenin-POD Fab fragments (Horseradish peroxidase conjugate) 150U/ml when 
reconstituted (Boehringer/Roche 1207733). Dilute 1:50 or 1:100 in TNB (see below) for 
use. Prepare 100ul per slide.
Streptavidin-Fluorescein 1ml, 1 mg/ml (NEL720). Dilute 1:500 in TNB (lul + 499ul TNB). 
Prepare 100ul per slide.
Reagent Preparation
Biotinyl Tyramide solution:
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Prepare a 1:50 dilution of Biotinyl Tyramide stock in 1 x Amplification Diluent. 
Approximately 300ul per slide required (6ul Biotinyl Tyramide + 294ul Diluent).
TNT Buffer (0.1M Tris-HCI pH7.5, 0.15M NaCI, 0.05% Tween 20):
1MTris-HCi pH7.5 60ml
3M NaCI 30ml
Purified water 510ml
Tween 20 300ul
TNB Buffer (0.1 M Tris-HCI pH7.5, 0.15M NaCI, 0.5% DuPont Blocking Reagent)
Mix in a 20ml Universal container (Sterilin):
1M Tris-HCI pH7.5 1.0ml
3M NaCI 0.5ml
DuPont Blocking Reagent 0.05g
Purified water to 10.0ml
Heat at 65°C for 1 hour to dissolve blocking agent. May store for 1 month at -20°C. 
Procedure
Digoxygenin label was used in the PRINS or FISH prior to tyramide amplification. Stop 
buffer was omitted following PRINS on most occasions (to avoid TSA inhibition, verbal 
communication, DuPont NEN).
The method used was essentially that recommended by the manufacturer, with some 
modifications while attempting optimisation.
For evaluation of amplification effect, control slides were included which were also
blocked with TNB and washed with TNT buffer but detected using anti-digoxygenin FITC
and anti-mouse FITC (though with intermediate TNT rather than 4XT washes) as in 
standard FISH.
1. Following post-ISH washes or PRINS, wash slide three times for 5min in TNT buffer at 
room temperature, with agitation.
2. Add lOOul TNB Buffer to each FISH/PRINS area and cover with Parafilm.
3. Incubate at 37°C for 30min floating on a metal tray in a water bath.
4. Drain off TNB Buffer, add lOOul of Anti-Digoxygenin-POD diluted in TNB Buffer (1:50 
or 1:100) and cover with Parafilm.
5. Incubate at 37°C for 30min floating on a metal tray in a water bath.
6. Wash slide three times for 5min in TNT buffer, with agitation.
7. Add 300ul of 1:50 dilution of Biotinyl Tyramide stock in 1x Amplification Diluent and 
incubate at room temperature for 7 or lOmin (manufacturer suggests 3-10min).
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8. Wash slide three times for Smin in TNT buffer, with agitation.
9. Add 100ul of a 1:500 dilution of Streptavidin-Fluorescein conjugate in TNB Buffer.
10.Incubate at 37°C, 20-30mln, floating on a metal tray in a water bath.
11 .Wash slide three times for Smin in TNT buffer, with agitation.
12.Counterstain and mount in Citifluor AF1 with DAPI or DAPI + PI as for conventional 
FISH. Evaluate using fluorescence microscopy with appropriate optical filters.
NEN suggest reducing anti-hapten antibody concentration, labelled probe concentration 
and time in Steptavidin-Fluorescein if signal overly bright and lacks resolution.
2.20.6 PCR
PCR in solution was performed to assess the amplification efficiency of some PRINS 
primers and reaction mixes. The variety of reagents and conditions used are described in 
Tables 3-29, 31, 33, 34, 36. Reaction mix (50ul) in 0.5ul microtubes was overlaid with 
mineral oil, the tubes placed in a thermal cycler (Perkin Elmer) and the PCR programme 
commenced.
Agarose gel electrophoresis of the PCR products was performed (see section 2.18) and 
the results photographed using a UV transilluminator and gel documentation system 
(UVP).
2.21 Proteinase K Pretreatment (broadly according to Kallioniemi et al 1994) 
Materials
0.2ug/ml Proteinase K (Sigma P2308) in 20mM Tris-HCI, 2mM CaCL pH7.5. Aliquot and 
store at -20°C.
Procedure
If pretreating CGH slides, first dehydrate and denature as usual.
Place 200ul 0.2ug/ml proteinase K on the slide, cover with a glass coverslip and incubate 
for 3min (PRINS) or 7.5min (CGH) floating on a metal tray in a water bath at 37°C. 
Remove coverslip and dehydrate in an ethanol series prior to PRINS (may first treat with 
ligase) or continuing CGH. Before preceding, examine slide using phase contrast 
microscopy to ensure metaphase speads have not been damaged.
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3. RESULTS
3.1 Chromosomal Localisation of Unique Sequences and Breakpoint 
Mapping
Following several years experience of chromosomal localisation using chromogenic ISH 
(publications included Morrison et al 1990, 1991a,b, 1992), fluorescence detection of ISH 
preparations was Introduced to this department in 1992. A period of considerable 
development followed during which several genes were localised and modifications to the 
methodology were introduced (Murphy et al 1993, Morrison et al 1994a,b, McBride et al 
1995a,b) with the aim of rendering the process more rapid and improving accuracy, 
reliability and sensitivity. Most notable was the digital recording of FISH images, which 
allowed software-enhanced reversed DAPI banding and therefore chromosome 
identification directly from the computer screen. This, and the availability of larger clone 
inserts for mapping, obviated time consuming pre-hybridisation banding and photography 
for chromosome identification and statistical analysis of signal distributions.
Mapping, in collaboration with a number of research groups, continued during the course 
of this study (1996 onwards). The research groups have been listed, together with probe 
details, in Appendix I and a chronologically ordered summary of the mapping results 
obtained is presented in Table 3-1.
Probes from these researchers were generally supplied ready for assessment of DNA 
concentration and incorporation of labelled nucleotide by nick translation. FISH mapping 
was executed on metaphase spreads prepared from the synchronised cultured 
lymphocytes of at least two karyotypically normal human males, more precise localisation 
involving selection of longer prometaphase spreads in these cultures. Initial mapping of 
clones was carried out with no knowledge of any previous chromosomal localisation 
results.
An obvious advantage of chromosomal localisation is that mapped DNA sequences may 
then be utilised in the characterisation of chromosome rearrangements. Chromosome 
21-specific YACs and chromosome 8 and 21 BACs and PAGs were sourced for 
breakpoint mapping investigations on fixed cytogenetic preparations from two patients 
with chromosomal rearrangements. These probes respectively required PCR 
amplification or culture and extraction prior to labelling. Their use in breakpoint mapping 
followed validation of probe map positions on karyotypically normal metaphase spreads. 
Unless stated, detection of all FISH localisations employed the biotin-avidin-FITC system, 
amplified at least once with biotinylated anti-avid in and another layer of avidin-FITC, and
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a hybridisation temperature of 37°C was utilised to reduce stringency. Probe 
concentration, hybridisation and detection conditions used for each probe are recorded in 
Table 3-2. These were established following preliminary experiments with each probe to 
determine the conditions which would maximise signal strength and minimise nonspecific 
background.
CLONE LOCUS SIZE
___________NAME (kb)
VECTOR DESCRIPTION RESULT OF MAPPING  
(BAND LOCATION)
1. PAC227 100 PAC
-300
2. 82~h2 MRCK^ 100 PAC
or -300
CDC42BPB
?hTERT
518C13 hTERT
70-100 P I
Endothelin-iike sequence 
from HGM program 
PAG library.
Isolated from RP1 
library by hybridisation 
to CDC42BPB 5’EST. 
Contains 460bp from 
exoni.
Putative telomerase 
protein component.
-180 BAC
11p12-p13
14q32.3
10q11.21~q11.22 
and 10q22.3 
5p15.33
4.
6 .
9:17;
22;30
925h10
937e12
949b09
866h04
858010
759d03
268F23
280N08
65E08
184E23
141D02
152M24
369E15 
177H13 
395114 
14117 
138J2 
356F24 
263C6 
564K10 
527N22 
350N15 
44K6 
51K12 
198M21 
231D20 
137L15
7SCD2
21q-specific
'35-45 cosmid Putative stearoy! 4q21.2~q21.3.
coenzyme A desaturase 2
21q-specific
21q-specific
PCR
amplified
YAC
inserts
BAC
PAC
8p-speclfic -18 0  BAC
8q-specific 100
-300
PAC
YACs from CEPH 
library.
Clones from RP11 library.
Clone from RP1 library. 
Clones from RP11 library.
Clone from RP1 library.
21q21.1~q21.2
21q11.2~q21.1
21q11.2
21q11.2~q21.1
21q11.2
21q11.2
21q11.2~q21.1 (2lq2l.l) 
21q11.2~q21.1 (2iq2l.l) 
21q11.2~q21.1 (2 iq2 i. i)  
21q11.2~q21.1 (2 lq2 l. l)  
21q11.2~q21.1 (2lq2i.i) 
21q11.2~q21.1 (2lq2i.i)
8p21 (8p21.3)
8p21 (8p21.2)
8p21 (8p21.2)
8p21 (8p21.2)
8p21 (8p21.2)
8p21 (8p21.2)
8p12 (8p12)
8p12 (8p12)
8p12 (8p12)
8p11.2~p12 (8p12) 
8p11.1~p11.2 (8p11.21) 
8p11.1~p11.2 (8p11.21) 
8p11.1~p11.2 (8p11.21) 
8p11.1~p11.2 (8p11.21)
8q11.21~q11.22 (8q11.21)
Table 3-1 Clones supplied for mapping and  
Chromosome 8 and 21 clones were only roughly 
localisation is bracketed.
results obtained.
localised, for identity confirmation. Their EnsembI
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3.1.1 Endotheiin 3-lîke Sequence
PAC227 had been isolated during a study of the role of endotheiin 3 in diabetic 
retinopathy. It was supplied for chromosome assignment to determine if its location 
would match that of the given map position for endotheiin 3 (20q13.2~q13.3, MIM 
131242) and hence support its identification as an endotheiin sequence.
Probe concentration was determined to be 1.05ug/ul prior to biotinylation by nick 
translation. Preliminary CISS hybridisations established optimal competitor concentration 
(0.8ug/ul total human genomic DNA in pre-annealing for a reduced period of 30 minutes), 
probe concentration (24ng/ul) and wash conditions (two 5 minute incubations in 50% 
formamide). Three layers of avidin-FITC were used in detection and human AB serum in 
4XT was used as blocking solution.
After counterstaining with DAPI alone to avoid the image registration difficulties 
encountered when using PI (see Methods) post-ISH metaphases were analysed directly 
from the screen using digitally-enhanced DAPI bands for chromosome identification. 
Twelve metaphase chromosome spreads were analysed. Signal was visible only on 
chromosome 11, at the junction of bands pi 2 and pi 3, and was present on both 
homologues of chromosome 11 in 50% of cells (Fig.3-1).
3.1.2 Myotonic dystrophy protein kinase-related Cdc42-binding kinase (3 {MRCKjS)
In the course of general characterisation of the human sequence our
collaborators had mapped it to 14q32.1~q32.3 using MRCKj3-speo\f\c oligonucleotides to 
screen radiation hybrid panels. To verify this assignment a PAC clone of the human 
homologue of MRCKJ3 (known as CDC42BPB or 82-h2) was isolated from the RP1 library 
and provided for chromosome localisation by FISH.
The concentration of 82-h2 supplied was lug/ul. Preliminary hybridisations of biotinylated 
82-h2 established optimal competitor concentration (lug/ul total human genomic DNA) 
probe concentration (8-10ng/ul) and wash conditions. Satisfactory results were obtained 
using post-ISH immersion in 2xSSC at 72°C for 5 minutes, which removed the 
requirement for formamide washes and the risk associated with their use. The use of 
only one FITC amplification did produce signal with this large sequence, but signal was 
easier to visualise without imaging following two rounds of amplification.
Twenty metaphase chromosome spreads were analysed. Signal was seen only on both 
homologues of chromosome 14, at band 14q32.3, in every cell (Fig.3-2, Moncrieff et al 
1999). More refined mapping to 14q32.31~q32.32 was achieved by examination of the
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ten longest metaphases (some with approximately 850 bands). Twelve of the signals on 
twenty chromosome 14 homologues were located at 14q32.31 and eight at q32.32.
3.1.3 Human Telomerase Reverse Transcriptase {hTERT, MIM 187270)
Our collaborators were involved in the isolation of a probe for the reverse transcriptase 
catalytic subunit of telomerase which would be suitable for FISH. This probe would allow 
direct physical mapping of the gene and additionally be a useful tool in their investigation 
of hTERT copy number in cell lines and tumours.
Initially FISH mapping was performed with a PI clone containing a putative hTERT 
sequence. Its localisation to lOql 1.21-11.22, with a weakly hybridising secondary site at 
10q22.3, suggested it could not be hTERT, as hTERT had previously been tentatively 
mapped to distal chromosome 5p by PCR analysis of hybrid panels (Meyerson et al 
1997). An hTERT BAC probe was therefore subsequently isolated by our collaborators 
and submitted for chromosomal assignment.
Two preparations of this probe, 518C13, were provided. One was biotinylated and the 
other (concentration 3ug/ui) was used for DIG labelling. The biotinylated 518C13 was 
hybridised to metaphase chromosome spreads at a concentration of 5ng/ul with 0.5ug/u! 
Cot1 DNA as competitor. Post-ISH washing involved two 10 minute incubations at 42°C 
in 50% formamide, and two layers of avidin-FITC were used in detection.
Only metaphase spreads with clear bands at 5p15.2 were analysed. Signal was present 
only on both chromosomes 5, at bands p15.32~p15.33, in all cells examined.
Biotinylated 518C13 was also co-hybridised with DIG-labelled 6p15.2-specific sequence 
(D5S23, Oncor Inc., Gaithersburg, MD). All ten metaphases examined showed 518C13 
signal in the distal 5p15.3 region and distal to 5p15.2 signal on both chromosome 5 
homologues.
DIG-labelled 518C13 (lOng/ul) was co-hybridised with biotinylated cri du chat region 
probe (5p15.3, Oncor), ascertaining that the cri du chat probe localised to proximal 
5p15.3 and confirming that 518C13 lay distal to this locus (Fig.3-3).
As 518C13 appeared to have a very distal location on chromosome 5p, it was then co- 
hybridised with Chromoprobe-T 5ptel/5qtel probe combination (Cytocell, Adderbury, 
Oxfordshire), no individual 5ptel probe being commercially available, to determine if 
518C13 could be ordered relative to the telomeric sequence. Biotinylated 518C13 
(5ng/ul) in hybridisation buffer was used in place of the hybridisation buffer supplied with 
the coverslip-bound telomere probes. Formamide post-ISH washes were performed as 
for 518C13 single hybridisation and dual colour signal detection carried out with Cytocell
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detection agents. All twenty metaphases examined, with chromosomes in the 550-850 
band range, showed apparent co-localisation of 518C13 and the 5ptel cosmid 114j18.
This confirmed 518C13 location to 5p15.33 and suggested that the sequences are no 
more than 1Mb apart. Sequence 114j18 was considered, by Cytocell, to lie within 300kb 
of the telomere associated repeats (these repeats may extend for several hundred kb, 
Knight and Flint 2000).
To ascertain that the 5ptel probe signal was, as expected, more distally located than 
518C13, interphase analysis was attempted following the co-hybridisation of biotinylated 
518C13, 5p 15.2-specific probe (Oncor) and 5ptel/5qtel probe combination (Cytocell) 
visualised using Cytocell detection agents. As confirmed on control metaphase spreads, 
the red 5qtel probe signal was fortuitously consistently weaker than the red 518C13 signal 
and could be removed, by adjusting the colour Intensity, for analysis. Although it was 
realised that tertiary structures in nuclei could interfere with reliable interphase ordering 
above 1Mb (Trask et al 1991) and that the 5p15.2 sequence would lie more than 1Mb 
from 518C13, no other distal 5p sequence was then commercially available, the 5p16.3 
probe used in earlier FISH having been discontinued.
Only nuclei with three signals in a straight line (one signal distant from the other two) and 
with no doublet signals (which could be misinterpreted as two single signals of the same 
colour) were scored. Of thirty nuclei examined, seventeen met these criteria. All 
seventeen showed co-localisation of a green (presumably 5ptel) and red (518C13) signal, 
with a green 5p15.2 signal separate from this combination. Nuclear scoring was 
discontinued as it became obvious that the distance between the 5p15.2 signal and the 
other sequences was complicating analysis (signals were often in a curved line, for 
example). This investigation did, however, appear to suggest that the distance between 
the 5ptel sequence and 518C13 might be as little as 50kb - the lower limit of resolution for 
interphase analysis (Trask et al 1991).
In summary, these experiments confirmed the mapping of hTERT to the distal short arm 
of chromosome 5 and refined this localisation to band 5p15.33, distal to the commercial 
5p15.3 cri du chat probe sequence (Oncor) and within 1Mb of subtelomeric sequence 
114j18.
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Fig.3-1 Localisation of PAC227 Endothelin-like sequence to 11p12-p13. Image on right 
shows reversed DAPI image used for chromosome identification.
H ■
Fig.3-2 Localisation of MRCKpXo 14q32.31~q32.32. Image on right shows reversed 
DAPI image with MRCKp signal (green) superimposed.
B
J
D
Fig.3-3 Localisation of hTERT to 5p15.33.
A: hTERT (red) co-hybridisation with 5p15.3-specific cri du chat probe (green, Oncor). 
B: Reversed DAPI image of A.
C; hTERT (red) co-hybridisation with 5ptel probe 114j18 (green, Cytocell). 5qtel probe 
was also hybridised but the signal was weak and not apparent in this image.
D; Reversed DAPI image of C.
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Fig.3-4 Localisation of putative SCD2 to 4q21.2-q21.3.
A: SCD2 cosmid 17.
B: Reversed DAPI image of A.
C; SCD2 cosmid 9 (red) co-hybridisation with chromosome 4 alpha satellite probe (green, 
Oncor).
D: Reversed DAPI image of C with SCD2 (red) and chromosome 4 alpha satellite probe 
signal (green) superimposed.
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3.1.4 Stearoyl coenzyme A desaturase 2 {SCD2)
Prior to this mapping experiment rodent studies had identified two SCO genes with tissue- 
specific expression patterns. Human SCD1 had been completely characterised (MIM 
604031) and the gene localised to chromosome 10, whereas SCD2 had not been widely 
investigated in humans and its existence was even in doubt (Zhang et al 1999).
As detailed In Appendix I, while attempting to isolate human SCD2 our collaborators 
obtained four cosmid clones (9,17, 22 and 30) with positive hybridisation to a putative 
SCD2 sequence. These clones, at concentration 0.18ug/ul, were then supplied for 
regional localisation by FISH.
The four clones were biotinylated and 9 and 17 hybridised, using a concentration of 
lOng/ul, with lug/ul total human DNA as competitor. Post-ISH washing was in 0.4xSSC 
at 72°C for 2 minutes and two layers of avidin FITC were used in detection.
Ten metaphase chromosome spreads were analysed from both the clone 9 and 17 
hybridisations. In each cell, signal was seen only on both homologues of a B group 
chromosome, tentatively identified as chromosome 4 (Fig.3-4).
To verify their chromosome 4 localisation, cosmids 9, 22 and 30 were then hybridised to 
normal metaphase spreads in combination with 0.5ul DIG-labelled chromosome 4 alpha 
satellite probe (Oncor) per lOul of probe mix. Ten metaphase spreads were analysed for 
each FISH, confirming that the cosmid sequences all mapped to the boundary of 
chromosome bands 4q21.2 and q21.3.
3.1.5 Chromosome Breakpoint Definition Using Mapped FISH Probes
3.1.5.1 Mapping and Ordering of Chromosome 21-Specific Probes for Breakpoint 
Definition in a Case of Partial Trisomy 21
Patient DP
The patient was a two day old infant (born at 36+1/40) referred as query Down syndrome’ 
with intrauterine growth retardation below the 3"^  ^centile and dysmorphic features 
including bilateral single palmar crease, microphthalmia and increased distance between 
1®‘ and 2"^  toes. The infant subsequently died aged 5 days.
Chromosome analysis revealed the presence of a derivative chromosome 12 with an 
apparent inverted and duplicated segment of chromosome 21 on the short arm: 
45,XY,der(12)(12qter-^12p13.3::21 q22.3-»21 q11.2::21 q11.2->21qter),-21 de novo
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Diagnostic FISH studies confirmed the chromosome 12 breakpoint as 12p13.3 (by 
chromosome paint end points) and that the 21 material had both 21q22-specific sequence 
(YAC 831B9, Morris et ai 1999) and 21qtel sequence (D21S1575) at its distal and 
proximal ends but no 13/21 alpha satellite signal;
ish der(12)t(12;21 )(wcp21 +,D21 SI 575++,831 B9++,D13Z1 /D21Z1 -,wcp12+).
Blood had been taken from the patient’s 27 year-old mother at 16 weeks gestation and 
serum levels of chorionic gonadotrophin (hCG) and alpha-fetoprotein (AFP) were within 
normal ranges despite foetal trisomy of almost all of the long arm of chromosome 21.
This prompted further definition of the region of 21 q monosomie in this patient as part of a 
collaborative study aimed at the identification of a candidate region involved in the 
regulation of these serum protein levels in pregnancy.
Test Material
Karyotypically normal metaphase spreads were used for band localisation and preliminary 
probe ordering before ISH to patient chromosomes. Metaphase spreads were available 
from patient blood. Gonad had also been cultured for diagnostic purposes.
Probes
Initially three probes which had previously been mapped to 21q11.1-q21 (more precise 
band localisations were not available) were selected and obtained from the Max-Planck 
Institute for Molecular Genetics repository database (MPI, Berlin). These particular YACs 
(949b09, 937e12, 925h10) were chosen, on the basis of FLpter and cMpter values, to 
span this region and therefore, hopefully, the breakpoint on the duplicated chromosome 
21 component of the der(12) in patient DP.
Following initial mapping with these probes which identified that the breakpoint lay 
between YAC sequences 937e12 and YAC 949b09 (as explained below), further clones 
believed to lie within this interval were requested. Three, which had not previously been 
mapped by ISH, were supplied (YACs 858e10, 856h04, 759d03).
YAC inserts were amplified by DOP-PCR essentially according to the MPI method and 
labelled, following yield determination (Table 3-3), by nick translation with biotin and/or 
DIG.
PROBE DILUTION ABSORBANCE 260nm CONCENTRATION
925h10 1/200 0.034 0.34ug/ul
949b09 1/200 0.058 0.58ug/ul
937e12 1/200 0.051 0,51ug/ul
759d03 1/200 0.035 0.35ug/ul
858e1D 1/200 0.038 0.38ug/ul
856h04 1/200 0.026 0.26ug/ul
Table 3-3 DNA yield following DOP-PCR amplification of chromosome 21-specific YACs.
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Hybridisation Results
Preliminary hybridisations were performed to discern optimal signal amplification and 
probe and competitor DNA concentrations for biotinylated probes. These conditions were 
re-assessed and if necessary adjusted for DIG label and dual hybridisation (Table 3-4). 
Single and dual colour ISH to normal metaphase spreads (-550 band chromosomes) 
provided refined band localisation and, where possible, clarified or confirmed the order of 
these six sequences. Results (Fig.3-5, Tables 3-5, 3-6), suggested the order:
21 cen-949b9gr858e10-759d03-856h4gr937e12-925h10-21 qter 
Hybridisation to patient DP showed YAC 925h10 and 937e12 sequences were present 
centrally on the chromosome 21 region of the derivative chromosome 12 as two copies 
and an indeterminate copy number respectively (Fig.3-6). YAC 949b09 sequence was 
absent, indicating, as 925h10 and 937e12 order had been determined, that the breakpoint 
on at least one chromosome 21 component lay between 937e12 distally and 949b09. 
Though of adequate quality for probe ordering, YACs 759d03 and 858e10 produced less 
consistent ISH signals than the others. When the stored gonad cultures from patient DP 
failed to grow on reconstitution it was therefore decided that, to conserve the small 
amount of patient material remaining, alternative clones with higher hybridisation 
efficiency should be sourced for any further mapping of the breakpoint.
Six proximal 21q21.1 clones (RP11 141D02, 184E23, 65E08, 280N08, 268F23 and RP1 
152M24) were therefore later selected using the EnsembI Genome Browser (Birney et al 
2004, Fig.4-5) and ordered from the Human BAC Resource, The Sanger Centre, 
Cambridge. The cultures received were grown in broth containing chloramphenicol, or in 
the case of RP1 152M24, kanamycin, and probes extracted using a ‘miniprep’ technique. 
5ul of BAC/PAC DNA was biotinylated by nick translation. ISH using an estimated 6ng of 
probe/ul with lug/ul genomic competitor DNA confirmed that all did map to proximal 21 q. 
The two most proximal sequences according to EnsembI, 268F23 (16.03Mb) and 280N02 
(16.1Mb), were hybridised to patient metaphases, the latter with 2ug/ul competitor DNA. 
Both sequences were present on the der(12) chromosome, with indeterminate copy 
number. This refined at least one breakpoint on the duplicated chromosome 21 region of 
the derivative 12 to between 949b09 proximaliy and 268F23 distally (Table 3-7).
Use of 21-Specific YACs to Aid Definition of an Abnormal Chromosome 21 in Patient LF 
YACs 949b09 and 937e12 were also hybridised to a chromosome preparation from LF 
(Appendix II), a patient with karyotype 46,XX,?del(21)(p). Although the ?del(21)(p) and 
normal chromosome 21 could not be differentiated in the poor quality metaphase 
preparations available, all eight cells examined showed no deletion of these sequences 
on either chromosome. The more proximal location of 949b09 was confirmed (Fig 3-6).
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PROBE
NAME
PROBE COMPETITOR FLUOR 
ng/ul DNA LAYERS
CHROMOSOMES 
21 WITH SIGNAL
HYBRIDISATION QUALITY
925h10 BIO 5 1ulCot1 2 100% (20/20) Signal large, some b/g
10 2ulCot1 2 lA as 5ng/ul
15 2ul Cotl 2 lA as 5ng/ul
20 2ul Cot1 2 lA as 5ng/ui
925h10DIG 6 DH 2ul Cotl 2 100% (11/11) signal strong, no b/g
949b09 BIO 5 1.5ulCot1 2 90% (36/40) some b/g, little cross
hybridisation, easier to analyse
without imaging than single
layer
5 1.5ulCot1 1 lA no b/g, see above
6 DH 2ul Cot1 2 100% (12/12) signal strong, no b/g
949b09 DIG 6 DH 2ul Cot1 2 96.6% (29/30) signal large
10 2ul Cotl 2 lA signal excessively large
937e12 BIO 5 1.5ulCot1 2 50% (12/24) some cross hybridisation, b/g,
easier to analyse without
imaging than single layer
5 1.5ul Cotl 1 lA see above
8 DH 2ul Cotl 2 80% (24/30) slight b/g
10 DH 2ul Cotl 2 100% (11/11) some b/g, signal consistent
759d03 BIO 10 OH 2ul Cotl 2 68.8% (11/16) some b/g
856h04 BIO 10 DH 2ul Cotl 2 90% (9/10) some b/g
856h04 DIG 10 DH 2ul Cotl 2 89.5% (17/19) slightly weak but acceptable
858610 BIO 10 DH 2ul Cotl 2 16.7% (5/30) weak, b/g
16 lul genomic 2 5% (1/20) weak, very infrequent signal
16 DH 2ul Cotl 2 14.7% (5/34) very weak
Table 3-4 Hybridisation conditions assessed for chromosome 21 YACs.
b/g: background signal; DH: dual hybridisation; lA.incomplete analysis
YAC FLpter cMpter CHROMOSOME 21 BAND
(MPI) (MPI) MPI THIS STUDY
949b09 0.15-0.2 0 q11.1~q21 q11.2
858e10 0.15-0.2 unknown unknown q11.2
759d03 unknown unknown unknown q11.2
856h04 0.15-0.2 9 unknown q11.2-q21.1
937012 0.15-0.2 9/13 q11.1-q21 q11.2-q21.1
925h10 0.30-0.37 21 q11.1-q21 q21.1~q21.2
Table 3-5 Metaphase mapping to determine localisation of chromosome 21 YACs.
949b09, 937e12 and 925h10 were hybridised singly. Dual FISH (with 949b09) was used for
858e10, 856h04 and 759d03. MPI map data, if available, was obtained from the MPI website.
POSITION OF RELATIVE TO: NO. OF CHROMOSOMES TOTAL NUMBER
proximal even distal OF CHROMOSOMES SCORED
949b09 858e10 0 10 0 10
949b09 759d03 2 9 0 11
949b09 856h04 8 1 0 9
949b09 937e12 20 4 0 24
856h04 937e12 6 9 2 17
949b09 925h10 6 0 0 6
937e12 925h10 11 0 0 11
Table 3-6 Dual colour metaphase ordering of chromosome 21 YACs.
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Fig.3-5 Mapping and ordering of chromosome 21-specific YACs on normal metaphases. 
A: 949b09 (green, proximal) and 937e12 (red).
B: Reverse DAPI image of A.
C; 937e12 (red, proximal) and 925h10 (green).
D: 949b09 (red, proximal) and 856h04 (green).
t1el(21)(p)
Fig.3-6 Hybridisation of chromosome 21-specific YACs to patient metaphases.
A: Ideogram of der(12)(12qter->12p13.3::21q22.3^21q11.2::21q11.2->21qter) in DP.
B: left - 937e12 on normal 21 and on der(12).
right - 949b09 (red) and 925h10 on normal 21 and on der(12). Note 949b09 signal is 
not present on the chromosome 21 component of the der(12) chromosome.
C: 949b09 (green) and 937e12 ISH to a metaphase from patient LF.
PROBE STS MARKER FISH STUDY
949b09 D21S1911 DELETED
RP11 268F23 D21 S I 89/1830 NOT DELETED
RP11 280N08 D21 S I 89/1830/1432 NOT DELETED
937e12 □21 S I 256/1699 NOT DELETED
925h10 □21S I257 NOT DELETED
Table 3-7 Breakpoint mapping on der(12)t(12;21) in patient DP. 
STS:sequence tagged site associated with probe sequence 
(source MPI or EnsembI Genome Browser).
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3.1.5.2 Mapping and Ordering of Chromosome 8-Specific Probes for Orientation of 
Duplicated Region and Breakpoint Definition in a Case of 8p Duplication
Patient RM
The patient was referred, when three years old, with mild global delay, language and 
social problems and mild dysmorphic features (detailed in Appendix II).
Chromosome analysis revealed the presence of an abnormal chromosome 8 with an 
apparently duplicated region on the short arm, karyotype: 46,XX,dup(8)(p11.2p21.3). 
Preliminary FISH investigations showed normal signal patterns with chromosome 8 paint 
and telomere probes. As direct duplications of proximal 8p are rare, breakpoint and 
orientation investigations were initiated with BAC probes from this region.
Probes
Four clones, RP11 350N15, RP11 564K10, RP11 527N22 and RP11 23D17, estimated to 
lie within the duplicated region (and hence be useful for orientation studies) were selected 
using EnsembI and ordered from the Human BAC Resource at the Sanger Centre. A 
clone labelled 23D7 was sent in place of 23D17.
The bacterial stab cultures were first plated on chloramphenicol agar. Selected colonies 
were cultured and extracted using the ‘miniprep’ technique. Gel electrophoresis was 
carried out to ascertain that high molecular weight (BAC) DNA had been obtained (Fig.3- 
7).
5ul of BAC DNA was either biotinylated (RP11 350N15 and 564K10) or labelled with DIG 
(RP11 527N22 and 23D7) using nick translation. Dual hybridisation using lOng/ul of each 
probe and 1.5ug/ul human genomic competitor DNA confirmed that all except 23D7 did 
map to 8p, in order 8cen-350N15-527N22-564K10-8pter, and were included in the 
duplicated region. 23D7 mapped to 2p16.
ISH of DIG-labelled RP11 527N22 (FITC detection) with biotinylated RP11 564K10 
(Texas Red detection) produced an alternating green/red signal pattern (Fig.3-7). This 
confirmed that the duplication was not inverted.
Further clones, generously provided by Dr J Fantes (MRC, Western General Hospital, 
Edinburgh), were selected from EnsembI to further define the duplicated area. These 
were biotinylated and individually hybridised to patient metaphases at an estimated 6ng/ul 
with lug/ul human genomic competitor DNA (initial experiments with lOng/ul probe 
produced excessive background).
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11 22
Fig.3-7 Breakpoint mapping of 8p duplication in patient RM
A. G banded image (normal chromosome 8 and ideogram of 8p on the left).
B. FISH with BACs RP11 527N22 (FITC label) and 564K10 (Texas red) confirms that the 
duplication is direct and involves both 8p12 BAG sequences.
0. FISH with 8 alpha satellite centromeric probe (8p11.1) confirms that these centromeric 
sequences are included in the duplication.
D. Agarose gel electrophoresis of extracted BAG DMA.
Lanes from left; 1kb size ladder; 23D7; RP11 527N22; 564K10; 350N15.
Only high molecular weight DMA is apparent.
CLONE ENSEMBL MAP LOCATION FISH RESULT
RP11 369E15 8p213 20.67Mb not dup
RP11 177H13 8p212 23.07Mb not dup
RP11 395114 8p212 25.12Mb not dup
RP11 14117 8p212 26.17Mb not dup
RP11 138J2 8p212 27.24Mb not dup
RP11 356F24 8p21.1 28.39Mb dup
RP11 263G6 8p12 28.89Mb dup
RP11 564K10 8p12 29.19Mb dup
RP11 527N22 8p12 37.12Mb dup
RP11 350N15 8p12 38.22Mb dup
RP11 44K6 8p11.21 39.73Mb dup
RP11 51K12 8p11.21 40.39Mb dup
RP1 198M21 8p11.21 41.41Mb dup
RP11 231D20 8p11.21 42.04Mb dup
RP11 137L15 8q11.21 48.57Mb not dup
Table 3-8 Hybridisation of chromosome 
RM. Glones used for initial, dual colour,
8-specific clones to a duplication of 8p in patient 
duplication orientation are shown in bold type.
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Analysis of at least three metaphases from each hybridisation (the results of which are 
recorded in Table 3-8) demonstrated that the chromosome 8 breakpoints were actually at 
8p11.1-p11.2 and 8p21.1~21.2. Clone RP11 138J2, excluded from the duplicated 
region, lies 0.03Mb from the 8p21.1-21.2 junction. Clone 137L15, which lies < 0.6Mb 
from the centromere in band 8q11.21, was also not included in the duplication, but ISH to 
8 alpha satellite centromeric probe (Qbiogene, Cambridge) showed 8 alpha satellite 
signal had been duplicated, further refining the proximal breakpoint:
46,XX,dup(8)(p11.2p21,3).ish dup(8)(p11.1 p21.1 ~p21.2)(356F24++,263C6++, 
564K10++,527N22++,350N15++,44K6++,51K12++,RP1 98M21++,231D20++,D8Z1++)
3.2. Detection of Cryptic Chromosomal Abnormality
3.2.1 DG/VCF Syndrome Microdeletion Testing
The objectives of this study were primarily to establish a diagnostic test and, in the earlier 
stages, collect some basic information on deletion size by use of a dual locus probe 
known to be deleted at only one locus in some individuals (Lindsay et al 1995).
When the study began, the DGA/CFS critical region was only loosely defined and no 
commercial probe was available, so it was necessary to culture and label probe ‘in house’. 
As it progressed probe selection altered because new clones, considered possibly to 
have improved ISH efficiency, specificity, or diagnostic utility, were recommended by the 
probe developers. Probe and patient sample details are in Appendices I and II.
DGA/CF Syndrome Probes Used
Five different DGA/CFS region cosmids were made available over an eighteen month 
period. These were plated out on either ampicillin (sc4.1) or kanamycin-containing agar. 
Five colonies were picked from each plate, starter cultures incubated and glycerol stocks 
prepared from these for storage at -20®C. One or two of these starter cultures or glycerol 
stocks from each of the cultures were used to inoculate 100ml LB broth for further culture 
and subsequent cosmid isolation using the Circleprep kit (Bio 101). The DNA yield was 
typically 0.21-0.44 ug/ul (21-44ug).
The earliest investigations utilised cosmids sc4.1 (D22S134) and sc11.1, which detected 
two loci, sc11.1a and s e l l  1b, at opposite ends of the commonly deleted 2-3Mb region. 
Two patients, one deleted, were tested with only one of these probes due to shortage of 
patient material. Two relatives of suspected microdeletion cases were tested only with 
sc11.1, one because of shortage of material and the other because testing was
106
discontinued when deletion was not detected in his son. Investigation of two relatives of 
recognised deletion cases, who had an untested or deletion-negative intervening relative, 
was restricted to sc11.1 testing because this probe was informative in the probands. 
Combinations of se ll. 1 and/or sc4.1 with E0472 (D22S697), D0832 (D22S502) and 
eventually H1012 were subsequently used. By the end of the study, most cases were 
being tested only with H I012, as this contained the TUPLE 1 sequence which was 
considered to be a strong candidate gene for DG/VCFS. Other probes were then only 
employed if a negative result was obtained in conjunction with strong clinical suspicion of 
22q11.2 deletion. Cosmid H I012 shares some sequence with commercial TUPLE 1 
probes. The order of these sequences is shown in Figs. 1-11 and 3-8.
When testing relatives of deleted individuals the probe (or one of the probes) employed 
had been shown to disclose deletion in the proband.
22cen s c ll . la  TUPLE 1 D0832 sc4.1 E0472 sell.1b
-~300kb-  450kb----
------------------------2Mb------------------------------------ —
Fig.3-8 Order of probes used for DG/VCFS microdeletion testing. Determined by pulsed 
field gel or interphase FISH measurements (Lindsay et al 1993, Halford et al 1993a).
Hybridisation Strategies and Conditions
Following preliminary ISH experiments, biotin labelling and amplified avidin-FITC 
detection was used for all probes as it proved difficult to obtain signal of adequate 
strength from DIG labelling without unacceptably high background, despite altering probe 
concentration and wash stringency. A working probe concentration of lOng/ul was 
established for scll .1, sc4.1 and D0832, and 15-20ng/ul for E0472. Total human 
genomic DNA (1 ug/ul) was used as competitor. A rapid ‘combined’ detection method 
which (by providing a mix of appropriate detection reagents) produced amplification but 
required only a single detection step, was tried with sol 1.1 and E0472. This approach 
was not adopted as it generally required digital imaging, rather than conventional 
microscopy, for satisfactory visualisation of signals on both homologues in most cells.
In an attempt at dual colour FISH which avoided the problems associated with DIG label 
while reducing detection time, sc4.1 and scll.1 were directly labelled with fluorogreen 
and fluorored (Amersham), but the signal produced was too weak for diagnostic 
purposes. To provide a control signal in co-hybridisation with these directly labelled 
DG/VCFS probes, chromosome 22 alpha satellite centromeric probe (22/1:2.1, ATCC 
61578) was cultured, extracted, directly-labelled (fluorogreen or fluorored) and used at 5- 
lOng/ul. Again the direct signal obtained was weak, despite modifying the ISH and wash 
conditions, though biotinylated, indirectly detected 22 centromere probe signal was
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strong. FISH with another similarly extracted and directly labelled sequence, 
chromosome 18 alpha satellite probe (L I84, ATCC 61394), did produce satisfactory 
signal, but optimisation of 22 alpha satellite co-hybridisation was not pursued as the 
introduction of digital imaging allowed chromosome identification by reverse DAP I 
banding, making control signals unnecessary.
Analysis
Initially ten, then, with experience, five cells were scored for the presence of probe signal 
on one or both chromosomes 22 (Fig.3-9). If available, more metaphase spreads, up to 
thirty if necessary, were scored where deletion was suspected.
Patients Tested and Outcome of Testing
Of the 244 individuals tested with in-house probe, 161 were referred because they 
exhibited phenotypic features of DGA/CFS (Table 3-9). Deletion was found in 34 
(21.1%), including the three patients with unusual signal patterns listed in Table 3-13 and 
discussed below. Only one of these 34 deletions was visible cytogenetically.
Eighty three individuals were referred for testing primarily because of their relationship to 
affected individuals, rather than possession of a DGA/CFS phenotype. These included:
• Forty six parents, from twenty four two-generation and three, three-generation families, 
and one child of a deleted individual. Five parents were deleted (Table 3-10). One 
exhibited VCFS but the other deleted parents had not been considered to have a 
‘syndromic’ phenotype. One parent had submucous cleft palate and transient 
hypocalcaemia at birth, one had mild learning difficulty, one had mild learning difficulty 
and a VSD and the other exhibited a degree of brachycephaly.
• Six relatives of deleted individuals whose intervening relative(s) were of unknown or 
negative deletion status. Though one patient, whose sister and nephew were deleted, 
was described as “query VCFS ” no microdeletions were found in this group (Table 3- 
11).
• Thirty parents or other relatives of individuals who either had suspected microdeletion 
but subsequently tested negative or who were not available for testing. Again, no 
microdeletions were found (Table 3-12).
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PROBES USED ' '  CASES STUDIED CASES DELETED
sc11.1/sc4.1 15 4
sc4.1 1 1
s c l l .1 1 0
s c l 1.1 /s c 4 .1 /E 04 72 7 2
s c1 1 .1 /sc4 .1 /E 0472 /H 1012 2 1
SC11.1/E0472 4 5 6
S C 11.1 /E 0472/H 1012 3 1
s c l l .1  /s c 4 .1 /E 0 4 7 2 /D 0 8 3 2 /H 1012 1 0
SC11.1/H1012 12 5
H 1012 74 14
Table  3 -9  Breakdown of 22q11 probe combinations used to test 161 affected individuals.
PROBES USED CASES STUDIED CASES DELETED
sc11.1/sc4.1 9 2
sc11 .1 /sc4 .1 /E 0472 1 1
SC11.1/E0472 10 (child in this gmup) 1
SC11.1/H1012 2 0
H 1012 25 1
Table  3 -10  Probe combinations used to test 46  parents and 1 child of deleted individuals
PROBES USED______________________CASES STUDIED_________CASES DELETED
sc11.1/sc4.1 1 0
SC11.1 2 0
SC11.1/H1012 1 0
H1012 2 0
Table 3-11 Probe combinations used to test 6 relatives of deleted individuals. The
intervening relative(s) were either not tested (4 cases) or subsequently shown not to be
deleted (2 cases).
"PROBËSIJSËD "cÂS]^"STUDiÊD CÂSES^ËLÊfËD"
sc11.1/sc4.1 2 0
sc11 .1 /sc4 .1 /E 0472 1 0
SC11.1/E0472 9 0
s c l l .1 2 0
SC 11.1 /E 0472/H 1012 2 0
E 0 47 2 /H 10 12 2 0
SC11.1/H1012 1 0
H 1012 11 0
Table 3-12 Probe combinations used to test 30 relatives of individuals who either had 
suspected microdeletion but subsequently tested negative or who were not available for 
testing.
Possible Atypical DGA/CFS Region Deletions
Not all DG/VCFS cases tested produced unequivocal probe ISH results (Table 3-13). 
Three of the 34 patients in whom hemizygosity was clearly demonstrated (JF, KA, HG) 
showed deletion of H1012 sequence but scll.1 signal on both chromosomes 22 in 33- 
60% of metaphase spreads. In all other scl 1.1 hybridisations to patient material with 
deletion at another DG/VCFS probe locus no cells examined exhibited scll.1 signal on
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both chromosomes 22. The presence of a second sc11.1 signal, at reduced frequency, 
suggested that these deletions did not include one scll.1 repeat (a or b).
Unfortunately, hybridisation to other probes either failed or gave ambiguous results. The 
low number of cells with signal on both chromosomes 22 with probe E0472 (in patients JF 
and KA) could conceivably represent background. While generally of acceptable quality, 
variable hybridisation efficiencies and background levels could occasionally be associated 
with these probes, particularly on very poor chromosome preparations. However, one 
alternative explanation for the apparent incomplete deletion of E0472 in cases JF and KA 
is that E0472 sequence, like scl 1.1b, appears to lie within the markers flanking the distal 
breakpoint in smaller deletions (Morrow et al 1995, Carlson et al 1997).
As no patient material remained these investigations could not be repeated to confirm 
results or exclude the possibility that poor quality hybridisations were responsible for the 
ambiguous signal patterns with probe E0472.
"PÂfÎENT^^^ S Î G N Â L Ô Ï T B Ô f i T c ^
s c ll.1  H I 012 E0472
JF 6/10 0/17 5/20 2’^  ^signal pale
KA 6/18 0/10 1/10
HG 5/10 0/19 not tested
Table 3-13 Apparently atypical deletions in three DG/VCFS patients.
Inheritance of 22q11.2 Deletion
Testing was able to be performed on one or both parents of 27 of the deleted patients, 
three of whom were themselves parents of deleted children. Whether a deletion was 
inherited could be determined in 21 of these 27 patients either because they had both 
parents tested or because the single parent who was tested exhibited deletion. Five 
deletions were detected in this group of 21, therefore 23.8% of deletions could be 
confirmed as inherited. Four of the five inherited deletions were maternal in origin.
Microdeletion Testing in Patients with Tetralogy of Fallot
As hemizyosity at 22q11.2 had been reported in patients with non-syndromic conotruncal 
defects (Wilson et al 1992a), a series of 24 patients diagnosed with TOF were examined 
for microdeletion at the DG/VCFS locus (Table 3-14). Deletion at 22q11.2 was detected 
in four patients. Whether a deletion was inherited could be determined in three of these 
cases, and one maternal deletion was demonstrated. The deleted parent was 
subsequently described as “possibly having some facial features of VCFS” but had no 
cardiac defect or any other apparent abnormality.
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PROBES USED___________________________CASES STUDIED_________ CASES DELETED
sc11.1/sc4.1/E0472/D0832 3 2
SC11.1/E0472 19 0
SC11.1/H1012 1 1
scll.1 1 1
Table 3-14 Probe combinations used to test 24 patients with TOF.
The results from this series were combined with those from individuals with TOF in the 
main DGA/CFS series. In total, seven deletions were disclosed in thirty three individuals 
with TOF. Three of the seven patients had, in the opinion of a clinical geneticist, isolated 
TOF with no other suggestive clinical features (Trainer et al 1996).
22q11 Deletion Diagnosis With Commercial Probes
Studies with commercial probes (Appendix I), principally for the TUPLE 1 region, have 
continued as part of the routine diagnostic service. TUPLE 1 probe rather than N25 was 
chosen both for continuity, as the TUPLE 1 sequence was present in the ‘home-grown’
H I012 probe, and because TUPLE 1 was a candidate gene.
In the course of providing this service patient KC, who had been shown by another 
cytogenetics laboratory not to be deleted at the N25 (Oncor) locus, was tested with 
TUPLE 1 probe (Vysis) because of a strongly suggestive phenotype including VSD, 
interrupted aortic arch, absent thymus and hypocalcaemia. Deletion was detected. To 
determine the extent of the deletion, 22q11 microsatellite analysis was performed by the 
Molecular Genetics Service, Western General Hospital, Edinburgh and showed 
homozygosity for all markers tested telomeric to D22S1638. This was strongly 
suggestive of a typical distal deletion junction at or near D22S938. Heterozygosity for 
marker D22S1638 confirmed the proximal breakpoint was unusual. However, as this 
marker proximally flanks N25 and the closest telomeric marker (D22S1648) distally flanks 
TUPLE 7, this test could not, unlike FISH, discern that TUPLE 1 was deleted but N25 was 
not.
As a result of finding this variant deletion most ‘query 22q11 deletion’ referrals to this 
department are now tested with both N25 and TUPLE 1 probe. In over 100 cases tested 
with both probes to date all are either undeleted or deleted for both sequences.
By the end of 2003, 855 patients - of which 100 had a deletion - and 206 relatives had 
been tested (excluding the TOF series). Inheritance could be confirmed or excluded for 
59 of these deletions, and 11 (18.6%) were shown to be inherited, 9 of them (81.8%) from 
the mother. Thirteen (13%) of the deletions were cytogenetically visible. Prenatal 
diagnosis was performed on four pregnancies of deleted individuals (deletion was 
detected in one foetus) and on two pregnancies with cardiac defects (not deleted).
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other Cytogenetic Abnormalities Found in Patients Referred for ‘22q Deletion Testing’ 
By January 2004 thirteen cytogenetic abnormalities, some of which may not be 
pathological, had been found in patients referred for testing with DGA/CFS probe (Table 
3-15).
CASE NUMBER CHROMOSOME ABNORMALITY
202847 46.XY.inv(10)(q11.2q21.2)
203408 46,XX,fra(10)(q23.3)
963498 46,XX,v(20)(cen)
963751 46,XY,t(1;3)(q25;q27)
970814 46,XX,dup(1 ){q42;q43)
970984 46,XY.Inv(9)(p11q13)
971481 47.XYY
975771 46,XY,add(21)(q22.3)
993196 46,XY,der{3)t(3;5)(p26;p13)
995648 46,XY,inv(12)(q22q24.22)
230161 47.XY+13 [7]/46.XY[43]
231503 46,X,iX(q10)
236483 46,XY,t(2;3){p15;q21)
Table 3-15 Cytogenetically visible chromosome abnormalities, other than 22q11 deletion, 
found in individuals referred to the Duncan Guthrie Institute for DG/VCFS FISH testing.
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Fig.3-9 FISH with DGA/CFS region probes.
A: Cosmid sc11.1 hybridised to a metaphase from an individual with no 22q11 deletion. 
Signals are present on both chromosomes 22.
B: Cosmid sc4.1 hybridised to a metaphase from a patient with a deletion at 22q11. 
Signals present on only one chromosome 22. The presence of four other G group 
chromosomes in this 46XY cell was confirmed by reverse DAP I banding (see image D 
below).
C: Commercial TUPLE 1 probe (Vysis) hybridised to a metaphase from a patient with a 
deletion at 22q11. TUPLE 1 signal (red) is present on only one chromosome 22. Green 
control signal (ARSA sequence, 22q13.3) identifies both chromosomes 22.
D; Reverse DAPl banding of image B, showing presence of both chromosomes 22.
Fig.3-10 Hybridisation to biotinylated RT1 
cosmid (16p13.3) and DIG-labelled 
chromosome 16 alpha satellite probe.
Neither chromosome 16 shows deletion 
of RT1 sequence (red signal).
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3.2.2 Detection in a Large Pedigree of a Cryptic Chromosomal Rearrangement 
Involving the Wolf-Hirschhorn Syndrome Locus
ISH with mainly non-commercial probes on metaphase preparations from blood and/or 
lymphoblastoid cell lines was used to demonstrate the segregation of a submicroscopic 
reciprocal translocation between chromosomes 4 and 11 in an extensive family (Fig.3-11).
Patients
The proband, V 11 and her second cousins once removed (IV 8 and IV 10) displayed a 
collection of severe congenital defects (detailed in Appendix II). Unusual prominence of 
the glabella and nasal root in the proband led to a tentative clinical suspicion of WHS. 
However high resolution study of banded chromosome preparations in addition to flow 
cytometry karyotyping in this department revealed no detectable abnormality of 4p. This 
prompted molecular cytogenetic studies.
Probes and Hybridisation Strategies
Plasmid pK082 was cultured with ampicillin selection, extracted (Circleprep, yield lOOul, 
0.35ug/ul), and biotinylated, generally by nick translation, for use as a region 4p16.3 
probe. For early investigations on V I I ,  IV-11 and V-12, all poor cytogenetic preparations, 
marginally better results were obtained using pK082 biotin-labelled by random priming 
(Feinberg and Vogelstein 1983) with a commercial kit (Boehringer Mannheim Random 
Primed DNA Labelling Kit 1004760).
Initially region 11 pi 5.5-specific plasmid phinsSIO, then phins311, were similarly prepared 
(yield lOOul, 0.31 ug/ul and 0.11 ug/ul respectively) and biotinylated by nick translation. 
Following optimisation experiments, early pK082 hybridisations (to V-11, IV-11, IV-12,
IV-16, IV-17) employed 1-2ng/ul probe chromogenically detected (Garson et al 1987). 
Plasmid phins310 hybridisations, which were performed only on the proband, her parents 
and two affected second cousins once removed (V-11, IV-11, IV-12, IV-8, IV-10), used 5- 
lOng/ul biotinylated probe, also detected enzymatically.
Subsequent investigations used 5-10ng/ul pK082 or phins311 for FISH detected with 
three layers of avidin-FITC following reduced stringency post-ISH washing (two 50% 
formamide washes at 42°C, each for two minutes). The quality of plasmid phins311 FISH 
was improved with CISS (0.5ug/ul total human DNA).
Two of three PND investigations employed commercial WHS probe (D4S96) and 4p and 
l ip  telomere sequences (all from Oncor) following ascertainment of their 
informativeness.
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Analysis
In the earliest ISH experiments with the small plasmid probe sequences, signals 
visualised on post-ISH metaphases were marked on pre-hybridisation, banded, 
photographs of these metaphases, then on an ideogram, and the chromosomal 
distribution of signals analysed statistically using the test (Fig.3-12). Chromosome
identification for signal distribution assessment was subsequently by software enhanced 
reverse DAPl banding or co-hybridisation with centromeric marker probes.
The proband had signal at 4p16.3 on only one chromosome 4 following ISH to pK082, 
which confirmed the clinical suspicion of WHS. The same probe produced signal on both 
chromosomes 4 in the proband’s mother but a signal peak on one chromosome 4 and 
one 11, at 11 pi 5.5, in her father. Confirmation of a familial translocation involving 
chromosomes 4 and 11 was initially sought with plasmid phins310. This very short 
sequence (0.8kb) did demonstrate small signal peaks at 4p16.3 and 11 pi 5 in individuals 
V-11, IV-11, IV-8, and IV-10 but, except in V-11 and IV-8, the peak on 11 was usually not 
statistically significant (0.5>p>0.1). The poor hybridisation efficiency of this 11 pi 5.5- 
specific probe led to Its replacement with phinsS11.
To summarise ensuing experiments (Table 3-16), ISH to pK082 and phins311 revealed 
cytogenetically cryptic monosomy at distal chromosome 4p and trisomy at distal l ip  in 
the proband and her affected second cousins once removed. Four phenotypically normal 
individuals in the family, IV-7, IV 11, IV 14 and III-6, were shown to have a t(4;11) 
translocation in the balanced form (Fig.3-13 A,B) and normal karyotypes were confirmed 
in seven subjects (including the proband’s mother).
To estimate approximately the size of the translocated segments, and to investigate the 
usefulness of chromosome paints for the demonstration of the translocation in this family, 
whole chromosome 4 and 11 paints (Cambio, Cambridge) were hybridised to metaphases 
from a translocation carrier (IV-11). Chromosome 11 material was only just detectable 
with 11 paint on the der(4) in six of sixteen metaphases, even to an analyst aware of the 
abnormality, and 4 paint detected translocated 4 material on the der(ll) in four of ten 
metaphases.
Prenatal Analyses
PND was successfully performed for one female carrier (IV-7) of the balanced t(4;11) 
translocation using FISH on cultured amniocytes. This showed the foetus (V-7) to be a 
karyotypically normal female: 46,XX.ish 4p16.3(pK082x2),11p15.5(phins311x2)
Two subsequent prenatal FISH investigations were performed for this patient using the 
WHS probe (D4S96) and telomeric probes for the short arms of chromosome 4 (D4F26)
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and 11. The first, on a chorionic villus preparation (V-8), demonstrated partial monosomy 
4p and partial trisomy 11p as in the proband (Fig.3-13 C,D);
46,XX.ish der(4)t(4;11)(p16.3;p15.5)mat(D4S96-,D4F26-,11ptel+)
The other, an amniotic fluid sample (V-9), yielded a normal foetal karyotype (Fig.3-13 
E,F): 46,XX.ish 4p16.3(D4F26x2,D4S96x2),11p15.5(11ptelx2)
PATIENT pK082 RESULT* phins311RESULr KARYOTYPE
V-11 one 4 one 4, both 11 ish der(4)t(4;11)
IV-11 one 4, one 11 one 4, one 11 ish t(4;11)
IV-12 both 4 NOT TESTED NORMAL
IV-8 one 4 one 4, both 11 ish der(4)t(4; 11 )
IV-10 one 4 NOT TESTED** ish der(4)t(4;11)
IV-16 both 4 NOT TESTED** NORMAL
IV-17 both 4 NOT TESTED** NORMAL
IV-7 one 4, one 11 one 4, one 11 ish t(4;11)
III-6 one 4, one 11 one 4, one 11 ish t(4;11)
IV-14 one 4, one 11 one 4, one 11 ish t(4;11)
IV-21 both 4 both 11 NORMAL
IV-4 both 4 both 11 NORMAL
IV-1 both 4 both 11 NORMAL
111-10 both 4 both 11 NORMAL
Table 3-16 Results of probe pK082 (4p16.3) and phins311 (11p15.5) hybridisations to 
chromosomes from members of a family with a cryptic t(4;11) translocation. 
^Chromosomes with signal. ^^Insufficient material.
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Fig.3-11 Pedigree of family with inherited cryptic translocation of chromosomes 4 and 11 
The proband is individual V  11. Solid symbols represent affected subjects, half solid symbols 
represent carriers.
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Fig.3-12 Ideograms showing signal distribution following phinsSii (11 p i5.5) or 
pK082 (4p16.3) ISH to members of a family with inherited cryptic t(4;11).
TOP; 136 signals, with signal peak at4p16.3, recorded from 27 cells following pK082 
hybridisation to IV-12, mother of proband V-11.
MIDDLE: 640 signals, with signal peaks at 4p16.3 and 11p15.5, recorded from 114 cells 
following pK082 hybridisation to balanced translocation carrier IV-11, father of proband
V-11.
BOTTOM: 93 signals, with signal peaks at 4p16.3 and 11p15.5, recorded from 24 cells 
following phinsS11 hybridisation to proband V-11. Larger dots represent ten signals. 
Signal number at distal 4p (28) is approximately half that at lip  (59).
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Fig.3-13 Hybridisation of chromosome 4 and 11 probes to a familial t(4;11) translocation. 
A and B; Hybridisation, of pK082 (4p16.3) and phins311 (11p15.5) respectively, to 
metaphase spreads from a balanced translocation carrier. Chromosome identification 
was by reverse DAPl banding (not shown).
C and D: Hybridisation of chromosome 4 (0) and 11 (D) telomere probes (Oncor) to CVS 
metaphases. Chromosome 4 and 11 alpha satellite sequences (Oncor, in red) provide 
chromosome identification. C shows one copy of 4ptel probe sequence, D shows three 
copies of 11 ptel sequence.
E and F: Hybridisation of chromosome 4 (E) and 11 (F) telomere probes (Oncor) to 
amniotic fluid metaphases. Both chromosomes 4 and 11 show normal signal patterns.
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3.2.3 Microdeletion Testing in Rubinstein-Taybi Syndrome
Probe Preparation
A bacterial stab culture containing cosmid RT1 was grown in ampicillin-containing LB 
broth. The cosmid was then extracted (Circleprep, yield 100ul 0.24ug/ul) and biotinylated 
by nick translation.
Following a publication reporting microdeletions at the RTS CBP gene locus which would 
not have been detected with probe RT1 (Petrij et al 2000), DNA from cosmids RT102, 
RT191, RT203 and RT 166, which span the CBP gene, was later obtained and similarly 
labelled.
Hybridisation Strategy
RT1 Probe: Optimisation experiments were necessary as preliminary ISH with 10 and 
20ng/ul probe plus 1 ug/ul total human genomic DNA produced excessive background in 
addition to 16p13.3 signal. These experiments Included altering probe and competitor 
DNA concentration, using Cotl competitor, and slide pretreatments (ageing at 65°C for 2 
hours or incubating in 2xSSC at 37°C for 30 minutes). A probe concentration of Gng/ul 
and inclusion of 0.5 or 1 ug/ul total human DNA produced acceptable signal strength and 
background levels without slide pretreatment. Post-ISH washing, at 72°C, in 2xSSC for 5 
minutes or 0.4xSSC for 2 minutes was later tested to avoid the use of formamide. 
Washing at 0.4xSSC for 2 minutes produced a satisfactory result.
A DIG-labelled chromosome 16 alpha satellite centromeric probe (Oncor) was co­
hybridised (0.3u! per lOul hybridisation mix) to assist chromosome 16 identification, 
otherwise DAPl bands were enhanced and reversed following digital imaging.
RT102. RT191. RT203. RT166 Probes: Initial ISH with 10ng/ul probe on control 
metaphases established that the specific signals from these sequences were weak and/or 
always accompanied by excessive background hybridisation, which rendered optimisation 
difficult. Repeat labelling and assessment of different probe concentrations (6 to 20ng/u!) 
and 1 ug/ul total human DNA produced preparations of variable quality. Labelling using 
twice the recommended concentration of DNA did produce some improvement in 
signaLbackground ratio. This allowed the probes to be used diagnostically, at 12ng/ul 
with 1 ug/ul total human DNA competitor.
Hybridisation to Patient Samples
Metaphase chromosome preparations from fifteen patients referred with "query RTS" 
were hybridised to RT1 probe and at least five metaphases with good signal quality
119
examined in each preparation. All showed signal on both chromosomes 16, indicating 
absence of deletion at the RT1 locus (Fig.3-10).
It has been possible to test six of the original RTS patient samples with RT102, RT191, 
RT203 and RT166. No microdeletions have been detected.
3.2.4 Duchenne and Becker Muscular Dystrophy Carrier Studies
Prior to the development of quantitative PCR there was no method in use in this 
department which could simply and unequivocally diagnose DMD/BMD carrier status.
The work described here was performed to instigate such a service. It was then 
continued to support quantitative PCR testing during the period of its introduction to the 
diagnostic repetoire of the molecular genetics division.
Isolation of Probes
Twenty nine bacterial cultures carrying different DMD/BMD exon-specific cosmids were 
first plated out on either ampicillin (the Leiden clones) or kanamycin-containing agar. 
Three to six colonies were picked from each plate, starter cultures incubated and glycerol 
stocks prepared from these for storage at -20°C. Initially one or two of these starter 
cultures or glycerol stocks from each of the twenty nine bacterial cultures were used to 
inoculate 100ml LB broth for further culture and subsequent cosmid isolation using the 
Circleprep kit (Bio 101). The DNA yield was typically 0.2-0.5ug/ul (20-50ug).
In an attempt rapidly to provide small yields of cosmid isolate for initial ascertainment of 
probe suitability the Insta-mini-prep kit (5 Prime^3 Prime Inc.) was used with cosmids 7a 
and e47, but this approach failed to produce signal. It was not possible, with the small 
amount of DNA produced, to measure the yield therefore quantities for labelling had to be 
estimated. The use of twice the recommended culture volume in the Insta-prep process 
and twice as much Insta-prep product in nick translation was also tried without success.
Contamination of Probes
During the course of this study, detection of weak signal on the X chromosome in a low 
proportion of metaphases from males with confirmed deletion indicated possible 
contamination of some probes with other exons. Aliquots of probe isolates were therefore 
sent to the molecular genetics division of this department for testing by multiplex PCR 
with exon-specific primers (Table 3-17).
Extra colonies were cultured, extracted and hybridised for probes which failed to produce 
adequate signal or showed contamination with other exons. Although this did result in
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contamination-free probe isolate in one case (NRM10/11), the hybridisation efficiency of 
this probe remained unsatisfactory.
NRM47, NRM51 and NRM52 were among those probes exhibiting contamination. These 
cosmids were also used in the Wessex Regional Genetics Laboratory, Salisbury, where 
the presence of contaminating sequences was confirmed. Following selection of 
subclones of these probes the Wessex Laboratory generously supplied glycerol stock of 
which e47b, e51b and e52 were ‘pure’ isolates.
PROBE CLONE' CONTAMINATING
EXON
EVENTUAL DIAGNOSTIC ** 
USE
NRM10/11 a 47 no
b 8 no
f none no
g none no
NRM47 original stock 19, possibly 52 no(on recognition of contamination)
e47a (S) 45 no
e47b (S) none yes
CMA1G3 a 53 no
{exons 50,51) b 53 no
C ?4 no
d ?4 no
NRM51 original stock 19,47,50,52 no(on recognition of contamination)
051 a (S) 47 no
e51b(S) none yes
NRM52 original stock 19 no(on recognition of contamination)
052 (S) none yes
CMA1G6 a 51,53 no
(exon 54) b 51,53 no
Table 3-17 DMD/BMD cosmid clones with contaminating dystrophin sequences.
* Probes marked (S) were supplied by the Wessex Regional Genetics Laboratory, Salisbury. 
** Probes employed diagnostically showed no contamination with other exons and adequate 
hybridisation efficiency.
Probe Labelling
Isolated DMD/BMD exon-specific probes were labelled with biotin by nick translation and, 
to assist chromosome identification, co-hybridised with biotinylated chromosome X alpha 
satellite centromeric probe (DXZ1, Oncor). Addition of 0.8ul of a denatured 1:20 dilution 
of DXZ1 in hybridisation buffer to 10ul of pre-annealed cosmid probe mix provided 
adequate centromeric signai.
During these investigations temporary problems with biotin-11-dUTP supply prompted 
investigation of another labelling approach. The newly-avaiiable BioNick kit (Gibco BRL
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Life Technologies) was therefore tried with cMA2B3 and e47 probe DNA. This is similar 
to the standard Gibco nick translation kit but biotin-14-dATP is supplied ready-mixed with 
the unlabelled nucleotides. Although slight improvement did result from the use of twice 
the recommended DNA concentration in the BioNick reaction the signal obtained from 
these cosmids was weak, so the original labelling approach was re-adopted when biotin- 
11-dUTP supply recommenced.
Optimisation of Probe Hybridisation
Prior to diagnostic use, probes were assessed at a range of concentrations (10-20ng/ul) 
for hybridisation efficiency and background level. Most of the satisfactory probes, i.e. 
those which produced signals on both X chromosomes in at least 80% of metaphases, 
were used at a concentration of 20ng/ul.
Initially an incubation temperature of 42 '^C was used for hybridisation but this was later 
reduced to 37®C to improve weaker probe signals.
An extra round of amplification was attempted for several of the weaker probes but, 
because of increased background, this produced a consistent improvement with only one 
cosmid, CYD4.66. Extra amplification appeared to be most beneficial if target 
metaphases were membrane-bound.
Although probes were assessed with both competitor DNAs, those originating from 
Leiden were found to work better or as well with Cotl DNA and those supplied by 
Manchester worked better or as well with total human genomic DNA. Either Cotl DNA at 
0.2ug/ul or total human genomic DNA at 1 ug/ul was used for all probes except NRM17 
(0.25ug/ul Cot1), NRM19 (0.23ug/ui Cot1), cYD4117 (0.4ug/ul total human genomic DNA) 
and CMA2F5 (1.25ug/ul total human genomic DNA).
Post-hybridisation stringency washing was initially two 5 minute treatments in 50% 
formamide at 42°C, with a shorter wash attempted for weaker probes. Later in the study 
all probes were washed for 2 minutes in 0.4xSSC at 72°C.
Following ISH efficiency and contamination testing, twenty probes proved to be of 
acceptable quality for diagnostic use (Table 3-18). Adequate hybridisation was however 
only achieved with cosmid cYD4117 by using twice the normal concentration of DNA for 
labelling, 400ng probe and just 0.4ul total human DNA per area, and reducing wash 
stringency. This probe was only used on one patient who had a male relative with an 
exon 44 deletion.
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PROBE LOCUS % OF ALL EXONDELETIONS
DETECTABLE'
ORIGIN COMPETITORDNA
COMPETITORCONCENTRATION
NRM1
C104C038
exon1 1 M Cotl 0.2ug/ul
NRM3
C104A1047
exon3 8 M Cotl 0.2ug/ul
CLA1A5 exonS/exon4
89
L total genomic 1 ug/ul
NRM7
C104E0790
exon7 10 M Cotl 0.2ug/ul
NRM8
C104F02123
exonS 10 M Cotl 0.2ug/ul
CLA1F2 exon8/exon9
10
10
M total genomic 1 ug/ul
NRM13
C104F0393
exon13 11 M Cotl 0.2ug/ul
NRM17
C104D02129
exon17 9 M Cot1 0.26ug/ul
NRM19
C104B0281
exon19 9 M Cotl 0.23ug/ul
CYD4117 exon44 7 L total genomic 0.4ug/ul
cPT4 intron44 N/A L total genomic 1 ug/ul
CAL24 intron44 N/A L total genomic 1 ug/ul
cPT1 intron44/exon45
N/A
37
L total genomic 1 ug/ul
CYD4.66 intron44
(3'P20)/
exon45
N/A
37
L total genomic 1 ug/ul
NRM47/e47
C104E0143
exon46/
exon47
41
41
M/S Cotl 0.2ug/ul
CMA2B3 exon48/exon49
37
34
L total genomic 1 ug/ul
CMA2F5 exon49/
exonSO
34
33
L total genomic 1.25ug/ul
NRM51/e51
C104C0461
exon51 26 M/S Cotl 0.2ug/ul
NRM52/e52
C104A1287
exon52 23 M/S Cotl 0.2ug/ul
CMA1C4 exon55 7 L total genomic 1 ug/ul
Table 3-18 DMD/BMD cosmids used diagnostically.
N/A: Not applicable - the probe is an intronic sequence. Intron 44 is the intron with the most 
deletion breakpoints.
'The percentage of all DMD/BMD exon deletions which involve the exon sequence in this probe. 
Information obtained from http://www.dmd.nl/DMD_deldup_Leiden.html 
^M=Manchester,S~Salisbury, L=Leiden.The ICRF numbers of the cosmids provided by the Manchester group are written in italic beneath 
the probe names.
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strategy for Diagnostic Testing
Prior to diagnostic use, probes were preferably assessed on affected or known carrier 
relatives. If the probe failed to produce signal on the deleted chromosome X it was 
considered informative and suitable for carrier determination in that family. Carriers 
showed this probe signal at Xp21 on only one of their X chromosomes, whereas both X 
chromosomes showed signal in non-carriers (Fig.3-14).
Ten metaphases were analysed for each test with a normal result, twenty to twenty-five if 
abnormal. ISH was repeated, with normal controls, for all apparently deleted or carrier 
cases.
Diagnostic Results
One hundred and twenty one females were tested, using appropriate cosmids from the 
optimised panel of twenty probes, to determine DMD/BMD carrier status (Table 3-19).
In the majority (eighty five) of these investigations, the results of previous DNA studies 
indicated the appropriate exons for FISH testing and the informativeness of a FISH probe 
could be confirmed by hybridisation to a known carrier or affected male relative. One 
individual (SC), in whom carrier status was excluded, had previously been classified as a 
carrier by CK levels.
Another FISH result might have indicated possible gonadal mosaicism - an allegedly 
obligate carrier (MW) was not deleted at exon 7, unlike her son. Unfortunately the other 
reputedly affected male relative was not available for testing. FISH also identified a 
deletion at exon 52, in carrier SE, which was missed by quantitative PCR. The FISH 
result was confirmed by further molecular studies at another centre.
Seven females were referred for testing but FISH studies on their male relatives, who had 
exon deletions identified by molecular means, showed the available FISH probes to be 
uninformative.
In nineteen cases, no relative was available for FISH confirmation and the family deletion 
was recognised by DNA studies alone. In these cases, failure to detect hemizygosity in 
the test female by FISH was not considered to exclude carrier status unless the deletion 
defined by molecular means was at least one exon longer at each side than the FISH 
probe sequence used (e.g. the deletion included exons 48-52 and the FISH probe used 
was specific for exons 49/50). Carrier status could then be provisionally excluded. 
Seventeen of the females tested had no available affected or carrier relative to allow 
identification of deletion (or confirmation that dystrophin deletion was the cause of the 
muscular dystrophy in their family). Nineteen of the twenty-probe series (excluding
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CYD411.7) had to be used in the FISH investigations on this group. This did achieve 
detection of deletions in three of these individuals:
• JG (cPT 1, cAL24, cPT4 deletion), who later had PND by FISH on cultured amniocytes. 
The female fetus was also a carrier.
• MB (e52 deletion). Determination of this deletion also allowed exclusion of carrier 
status in her daughter and another female relative.
• EB (NRM51 deletion), although signal was present on both chromosomes X in 1/20 
metaphases. This could have been due to background, the contamination of the probe 
with exon 52 DNA (and no deletion at exon 52) or to only partial deletion of NRM51 
sequence. No material remained for subsequent testing with ‘pure’ exon 51 probe.
In addition to the fifty two male patients tested to assess the suitability of particular FISH 
probes for carrier detection, two were tested for inheritance of a familial BMP deletion 
(Table 3-20). FISH confirmed deletion in one of these individuals.
In total eighty three families were investigated with DMD/BMD cosmids.
125
Fig.3-14 DMD/BMD carrier determination by FISH with dystrophin exon-specific probes. 
A: Metaphase from a DMD patient following hybridisation to a dystrophin exon probe which detects 
the deletion in this individual. No signal is present at Xp21. The X centromere is highlighted with 
an X alpha satellite probe to aid chromosome identification.
B; Metaphase from a female relative of this DMD patient following hybridisation to the same 
dystrophin exon-specific probe. Signal at Xp21 (arrowed) is present on both chromosomes X, 
indicating that this individual is not a carrier of the familial deletion involving this sequence.
C: Metaphase from another female relative of this DMD patient following hybridisation to the same 
dystrophin exon-specific probe. Signal at Xp21 (arrowed) is present on only one chromosome X, 
indicating that this individual is a carrier of the familial dystrophin deletion involving this sequence.
METHOD OF
IDENTIFICATION/CONFIRMATION 
OF FAMILIAL DELETION
NUMBER
REFERRED
DELETION/CARRIER STATUS 
CONFIRMED EXCLUDED
PROBES
UNINFORMATIVE
FISH on a male relative 77 21 52
(one a possible GM)
4
FISH on a female carrier 8
(one PND)
2 6 0
DNA studies then FISH on male 
relative, but FISH uninformative
7 0 0 7
DNA studies only 19 6 7
(provisional)
6
DMD/BMD unconfirmed/ 
deletion uncharacterised 
(affected male unavailable for testing)
17 3 0 14
Total number of potential female 
carriers referred 128 32 65 31
Table 3-19 Confirmation or exclusion of carrier status achieved by FISH on female 
relatives of affected males. GM:gonadal mosaic
REASON FOR FISH TESTING NUMBER TESTED
DELETION DETECTED 
YES NO
To assess suitability of FISH probe 
for carrier testing
52 43 9
To confirm affected with BMD
(FISH prot>es informative)
2 1 1
Total number of males tested 54 44 10
Table 3-20 Numbers of male patients tested using FISH with DMD/BMD probes and 
reasons for testing.
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3.2.5 Screening for Cryptic Subtelomeric Rearrangements
As a consequence of the report that around 6% of patients with idiopathic MR might have 
cryptic subtelomeric rearrangement (Flint et al 1995), contact was made with this group 
which was then attempting to isolate efficient, specific FISH probes for all subtelomeric 
regions. A series of cosmids was received for assessment as part of this effort.
The probes which the group isolated (Ning et al 1996) were then used in the development 
of the commercial Multiprobe-T device (Cytocell), designed to allow diagnostic screening 
for subtelomeric rearrangements. The first part of the study described here concerns a 
contribution to these developments.
The subsequent introduction of the Multiprobe-T device allowed diagnostic screening of 
individuals with idiopathic MR to commence. Its use, also reported in this study, laid the 
foundations of a diagnostic service and afforded an initial assessment of the incidence of 
subtelomeric rearrangements in Scottish patients with idiopathic metal retardation.
Assessment of Subtelomeric Cosmids for Specificity and Hybridisation Efficiency 
Eight bacterial culture plates were received from the Institute of Molecular Medicine, John 
Radcliffe Hospital, Oxford. Two contained scos cosmids subcloned from unidentified 
telomeric YAGs (2067 and D3) and six had subclones from chromosome 1q, 2q, 3q, 8q, 
9q, and 18q telomeric YAGs. For each plate a g ridded ‘plan’ had been provided on which 
was noted the positions of those colonies which had hybridised to Got1 DNA and 
therefore contained human rather than purely YAG DNA.
In total, 140 colonies carrying cosmids with human DNA inserts were picked and 
incubated as 5ml starter cultures in ampicillin-containing broth. Gultures which failed to 
grow were re-picked. Glycerol stocks were prepared from the 69 cultures which produced 
growth at the first or second attempt. By the time a set of subtelomeric probes had been 
completed by the Oxford group, cosmid DNA had been extracted from 18 of these 69 
glycerol stocks (using a Qiagen kit) and 16 of these cosmid extracts with strong bands on 
electrophoresis had been DIG-labelled and hybridised to normal metaphase preparations 
at 10-15ng/ul with 1 ug/ul total human DNA competitor. DIG, rather than biotin, label was 
chosen because of the shorter detection protocol. Extractions were repeated for some 
cosmids with low yield and no signal on FISH (e.g. 2112.2b2), in one case using a colony 
from a duplicate plate (2053.2d4). If only weak FISH signals were present with any 
cosmid (e.g. 2123.2d1, 2050.2d2) further trial hybridisations were performed. These 
involved changing, separately, the cosmid concentration (to 20ng/ul), the DNA competitor 
(to Gotl) or the total human competitor DNA concentration (to 0.5ug/ul). It was noted that 
200ng/ul Cotl was a less effective competitor than 1 ug/ul total human genomic DNA.
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Where excess signals were present (e.g. D3g5), the cosmid concentration used was 
reduced to 5ng/ul. None of the hybridised cosmids produced signal of adequate strength 
or specificity (Table 3-21) and only two (2112.2b2 and 2123.2d1) produced clear signal on 
the chromosome telomere to which they were expected to hybridise.
Lack of success with other cosmid clones occurred at various stages in the cosmid 
extraction and ISH process. Failure of some colonies to grow in broth might have 
occurred because they had died in transit, or because they were picked from plates which 
were not freshly streaked, which can lead to loss or mutation of construct. Also, it was 
recognised in advance that not all colonies would grow well, and that this depended on 
the cosmid insert (Dr Flint, personal communication).
Cosmid inserts which produced no, or only very weak, FISH signal may have had a high 
proportion of repetitive sequences, and these were competed out’ during CISS ISH.
Cross hybridisation to many chromosomes (as seen with 2123.2c5 and 2053.2b5) is likely 
to have arisen because of the inclusion, in the cosmid insert, of distal subtelomeric 
sequences which are common to many chromosomes (as explained in Knight and Flint 
2000). The presence of more proximally located non-unique subtelomeric sequences is 
likely to have been the cause of some cosmids (such as 2112.2b2 and 2050.2d2) cross 
hybridising to a few chromosomes (Knight and Flint 2000). Homology of 2q and 8p 
telomeric sequences had been recognised previously (Dr Flint, personal communication), 
which explains the cross hybridisation (to 8p) of 2qtel sequences in cosmid 2112.2b2.
This work excluded the studied cosmid sequences as suitable probes.
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Fig.3-15 The Multiprobe-T device.
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Vac ' TEL STARTER GLYCEROL COSMIDS FISH RESULTS
CULTURES STOCKS PREPARED [yield]
2112.2 2q 3 1 b2 repeated [22ug] 2q and 8p
2123.2 1q 20 14 c5 repeated [27ug] nonspecific
d1 [13ug] 1q,1p,few other telomeres
el [1.1 ug] no signal
g3 [1-3ug] no signal
2050.2 18q 21 7 e6 [8ug] weak, nonspecific
d2 repeated [25ug] Bgrp,10q,1cen,acro p arms
c4 [36ug] Bgrp, 10q,1cen,aero p arms
a5 [17ug] no signal
2053.2 8q 12 1 b5 [7ug] nonspecific
d4 repeated [2ug] no signal from  e itheroriginal or duplicate plate
2175 3q 25 21 none FISH not performed
2048 9q 16 8 a3 [1.3ug] no signal
b6 [1.9ug] no signal
c4 [6ug] not hybridised-weak gel
bands
f  1 [6ug] not hybrid ised-w eak gel
bands
2067 ? 3 3 a1 [4ug] no signal
D3 ? 39 8 g5 [15ug] nonspecific
h3 [35ug] nonspecific
Table 3-21 Hybridisation results with cosmid subclones of telomeric YACs.
Bgrp: B group chromosome; aero: acrocentric chromosome; cen: centromere
The Cytocell Multiprobe-T Device
The Multiprobe-T is a disposable device which allows the independent hybridisation of 
each of a 41 telomere probe set to a fixed metaphase preparation spotted on a single 
template microscope slide (Fig.3-15). There are no probes for the short arms of 
acrocentric chromosomes. The device consists of a 2.5 x 6.5cm array of raised square 
panels each of which carries one (in the case of the acrocentric probe panels) or a pair of 
telomeric probes. Hybridisation solution is placed on each of the panels then both probe 
and target DNA on the template slide are denatured simultaneously under the device 
when the slide is heated to the denaturing temperature. This technology had previously 
been applied to sets of whole chromosome paints (the Multiprobe-M) and centromeric 
probes (the Multiprobe-I). Involvement, in 1995, with evaluation of the original plastic 
Cytocell Multiprobe-M, and subsequently of a glass device with directly labelled paints, led 
the company to request assistance with the assessment of a prototype Multiprobe-T in 
October 1997. Generally poor results were obtained with this plastic device and twelve of 
the probes failed to produce signal on one sample. It was decided, from the results of the 
Multiprobe-M assessments, that the use of glass rather than plastic allowed more even
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contact of device and template slide and prevented ‘drying out’, so a glass version of the 
Multiprobe-T was commercially launched in early 1998.
During the course of this investigation the device specification altered, it initially carried 
indirectly labelled probes requiring detection with fluorescent antibodies (this version was 
used on 59 cases in this study). In 2000 this was superceded by a device with directly 
labelled fluorescent sequences (used on 41 cases). This change to direct labelling was 
made feasible by the replacement of most of the original cosmid probes with more robust 
PAG, PI or BAG clones (Knight et al 2000).
Multiprobe-T Protocol Modifications
The Multiprobe-T device was used broadly according to the manufacturer’s instructions 
and as described by Knight et al (1997), however the recommended protocol had to be 
slightly modified for use on the cytogenetic preparations produced in this department. 
Alterations included prior dénaturation of the test slide in 70% formamide, prolonged pre­
warming (for over twenty minutes) of device plus slide combination prior to co- 
dénaturation, and altered co-denaturation time. Version 1 of the manufacturer’s method 
stipulated five minutes dénaturation, but this was reduced to two to three minutes for this 
study to avoid damage to chromosome preparations. This was communicated to the 
manufacturer, and later versions of the recommended protocol advised denaturing for two 
minutes.
It was found that, when dropping fixed samples on to the template slide, pre-warming of 
the slide in a humid atmosphere over a water bath at 65°G produced an improvement in 
the chromosome spreading obtained from poorer quality samples.
Testing with Gytocell Multiprobe-T for the Detection of Cryptic Subtelomeric 
Rearrangements in Idiopathic MR
Employing the modifications described above, the device was used to study a series of 
100 patients to assess the incidence of subtelomeric rearrangement.
Patients
Eighty eight unrelated individuals with unexplained moderate or severe MR, eight with 
mild or mild to moderate MR, and four with mild to moderate MR plus behavioural 
difficulties (a total of 55 males and 45 females) were selected for subtelomere screening 
based on clinical examination and family history by consultant clinical geneticists in 
Glasgow, Aberdeen, and Newfoundland, Canada.
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Retrospective examination of genetic records revealed that thirty four patients presenting 
with moderate to severe MR and three patients with mild to moderate retardation had a 
family history of MR. All patients with moderate to severe MR and eleven of the twelve 
individuals with mild MR had been assessed as having at least one physical abnormality, 
as summarised in Appendix II.
Fixed chromosome suspensions were prepared by standard cytogenetic methods from 
lymphocyte or fibroblast cultures. All patients had initially undergone other cytogenetic 
investigations with normal results. These included karyotyping at 550 band resolution to 
exclude overt chromosome abnormalities and FISH testing for microdeletion at the 
DGA/CFS (5 patients), Williams syndrome (3 patients), Smith-Magenis syndrome (2 
patients), RTS (3 patients) and retinoblastoma (1 patient) loci.
Analysis
To verify the reliability of the Multiprobe-T device and its analysis, three samples from 
cases of recognised cryptic abnormality were anonymised and tested with the first 46 
patients to be screened. Two of these three samples were from individuals with cryptic 
t(2;17), the third had cryptic t(4;20). These familial rearrangements had previously been 
Identified by CGH (Ghaffari et al 1998).
Analysis of the 100 patients in the test series involved examination of at least three 
metaphases in each probe area. Images of two of these metaphases were stored and 
independently checked for result confirmation.
In seventy nine cases screened further analyses had to be performed using individual 
chromosome subtelomere probe sets (Chromoprobe-T, Gytocell) because of inadequate 
hybridisation quality in some of the Multiprobe-T device areas. An average of 3.8 probes 
had to be repeated for 59 indirectly-labelled devices, ranging from 0 probes (in six cases) 
to 19 (in one case). In three of the four cases with ten or more failed probes a second 
device was used for repeat testing. With directly-labelled devices, an average of 2.5 
probes per device were repeated, range 0 (in fifteen cases) to 16 (in one case with a very 
poor quality metaphase preparation).
As the manufacturer advised, and as reported (Knight and Flint 2000), cross hybridisation 
involving several of the subtelomeric regions was occasionally observed. Probe selection 
had necessarily involved a compromise between sensitivity and specificity - more distal 
sequences are most sensitive to small rearrangements but are more likely to include 
nonspecific elements. In particular, cross hybridisation of 8p sequence to Ip, not 
recognised by the device manufacturer until the third version of the direct label protocol
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was released, was detected in 10 cases tested with the direct device. No polymorphic 
deletions of 2q sequence were observed in this series.
Three rearrangements, detailed below and in Table 3-22, were detected in the test series 
of 100 affected individuals and the cryptic rearrangements included as positive controls 
were correctly identified.
Subtelomeric Rearrangement in Patient DR
This boy with severe MR, oculomotor apraxia and mild facial dysmorphism was shown to 
have an unbalanced subtelomeric rearrangement involving a derivative chromosome 9 
with deletion of the subtelomeric region of the short arm including probe sequence 43N6, 
and additional material from the subtelomeric region of the long arm of chromosome 3 
including sequence D3S1272, karyotype:
46,XY.ish der(9)t(3:9)(q29;p24)(wcp3+,D3S1272+,43N6-,D9S2168+). This result (Fig.3-
16) was confirmed with another subtelomeric probe for chromosome 3 long arm 
(D3S1445/D3S1446, believed by the manufacturer, Oncor, to lie proximal to the Gytocell 
3q probe but less than 450kb from telomere). Whole chromosome 3 paint (Gambio) 
showed chromosome 3 material on the derivative chromosome 9 in all 10 cells examined, 
including one metaphase with very short chromosomes of approximately 300 bands, and 
chromosome 9 paint showed an unpainted region on the derivative 9 in all of 15 
metaphases. Paint endpoints on reverse DAPI banded images allowed the estimation of 
translocation breakpoints as 9p22.3~p23 and 3q27.3~q28. ISH of chromosome 3 and 9 
subtelomere probe sets to chromosome preparations from the child’s parents showed that 
the rearrangement was de novo.
Subtelomeric Rearrangement in Patient AS
A male baby with TOP and developmental delay, and subsequently his affected uncle 
(DS), were shown to have partial monosomy of chromosome 9q (involving probe 
sequence D9S2168) and partial trisomy 16q (involving sequence D3b1) (Fig.3-17).
Whole chromosome paint could demonstrate a trace of chromosome 16 material on the 
derivative chromosome 9 in seven often metaphases examined. ABL probe sequence 
(9q34, Vysis) was present on both chromosomes 9. The karyotype was recorded as: 
46,XY.ish der(9)t(9;16)(q34;q24)(43N6+,wcp9+,D9Z1+,ABL+,D9S2168-, wcp16+,
D3b1+).
Hybridisation of chromosome 9 and 16 subtelomere probe sets to chromosomes from the 
father of AS showed that he carried the balanced reciprocal translocation involving 
chromosomes 9 and 16 (Fig.3-17).
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Despite careful and focussed scrutiny of the chromosomes 16 in this carrier, whole 
chromosome 9 paint revealed chromosome 9 material on the derivative 16 (representing 
the monosomie region in AS) in only one out of ten metaphases.
When the mother of AS became pregnant the prior identification of this familial 
chromosome rearrangement allowed PND. Individual chromosome 9 and 16 telomere 
probes hybridised to a CVS preparation showed no rearrangement of these sequences in 
the foetus (Fig.3-17).
Subtelomeric Rearrangement in Patient MG
This male patient, aged 18 years, presented with severe MR and multiple congenita! 
abnormalities (detailed In Table 3-22). His brother (SG, 21 years) was similarly affected 
but with VSD, no pulmonary stenosis, scoliosis or hypospadias. Another, deceased, 
brother had similar features. Both live sibs were shown to have partial monosomy of the 
long arm of chromosome 18 (involving sequence D18S1390) and partial trisomy of the 
short arm of chromosome 10 (involving sequence D10S2488). Chromosome 10 material 
on the derivative chromosome 18 in patient MG was clearly demonstrable with 
chromosome 10 paint in all cells (Fig.3-18). The karyotype was recorded as:
46,XY.ish der(18)t(10;18)(p15;q23)(52M11+,D18S1390-,D10S2488+,wcp10+).
Relatives subsequently tested included the similarly affected nephew (DO, Appendix II) 
and the boys’ father (DM) and brother (DE) who both carried the balanced form of this 
reciprocal translocation. Chromosome 18 paint showed translocated material on one 
chromosome 10 in all cells of carrier DE (Fig.3-18).
In summary, the three different unbalanced subtelomeric chromosome rearrangements 
detected were all found in the group of patients with severe to moderate learning difficulty 
or developmental delay, making the prevalence of subtelomeric rearrangements in this 
cohort of eighty eight unrelated individuals 3.4% (95% Gl 0.7%-9.6%).
All three probands had dysmorphic features. Two had a family history of learning 
difficulty, inheriting an unbalanced form of a parental balanced translocation. A de novo 
rearrangement was found in the third patient, who had an eye movement disorder and 
premature puberty. Re-examination of 550-band chromosomes was possible for patients 
DR and DS, the affected uncle of AS, and revealed no apparent karyotype abnormalities. 
None of the 12 individuals with mild MR exhibited subtelomeric rearrangement.
Update of Subtelomeric Screening Results
Subtelomeric screening has continued as part of the diagnostic service at the Duncan 
Guthrie Institute. The Totelvysion kit (Vysis), which allows larger hybridisation areas, has
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been used instead of the Multiprobe-T device for cases with very low mitotic index. By 
the end of 2003 a further 107 cases had been tested (of which two were noted to have 
only mild MR) and 12 produced abnormal results.
Six of these abnormalities were considered unlikely to be clinically significant, being cases 
of 2q subtelomeric sequence D2S2986 deletion with no deletion of 2q subtelomeric 
sequence D2S447, suggesting 2qtel polymorphism. In one case the polymorphism could 
also be demonstrated in the patient’s father, in another it was present in an affected twin. 
The four cases believed to be clinically significant comprised two with syndrome- 
associated abnormalities (del(1)(p36.3), del(22)(q22.3)), one with a der(18) representing 
the unbalanced product of a translocation between chromosomes 18 and 20 
(der(18)t(18;20)(q23;q13.3)), and one de novo del(6)(q27) which includes the TATA box- 
binding protein (TBP) gene (as determined by FISH with a TBP DNA probe (Oncor)).
The clinical significance of the remaining abnormal subtelomere screens could not be 
conclusively determined. A 7p deletion detected was also present in the patient’s mother 
who had a much milder phenotype. This could be a pathogenic abnormality but with 
variable expression, or the mother’s mildly abnormal phenotypic features could be 
coincidental. The other abnormality in this category included a case of Bp deletion which 
was also present in the patient’s unaffected father.
Two suspected carriers of subtelomeric deletion were also tested in the absence of 
material from affected relatives. No abnormalities were found.
Combining these results with those from the initial cohort of 100 patients suggests that 
the detection rate of clinically significant subtelomeric rearrangement in patients clinically 
determined to be appropriate candidates for subtelomeric screening lies between 3.4 and, 
when the 7p and 8p deletions are included, 4.3%. If the patients known to have only mild 
MR are excluded, giving a population of 193, then the detection rate is 3.6% (95% 01 
1.47-7.3) to 4.7% (Cl 2.15-8.67%).
KARYOTYPE DEGREE OF MR PHENOTYPE
46,XY.ish der(9)t(3:9)(q28;p23) 
(wcp3+,D3S1272+,43N6-. D9S2168+) 
de novo
m ode ra te /severe Cogan’s oculomotor apraxia,
Duane’s ocular retraction, premature puberty
46.XY.ish der(9)t(9;16)(q34;q24) 
(43N6+, wcp9+, D9Z1 +, ABL+, D9S2168-, 
D3b1+,wcp16+)pat
46,XY.ish der(18)t(l 0; 18)(p16;q23) 
(52M11+,01831390-,
□10S2488+,wcp10+)pat
m odera te /severe
severe
tetralogy of Fallot 
developmental delay
pulmonary stenosis, scoliosis, hypospadius, 
microcephaly, hypopastic midface, short stature, 
gastro-oesophageai reflux, asthma, 
cholelithiasis, joint laxity, hypotonia, reduced 
pigment
table 3-22 Subtelomeric rearrangements detected using FISH.
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Fig.3-16 Identification of der(9)t(3;9) in individual DR using FISH.
A: Hybridisation to 3p (green) and 3q (red) telomere probes (Gytocell Multiprobe-T) 
showing an extra 3qtel signal on a derivative chromosome 9.
B; Hybridisation to chromosome 3 paint showing complete paint coverage of both 
chromosomes 3 and signal on the distal short arm of the derivative chromosome 9. 
C: Hybridisation to 9p (green) and 9q (red) telomere probes (Gytocell Multiprobe-T) 
showing deletion of one 9ptel sequence.
D: Hybridisation to chromosome 9 paint showing an unpainted region due to the 
translocated chromosome 3 material (arrowed) on the derivative chromosome 9.
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Fig.3-17 Identification of a familial t(9;16) using FISH.
A and B: Hybridisation to 9p and q (A) and 16p and q (B) telomere probes 
identifies, in affected individual AS, a derivative chromosome 9 with deletion of 9qtel 
sequence and an extra copy of 16qtel sequence.
C and D: Hybridisation to 9p and q (C) and 16p and q (D) telomere probes 
identifies derivative chromosomes 9 and 16 in carrier KS, the father of AS.
E and F: Hybridisation to 9p and q (E) and 16p and q (F) telomere probes shows 
chromosomes 9 and 16 with normal signal patterns in a CVS from the wife of KS.
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Fig.3-18 Identification of a familial t(10;18) using FISH.
A: Hybridisation to chromosome 18 p and q telomere probes detects deletion of 
the ISqtel sequence from the derivative chromosome 18 in affected individual SC.
B: Hybridisation to chromosome 10 p and q telomere probes detects an extra copy of 
10ptel sequence on the derivative chromosome 18 in affected individual SC.
C: Hybridisation to chromosome 10 paint (red) and 18 alpha satellite probe shows 
chromosome 10 material on the der(18) indicating, as it is detectable using paint, that 
this translocated region is likely to be >5Mb in size.
D and E; Hybridisation to p and q telomere probes for chromosomes 10 (D) and 18 (E) 
identifies derivative chromosomes 10 and 18, indicating that this brother of SC carries 
the rearrangement in the balanced form.
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3.3 Comparative Genomic Hybridisation
CGH provides a global approach for the determination of quantitative genomic change in 
cases of apparent but unresolvable chromosomal abnormalities. Its sensitivity, 
approximately that of chromosome painting, also enables it to disclose some subtle or 
cryptic abnormalities hidden by conventional banding. The work described here involves 
the development of this technique for diagnostic use and its application to such cases.
3.3.1 Preliminary CGH Experiments Using Indirectly Labelled DNA
The first CGH attempted in this study, performed primarily to gain experience of the 
procedure, utilised DNA indirectly labelled with biotin and DIG and detected with FITC and 
Texas Red conjugates. This approach was used for hybridisations of 46,XY and 45,XO 
versus 46,XX reference DNA. These experiments established a working DNA 
concentration for CGH with indirect labelling of 120-300ng per area (published values 
ranged through 60ng (Kallioniemi et al 1992b), 120ng (Kallioniemi et al 1994), to lug (du 
Manoir et al 1993)). They also showed that pretreatment with 0.2ug/m! proteinase K in 
20mM Tris-HCI, 2mM CaCb, pH7.5 for 7.5 minutes at 37'^ C (Kallioniemi et al 1994 used 
0.1ug/ul) produced no improvement in hybridisation efficiency with 3 day-old slide-bound 
chromosome preparations, and that methanoliacetic acid (3:1) fixation of slides for one 
hour adversely affected signal.
3.3.2 CGH with Directly Labelled DNA
Direct labelling and detection was quickly adopted for all subsequent CGH experiments 
because of its convenience. Prior to clinical application, modifications to a standard 
protocol were briefly investigated to determine if these could make CGH simpler, faster or 
more reliable and therefore more readily applicable in a routine diagnostic environment. 
This included examining the effect on signal quality of newly available commercial 
products including CGH kits. Some of the modifications examined are listed in Table 3-23 
and the results of these detailed below. The standard direct protocol used for comparison 
was essentially that of Kallioniemi et al (1994), but using 800ng rather than 200ng of each 
DNA per 2cm  ^hybridisation area in line with the prevailing drift upwards in CGH DNA 
concentration (by 1996, Kallioniemi et a! were using 400ng).
Where the effect of a modification on hybridisation quality was significant, it could be 
assessed by subjective observation. An attempt was made to provide a more objective
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measure of signal intensity by calculation, for each fluor, of average automatic exposure 
times from several cells. This was abandoned as meaningful comparisons were difficult 
to achieve because non-chromosomal fluorescent bodies in the vicinity of metaphases 
affected exposure times.
A preliminary comparison of dénaturation conditions was first undertaken. This showed 
that formamide dénaturation of 1 to 3 day-old slides at 73°C or 80°C for 3 minutes 
produced metaphases of broadly acceptable quality, on examination prior to CGH, with 
either temperature. However DAPI staining was generally paler with 80°C dénaturation, 
more C-bands were apparent and chromosomes did appear more ‘ghost-like’. A 
dénaturation temperature of 73°C (as used by Kallioniemi et al 1994) was therefore 
confirmed as appropriate for ‘in house’ slide preparations.
3.3.3 The Effect of Modifying Elements of the CGH Procedure
i) Use of frozen metaphase preparations
Many protocols advocate providing metaphase preparations of suitable quality for CGH by 
preparation of large numbers of slides, testing of each batch and freezer storage, in 
separate containers, of small quantities of slides. This time-consuming method was 
investigated to determine if it produced optimal results and if an alternative approach 
might be more convenient.
On several occasions, as in tests 2 and 8 (Table 3-23), slides which had not been stored 
at -20°C were assessed against those which had been frozen. Although used by many 
groups to allow extended utilisation of satisfactory batches, in this study frozen slides 
produced poorer CGH quality (though analysis on the frozen slide might still be possible).
ii) Use of commercial target slides
The introduction of high mitotic index, well spread commercial target metaphase 
preparations (Vysis) promised great convenience. However these frequently appeared 
damaged, with many of the metaphases found to be covered with cytoplasm following 
processing (test 13). Analysis was sometimes possible but protracted slide scanning and 
imaging was required to identify suitable metaphases. After repeated complaints and 
trials of different batches, the manufacturer disclosed that the slides were being 
inappropriately frozen and thawed in transit. Despite eventual availability of correctly 
transported slides, quality barely improved (test 14). As reported below, increasing 
dénaturation time to 3.5 or 4 minutes (an increase presumably required because of the 
slide age-Vysis even suggested 5 minutes but this caused extensive damage) could
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improve the signal quality obtained from Vysis slides (tests 22, 23), but in-house, 
unfrozen, preparations of metaphase spreads were subsequently used where possible.
iii) Altering the fluorescent label and/or its concentration
The use of a double concentration of nucleotide-conjugated fluor in the labelling mix (tests 
1 and 2) produced no improvement in signal strength.
The effect of different fluorescent labels was briefly assessed, incorporating these with 
the standard Gibco BRL nick translation kit (tests 4-12) or an alternative labelling system 
(Amersham or Vysis). Amersham fluor-X did appear to produce an enhanced green 
signal. This improvement was, however, variable, or only present when the fluor-X was 
incorporated using the Amersham labelling reagents supplied with this fluorochrome (test 
3). As CY3 did not produce red signal enhancement, an alternative red fluor would have 
to be used, incorporated by the Gibco BRL system. This parallel use of two labelling 
systems was judged unwieldy and the use of fluor-X not pursued. An Amersham dUTP- 
FITC was later marketed separate from a labelling kit, but when incorporated by the 
Gibco BRL reagents this produced a weaker green signal than the NEN fluor (test 12). 
Signal produced by Vysis SpectrumRed label was very bright when lul (20uM) was used 
in labelling and the standard 800ng of labelled DNA hybridised, too weak when 0.5ul used 
in labelling and 200ng hybridised (Vysis recommend lOOng) and satisfactory when 500 or 
eoOng employed (tests 4, 6, 7 and 9). Acceptable signal was also obtained with 600 or 
GOOng of SpectrumGreen labelled DNA in 10ul hybridisation mix (test 7, 9).
Only lOuM SpectrumRed-dUTP or SpectrumGreen-dUTP was therefore used in labelling. 
Addition of dTTP to bring combined dUTP/dTTP concentration to 20uM (like that of each 
of the other dNTPs) produced no obvious benefit (test 10) and the labelled fragments 
were smaller. Use of a lower concentration of labelled-dUTP (lOuM) than each of the 
other dNTPs (20uM) and topping up the concentration with dTTP is recommended by 
Vysis because, though label incorporation is lower, the polymerase may be more efficient.
iv) Use of the Vysis CGH nick translation reagent kit
Hybridisation quality across the slide was more variable when the Vysis CGH nick 
translation kit (Vysis 32-801024) was used for labelling (test 11). This system was also 
more expensive than the Gibco BRL kit and involved longer incubation (2-4 hours instead 
of 1 hour), therefore no attempt was made to optimise it.
v) Co-denaturation of probe and target DNA
Co-denaturation of probe and chromosomes using a hotplate (74.5®C, 5 minutes) was 
investigated, as directly-labelled chromosome paints can produce improved signal with 
this approach (Oncor, verbal communication). This would additionally have reduced
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processing time, but though it was initially found to be very successful (test 15), the result 
was in fact variable as the degree of dénaturation increased noticeably with only slight 
reduction in slide age (tests 16, 17). Using different co-denaturation temperatures or 
times for different ages of slide might have addressed this problem, but the approach was 
abandoned to avoid introducing this unnecessary complexity and as it was noted that the 
DAPI banding obtained following co-denaturation could be poorer.
vi) Use of commercial labelled control DNA
Commercial labelled control DNA (Vysis female and male) was tested, as it offered 
convenience, by halving the number of labelling reactions required, and the possibility of 
improved and consistent red signal quality. A higher concentration than that suggested 
by the manufacturer (150ng or 200ng instead of iOOng in the hybridisation mix) was 
required in order for the signal to be clearly visible without imaging (tests 18,19, 20). It 
gave stronger, though still poor, signal than the in-house control DNA hybridised to a 
different area on the same Vysis slide (test 20). Using 200ng Vysis control DNA on Vysis 
slides denatured at 3.5 or 4 instead of 3 minutes could generate acceptable, if variable, 
results (tests 21, 22). However the best signal was obtained using Vysis control DNA on 
in-house slide preparations (denatured for 3 or 3.5 minutes, test 24) so this approach was 
accepted as standard.
vii) Alterations in post hybridisation washing
Reducing the post hybridisation formamide wash temperature to 43°C produced no 
improvement in signal intensity (tests 1 and 2).
0.4xSSC + 0.15% Tween 20 was assessed as an alternative stringent wash, in hope of 
improving on the background removal achieved with 50% formamide or at least 
maintaining this standard while using a time-saving, less hazardous, salt solution. Use at 
73'^C for 2 minutes resulted in partial destruction of the cell sheet on Vysis slides (test 25). 
Lowering the temperature to 70°C for 2 minutes produced the same result as a 
formamide wash, offering potential as a more convenient, safer approach (test 26).
An attempt was made to reduce the excessive background present following some 
hybridisations by removing the coverslip and additional slide washing. A 4XT wash for 5 
minutes at 37®C followed by 0.4xSSC for 1 minute did result in a slightly cleaner 
preparation, but, as signal was also weaker, there was no advantage in this approach.
vii) Slide pretreatment
A pre-wash in 2xSSC for 30 minutes was trialled as this could reduce the ‘dirtiness’ of 
other FISH preparations. No effect was noted on Vysis slides (test 27).
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In summary, examination of procedural variations resulted in only slight modification of 
the protocol of Kallioniemi et al (1994,1996). In particular, commercial labelled control 
DNA was adopted for its convenience and consistently high quality, and the use of frozen 
slides was avoided where possible. When the protocol for assessing metaphase 
suitability was strictly followed and only the highest quality slides selected as targets, the 
CGH standard was usually acceptable. To improve the likelihood of a satisfactory result, 
CGH was generally performed on metaphase spreads from two different individuals. 
Alteration and improvement in analysis procedure accompanied the acquisition of Quips 
CGH software (Vysis). This allowed production of a set of averaged ratio profiles for the 
entire karyotype and interpretation became more rapid and less complex. However 
software-enhanced reverse DAPI banding could be poor with Quips. This was overcome 
by enhancing DAPI with Smartcapture software before formatting images for Quips 
analysis.
The most pronounced improvement in CGH signal quality followed eventual procurement 
of a more powerful, 100W, fluorescent light source. This additionally allowed faster 
exposure permitting images to be re-taken if necessary without extreme fading.
3.3.4 Initial Assessment of the CGH Protocol
CGH was performed with DNA from a neuroblastoma case with recognised abnormalities 
to assess the efficacy of the CGH approach.
Chromosomally Abnormal Neuroblastoma Case
Cytogenetic analysis of this case was performed on direct preparations of lymph node: 
47,XY,add(1)(p31),der(3)t(1;3)(q23;p26),+9,+11-15hsr(r)[cp9]. A marrow sample from 
the same individual revealed a grossly abnormal karyotype with chromosome counts in 
the hypotetraploid range, two copies of add(1)(p31) and der(3)t(1 ;3)(q23;p26) in most 
cells plus a variable number of double minutes. FISH investigation of the lymph node 
sample was not possible because no cytogenetic preparation remained, though FISH was 
used to demonstrate N-myc amplification on the double minutes in the marrow sample, 
DNA was extracted from frozen lymph node tissue and CGH performed, initially with Vysis 
female control DNA (Fig.3-19), and interpreted with no knowledge of the cytogenetic 
analysis. The result was confirmed by repeat CGH using male control DNA.
CGH detected substantial gain at 2p22-p24, i.e. at the N-myc locus, in this tumour DNA, 
which may have represented N-myc amplification in the unidentified rings. It was also 
able to exclude a clinically significant 17q imbalance, which would have compounded the
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poor prognosis associated with N-myc amplification and loss of 1p36. Loss of 1p22-pter 
was demonstrated, though cytogenetic analysis had placed the add(1) breakpoint at 
1p31. Gain of 1q was disclosed by CGH, but appeared to involve approximately the whole 
arm whereas karyotyping placed the breakpoint at 1q23. CGH also detected gain of 
9p13-q12, 9q22.1-q22.2 and 9q33-qter, although visual examination actually suggested 
gain of an entire chromosome 9 as reported in the karyotype.
CGH did not detect the deletion of 3p26-pter from the der(3), probably due to its small 
size and telomeric position, but registered an apparent gain of 4q (4q28, 4q32-q34) which 
was not included in the cytogenetic karyotype. The 4q gain could represent the 
unidentified material present on the cytogenetically determined add(1)(p31) chromosome.
3.3.5 Clinical Application of CGH in Cases of Abnormal Phenotype
The technique was then applied to some examples of the type of cytogenetic problem 
CGH might be expected to be useful in resolving. Testing was generally repeated at least 
once, to confirm results and exclude the significance of slight variations. Normal male 
versus normal female control hybridisations were performed to assess normal ratio 
variation and assist threshold setting (Fig.3-20).
3.3.5.1 Testing of Patients with Apparently Balanced Constitutional Chromosomal 
Rearrangements but Abnormal Phenotypes
Patient KD
This case represented a familiar cytogenetic problem - apparently identical balanced 
karyotypes in phenotypically normal and abnormal individuals in the same kindred. One 
explanation is the presence of a cryptic imbalance in the affected individual(s). 
Cytogenetic analysis identified that patient KD, who exhibits congenital abnormalities 
including dysmorphism and MR, carries an apparently balanced translocation involving 
the short arm of chromosome 10 and the long arm of chromosome 14 
(46,XX,t(10;14)(p13;q24)), a rearrangement also present in phenotypically normal 
members of her family. DNA from patient KD was hybridised five times, producing 
analysable preparations on only three of these occasions. Preparations were always 
considerably poorer - mostly ‘dirtier’ - than control hybridisations. On electrophoresis 
following labelling, fragments were noted to be rather small and the DNA smear weak. 
Electrophoresis of unlabelled KD DNA alongside a confirmed quantity of control DNA 
showed far less high molecular weight DNA in the KD lane, and, indicated by the smear,
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that a proportion of the KD DNA was degraded (Fig.3-21). As no other DNA sample was 
available from this patient, the amount of KD DNA used in labelling was increased by 50% 
which appeared to compensate at least in part for its poor quality, and resulted in the 
analysable CGH preparations.
Of the three experiments analysed, one used normal male control DNA, one Vysis male 
and the other Vysis female control DNA. Normal male versus female control 
hybridisations showed that a threshold of 0.8/1.2 was sufficient to detect loss of the entire 
X and gain of entire Y without introducing false positive gains and losses.
No consistent regions of gain or loss were detected in the test DNA over the three 
experiments at thresholds of 0.8/1.2 or 0.85/1.15. Any regions of gain or loss detected in 
individual experiments involved variable telomeric or heterochromatic regions (Table 3- 
24).
Patient GS
On conventional cytogenetic analysis, this individual, who exhibited Asperger’s syndrome 
and mild MR, was shown to have an apparently balanced pericentric Inversion 
46,XY,inv(7)(p15q21.2). Separate CGH experiments with two different male and one 
female control were performed to exclude possible subtle segmental aneusomy at this, or 
another, chromosome site but revealed no consistent or significant imbalances using 
either Quips (Vysis) or Smartcapture ‘global’ analysis software (Digital Scientific).
Patient SM
Cytogenetic analysis of phenotypically abnormal patient SM had disclosed an apparently 
balanced de novo translocation involving chromosomes 5 and 6 (46,XY,t(5;6)(p11 ;q11 )). 
The smaller derivative chromosome (comprising chromosomes 5 and 6 short arms) was 
identified as the derivative chromosome 6 and the larger as the derivative chromosome 5 
by FISH with alpha satellite probes.
CGH experiments were performed as the patient’s phenotype (which included profound 
MR, cleft lip/palate and facial dysmorphism) was inconsistent with a balanced 
abnormality. Reference DNAs were from two different female controls. Preliminary 
examination of images using global analysis showed loss in mid 1q as the only consistent 
imbalance. CGH interpretation of seven CGH karyotypes revealed a deletion involving 
1q25-proximal q31 (.rev ish dim(1q25q31)) with a threshold of 0.8/1.2 (Fig.3-22). The 
limits of the 99% Cl of test versus reference CGH ratio profiles were used as thresholds 
and did not contain 1 at the site of this apparent imbalance, supporting its significance 
(Weiss et al 1999 advocate this approach for identifying gains and losses). No extra 
gains or losses were detected with the more permissive threshold 0.85/1.15.
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This result was verified by re-examination of G-banded preparations (Fig.3-22).
3.3.5.2 Testing of Patients with Apparent but Unresolvable Chromosomal Abnormality 
Here CGH was applied to the characterisation of structural abnormalities which were 
apparent but difficult to resolve cytogenetically, and which may or may not represent 
clinically insignificant variations.
Patient LF
Cytogenetic analysis of LF, a patient with mild MR, seizures and multiple physical 
abnormalities, revealed a 46,XX,?del(21)(p) karyotype. The small chromosome 21 
derivative was considered to represent a chromosome 21 with deletion of the short arm.
In light of the patient’s phenotype a possible deletion of 21 q material was investigated. 
FISH with 21q21 partial chromosome paint (Biovation), the only proximal chromosome 21 
probe commercially available at that time, revealed signal on both chromosomes 21. It 
was not possible to discern any size difference in the signals on the different 
chromosomes 21. As already reported, YACs 949b09 and 937e12 were also hybridised 
to metaphase spreads from this case. All metaphases examined showed no deletion of 
these sequences on either chromosome 21.
Separate CGH with two different female control DNAs (one Vysis) revealed no consistent 
or significant imbalance. ‘Global’ analysis with Smartcapture software also revealed no 
abnormalities.
Patient LH
Cytogenetic analysis of patient LH, who exhibited severe developmental delay and 
physical abnormalities including webbed neck, kyphosis and facial dysmorphism, revealed 
a 46,XX,v(9)(p13) karyotype. This variant 9p13 was also found in other, phenotypically 
normal, family members. Three CGH experiments, carried out with different male control 
DNAs, failed to disclose definite abnormality.
In two hybridisations (one assessed only with global analysis) which used the same in- 
house male control DNA but different template metaphases from different patient 
specimens there was regular apparent gain around the 9 centromere (at very proximal 9p 
and 9qh). So much that, in the hybridisation analysed with Quips software, the peak was 
still marked at 0.4/1.4. This effect may have been a reflection of wide variation in 
chromosome 9 pericentromeric repetitive sequence content, and blocking, between the 
in-house control and patient DNA. In three further hybridisations using other control DNA 
this effect was not repeated - with Vysis control DNA only a very slight gain was seen at 
9cen (as well as 3cen and 14q13) with a 0.85/1.15 threshold. However, as the apparent
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imbalance in the original hybridisations involved an area adjacent to the variant region of 
the patient’s karyotype, it could not be discounted entirely.
Subsequent FISH with whole chromosome 9 paint and 9 classical satellite probe also 
detected no abnormality.
Patient KK
Initial cytogenetic analysis of this infant’s lymphocytes revealed a 46,XY karyotype, 
although the quality of the preparation was inadequate for the exclusion of a small 
structural abnormality. Skin biopsy analysis resulted in reporting of an ‘unusual’ 
chromosome 17 which might represent normal variation. DNA was prepared from 
cultured fibroblasts and CGH performed, blind to the cytogenetic evaluation, using only 
the global analysis approach as interpretation software was not available at that time. 
Fifty percent of cells analysed suggested a region of loss on the short arm of 
chromosome 17 (Fig.3-23). This triggered FISH testing, which revealed deletion of 
17p11.2 including the Smith-Magenis (D17S258) region but not Charcot-Marie-Tooth 1A 
(D17S122) region, karyotype: .ish del(17)(p11.2p11.2)(D17S122+,D17S258-). 
Miiler-Dieker (D17S379 17p13.3), 17p subtelomeric (D17S2199), KARA (17q12) and 17 
alpha satellite sequences (D17Z1) were all present on the deleted chromosome at their 
normal loci. Confirmation of these findings on lymphocyte preparations was not possible 
as no material had been retained and the infant died, aged 6 months.
Cytogenetic analysis of parental blood disclosed no abnormality.
Patient LS
This patient had speech delay and slightly abnormal toes. Cytogenetic analysis revealed 
one abnormal chromosome 3 with a small amount of unidentified additional material and 
FISH demonstrated total 3 paint coverage of this chromosome and deletion of 3ptel.
CGH was performed with male control DNA (Vysis) on metaphase preparations from two 
different normal individuals. Software interpretation, using the 0.8/1.2 threshold 
suggested to be appropriate by the normal male:female control CGH, confirmed loss at 
3p telomere and showed gain at 3p24.2-p25 (Fig.3-24), karyotype;
46,XX,add(3)(p26).rev ish der(3)dup(3)(p24.2p25)enh(3p24.2p25)del(3)(3p26)dim(3p26) 
Slight gain was also apparent at other locations (1p36.1~pter, 19q, distal 9q and distal 
22q) all of which are regions of recognised CGH variability. Hybridisations to Ip  and 9q 
telomere FISH probes were performed to investigate the apparent imbalances at these 
regions, and produced normal signal patterns.
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Patient JG
A 46,X,dup(X)(q26q28) chromosome constitution was found in cultured amniocytes 
following amniocentesis for maternal age indication. Chromosome painting confirmed 
that the abnormal X was comprised completely of X material, and Xq24 macrosatellite 
probe sequence (Oncor) was present in the usual position and not involved in the 
duplication. Presence of an XYqtel sequence (Cytocell) at distal Xq demonstrated that 
the duplication was interstitial. Both parents had a normal karyotype. At age 3.5 the child 
showed normal, or only very slightly delayed development.
CGH, a technique which could have refined characterisation of this rearrangement in one 
step, failed, and electrophoresis of unlabelled patient DNA showed the high molecular 
DNA band size was approximately one quarter the intensity of that from control DNA of 
apparently similar concentration (Fig.3-21). A smear, the usual sign of DNA degradation, 
was not present, but it is possible that much of the DNA was degraded to such a degree 
that very small fragments were produced which ‘ran off the gel. No alternative DNA 
sample was available and amniocyte cultures had not been stored due to contamination.
3.3.5.3 Testing of a Patient with Abnormal Phenotype but No Apparent Chromosomal 
Abnormality
Patient RK
Conventional cytogenetic analysis revealed no abnormality in this patient with MR and 
dysmorphic features. Separate CGH investigations were performed with two different 
female (one Vysis) and one male (Vysis) control DNAs. On interpretation, appropriate 
gain/loss of X and Y with male control DNA suggested 0.8/1.2 as threshold. Neither this 
nor a more permissive threshold, 0.85/1.15, disclosed any consistent or apparently 
significant imbalances. Subsequent subtelomere screening and DG/VCFS deletion 
testing by FISH also failed to reveal any abnormality.
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TEST WASH
CONDITIONS
LABELLED
NUCLEOTIDE
TEST 
DNA (ng)
CONTROL 
DNA (ng)
SLIDE
TYPE
DENATUR
-ATION
RESULT
STANDARD CON )ITIONS
s
T
A
N
D
A
R
D
2x50%F
45°C
NEN
Texas Red & 
FITC-dUTP/
Gibco NT reagents/ 
No added dTTP
800ng GOOng
1-4
days
old/
not
frozen
Separate 
DNA: 
70°C 5mln 
SLIDE: 
73°C 3min
1 43°C x2 NEN Texas Red/ 
FITC-dUTP
not Improved
2 43°C x2 NEN Texas Red/ 
FITC-dUTP
frozen worse than 1
3 Amershamfluor-X /CY3
Amersham NT 
reagents
frozen green :good red'.poor
4 Amershamfluor-X / 
20uM Vysis 
SR-dUTP
Gibco NT reagents
green: poor 
red .too bright
5 Amershamfluor-X / 
10uM Vysis 
SR-dUTP
Gitxx) NT reagents
GOOng green: poor red:good 
paler than 4
6 Amershamfluor-X / 
10uM Vysis 
SR-dUTP
Gibco NT reagents
200ng green: poor red; pale
7 10uM Vysis
SG-dUTP/
SR-dUTP
Gibco NT reagents
500ng GOOng green-.OKred:OK
8 10uM VysisSG-dUTP/
SR-dUTP
Gibco NT reagents
500ng GOOng frozen green: OK 
paler than 7 
red: OK
9 10uM VysisSG-dUTP/
SR-dUTP
Gibco NT reagents
GOOng GOOng green:OK red:OK 
as 7
10 10uM Vysis 
SG-dUTP/ 
SR-dUTP  
10uM dTTP
Gitxx) NT reagents
GOOng GOOng green-.OK red.OK 
as 7 but gel 
fragments 
smaller
11 10uM Vysis 
SG-dUTP/ 
SR-dUTP+ 
10uM dTTP
Vysis NT reagents
GOOng GOOng frozen green:varied red: varied
more variable 
than Gibco NT
12 AmershamFITC-dUTP
Gibco NT reagents
Vysis green:poorer cytoplasm over 
parts of cells
Table 3-23 Modifications to the (direct labelling) CGH protocol (continued overleaf).
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TEST WASH
CONDITIONS
LABELLED
NUCLEOTIDE
TEST 
DNA (ng)
CONTROL 
DNA (ng)
SLIDE
TYPE
DENATUR
-ATION
RESULT
STANDARD CO EDITIONS
s
T
A
N
D
A
R
D
2x50%F
45°C
NEN
Texas Red & 
FITC-dUTP/
Gibco NT reagents/ 
No added dTTP
800ng GOOng
1-4
days
old/
not
frozen
Separate DNA: 
70°C 5min SLIDE: 
73°C 3min
13 Vysis cytoplasm over cells
14 Vysisdifferent
batch
chromosomes
'ghost-like'
15 4 days old
co-denature
74.5°C
5min
green: better 
banding poorer 
red: better
16 3 days old
co-denature
74.5°C
5mln
green.OK
red:poorer
over-denatured
17 Idayold
co-denature
74.5°C
5min
green:OK 
red: poorer 
over-denatured
18 100ng Vysis SR
control DNA
Vysis green:OK
red.invisible
19 150ng Vysis SR 
control DNA
Vysis green: poor 
red: poor 
chromosomes 
have ‘holes’
20 200ng Vysis SR 
control DNA
Vysis green: poor 
red: poor 
better than in- 
house control 
DNA
21 200ng Vysis SR 
control DNA
Vysis 4min green:OK 
red:OK 
better than in- 
house control 
DNA
22 200ng Vysis SR 
control DNA
Vysis 3.5min signal goodcells over­
denatured
23 Vysis 4min green; OK red; OK 
varies (typical 
Vysis slide)
24 200ng Vysis SR
control DNA
3.5min green:good
red:good
25 0.4xSSC+Tween20
73”C 2min
Vysis damaged 
cell sheet - 
no analysis
26 0.4xSSC+Tween20
70-C 2min
Vysis as 50% F 
but slide 
quality poor
27 pre-wash2xSSC
37“C 30min
Vysis particulate, holes, uneven 
(typical Vysis 
slide)
Table 3-23 Modifications to the (direct labelling) CGH protocol (continued).
Where no details are entered, the condition was standard, as described in the first row. 
The standard conditions used were broadly those of Kallioniemi et al (1994), but using 
800ng of labelled control and test DNA.50%F: 50% formamide in 2xSSC; min: minute; SR: SpectrumRed; SG: SpectrumGreen; Vysis SR 
control DNA: Vysis normal control DNA labelled with Spectrum Red; NT:Nick Translation.
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Fig.3-19 Karyotype (above) and set of averaged ratio profiles (below) following CGH with 
lymph node DNA from a patient with neuroblastoma. Each profile is presented to the side 
of the relevant chromosomal ideogram. A central line reflects the balanced state with 
upper and lower thresholds respectively represented by lines left and right of the central 
line. The test DNA (labelled green) is male, and female DNA was used as reference. 
CGH detects substantial gain at 2p22-p24 (greenired ratio profile peak and green bar to 
the right of the chromosome 2 ideogram), loss of 1p22-pter (ratio profile trough and red 
bar to the left of the chromosome 1 ideogram), and gain of 1q, 9p13-q12, 9q22.1-q22.2 
and 9q33-qter (visual examination suggested gain of an entire chromosome 9). An 
apparent gain of 4q (4q28, 4q32-q34), which was not included in the cytogenetic 
karyotype, was also detected.
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Fig.3-20 Averaged set of ratio profiles from 5 metaphases following control CGH with 
normal female test and normal male reference DNA.
400 2 0 0 n g J G D N A  
125 250 500ng Gibco BRL control DNA  
200ng Vysis control DNA
400 200ng KD DNA  
200ng Gibco BRL control DNA  
200ng JG DNA
Fig.3-21 Agarose gel electrophoresis of unlabelled JG, KD, Gibco BRL plasmid and Vysis 
human control DNA. This demonstrated far less high molecular weight DNA in patient JG 
samples which had been determined to contain 200ng and 400ng by optical density 
readings than in the equivalent concentrations of control DNA. The unlabelled DNA from 
patient KD was shown to be degraded (by the presence of a smear below the high 
molecular weight band of DNA). JG DNA failed to produce CGH results of analysable 
quality and KD CGH had to be repeated several times.
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Fig.3-22 CGH to DNA from an individual (SM) with an apparently balanced t(5;6) 
translocation.
Above: A set of averaged ratio profiles from 7 metaphases. A variation, outwith the 
threshold level, in the green:red ratio at 1q25-proximal 1q31 (shown as a trough in the 
ratio profile and as a red bar to the left of the chromosome 1 ideogram) indicates deletion 
at this locus.
Below: Following CGH, re-examination of the banded karyotype clearly demonstrated this 
deletion (arrowed).
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Fig.3-23 CGH and FISH analysis of patient KK.
A1/Global' analysis following CGH showing loss of test DNA (red areas) on the short 
arms of the chromosomes 17. The test DNA (green label) is from a male and the 
reference DNA (red label) from a female, hence chromosome X also shows red and the Y 
green. Other red or green areas were not consistently located and tended to be at 
centromeric or telomeric regions.
A2: Software-enhanced reversed DAPI banding assists chromosome identification.
A3: Agarose gel lanes 1 and 2 show control DNA and KK DNA following labelling.
Smears show fragments of >500bp. Bright spots are unincorporated fluorescent 
nucleotides.
A4: FISH to Smith-Magenis syndrome (SMS) probe (Vysis) confirms the presence of a 
deletion at 17p11.2 involving this locus. The SMS signal on the undeleted chromosome 
17 is arrowed. The other signal on both chromosomes 17 is control probe RARA, 17q12. 
A5: FISH to commercial Charcot-Marie-Tooth (CMT) probe shows that the 17p11.2 
deletion does not involve the CMT locus.
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Fig.3-24 Averaged set of ratio profiles from 6 metaphases following CGH with female 
patient LS DNA. Reference DNA is male. Deletion at 3ptel and duplication involving 
3p24.2-p25 is indicated. The possible imbalances at 1ptel and 9qtel were excluded 
by FISH testing.
TEST CONTROL DNA THRESHOLD 1.2/0.8 THRESHOLD 1.15/0.85
KD FEMALE (Vysis) NO GAINS/LOSSES GAIN (very slight): 7pter
MALE (Vysis) GAIN; 3pter,9pter,12pter,9qh GAIN: as 1.2/0.8 plus 
14qter,4qter, 17qter, 18qter
MALE GAIN (very slight):
5qter,6qter,2qter,2pter
LOSS:19p
NOT USED
GS FEMALE (Vysis) GAIN: 2q31 (slight), 
3q23,12q21(very slight) 
LOSS: 9q,19q
NOT USED
MALE (Vysis) GAIN: proximal Xq, 
proximal Xq21
NOT USED
MALE (FITC) NO GAINS/LOSSES NOT USED
LF FEMALE LOSS (slight): parts of 4q, 
terminal 4q,5q,6p,6q, 
7p,8p,11q,12p,18p,Xq
NOT USED
FEMALE (Vysis) NO GAINS/LOSSES NOT USED
LH MALE GAIN; 9qh GAIN: 9qh/cen, 9q34 (slight)
MALE (Vysis) NO GAINS/LOSSES GAIN (very slight): 
9cen,3cen,14q13
RK FEMALE NO GAINS/LOSSES NO GAINS/LOSSES
FEMALE (Vysis) NO GAINS/LOSSES NO GAINS/LOSSES
MALE (Vysis) NO GAINS/LOSSES NO GAINS/LOSSES
Table 3-24 Regions of fluorescence ratio fluctuation in patients with no consistently 
detectable genomic imbalance on CGH.
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NAME LOCUS SEQUENCE
(5’ TO 3’)
SIZE
(bp)
ANNEALING 
TEMPEFRATURE/ 
RECOMMENDED 
CONCENTRATION 
IN 50ul
REFERENCE
45-60°C Gosden and
50-250ng Lawson (1994)
45-60°C Gosden and
50-250ng Lawson (1994)
58°C Cinti et al (1993)
200pmol
58°C Cintietal (1993)
200pmol
PCR:58°C Vogt et al (1996)
SOpmol
PGR 58°C Vogt et al (1996)
SOpmol
PGR 58°C Vogt et al (1996)
SOpmol
PGR 58“C Vogt et al (1996)
SOpmol
60°C Pellestor et al
lOOpmoi (1995)
61 °C Pellestor et al
lOOpmol (1995)
60°C Gosden and
50-500ug Hanratty (1993)
60°C/ Gosden and
S0-500ug Hanratty (1993)
60°C Abbs et al
25pmol (1991)
60°C Abbs et al
25pmol (1991)
60°C Abbs et al
25pmol (1991)
60°C Abbs et al
25pmol (1991)
E570
+strand
E574
-strand
FactorIX
X1
FactorIX
X2
RBM1
forward
RBM1
reverse
DAZ
forward
DAZ
reverse
13A
21A
267
435
DMD 
exon 6 
forward 
exon 6 
reverse
DMD 
exon 61 
forward 
exon 51 
reverse
D3Z1
D3Z1
Xq27
Xq27
Y q ll
Y q ll
Y q ll
Y q ll
13 alpha 
satellite
21 alpha 
satellite
human 
satellite III
human 
p satellite
Dystrophin
Xp21
Dystrophin
Xp21
Dystrophin
Xp21
Dystrophin
Xp21
TCTGCAAGTGGATATTTAAA
TGAGTTGAACACACACGTAC
>1000
ACCTTATGGGACCAGTGTCG 3 7 0
ATATTTCTCCTTCCCTCCCTC  
ATGCACTTCAGAGATACGG gQO
CCTCTCTCCACAAAACGAACA
GGAAGGTGGTTTGGTAGATAG 1 3 0 0
TAGGTTTGAGTGTTTGGATTGG
G
TGATGTGTGTAGGGAGGT
TGATGTGTGTAGGGAGGG
AATGGGATGGAGTGGAATGAAG
GGGAATGGAATGG
AGTGGAGAGATATGTGAGAATG
GGGG
GGAGATGTAGGTGAAAAATGTA 202 
ATGAA
GTGTGAGTAATGTTGTTAGGTAT
GAGTATGG
GAAATTGGGTGTTTAGGTTGTG
TTTG
GGAGAGTAAAGTGATTGGTGGA
AAATG
388
Table 3-25 Oligonucleotide primers used in PRIMS studies.
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3.4 Primed In Situ LabeHing
These experiments principally examined means of improving penetrance to target sites 
(by slide pretreatment), increasing amplification efficiency (with alternative DMA 
polymerases and reaction conditions), and augmenting signal size and hence visibility (by 
cycling and TSA), in order to optimise potential for achieving detectable PRINS labelling 
of unique chromosomal sequences. Primer sequences used are listed in Table 3-25.
Commercial Repetitive Target Sequence Primers and Kits
Initial familiarisation with this novel process was acquired through use of the PRINS 
Reaction Set with a human chromosome 12 alpha satellite primer (Boehringer 
Mannheim). The reaction mix and recommended dénaturation and annealing/ 
extension conditions used were as test 1, Table 3-28. Satisfactory signal and minimal 
background was obtained using fixed-temperature hotplates or the surface of tube 
thermal cycler blocks for dénaturation. Interphase scoring of a cytogenetic preparation 
from an individual with suspected B-cell GLL was subsequently performed (Table 3-26), 
clearly identifying a raised proportion of nuclei with 3 copies of 12 alpha satellite (60%) 
compared to a normal control preparation (1%).
INTERPHASE NUMBER OF CHROMOSOME 12-SPECIFIC SIGNALS SCORED 
NUCLEI
_____________________g_________1__________2__________ 3__________4______ ^
patient 0 1 23 60 14 2
control 0 2 95 1 2 0
Table 3-26 Interphase scoring following PRINS with the PRINS Reaction Set and human 
chromosome 12 alpha satellite primer (Boehringer Mannheim).
PRINS with Chromosome 12 Print Kit (Advanced Biotechnologies)
During the course of later PRINS work, another commercial PRINS system, Chromosome 
Print Kits (Advanced Biotechnologies), became available. Limited assessment of the 
chromosome 12 Print oligonucleotide was carried out using both the kit procedure and 
reagents and alternatives to these (Table 3-27). All tests used 1 day-old slides and the 
recommended PCR conditions for these primers. An OmniGene flatbed (Hybaid, Fig.3- 
31) was used for dénaturation. The recommended label, biotin-16-dUTP, was visualised 
only weakly with one FITC layer (test 1). Subsequent tests were therefore performed with 
DIG-11-dUTP label and two detection layers (tests 2-4), and all exhibited stronger signal. 
Identical reagents produced stronger signal when two layers of FITC were used instead of 
one (tests 1 and 3).
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Using DIG labelling mix (Boehringer Mannheim) and AmpliTaq IS (Taq IS, tests 2 and 4), 
a 30% increase in enzyme (test 4) produced considerable signal increase (64% rather 
than 30% of ‘normal’ nuclei with two signals) but also increased background speckling.
All test results compared poorly with those obtained with the Boehringer Mannheim 
primers and PRINS kit (Table 3-26), where 95% of normal nuclei showed two signals.
Chromosome 3 Alpha Satellite (D3Z1) - Specific Primers
PRINS with in-house repetitive sequence primers was investigated in order to develop 
experience in the preparation of PCR primers and assess the effect of altering PRINS 
reaction conditions. A further aim was to identify a combination of reaction components 
which would produce weak but reliable signals with a repetitive sequence primer, allowing 
its eventual use as a control when assessing the effect of different reaction conditions 
(including cycling) on PRINS with unique target sequence primers. A series of 
experiments (chronologically described in Table 3-28) was therefore performed, mostly on 
1 to 3 day-old slides, with chromosome 3 alpha satellite (D3Z1)-specific primers (Gosden 
and Lawson 1994).
Initial PRINS with SOpmol of each primer in 30ul mix, Boehringer kit reagents and 
recommended dénaturation and amplification/extension temperatures produced strong 
specific signal but also heavy background signal (test 1).
Subsequent reactions were performed on the newly-acquired OmniGene thermal cycler 
with flatbed slide module. On investigating the effect of altered enzyme, extension at 
72°C (test 6), and varying dNTP, MgCL and label concentration (tests 2-5,11-13), 
satisfactory non-cycling results (signal on 100% of metaphase target sites with low 
background) were obtained using Taq IS, and DIG-11-dUTP (lOOuM), lOOuM dTTP and 
100 or 200uM dATP, dCTP, dGTP (tests 4, 5, Fig.3-25), with no extension step. Use of 
separate label and dNTP preparations was preferred, allowing independent alteration of 
their concentrations, but commercial label mix had been assessed because of its 
convenience and its use by Cinti et al (1993).
Cycling PRINS was attempted using test 4 reaction components. Extension (here at 
65°C) was used in accordance with Cinti et al (1993) and to improve specificity (tests 7, 8, 
Fig.3-25). This with (as in Cinti et al 1993) or without formamide slide dénaturation 
produced signal but also haze-like FITC background.
Tests 14 and 15 involved initial assessment of a cheaper and reputedly very effective 
PCR enzyme, Dynazyme, both with its supplied buffer and, as prolonged exposure to 
detergent during any cycling might cause chromosome damage, a detergent-free buffer 
(Gibco BRL) to which a low concentration of Triton X-100 could be added. Signal was
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produced, though accompanied by a high level of background. This might have been due 
to reduced dTTP (as in tests 12 and 13), but prompted solution PCR to further compare 
amplification with this enzyme against that with Taq IS (see below and Table 3-29). 
Following this, PRINS tests 16-20 used similar components to D3Z1 solution PCR tests 3 
and 5 and employed a higher annealing temperature than previous D3Z1 PRINS to 
attempt background reduction. The Dynazyme tests (16, 17) also used less label. One 
detection layer was adequate for specific signal visualisation with Dynazyme (tests 16,
17) or Taq IS (18, 19), but did not eliminate background. Background was reduced with 
Taq IS on lowering dénaturation and increasing annealing/extension temperatures (test 
20). Using Dynazyme and reduced label (33uM) with annealing temperatures of 66°C or 
68°C produced, as sought, reliable, specific, signal which was not overly strong (tests 21, 
22).
The effect of T4 ligase pretreatment on cycling PRINS was then investigated on 3 and 10 
day-old slides, using test 22 reaction conditions (tests 24-27, Fig.3-25). Signal (and 
incidentally no background) was only obtained on the 3 day-old slides which had been 
treated with ligase (test 27), but, as in test 7, a ‘haze’ could be present around 
metaphases.
The potential benefit to cycling PRINS of, in addition to ligase, proteinase K pretreatment 
as employed in CGH (0.2ug/ml, 7.5min at 37°C) was initially assessed in non-cycled 
preparations. Even with reduced primer, reliable signal was still obtained on a control 
slide treated with only ligase (test 28). However, the proteinase K treatment used 
resulted in complete destruction of metaphases (test 29), suggesting that preparations for 
PRINS must require gentler pretreatment than those denatured under the milder 
conditions (lower temperature/high formamide) employed in FISH and CGH.
The newly reported Tyramide Signal Amplification system (TSA, Dupont, Raap et al 1995) 
was tried with PRINS as an alternative to cycling, because the latter consistently resulted 
in poor post-PRINS metaphase quality. Reactants and conditions were as used in tests 
20 and 21. On the recommendation of the TSA system manufacturer, stop buffer was 
omitted in case it inhibited TSA enzymes. Many, bright, signals were produced (tests 30, 
31). Simultaneously, TSA of the FISH signal from DIG-labelled H1012 probe was 
performed following one FITC layer (Fig.3-26). This produced stronger specific 22q11 
signals than on a control slide and bright signals elsewhere, confirming the efficacy of 
TSA but further demonstrating the reduction in specificity it could produce.
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Solution PCR with D3Z1 Primers
While recognising the results may not reflect those obtained in PRINS, PCR was 
performed in solution to provide some assessment of the effect on amplification of altered 
enzyme and reduced MgCb and primer concentration.
As initial tests showed DIG-labelled DNA failed to migrate on electrophoresis only 
unmodified nucleotides were used. Reducing primer (to 25 from 50pmoles/30ul), with 
Taq IS or Dynazyme, most effectively reduced product while improving specificity (Table 
3-29, Fig.3-27A). Reagent combinations 3 and 5 appeared to be equal candidates for a 
reaction mix which might produce good results on cycling PRINS.
PRINS with Factor IX Primers
Both PRINS and, because Cinti et al (1993) had described Factor IX signal as ‘barely 
detectable with conventional fluorescence microscopy’, cycling PRINS was attempted with 
these primers.
The reaction mix (tests 1, 2, Table 3-30) was essentially as reported but with Taq IS. One 
day-old slides were used as it had been shown (D3Z1 test 25) that slide age could affect 
amplification efficiency. Dénaturation involved an OmniGene flatbed (effectively essential 
in cycling) whereas Cinti et al (1993) had used formamide. Detection had two FITC layers 
to assist amplification visualisation. These tests failed to produce specific signal, which 
was expected as the reaction mix, like that reported by Cinti, contained no MgCl2 . 
Subsequent, non-cycling PRINS with 10 day-old slides and formamide dénaturation (as 
Cinti et al 1993) was performed both with and without MgCb. Signal was obtained with 
MgClzin the control (D3Z1 test 9), but mainly speckling on the Factor IX-primed slide 
(Table 3-30 test 4). Possible signal was visualised on the distal long arm of just one 
chromosome X in the preparation. No signal was produced in the absence of IVIgClg with 
either Factor IX (test 3) or control primers (D3Z1 test 10).
Solution PCR with Factor IX Primers
Solution PCR was performed to check the primers were functioning and to assess the 
suitability of different buffer/enzyme and primer concentrations and annealing 
temperatures (Table 3-31, Fig.3-27 C, E).
Though ammonia traces following primer evaporation can affect amplification (Flowgen, 
personal communication), evaporated and precipitated primers (Table 3-31 tests 1, 2) 
both produced nonspecific bands demonstrating that evaporation had not been the cause 
of nonspecificity here. Controls with evaporated DMD exon 6 primers did amplify 
specifically. Reducing primer and raising annealing temperature (tests 4, 5) failed to
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improve specificity. Use of Taq IS (test 6) did give some improvement, though increasing 
MgCl2 (to the 4.5mM recommended for in situ use, test 7) again produced nonspecific, 
though stronger, bands (this pattern of increased band strength but loss of specificity was 
mirrored in controls). Further reduction of primer (to 20pmol) and increased annealing 
temperature (63°C) with Dynazyme could result in a strong, specific band (~370bp, test 
8).
in summary, Factor IX-primed solution PCR worked best with Dynazyme and at lower 
primer concentration and higher annealing temperature than cited by Cinti et al (1993) for 
PRINS with these primers. However successful, specific, amplification might not be 
consistently reproducible (test 9).
PRINS with Dystrophin Primers
PRINS with these alternative unique sequence primers (Abbs et al 1991) was attempted 
as they were known to work well in PCR in this department and because DMD/BMD 
multiplex primers represented a readily available set of nested sequences. PRINS with 
several primers for the same gene, an initial intention of this study, seemed one way to 
approach signal amplification. Individual primers, exon 51 oligonucleotides, were 
investigated first, with repetitive primers 267 and 435 as positive controls, during 
assessment of a loaned Perkin Elmer in situ PCR system. Using the same cycling 
conditions as in solution PCR, no exon 51 signal was obtained (Table 3-32 tests 1, 2), At 
30 cycles standard Taq polymerase (Boehringer Mannheim) produced extensive damage, 
confirming the importance of using reagents with minimal detergent in cycling PRINS. 
Subsequent tests (3-6) involved exon 6 primers and used Taq IS, two FITC layers and 
raised concentrations of primer, MgCla, label and dNTPs, to maximise the likelihood of 
obtaining signal. Both formamide and OmniGene dénaturation were used (tests 3, 5). 
Enzyme was omitted in tests 4 and 6 to assess the degree of background caused by the 
detection system, which was minimal. Substantial signal, all of it nonspecific, was only 
obtained in the presence of enzyme (Fig.3-28).
Solution PCR with Dystrophin Exon 6 Primers
The dystrophin exon 6 primer set was used as a (single-copy target) positive control in 
solution PCR when testing Factor IX primers and the effect of alternative buffer/enzyme 
combinations, and enzyme, primer and MgCl2 concentrations (Table 3-33, Fig.3-27 C, D, 
E). Equivalent, specific, amplification was achieved using Dynazyme or Taq IS and 
1.5mM MgCl2 (tests 1-4). Doubling the primer concentration produced no apparent 
increase in yield (tests 7, 8). Raising MgCb to 4.5mM could produce slightly increased
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amplification but also some nonspecific product (test 5). Test 6 was run to confirm that 
detergent omission resulted In amplification failure (as In DAZ tests 5 and 6, Table 3-34).
Amplification of Y-specific Sequences
DAZ (Reijo et al 1995, Vogt et ai 1996) and RBM1 (RNA-Binding Motif, formerly known as 
Y chromosome RNA Recognition Motif, YRRM, Ma et al 1993) sequences are candidate 
genes for male germ cell differentiation. These gene families map to the Azoospermia 
Factor (AZF) region of Y q ll .2 that controls spermatogenesis. Primers for these 
sequences were being used in this department (Thesis of Mohammed FM, 1999) when 
their behaviour in PRINS was briefly investigated.
Solution PCR with DAZ Primers
The DAZ transcription unit spans about 42kb, including nine tandem repeats of a 2.4kb 
unit (Saxena et al 1996). Published DAZ oligonucleotides have a large amplification 
product (1300 base pairs, Vogt et al 1996), which suggested that they could be useful as 
PRINS primers.
PCR with these primers was firstly investigated in solution, to identify the optimal 
constitution of the reaction mix (Table 3-34, Fig.3-27 D, E). Even with 4.5mM MgC^, Taq 
IS produced a weaker band than 2.5U of standard AmpliTaq (tests 1,2), though 
increasing Taq IS did give acceptable amplification (test 3), Dynazyme with Dynazyme 
buffer produced a strong band on electrophoresis (test 4). As cycling PRINS would 
require minimal detergent, buffer minus detergent was tested with AmpliTaq and 
Dynazyme (tests 5, 6). In the absence of added detergent the PCR failed, but a 
Dynazyme mix with 0.01-0.02% Triton X-100 amplified well (tests 7,8).
Cycling PRINS with DAZ Primers
DAZ solution PCR mix 3 was selected as the basis for a DAZ cycling PRINS reaction mix 
as it produced an extremely specific, but not overly strong, band. Both 30 and lOOpmoles 
of each DAZ primer were used in cycling PRINS, but no signal, only speckle background, 
was produced, with metaphase damage (Table 3-35 tests 1, 2). TSA of a separate 
30pmole reaction produced no speckling but spurious, bright fluorescence on a few 
chromosomes (test 3).
Solution PCR with RBM1/YRRM Primers
RBM1/YRRM sequences, expressed specifically in the testis, may map to Yp (Vogt et al 
1996) as well as Yq11 (Ma et al 1993, Vogt et al 1996). They were reported to occur as
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multi-copy clusters, which suggested PRINS with primers for these sequences might be 
successful.
Again solution PCR was used first to assess different reaction conditions with these 
primers. The effect of Taq IS and Dynazyme with low detergent was compared with 
amplification using established RBMWRRM PCR conditions (Table 3-36, Fig.3-27B).
The specific 800bp electrophoresis band was produced by all reaction mixes used.
Cycling PRINS with RBMWRRM Primers
PRINS was initially performed using Taq /S with 4.5mM MgCL (Table 3-37 test 1) as 
higher MgCb concentrations are recommended for PRINS and the equivalent PCR mix 
(Table 3-36 test 3) had produced very specific amplification. It was thought TSA might 
work optimally in the absence of nonspecific product. In retrospect the primer 
concentration (30pmol/50ul) might have been too low, but increasing DAZ primer to 
lOOpmol had given no improvement. Cycling (30 cycles) damaged metaphases, and TSA 
following cycling (test 2) gave very bright, nonspecific signal.
Biotin PRINS labelling with fewer cycles (10) was also attempted (tests 3, 4), in an effort 
to reduce damage. It was hoped the amplification effect of the three layers used in 
detecting biotin with two layers of FITC might compensate for fewer cycles. No 
convincing signal was produced, but speckles were present on chromosome Y in a few 
cells (test 3). TSA (test 4) failed to amplify signal and caused a ‘clouding’ effect.
As chromosome damage during or prior to heat treatment might have been the cause of 
failure, dénaturation, annealing and extension temperatures were reduced slightly and the 
effect of using older (10 day) slides with ligase pretreatment assessed (tests 5, 6). 
Reaction mixes were based on PCR test 6. No Improvement was conferred, with or 
without ligase (as in D3Z1 tests 24, 25), and only nonspecific speckle produced.
PRINS with Primers for Human Satellite III (267) and p Satellite (435) DNA 
Experiments with these primers investigated their potential as a more objective means 
(than just signal intensity) of monitoring the effect of altering PRINS reaction conditions 
and of amplification.
Oligonucleotides 267 and 435, for human satellite III and p satellite DNA respectively, had 
been used to demonstrate the increased sensitivity of cycling PRINS (Gosden and 
Hanratty 1993). Satellite III DNA is present at the centromeric regions of chromosome 9, 
the acrocentric chromosomes and chromosome 16 (in decreasing order of sequence 
copy number). Human p satellite sequences occur in relatively few copies on a number 
of chromosomes and in higher copy number on some acrocentric chromosomes and
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chromosome 1. It was reported that cycling augmented not just signal strength but the 
number of chromosomes exhibiting signal, the sites with fewer sequence copies 
becoming gradually detectable as cycle number increased. With a single PRINS cycle, 
267 primer gave signal only on chromosome 9. After five, signal was also visible on 16 
and all acrocentric chromosomes. Primer 435 labelled six sites after a single cycle: 
chromosomes 1, one pair of acrocentric chromosomes and, weakly, chromosomes 9. 
Thirty cycles revealed eighteen sites, including all acrocentric chromosomes.
A collection of forty five tests were performed (Tables 3-38, 3-39). These attempted to 
reproduce the published results then use the model obtained to gauge the success of 
cycling and amplification experiments.
Initial PRINS was essentially according to Gosden and Hanratty (1993), but replaced 
AmpliTaq with Dynazyme and low detergent buffer to minimise cell damage during any 
cycling. Signal excess with this mix necessitated tests 2-4 (Tables 3-38, 3-39, Fig.3-29A), 
designed to reduce the signal number in one cycle to that reported (Gosden and Hanratty 
1993). Rough equivalence to the published signal pattern, convincing signal only on 
chromosomes 9, was achieved in 267 test 4. Efforts then focussed on 267 as primer 435 
PRINS appeared more difficult to optimise.
Since a promising result had been obtained in 267 test 4, similar conditions were 
employed in single and five-cycle PRINS but using ligase pretreatment and either 
increased dTTP or less primer to attempt to remove small excess signals (tests 6-10). 
However use of 1 day-old slides for these tests, as would be preferred in rapid diagnostic 
work, actually resulted in an increase in signals compared with test 4.
Increasing the annealing temperature, with no ligase, produced no reduction of signal in 1 
day-old slides on single cycle PRINS, instead giving increased background speckling 
(tests 17-20). Neither increasing dTTP nor decreasing primer in these tests removed this 
background, though signal strength and number was slightly reduced. Test 28 also had 
raised annealing temperature and it too showed excessive speckling and weakened 
specific signal.
Reverting to 63°C annealing, a further reduction in excess signal (including most of the 
weak signal on acrocentrics as seen in test 4) was as expected achieved by use of 6 day- 
old slides and reduced concentrations of labelled and unlabelled nucleotides and primer 
(tests 21, 22).
On 1 and 3 day-old slides with the same dNTP mix and annealing temperature as test 22, 
but less primer, the signal number was again higher than in older slides (tests 24, 26). 
Test 25 (1 day-old) also gave more signal than test 23 (6 day-old slide). Further primer
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reduction (Spmoles, test 27) produced fairly strong signals only on chromosomes 9 (Fig.3- 
29B).
PRINS with five cycles, tests 29 and 30, was then performed using the same conditions 
as tests 26 and 27, including 63°C annealing. This produced ‘haze’ and 1-2 signals per 
cell which were faint, especially with only Spmoles of primer (test 30). However cycling 
using 65°C annealing could paradoxically produce slight signal increase (test 31 Fig.3- 
29C, compared to test 29).
On 1 day-old, ligase treated slides, annealing at 65^C for the first cycle only, then at 63°C 
(test 37) in an attempt to reduce damage failed to improve this result. Ten, rather than 
five, cycles with test 37 conditions (test 38) gave no signal at all, though raising primer to 
20pmoles produced six signals (test 39).
TSA without cycling was attempted (tests 13-16) with 1:100 anti-DIG antibody, as a 1:50 
dilution had produced excess amplification in D3Z1 tests 30 and 31 (Table 3-28).
However TSA (tests 13, 14, 15) produced green ‘haze’ and no improvement in metaphase 
signal strength or number compared with equivalent non-amplified preparations (tests 6,7, 
8).
Test 34 (Fig.3-29D), involving TSA following single cycle PRINS with only 5pmoles of 
primer, no ligase, reduced dNTP concentrations and 65°C annealing (as in cycling test 
31) again produced green haze’ but possibly larger, more diffuse signals than the non­
amplified control (test 33). Contrary to D3Z1 findings, there was no evidence in 267 tests 
(e.g. 35, 36) that ligase treatment could reduce nonspecific background signal.
Fixation in 3:1 methanol:acetic acid followed by 37°C incubation in 2xSSC had been 
introduced, initially for newer slides, as this could produce slightly ‘cleaner’ FISH 
preparations. However fixation appeared to increase penetrance (tests 6 and 7, 9 and 
11,10 and 12, 14 and 13, 16 and 15). As this was not the aim in these particular 
experiments, no fixation, only 2xSSC incubation, was used in later tests. Probably the 
best non-cycling (test 27) and cycling (test 31) results were achieved with this 
pretreatment - though this may have been due to other condition alterations described 
above.
Mild proteinase K slide pretreatment (0.2ug/ml, 3 minutes at 37°C) instead of fix/2xSSC 
(test 5), appeared to improve the preparation. Not, as expected, by increasing 
penetrance, but by reducing ‘speckle’ background and rendering the specific signal on 
chromosome 9 more distinct, with other signals diminished.
PRINS with Chromosome 13 and 21-specific Primers (13A and 21 A)
An attempt was made to replicate the specific results obtained by Pellestor et al (1994,
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1995a,b) with chromosome 13 and 21 alpha satellite primers. DIG label was used for this 
study as this produced stronger signal when one detection layer was used (Pellestor et a! 
1995b). The Boehringer DIG labelling mix has less dNTP (lOOuM instead of 200uM), 
more labelled dUTP (35uM rather than 20uM) and dTTP (65uM rather than 20uM) than 
used by these authors. One day, rather than the recommended 3 to 10 day-old, slides 
were used because the main use for this PRINS would be in rapid testing, e.g. in PND. 
With 13A primers annealed at 60°C, only 14 of a possible 38 signals were present on 
chromosome 13 in 19 metaphases even with two, rather than one, detection layers to 
optimise signal visualisation. Three of these cells also showed one chromosome 21 
signal and one had two chromosome 21 signals. PRINS with 21A primers and annealing 
at 61 °C gave strong chromosome 21 signal but a lot of speckle background. Twelve of a 
possible 14 chromosome 21 signals were present in seven metaphases, four of which 
also showed in total 6 signals on chromosome 13 and two of which also showed 3 signals 
on other chromosomes (Fig.3-30).
This work was abandoned as it continued to give nonspecific results and because of 
concerns regarding the robustness and reliability of this approach in a clinical setting (just 
^°C variation in annealing temperature produces both chromosome 21 and 13 signal in all 
cells).
Additionally Pellestor et al (1994, 1995a,b) reported both that the 13A primer is 
polymorphic, producing no signal on one 13 homologue in one often individuals tested, 
and that ‘background staining can sometimes be observed’ with 21 A.
Overall Summary of PRINS Investigations
Although optimal PCR conditions might not correspond to those in PRINS, solution PCR 
was used to provide some assessment of primer efficacy and of the effect of modifying 
reaction mix constituents and reaction conditions. However, though optimisation of 
solution PCR was generally achieved with the unique primers tested, PRINS was not. 
Convincing PRINS signal was only obtained with repetitive sequence primers (D3Z1, 267 
and 435, 13A, 21 A), where amplification occurs over a longer DNA stretch so is more 
easily visualised. The signal augmentation effects of cycling PRINS and TSA were 
assessed with these and with unique sequence primers.
Use of standard Taq polymerase produced extreme damage on cycled PRINS 
preparations. Taq IS, specially developed for in situ PCR, generally rendered cycling less 
destructive (D3Z1 tests 7, 8, Factor IX test 2, dystrophin exon 6 tests 3, 5), though 
damage could still occur (e.g. DAZ tests 1, 2, RBM1 test 1). An alternative, relatively 
inexpensive, enzyme not previously reported in PRINS (Dynazyme) was shown, with low
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detergent, to produce satisfactory non-cycling PRINS results with D3Z1 (test 21) and 267 
(test 27) primers. However, as with Taq IS, significant amplification or total prevention of 
cycling damage was never achieved.
In some experiments (267 tests 37, 38) increased cycle number resulted in loss of signal, 
indicating diffusion may have been occuring. The only cycling PRINS which allowed 
possible visualisation of otherwise absent signal (RBM1 test 3) involved biotin label and a 
lower cycle number (10). Cycling could benefit from an increased primer concentration 
(267 tests 29, 30, 38, 39), although increasing unique target primer failed to achieve 
amplification (DAZ tests 1, 2).
TSA did produce an increase in D3Z1 signal but also heavy background (tests 30, 31). 
Anti-DIG antibody was therefore reduced to attempt to control production of extra signal 
(267 tests 13, 34, RBM1 cycling tests 2, 4, DAZ cycling test 3). Though 267 signal was 
somewhat enlarged TSA continued to produce extensive green ‘haze’ and failed to allow 
specific signal visualisation with unique target primers (though TSA could not be expected 
to work where cycling had caused damage to the preparation). This suggested that 
optimisation of TSA would require considerable modification of the recommended 
conditions.
It was observed that slight increase in slide age might affect outcome. Primer 267 test 26 
on a 3 day-old slide used the same conditions as test 24 (1 day-old slide) and produced 
generally similar results. However test 4 (3 day slide, pre-fixed, 1 Spmoles primer) had 
fewer signals than test 7, a 1 day-old slide with less primer. Similarly, lOpmoles of primer 
on a 6 day-old slide produced less signal than Spmoles on a 3 day slide (tests 22, 26). 
The use of 10 day-old slides apparently conferred no improvement with or without ligase 
treatment (D3Z1 tests 24 to 27). The best cycling and non-cycling results (e.g. 267 tests 
31, 27) were obtained on 3 day-old slides.
There was no evidence in this study (e.g. 267 test 36, RBM1 test 6) that ligase treatment 
(as in Gosden and Hanratty, 1993) could reduce nonspecific background signal. Its use 
did appear to improve cycling results, while not removing ‘haze’, with D3Z1 primers on a 
3-day but not a 10-day slide (tests 27, 25).
Pretreatment in fix then 2xSSC appeared to improve penetrance, increasing signal, as in 
267 tests 9 and 11 or 10 and 12. Signal number and strength with TSA was also 
enhanced with this treatment (tests 13-16).
Proteinase K treatment at concentrations used in CGH caused damage on non-cycling 
PRINS with D3Z1 primers. Reducing proteinase K incubation time could, unexpectedly, 
produce a ‘cleaner’ preparation than that obtained with fix/2xSS0 treatment (267 test 5) 
though this could have been due, rather, to the removal of fix/2xSSC.
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A. Test 4: No formamide dénaturation, 
68°C anneal, SOpmol primer, Taq IS.
B. Test 7: As test 4,15 cycles
C. Test 24: As test 27 ,10-day slide, 
10 cycles, no ligase.
D. Test 27: 25pmol primer, 68°C anneal, 
Dynazyme, 3-day slide, 20 cycles, ligase.
Fig.3-25 D3Z1 PRINS images. Specific signals on chromosome 3 arrowed.
A. Without TSA. B. With TSA.
Fig.3-26 H1012 FISH images with and without TSA. Specific signals on chromosome 22 
arrowed.
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1 2 3 4 5 6
iOOObp
A; D3Z1 primers (Table 3-29).
1. Test 1: SOpmol primer, 1.5mM M gCb.Taq IS
2 . Test 2; As 1 but 1mM MgCb
3. Test 3; As 1 but 25pmoi primer
4. Test 4: As 2 but 25pmol primer
5. Test 5: As 3 but Dynazyme
800bp
B: RBMI/YRRM primers (Table 3-36). 
t.T est 3: lOOuM dNTP, 1.5mM M g C b , Taq IS
2.Test 4; As test 3 but no enzyme
3.Test 5: 200uM dNTP, 4.5m M  M g C b , Dynazyme
4.Test 6; As test 5 but 1 .SmM MgCb
5.Test 7: As test 5 but lOOuM dNTP  
e.Test 8: As test 6 but 100uM dNTP
370bp
220bp
C; Factor IX (fIX) and DMD exon 6 primers.
(Tables 3-31 and 3-33).
1. fix  test 6  : SOpmol primer, 1 SmM MgCb, Taq IS , S8°C anneal 
2 fix  test 7; As flX test 6 but 4.SmM MgCb
3. DM D exon 6 test 4; SOpmol primer, 1 SmM MgCb, Taq IS , S8°C anneal
4. DMD exon 6 test S: As DM D exon 6 test 4 but 4 .SmM MgCb
5. DMD exon 6 test 3; As DMD exon 6 test 4  but Dynazyme
6. fix  test 8: 20pmol primer, 1 SmM MgCb, Dynazyme, 63°C  anneal
1300bp
D; DAZ and DMD exon 6 primers (Tables 3-34 and 3-33).
1. DAZ test 1 ; AmpliTaq (buffer contains MgCb) 2 DAZ test 3: 0.2U/ul Taq IS ,  4 .SmM MgCb
3. DAZ test 4: Dynazyme + Dynazyme buffer (contains M gCb) 4. DAZ test S: Dynazyme, no detergent, 1.SmM MgCb
S. DAZ test 6; AmpliTaq, no detergent, 1 SmM MgCb 6. DMD exon 6 test 6: Dynazyme, no detergent, 1 SmM MgCb
1300bp
370bp
220bp
E: DAZ, DMD exon 6 and Factor IX primers (Tables 3-34, 3-33 and 3-31).
1. DAZ test 7 :1  SmM MgCb, buffer+0.01% Triton X, Dynazyme
2. DAZ test 8; I.S m M  MgCb, buffer+0.02%  Triton X, Dynazyme
3. DAZ test 4: Dynazyme + Dynazyme buffer (contains M gCb)
4 and S. DM D exon 6 tests 7 and 8; 4 .SmM MgCb, 0.2U/ul Taq IS , SO or lOOpmol primer respectively
6. Factor IX test 9; 20pmol primer, 1.5mM MgCb, Dynazyme, 63°C anneal
Fig.3-27 Images of gel electrophoresis following solution PCR.
Unmarked lane on the left of each gel contains a Ikb ladder.
168
A. Test 5: 30 cycles.
Fig.3-28 DMD PRINS images.
B. Test 6: 30 cycles, no enzyme.
A. Test 3: 25pmol primer, 60°C anneal. B. Test 27: 3pmol primer, 63°C anneal, 
reduced dNTPs.
C. Test 31; 5 cycles 65°C anneal, 3pmol primer D. Test 34: As test 31 but no cycling, with TSA. 
Fig.3-29 267 PRINS images. Signals on chromosome 9 arrowed.
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13A 21A
Fig.3-30 13A and 21A PRINS images. Signals on chromosomes 13 and 21 arrowed.
Fig.3-25 Omnigene themal cycler with flatbed module for slides (Hybaid).
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4. DISCUSSION
4.1 Human DNA Sequence Mapping and Chromosomal Breakpoint Definition
The clone localisation, map confirmation and/or refinement performed during the course 
of this study was of substantial value to the collaborating scientists. By identifying 
restricted chromosomal loci it allowed consultation of, and comparison with, information in 
genetic databases. It also provided evidence that sequences were, or were not (as in the 
case of PAC227) likely to be the sequences they were believed to be. Identity 
confirmation allowed sequences to be used in further studies.
M R C K jd , S C D 2  and h T E R T  Localisation
MRCKJ3 0 K CDC42BPB is now known as CDC42 binding protein kinase beta (DMPK-like), 
Genbank Gene ID:9578. The map location first determined in this study, 
14q32.31~q32.32, has been confirmed, and it is now known to lie 101.38-101.5Mb from 
the chromosome 4 short arm terminus (EnsembI).
Mapping the putative S C D 2  sequences to 4q21, rather than chromosome 10 (the SC O  
locus) or 17 (the locus of a transcriptionally inactive SC O  pseudogene, Zhang et al 1999) 
gave some support to our collaborator’s proposal that this sequence could represent a 
second S C O  gene. However the existence of a second human S C O  gene has not yet 
been confirmed, although a third mouse Scc/3 gene has now been identified (Zheng et al
2001). All three mouse S cd  genes localise to mouse chromosome 19 which has reported 
synteny with human chromosome 10, but not with 4q21 (Gregory et al 2002). 
h T E R T co-localised with 5p subtelomeric probe sequence in this study, but it could 
actually lie up to - IM b  distant because of limited resolution on the metaphase 
chromosomes probed. Also sequence ordering can be distorted at telomeric regions 
(Trask et al 1991). h T E R T  \s now known to map 1.3Mb from the 5p telomere (EnsembI), 
however precise localisation information is not available for 5ptel sequence 114j18. It 
may be that mapping of the reverse transcriptase component of telomerase to a telomeric 
region could be relevant to the regulation of its expression by chromatin structure and 
telomere position effects (Bryce et al 2000).
Deletions at 5p15.3 are associated with cri du chat syndrome which is characterised by 
growth failure, microcephaly, facial abnormalities and severe retardation. It was hoped 
that the h T E R T  probe might assist definition of the genes clustering in this region and 
refining of deletion boundaries. Concomitant deletion at h T E R T  was demonstrated in all
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ten patients examined in a recent study, and the authors propose that h T E R T  
hapioinsufficiency may contribute to the cri du chat phenotype (Zhang et al 2003).
The widespread interest in the crucial role of h T E R T  \n cellular immortalisation and 
tumorigenesis has resulted in the h T E R T  sequence mapped in this study being marketed 
commercially by Qbiogene.
Mapping and Ordering of Chromosome 21-Specific Probes for Breakpoint Definition in a 
Case of Partial Trisomy 21
Breakpoint mapping with 21q-specific YACs showed that the 21 q region monosomie in 
individual DP was proximal to sequence RP11 268F23, which lies at 16.03Mb from 21 pter 
(the 21 centromere extends to 13.2Mb according to EnsembI). Concurrent quantitative 
PCR studies by Dr Sandy Cooke of the molecular genetics division of this Institute 
determined that sequence D21S172 is included in the monosomie region. The breakpoint 
on at least one of the two chromosome 21 components of the derivative chromosome 12, 
initially defined as der(12)(12qter~>12p13.3::21q22.3->21q11.2;;21q11.2->21qter), 
therefore lies between these two loci, at 15.86-16.03Mb in 21q21.1. This work has 
provided a focussed region for further biochemical and molecular study. According to 
EnsembI, eighteen genes are sited in the region between sequence 268F23 and the 
centromeric heterochromatin.
One of the chromosome 21 components could have a more distal breakpoint (though 
proximal to 925h10/D21S1257) as it was not possible, by metaphase FISH, to discern i f  
268F23 was present in one or two copies on the der(12) chromosome, an important 
distinction in this study. Nuclear scoring for 268F23 sequence copy number 
determination might resolve this, but would require optimisation of the probe for 
interphase FISH. Instead, further quantitative PCR would possibly be a more 
straightforward approach, and would conserve the remaining cytogenetic preparation of 
patient cells.
Localisation and ordering data on the MPI VAC sequences was incidentally obtained prior 
to and during breakpoint determination studies. This information was relayed to the MPI 
database, resulting in their re-positioning of 937e12 distal to 856h02 and 858e10. 
Accurate map locations for markers associated with the MPI sequences are now available 
and are presented in Table 4-1 with the mapping results from this study.
The co-localisation of 949b09 (at 15.06Mb) and 858e10 (15.8Mb) in all cells examined 
supports the finding that the resolution for ordering sequences by such two colour 
mapping is >1Mb (Trask et al 1991). Trask also observed that, even with a distance of 2- 
3Mb between probes, the apparent signal positioning reflects the true probe order on only 
59-70% of chromatids. It was noted here that the proportion of cells with apparently
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‘correct’ ordering of two probes varied not just with the probe distance (e.g. 100% for 
937e12 and 925h10 at 5.5Mb distant as compared to 88.9% for probes 949b09 and 
856h04 which are 1.65Mb apart), but also with particular probe sets (856h04 and 937e12 
are also -1.6Mb apart, and their correct signal order was only displayed in 35% of cells), 
although the variation might be a result of scoring only low numbers of cells.
YAC CHROMOSOME 21 BAND LOCATION
MPI THIS STUDY ENSEMBL
949b09 q11.1-q21 q11.2 q11.2, 15.0Mb
858e10 ? q11.2 prox/m a/q21.1, 15.8Mb
759d03 ? q11.2 EnsembI localisation not possible as marker unknown
856h04 ? q11.2-q21.1 q21.1, 16.6Mb
937e12 q11.1-q21 q11.2-q21.1 q21.1, 18.2Mb
925h10 q11.1-q21 q21.1-q21.2 prox/ma/q21.2, 23.7Mb
Table 4-1 Comparison of 21q YAC FISH mapping results with EnsembI localisation of 
these sequences. Original MPI map data was obtained from the MPI website.
Mapping and Ordering of Chromosome 8-Specific Probes for Orientation of Duplicated 
Region and Breakpoint Definition in a Case of 8p Duplication
A literature search revealed no other reports of patients with the direct duplication of 8p 
reported in this study. Apparent duplications of 8p are most frequently inverted 
duplication deletions. These appear to be generated as a consequence of a maternal 
submicroscopic inversion delimited by the 8p olfactory receptor gene clusters in band 
8p23. Inversion heterozygosity may cause susceptibility to unequal recombination, 
leading to the formation either of the inv dup del(8p) with deletion of the terminal region of 
8p or of the reciprocal product, the +der(8p) (Giglio et al 2001, Shimokawa et al 2004). 
The only other report of a direct duplication proximal to 8p23 involves a familial 
dup(8)(p12p21.1) with mild MR as the only associated phenotypic effect (Moog et al 
2000). As characterisation of this abnormality was by high resolution cytogenetic analysis 
and FISH with a microdissected probe for 8p12, the authors acknowledge that it was not 
possible to conclusively determine the exact breakpoints and nature of the duplication.
In this study it has been possible, by exploiting the power of bioinformatics and availability 
of well-characterised BAG and PAG clones, to establish that the duplication of 8p reported 
here is direct, rather than inverted. The duplication includes centromeric sequences (at 
43.1Mb from Spter) but not an 8q sequence located -0.6Mb from the centromere, and the 
distal breakpoint maps to 8p21.1-8p21.2, between 27.24Mb and 28.39Mb from Spter. 
Although alpha satellite sequences were shown to be present interstitially on the short 
arm, there was no visible constriction.
Accurate definition of breakpoints in all new cases of dup(8) will assist meaningful 
genotype/phenotype correlation in the future.
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4.2 Detection of Submicroscopic Chromosomal Rearrangements
4.2.1 DG/VCFS Wlicrodeletion Testing
Assessment of Detection Rates and Comparison with Other 22q11 Deletion Cohorts 
A European collaborative study of 558 individuals with 22q11 deletion has been reported 
(Ryan et al 1997). A comparison of some of this data with the combined results of this 
work and subsequent diagnostic 22q11 deletion testing in this department is presented in 
Table 4-2. The figures exclude the TOF study.
The detection rate in this department, 11.7%, is broadly in line with published figures 
(13%, Berend et al 2000). Even in this patient cohort, many of whom were referred with 
unconfirmed DGS or VCFS clinical diagnoses, FISH testing for 22q11 deletion has been a 
highly informative test.
The proportion of deletions which could be confirmed as inherited appears lower in the 
present study. It is feasible that a suggestive family history, and hence inheritance, might 
have been a more frequent clinical feature among the first set of individuals to be tested, 
and hence over-represented, in the 1997 collaborative study. However this information is 
not provided. The data from the present work does confirm an excess of deleted mothers 
of affected children. The 1997 report suggested that this excess might in part reflect the 
fact that, where only one parent was tested, it was most commonly the mother, a finding 
which this work corroborates. The collaborative study also confirmed that the parental 
origin of deletion has no apparent effect on the phenotype.
High resolution G-banding is not routinely performed in this department, which explains 
the low proportion of cytogenetically visible deletions (12.9%). Detailed cytogenetics has 
demonstrated deletion in 30% of cases (Wilson et al 1992b).
Retrospective examination of the clinical data on 67 deleted patients of this department 
allowed assessment of presenting phenotypes and preparation of guidelines for 
prospective clinical diagnosis and FISH investigation (Tobias et al 1999).
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DGI ___________  Ryan et al (1997)
Number of 22q11 deletions detected 100/855 (11.7%) 558
Inherited deletions 11/59 (18.6%) 81/285 (28%)
Maternal origin of inherited deletion 9/11 (81.8%) 61/79 (77%)
The proportion, where only one parent 14/19 (73.7%) 18/20 (90%)
was studied, of mothers tested
Table 4-2 22q11 deletions detected in 855 index cases at the Duncan Guthrie Institute 
and comparisons with a collaborative study.
Phenotype/Genotype Correlation
When this study commenced it was recognised that DG/VCFS is not a straightforward 
contiguous gene syndrome. The severity and complexity of the phenotype does not 
correlate with deletion size (the three patients in this study who may have smaller 
deletions are not more mildly affected than others in the cohort) and it varies greatly even 
within one family (Scambler et al 1991, Kelly et al 1993). Discordant phenotypes have 
even been observed in monozygotic twins (Goodship et al 1995, Hatchwell 1996, Singh et 
al 2002).
All of the patient/parent combinations in this study showed intra-familiai phenotype 
discrepancy. Phenotypic variability suggests the possibility of modifying genes at 
separate loci (Holder et al 1993) or, especially in the case of discordant twin phenotypes, 
a role for environmental factors or postzygotic events (Yamagishi et al 1999, Singh et al 
2002).
Other Cytogenetic Abnormalities Found in Patients Referred for 22q Deletion Testing'
Of particular interest was the absence, in our patients referred for DG/VCFS deletion 
testing, of lOp deletions, the only other chromosome anomaly consistently reported in 
DG/VCFS. Only three lOp abnormalities (all in patients not referred for 22q11 deletion 
testing) were detected cytogenetically in this department during the course of this study: 
del(10)(p14), del(10)(p13) and t(9;10)(q22.1;p13).
Molecular studies suggest there is more than one DG/VCFS critical region on 10p 
(Dasouki et al 1997, Gottlieb et al 1998), though it is feasible that patients with variant 
deletions could also have a small deletion, rearrangement, or point mutation that maps in 
the shortest region of overlap, or that position effects might be involved. Because of the 
lack of definition of deletion intervals, widespread screening for microdeletions of lOp has 
not been adopted. One group developed a dual-probe FISH test for both 22q11 deletion 
and deletion at the 10p13p14 DGSII locus described in 1996 by Daw and colleagues 
(Berend et al 2000). Of 412 suspected DG/VCFS patients tested, 54 had 22q11 deletion 
but only one had deletion of lOp, and this was clearly cytogenetically visible. The
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incidence of 10p13p14 deletion was therefore estimated as 1 in 200,000. Recently a 
cytogenetic and FISH study of 285 patients with suspected DGA/CFS identified 58 
individuals with a 22q11 deletion and none with 10p deletion (Bartsch et al 2003).
Study of Patients with Isolated TOF
This study appeared to confirm the benefit of testing patients with non-syndromic TOF for 
22q11 deletion. Four in 24 (16.6%) patients were deleted, compared to 2 in 40 (5%, 
Wilson et al 1992a) and 5 in 17 (29%, Goldmuntz et al 1993) in eariier studies.
Three deleted cases reported in the extended series of thirty three TOF patients in this 
study were thought to have no other DGA/CFS features (Trainer et al 1996). Other 
studies have concluded that subtle extracardiac anomalies are always present in 
association with apparently non-syndromic conotruncal lesions (Goldmuntz et al 1993). In 
one report, 0/107 patients with isolated TOF had 22q deletion. The only TOF cases in 
that study with deletion also had extracardiac anomalies, particularly dysmorphology 
(Amati et al 1995). Subtle dysmorphology, however, may not be useful for patient 
classification by clinicians other than clinical geneticists, and it is interesting that two of 
the VCFS patients with deletion in Amati’s study were initially considered, prior to deletion 
detection, to have isolated TOF.
As a result of the TOF study, this department now routinely tests all prenatal samples with 
abnormal cardiac scan and all neonates with congenital heart defect for 22q11 deletion, 
even if, as in some cases, no other clinical features are recorded and 22q11 deletion 
testing is not specifically requested. Patients may exhibit other features of DG/VCFS that 
are not recorded on the request form. Also, although it has been shown that general 22q 
deletion screening of all paediatric patients with isolated cardiac abnormality is unlikely to 
disclose more deletions than screening based on presentation of a syndromic phenotype 
(Yong et al 1999), apparent isolated heart defect in an infant may later be re-diagnosed 
as DG/VCFS. Facial dysmorphology, LD and speech difficulties, for example, may only 
become obvious in the older child. Deletion has been demonstrated in five (9.1%) of the 
fifty five neonates tested.
Variant 22q11 Deletions
85-90% of patients with deletions have a common 3Mb deletion that is flanked by markers 
D22S427 in 22q11.21 and D22S801 in q11.23 (the ‘typically deleted region’, TDR,
Carlson et al 1997, Edelmann et al 1999, Shaikh et al 2000), 8.5-12% have a variant 
proximal 1.5Mb deletion, and -3%  have a unique deletion or translocation (e.g. Levy et al 
1995).
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Both sc11.1 loci were shown to be included in one 1.5Mb deletion studied by detailed 
haplotype analysis (Edelmann et al 1999), and these authors claimed that all of the 3Mb 
and 1.5Mb deletions studied in a separate FISH investigation (Lindsay et al 1995) also 
involved both scll.1  loci. However that FISH study of 54 VCFS patients actually did 
disclose one deletion which, in common with the possibly variant deletions reported in this 
work, apparently excluded one scll.1  sequence.
By 1996 it was recognised that the phenotype could result from deletion distal to, and not 
overlapping, the DiGeorge critical region (Kurahashi et al 1996). There are at least two 
such non-overlapping deletion regions located distally in the typically deleted region. One 
includes HCF2, CHKAD26, and D22S935 but not ZNF74 (Kurahashi et al 1997). In 
another (McQuade et al 1999) the deletion is more proximal, including D0832 but not 
ZNF74 or HCF2. Other reported variants overlap these deletions (O'Donnell et al 1997, 
Garcia-Minaur et al 2002 etc.).
D0832 SC4.1 CHKAD26
2 2 c e n  U FD1L TBX1 C O M T  Z N F 7 4  H C F 2  L ZTR  IG L V  tel
O'Donnell e ta l 1997
____________________ McQuade et al 1999
 _________  Kurahashi et al 1997
__________   ^Garcia-Minaur et al 2002
Fig.4-1 Positions of reported variant distal deletion regions in 22q11.
Adapted from McQuade et al (1999) and Garcia-Minaur et al (2002). Not drawn to scale and some 
regions of possible (i.e. untested) deletion have been omitted for simplicity.
As well as the small deletions in the distal part of the 3Mb deletion, a deletion region 
associated with DGA/CFS has been reported that lies totally outwith and distal to the 3Mb 
TDR (Rauch et al 1999, Saitta et al 1999).
Homologous recombination involving four different blocks of low copy repeats (LCRs) are 
likely to be the cause of differently-sized and positioned deletions (Halford et al 1993b, 
Saitta et al 1999, Shaikh et al 2000). This mechanism for deletion/duplication formation 
has also been suggested for other recurrent chromosome rearrangements as found, for 
example, in Williams Syndrome (Dutly and Schinzel 1996) and in Charcot-Marie-Tooth 
disease Type 1A (CMT1A) and its reciprocal deletion, hereditary neuropathy with liability 
to pressure palsies (HNPP) (Stankiewicz et al 2003), as well as in non-recurrent 
rearrangements (Stankiewicz et al 2003). The breakpoint of the most common non- 
Robertsonian constitutional translocation, t(11;22), occurs in one of the 22q11 LCRs. 
Candidate genes for the del 22q11.2 phenotype in the shortest region of deletion (SRD) 
include clathrin heavy chain-like {C LTCL) and citrate transporter protein (OTP) (Gottlieb et
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al 1997). A balanced translocation breakpoint in an individual with DGA/CFS has been 
reported in CLTCL  (Holmes et al 1997). However the existence of other, phenotypicaiiy 
significant, non-overlapping regions, which now include a small (~20kb) deletion 
incorporating the U FD1L  and C D C 45L  genes (Yamagishi et al 1999), means all the other 
transcription units in the TDR, of which there are about 30, still remain candidate causes. 
TLIPLE 1 was excluded from the SRD on the basis of a case with N26 deletion without 
T U P L E  1 deletion, possibly the only reported instance of this type of variant deletion 
(Gong et al 1996). However, in the course of the diagnostic investigations reported in this 
study, patient KC was found to carry deletion of TU P L E  1 but not N25. The only other 
reported incidence of T U P LE  1 without N25 deletion may be a case described by Shaikh 
et al (2000). They found one of their 200 deleted patients had lost sequence 941 
(c102g9) but not c19d3 (i.e. the proximal breakpoint was 50-1 OOkb distal to N25). As N25 
and T U P LE  1 lie around 250kb apart (Gong et al 1996) presumably T U P L E  f, which was 
not tested, would be deleted in this case though N25 not deleted.
Currently Proposed Genetic Determinants of the DGA/CF Syndrome Phenotype 
Evidence has grown that hapioinsufficiency for TU P LE  1 is at least in part responsible for 
the DG/VCFS phenotype. For example, in situ expression analysis shows chick and 
mouse H IR A  homologues are expressed during embryogenesis in cells from which the 
main structures in DG/VCFS derive (Roberts et al 1997, Wilming et al 1997).
In addition it is now known that HIFiA  is homologous to the P60 subunit of human 
chromatin assembly factor 1 (Wilming et al 1997) and binds histones (particularly H2B 
and H4) and H//7A-interacting protein 3 (which binds H2B and H4), supporting its 
proposed role in regulation of local chromatin structure and hence gene expression 
(Lorain et al 1998). Its reported interaction with transcription factors P A X 3  and P A X 7  
(Magnaghi et al 1998) endorses the theory that insufficient H IR A  product could upset the 
assembly of multimolecuiar complexes involving homeodomain-containing protein binding 
factors required for normal embryonic development.
However, although extensive mapping, positional cloning, and sequencing of the 22q11 
critical region (Dunham et al 1999) and mutation analyses of candidate genes in humans 
and deletion studies in mice have been performed, to date there is no evidence for a 
mechanism of hapioinsufficiency that can fully explain the phenotype arising from 22q11 
deletion. Only very recently has a gene in which mutation appears responsible for the 
22q11 deletion syndrome been identified.
This is TBX1, one of the key candidate genes, which encodes a T-box transcription factor 
known to have an essential role in embryogenesis. Three different TBX1 mutations (one
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familial) have been found on analysis of ten CAP syndrome patients with no deletion at 
22q11. These mutations are associated with a typical 22q11 deletion phenotype but no 
learning difficulties, a presentation consistent with the lack of Tbx1 expression in the 
mouse brain, though a definitive clinical picture would require identification of large 
numbers of mutated patients (Yagi et al 2003, Baldini 2003).
Although it now appears that TBX1 hapioinsufficiency is responsible for a substantial 
subset of symptoms affecting 22q11 DGA/CFS patients, phenotypic variabiiity was still 
present in patients with the TBX1 mutations, suggesting that environmental factors and 
possibly interaction with downstream genes which are regulated by T-box transcription 
factors could be involved.
Investigators have also studied the association between variants and haplotypes of the 
remaining TBX1 gene and the manifestation of congenital heart defects in 22q11,2 
deletion patients, but common TBX1 variants do not appear to be modifiers of congenital 
heart defect expression in these patients (Rauch et al 2004).
Two very recent studies, having employed nuclear scoring of FISH singlet or doublet (i.e. 
replicated) TU P L E  1 probe signals, indicate possible roles in DGA/CFS aetiology for 
replication asynchrony. One publication reports comparable levels of asynchronous 
replication at 22q11.2 in all controls, translocation carriers and deleted individuals tested, 
and the authors propose that this asynchronous replication may favour LCR mispairing 
and generation of 22q11 deletion (Baumer et al 2004). The other study concentrated on 
the replication timing of the 22q11.2 region relative to a 22q13.3 control sequence and 
found that, in deleted DG/VCFS subjects, the remaining T U P L E  1 locus in the non­
deleted TDR replicates after the 22q13.3 locus, i.e. with a replication pattern opposite to 
that in normal controls. This suggests a possible alteration in the expression pattern of 
the genes in the non-deleted 22q11 DG/VCFS region (late replicating genes are inactive). 
H IR A  insufficiency could be causing the altered organisation of 22q11.2 chromatin 
resulting in deregulation of replication timing, and the mechanism responsible for 
DG/VCFS could be a transcriptional repression of other genes, including TBX1, in the 
TDR (D’Antoni et al 2004).
Allele asynchrony at 22q13.3 (as reported by Baumer et al 2004) is incidentally noted, but 
no reference is made by D’Antoni and colleagues to any observed allele asynchrony at 
22q11.2 in their undeleted control preparations.
22q11.2 Microduplication
Recent recognition of microduplication at 22q11.2 adds this to the growing list of 
complementary microdeletion/microduplication syndromes generated by reciprocal LCR-
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mediated rearrangements (Edelmann et al 1999, Ensenauer et al 2003, Massed et al 
2004). Though generally detectable with non-routine high resolution G-banding, 
interphase FISH with TU P L E  1 probe is recommended for definitive diagnosis. Reported 
duplications have the same centromeric breakpoint, at the proximal LCR implicated in the 
3Mb DGA/CFS deletion, but variant distal breakpoints, generating segmental aneusomy 
of 3, 4 or 6 Mb. As with 22q11 microdeletion there is no correlation of duplication size 
with phenotypic severity and the phenotype, though it can be suggestive of VCFS, is very 
variable. However urogenital tract malformation and/or hearing loss is present in a 
significant proportion of patients (Ensenauer et al 2003).
A retrospective interphase FISH study of patients referred with possible DG/VCFS who 
had no 22q11 microdeletion is now being undertaken in this department. No 
microduplications have been found in the first forty patients analysed.
4.2.2 Woif-Hirschhorn Syndrome Microdeletion Testing
WHS has been reported in association with de novo deletions and translocations and with 
familial translocations, of which the most frequently reported have been t(4;8) 
rearrangements (reviewed in Wieczorek et al 2000, Giglio et al 2002, Zollino et al 2004). 
The rate of familial translocations in WHS patients is now considered to be 15%, with de 
novo events occurring in -85%  of WHS patients (Wieczorek et al 2000).
At the start of this investigation, molecular genetic studies had defined a roughly 2Mb long 
WHS critical region, between loci D4S43 proximally and D4S90 (Johnson et al 1994).
DNA studies performed in our proband and her parents by a collaborating laboratory 
(Department of Human Genetics, Western General Hospital, Edinburgh) allowed 
shortening of the critical region by exclusion of markers D4S111 and D4S115, and also 
found that this deletion was preceded by a paracentric Inversion (Reid et al 1996). 
According to EnsembI the markers involved in this inversion lie distal to the most distal 
olfactory receptor (OR) gene cluster on 4p. Inversion polymorphisms in these OR 
clusters on 4p and others on 8p are known to predispose to the repeatedly reported 
t(4;8)(p16;p23) translocation which in an unbalanced form can result in WHS (Giglio et al
2002).
The minimal critical region has been narrowed to 165kb in band 4p16.3 (WHSCR1,
Wright et al 1997) though a recent report of a patient with a deletion that excludes this 
region (Zollino et al 2003) has resulted in the proposal of a second critical region 
(WHSCR2) which comprises 300-600kb in 4p16.3 between D4S3327 and D4S98- 
D4S168, and is contiguous distally with the WHSCR1.
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There has been some debate about whether deletion size correlates with phenotype 
severity and complexity, but patients with deletions of less than 3.5Mb have been reported 
to have a milder phenotype, usually with absence of major malformation (Zollino et al 
2000, 2003). This 'minimal' WHS phenotype comprises typical facies, mental and growth 
retardation, hypotonia and seizures. Other authors who agree that there is some 
evidence for partial genotype-phenotype correlation in WHS conclude that birth weight, 
length, postnatal head circumference and the severity of MR correlate with the deletion 
size (Wieczorek et al 2000).
Though molecular studies can determine LOH, FISH can readily demonstrate 
translocation and carrier status and allows identification of all unbalanced forms of a 
cryptic translocation. The disclosure of the cryptic translocation described in this work is 
of continuing relevance to the family, and FISH provides a straightforward diagnostic tool. 
Recently, two phenotypicaiiy normal children of a known carrier (Fig.3-11 V 12, V 13) 
were tested with 4p and 11 p telomere FISH probes (Cytocell) following confirmation that 
these probes were informative in their mother. This excluded carrier status in these 
individuals.
4.2.3 Mïcrodeletîon Testing in Rubinstein-Taybi Syndrome
During the course of this study the collation of data from a number of other investigations 
using the RT1 probe has allowed the frequency of microdeletion in RTS to be re- 
estimated at around 10%, rather than 25% (Petrij et al 2000). It is therefore 
understandable, especially as many of the referrals were not based on conclusive RTS 
diagnoses, that no microdeletions were detected in the small cohort of fifteen patients 
tested in this study. It has also been reported that microdeletions at the GBP gene can 
involve sequences other than the 3’ RT1 locus. In 89 patients tested with five cosmids 
spanning the gene, eight microdeletions were found but four of these were 5’ or 
interstitially located, and did not include RT1 (Petrij et al 2000).
As a result of the present study RTS testing with all five GBP-spanning cosmids is now 
available in this department.
Gytogenetically visible inversions and translocations have, more rarely, also been 
implicated in RTS, and truncating GBP mutations were found in 4 out of 37 RTS cases 
tested (Petrij et al 2000). Other types of mutation at GBP have also been linked to RTS 
(Kalkhoven et al 2003), however the cause of RTS remains unknown in -80%  of affected 
individuals, and a role for other genes is suspected.
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4.2.4 Microdeletion Detection in Duchenne and Becker Muscular Dystrophy
FISH with exon-specific dystrophin cosmids provided an unequivocal, easy to interpret 
method of diagnosing DMD/BMD carrier status prior to, and during the introduction of 
quantitative PCR in this department, when no other conclusive test was available. The 
probes used were potentially informative for the majority of DMD/BMD microdeletions 
(Blonden et al 1991, Table 3-18). This approach gave a definitive result in 97 of 128 
female relatives referred (75.8%), or in 94 of 111 female relatives referred (84.7%) if the 
17 individuals with unconfirmed familial deletion are excluded. Among the many 
abnormalities detected was one at exon 52 missed by quantitative PCR analysis. This 
study also revealed some contamination of probe sequences relevant to this investigation 
and to the work of other authors (Bunyan et al 1995).
Quantitative PCR is now widely used for DMD/BMD deletion and carrier detection. In this 
department two multiplex assays detect 27 exons and the promoter region (using a 
modification of the method of Yau et al 1996). This technique has the advantage of being 
rapid and semi-automated, it tests more exons, therefore detecting over 70% of all 
mutations (>98% of all deletions) in the dystrophin gene, it does not require the familial 
deletion location without which FISH becomes very laborious, and it is capable of 
detecting duplications as well as deletions. Duplication detection by FISH, if at all 
achievable, would mostly only be possible using interphase FISH analysis. Quantitative 
PCR will however miss any chromosomal rearrangement, while FISH can detect 
interchromosomal and some intrachromosomal rearrangements, although none were 
found in this study. Denaturing high performance liquid chromatography (HPLC) and the 
Wave nucleic acid fragment analysis system (Transgenomic, Nebraska, USA) can 
indicate mutation-containing exons for subsequent targeted sequencing and has recently 
made mutation screening in DMD/BMD patients practicable in the diagnostic environment, 
raising the abnormality detection rate to over 92% (Bennett et al 2001).
Despite the availability of reliable and simple molecular means of DMD/BMD deletion and 
carrier detection, FISH remained the method of choice in some institutions (Calvano et al 
1997, Voskova-Goldman et al 1997, Rosenberg et al 1998, Xiao et al 2003). A group 
from Texas, for example, has reported the use of 16 exon-specific cosmids to test 24 
families (Ligon et al 2000). As FISH is still perceived as a valid and useful approach, a 
Multiprobe device with DMD/BMD exon probes has been developed (Cytocell) to allow 
simultaneous detection of 15 dystrophin loci in one experiment.
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4.2.5 Screening for Cryptic Subtelomeric Rearrangement
Though the published prevalence of cryptic subtelomeric rearrangement in idiopathic MR 
varies from 0 to 23% in studies with varying sample sizes and selection criteria (Knight 
and Flint 2000), and an early report by the principal research group suggested an 
incidence of 7.4% (Knight et al 1999), a recent review of 20 studies incorporating 2500 
subjects with MR suggests subtelomeric rearrangement may actually occur in 
approximately 5% of these patients (de Vries et al 2003). The phenotypicaiiy significant 
subtelomeric rearrangement detection rate was lower in the present study, at -3.5%, but 
this is in accord with other reports, including a very recent study of subtelomeric 
screening by FISH in 94 individuals (Kirchhoff et al 2004). It may be that earlier studies 
with higher rates include a greater proportion of cases which are highly likely to be 
‘chromosomal’ through the presence of a suggestive family history.
Even at the lower overall incidence of around 3%, subtelomeric abnormality may be the 
second most frequent recognised cause of moderate to severe MR after Down syndrome, 
supporting the value of this admittedly expensive test. The cost per informative test, 
when the testing of appropriate relatives of individuals with subtelomeric rearrangements 
is included, has been calculated as $1600 (Knight et al 1999). However the value to the 
familes concerned is immeasurable. The abnormal finding should have particular 
diagnostic impact in the large family of affected MG and SC. Their father, DM, has seven 
untested phenotypicaiiy normal siblings. MG and SC have four other phenotypicaiiy 
normal sibs and their affected nephew, DD, has two.
Results of FISH testing have provided evidence for the existence of novel microdeletion 
syndromes including del 1p36.3 (Shapira et al 1997, Heilstedt et al 2003) and del 22ql3.3 
(Precht et al 1998, Knight et al 1999). One patient with deletion at 1p36.3 and one with 
deletion at 22q13.3 were detected in the course of routine subtelomeric screening in this 
department. The patient with 1p36.3 deletion was dysmorphic and suffered from 
epilepsy, and the patient with 22q13.3 deletion had, in addition to behavioural problems, 
absent speech. This is consistent with the clinical features reported to be associated with 
these deletions. The patient with a deletion at 6q27 exhibited moderate to severe MR 
though it is recognised that this abnormality, especially unaccompanied by another 
segmental aneusomy, can be associated with a fairly mild phenotype even when 
considerable loss of genetic material occurs (de Vries et al 2003, Kraus et al 2003). 
Interestingly this patient had a family history of MR, although the deletion at 6q27 was de  
novo.
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The authors of the original study invited reporting of further investigations to assist 
definition of appropriate clinical subcategories for testing (Knight and Flint 2000).
Although the numbers studied here (14) are very small, subtelomeric rearrangement has 
not been found in any patient where the degree of MR or developmental delay has been 
described as ‘mild’, which is in accord with previous reports of low detection rates in such 
individuals (0.5%, Knight et al 1999). This is reflected in the notable increased focus on 
patients with moderate to severe MR in the diagnostic referrals to this department.
A checklist of five criteria, including family history of MR, at least 2 facial dysmorphisms, 
and one or more non-facial dysmorphic feature or congenital abnormality, has been 
devised to assist patient selection for subtelomeric screening (de Vries et al 2001).
All three of the subtelomeric rearrangements detected in the 100 cases reported here and 
four in the next 107 cases tested in this department were considered to be clinically 
significant on the grounds that (as suggested by Knight et al 1999) either the 
rearrangement is familial and the unbalanced derivatives segregate with MR (AS, MC), 
the rearrangements include regions previously found to be deleted in known MR 
syndromes (18q (MC), 1p36, 22q13.3, 6q27). or are so large that they are almost certain 
to have associated phenotypes (DR). Concurrent monosomy and trisomy is highly likely 
to be phenotypicaiiy significant. The remainder comprise abnormalities which are likely to 
be polymorphic, involving the 2q region frequently reported as such (e.g. in Knight and 
Flint 2000). Some of these were shown to be do novo, however, therefore a slim 
possibility of their clinical significance remains. Additionally, even where a segmental 
aneusomy is present in an unaffected parent (as could be shown for the deletions of 7p 
and 8p and one 2q deletion described here) the phenomenon of variable penetrance, as 
occurs with 22q11.2 deletions, could possibly be involved, or imprinting of the affected 
region. A similar 7ptel deletion case has recently been reported (Kriek et al 2004). 
Mosaicism in the unaffected parent with the segmental aneusomy, or a telomere position 
effect silencing sequences on the non-deleted homologue in the child, have been 
suggested as possible causes for diverse phenotypic effect in such cases (van 
Karnebeek et al 2002). More detailed investigation and definition of the regions involved 
in segmental aneusomies is required to assist interpretation of such FISH results.
An ‘in depth’ comparison of the phenotypes associated with the abnormalities detected in 
this study with those associated with previously reported abnormalities involving these loci 
was not appropriate, as most of these reports involved much larger, cytogenetically visible 
aberrations. A recent review lists the phenotypes which have been associated with the 
reported cryptic and non-cryptic deletions of each subtelomeric chromosomal region (de 
Vries et al 2003) but, apart from the 1 p, 22q and 6q deletions discussed above, all of the
203
phenotypicaiiy significant subtelomeric rearrangements detected in this department have 
involved aneusomy at two loci, which is likely to complicate the phenotype.
Among the alternative approaches applied to subtelomeric screening have been high 
resolution cytogenetics (Joyce et al 2001) and short tandem repeat polymorphism 
(microsatellite) genetic markers (Colleaux et al 2001, Rio et al 2002).
Joyce and co-workers advocated that high resolution cytogenetics can detect most 
‘cryptic’ subtelomeric rearrangements and FISH was only required to confirm positive 
findings. Such detailed cytogenetic analysis, however, can not be uniform in quality, and 
despite the findings of these authors a more sensitive, less subjective technique, is surely 
preferable. A subtle subtelomeric segmental aneusomy (der(14)t(11 ;14)(p;q)) in a 
karyotypically normal child was recently disclosed by Multiprobe-T screening in this 
department, and only later determined to be cytogenetically visible when conventional 
cytogenetics was repeated (blind) by other cytogeneticists.
An advantage of genetic marker studies is that the sample, DNA, requires no cell culture, 
but the process can be cumbersome and may generate many more false positives than 
true positives, requiring customised follow-up for many of the screened cases (Biesecker 
et al 2002). Another disadvantage is that parental samples are required. However some 
aspects of the procedure can be automated and the microsatellite technique is capable of 
detecting uniparental disomy, although this phenomenon does not appear to be a 
significant contributor to the ‘idiopathic MR' phenotype (reviewed in Biesecker et al 2002). 
Multicolour FISH has also been investigated, but found to lack sensitivity. In one study of 
50 patients SKY detected only one of three subtelomeric rearrangements detected by 
FISH, and failed to show advantage in detecting any interstitial rearrangement (Clarkson 
et al 2002).
Other more readily automated, more sensitive subtelomeric screening approaches are 
currently in development as discussed below.
4.3 Comparative Genomic Hybridisation
The standard of CGH results in this study primarily depended on the quality of both the 
DNA and, as reported previously, the metaphase preparations. Commercial slides (Vysis) 
were of inconsistent quality, a finding confirmed by other investigators (Weiss et ai 1999), 
but use of commercial control DNA was convenient and removed some variability from 
the technique.
The numbers of cases in the different categories of patients studied here are obviously 
too small to allow conclusions to be drawn from the abnormality detection rates observed.
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However there were positive results, among these the detection of deletion in an 
individual with a balanced translocation involving other chromosomes. This phenomenon, 
overlooked abnormalities on cytogenetic analysis of cases with additional balanced 
abnormality, has been noted by other investigators (Kirchhoff et al 2001). Two of the six 
Imbalances these authors detected in five cytogenetically balanced cases (Table 4-3) 
were at regions outside those involved in the translocation. Both of these aberrations, like 
the 1q25-q31 deletion in this study, were visible on subsequent examination of G-banded 
karyotypes, suggesting that the finding of a translocation may divert a cytogeneticist's 
attention from other abnormalities.
This CGH study also identified a 17p deletion and determined the region of duplication in 
an add(3) case, a task which would otherwise have required in house’ culture of a range 
of chromosome 3 probes and sequential hybridisations.
One DNA sample (JG) repeatedly failed to produce CGH of analysable quality. Gel 
electrophoresis indicated that the proportion of high molecular weight DNA in this sample 
was low, but the OD260/OD280 ratio did not indicate protein contamination. The small 
volume of DNA available would, anyway, have precluded repeat phenol extraction and 
precipitation. More than the recommended amount of DNA will be used in labelling (as in 
the successful KD CGH experiments where the DNA was also degraded) if CGH with this 
sample is repeated, and alternative labelling methods will be attempted. Routinely 
assessing whether a DNA sample is degraded by preliminary electrophoresis makes an 
already lengthy CGH procedure less convenient in the diagnostic field. These studies 
suggest, however, that this should possibly be one of the first factors checked if the test, 
but not the reference, DNA fails to produce strong signal.
A case with a cytogenetic abnormality at 9p13 may have failed to exhibit imbalance on 
CGH because the chromosomal area of particular Interest was adjacent to a pericentric 
region for which CGH may not be informative, providing interpretation problems. It has 
been noted (Kirchhoff et al 2001) that imbalances at 9p11 can, as in the case reported in 
this study, be detected in euploid DNA on rare occasions then ‘disappear’ on repeat of the 
analysis. These authors considered that they may represent technical artefacts. This 
study suggests that use of particular reference DNA/test DNA combinations may 
contribute to the effect. As expected the 21 p deletion in case LF was also not detectable. 
Some CGH experiments, such as those with patient LS DNA, exhibited the locus-specific 
problems caused by unequal hybridisation of differentially-labelled test and reference 
DNAs to 1 p32-pter, 16p, 19 and 22. These problems are now known to be associated 
with high GO content at these regions (Karhu et al 1997).
The possibility that imbalance is present in some of the cases studied, but outwith the 
resolution of CGH, can not be discounted. Empirical study using two different image
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analysis systems and a threshold of 0.8 has determined CGH deletion resolution to be 10- 
20Mb, confirming earlier estimates (Bentz et al 1998), although cryptic subtelomeric 
translocations have been detected in three families with extensive histories of MR using 
this threshold, among them a subtelomeric deletion estimated at -4Mb (Ghaffari et al 
1998). However, rather than fluorescence ratio examination, the method Involved 
comparison of fluorescence profiles and required very early “hands-on” CGH software, no 
longer commercially available, to allow user interaction at most stages of the analysis.
This was even more time consuming than the use of current software.
Considering molecular cytogenetic alternatives to CGH, where the abnormality is 
cytogenetically visible but unresolvable. Identification of extra chromosome material is 
also possible by microdissection of that region from metaphase spreads (Meltzer et al 
1992) or by chromosome isolation by flow sorting (Blennow et al 1992) followed by FISH. 
Both techniques are limited in only analysing one chromosome region per hybridisation, 
and both require highly specialised instrumentation. M-FISH, the other global molecular 
cytogenetic technique, allows balanced rearrangement detection, but it requires 
reasonable quality patient chromosome preparations, it can miss small intrachromosomal 
aneusomies, and concerns have been raised regarding misinterpretation caused by 
overlapping fluorescence at the interface of translocated segments (Lee et al 2001). 
Multiprobe paint devices can offer simple alternative determination of imbalance resulting 
from interchromosomal rearrangement.
CGH has advantage over purely molecular methods, such as quantitative fluorescence 
(OF) PGR, in global detection of aneuploidies and unbalanced structural rearrangements, 
and is now widely applied to determination of quantitative genomic change in cases of 
subtle, suspected or apparent but unresolvable constitutional chromosomal aberrations 
(reviewed in Breen et al 1999) as well as in oncology studies. Refinements have included 
the use of alternative labelling techniques such as universal linkage system (ULS) 
chemical labelling (Alers et al 1999). This is particularly useful for the labelling of small 
fragment-sized DNA arising, for example, from archived tissue sections or generated by 
DOP-PCR, and may improve resolution, particularly at subtelomeric regions (Schoumans 
et al 2004).
Straightforward methods of CGH quality assessment have been suggested in a range of 
publications and were applied during this study. For example, mismatching the test and 
reference DNA sex and examination of the competitive hybridisation effect on the X 
chromosome to provide an internal control (Breen et al 1999). In the present study CGH 
was regularly capable of detecting dizygosity in individual cells at the X/Y 
pseudoautosomal region (-2.6Mb at Xp22.3 and Yp11.31, Rappold et al 1993) against a
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background of effective Y imbalance in sex-mismatched test and reference DNAs. Also, 
if the limits of 95% or 99% confidence intervals of test versus reference CGH ratio profiles 
are used as thresholds, gains or losses can be identified when the 95% or 99% Cl does 
not contain 1.0 (Weiss et al 1999).
Two modified CGH techniques have been introduced which improve CGH resolution by 
standardising interpretation. Both improve analytical quality by identifying inconsistently 
hybridised chromosomal regions. Four color CGH uses a second differentially labelled 
reference DNA as an internal standard (Karhu et al 1999). The alternative high resolution 
CGH (HR-CGH) approach employs software marketed by Applied Imaging. Instead of 
using fixed ratio thresholds and considering profiles deviating 15% or 20% from 1 (i.e. 
0.85-1.15 or 0.8-1.2) to be aberrant, this involves comparison of profile 99.5% Cl with a 
corresponding standard reference interval (an average of normal cases) which is wide at 
known variable areas (Fig.4-2). Where there is no overlap between the two intervals the 
chromosomal region is designated potentially aberrant (Kirchhoff et al 1998, 2000). As 
well as higher specificity, comparison of test case CIs with standard reference intervals 
also confers greater sensitivity (detection of 3Mb deletions) and therefore improved 
detection of mosaicism. No region needs to be excluded, and false positive results are 
infrequent. Among the patients tested in a major study using this approach were, as in 
this work, affected individuals with apparently balanced translocation and patients with 
apparent but unresolvable chromosomal abnormalities (Kirchhoff et al 2001, Table 4-3).
In addition nineteen cases, seven of them cytogenetically cryptic, were studied to confirm 
a recognised abnormal karyotype. HR-CGH detected four of the seven cryptic 
aberrations, including two Prader-Willi/Angelman syndrome deletions. The undetected 
deletions were at DGA/CFS and WS regions. The other recognised abnormal karyotypes 
not clarified in the 2001 study were considered undetectable because they either 
contained no euchromatin, were normal variants, or mosaic.
A very recent publication by the same group reports an imbalance detection rate of 12% 
(51) in 424 karyotypically normal individuals with MR and dysmorphology (Kirchhoff et al 
2004). Two-thirds of the abnormalities were interstitially and one third terminally located, 
and eight associated with recognised microdeletion syndromes including Smith-Magenis, 
blepharophimosis-ptosis-epicanthus inversus (BPES), Ipter, 2qter, and 22qter deletion 
syndromes.
Kirchhoff and co-workers acknowledge that not all of the abnormalities which could 
represent possible normal variants (through inheritance from a phenotypically normal 
parent) have been excluded from their HR-CGH detection figures. Adjustment of these 
figures to exclude six abnormalities in this category gives an HR-CGH detection rate of 
10.6%.
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A subset comprising 94 of these 424 patients were tested in a prospective study involving 
both HR-CGH and Multiprobe subtelomeric screening. Nine abnormalities were found, 
representing a detection rate of 9.6%. Eight of these abnormalities, two of which were 
terminal, were detected by HR-CGH (detection rate 8.5%). Three abnormalities, one of 
which was not detected by HR-CGH, were detected by subtelomeric screening (detection 
rate 3.2%). It is interesting that this group report a similar level of terminal deletions, 3- 
4% (Kirchhoff et al 2001, 2004), as found in the present study.
Kirchhoff and colleagues advocate use of HR-CGH in cases of dysmorphic MR and 
apparently balanced translocation, apparently balanced de novo  translocation detected 
prenatally, clarification of complex structural rearrangement, and dysmorphic MR with 
normal karyotype (Kirchhoff et al 2001, 2004). They suggest HR-CGH for initial 
investigation of patients with idiopathic MR and dysmorphic features unless a family 
history implicates involvement of an unbalanced translocation, when subtelomeric 
screening should be used in the first instance. Subtelomeric screening should also be 
used for secondary investigation where HR-CGH is negative.
However these authors recognise that high resolution chromosome analysis could reduce 
the need for these time consuming and expensive procedures, and estimate that 30% of 
the abnormalities which they detected might have been found at the 500-750 band level 
even with no prior knowledge of their location.
HR-CGH software is now available in this department and will be used to analyse any 
repeat CGH tests for the cases in this study in which imbalance failed to be established.
INDICATION NUMBER ABNORMALITIES
______________________ ______________________ANALYSED DETECTED
Affected, apparently balanced, de novo translocation 25 6 (21%)
Apparently balanced de novo translocation, PND 6 0
Clarification of abnormal karyotype 19 12
Confirmation of abnormal karyotype 19 (7 cryptic) 13
Table 4-3 Clinical cases analysed by HR-CGH (Kirchhoff et al 2001).
Further increase in the resolution of CGH has been provided by matrix CGH which uses 
cloned DNA arrays as a target instead of chromosomes and a laser scanner to record 
fluorescence Intensities following hybridisation (Solinas-Toldo et al 1997, Fig.4-3). The 
construction and analysis of genomic microarrays has been reviewed (Carter et al 2002). 
Sensitivity is dependent on clone size and density, 3.5 x 10  ^clones giving 1Mb resolution. 
Commercial chips, however, are expensive, e.g. the Spectral Genomics array of 2500 
clones costs £875 excluding labelling, though cost may reduce with increased demand. 
The alternative is to produce non-commercial diagnostic arrays. Researchers at the 
Sanger Centre, Cambridge have reported that an array of 500 clinically significant clones
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(including oncogene, tumour suppressor, microdeletion and telomere sequences) plus 
band-specific sequences at 10Mb intervals could cost only £11- £44 per test, although a 
robotic ‘arrayer’ is required, at £75,000, for array production (Carter 2002).
This group also work with a 1Mb array of BAC clones which are logged in EnsembI and 
available from the BACPAC Resources Center, Children's Hospital Oakland Research 
Institute, Oakland, CA, or the Human BAC Resource at the Sanger Centre.
Use of this array for Investigation of a chromosome derived from 21 in a child without 
Down syndrome physical features but with MR allowed characterisation of the over­
represented region of 21. The tetrasomie region defined contains thirty four genes, 
among them sequences likely to contribute to MR in this condition (Rost et al 2004).
They have also screened 50 patients with MR and dysmorphic features on the 1 Mb array 
and found twelve segmental aneusomies (Shaw-Smith et al 2004a). Five of these are 
inherited from phenotypically normal parents and so unlikely to be clinically significant, 
giving a detection rate of 14%. Though the numbers studied are small, this figure 
appears to correlate quite well with HR-CGH detection rates (10.6 -12%, Kirchhoff et al 
2004), and suggests slightly improved sensitivity.
Similar work has been performed reproducibly validating the sensitivity of matrix CGH to 
detect 1.5-2.9Mb deletions (Vissers et al 2003). This group then tested a series of 20 
patients with idiopathic MR and dysmorphism and demonstrated seven copy number 
alterations, five of which could be confirmed with FISH or high resolution arrays for the 
region of interest. Three of the five imbalances were considered likely to be genomic 
polymorphisms. The clinically significant abnormalities were 8.6 and 2Mb in size. To 
detect even more subtle abnormalities they are constructing microarrays completely 
covering the genome with an average resolution of 46kb (the BACPAC Resources 
Center’s Human BAC Minimal Tiling Set).
The Cambridge group also use such higher resolution, overlapping, ‘tilepath’ clones on a 
secondary microarray to span any defined breakpoint. They have in addition developed a 
technique which, unlike standard CGH or microarray studies, allows the investigation of 
balanced rearrangements (Fiegler et al 2003). This array painting, as in reverse painting, 
involves flow sorting the derived chromosomes and their differential labelling but, instead 
of FISHing these to chromosomes, they are mixed and hybridised to a microarray of 
chromosome-specific clones. As the analyst surveys a set of these clones a reversal is 
apparent in the predominant fluor, defining the breakpoint. A clone with an intermediate 
ratio suggests it may span the breakpoint (Fig.4-4). Array painting is unlikely to be 
applied in diagnostic laboratories as it requires both demanding microarray and flow 
sorting technology and expertise.
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Fig.4-2 Comparison of CGH and HR-CGH interpretation.
CGH left. 99.5% confidence intervals (yellow) versus fixed ratio thresholds 0.8-1.2 (black). 
HR-CGH right 99.5% confidence intervals (yellow) versus the corresponding standard reference 
intervals (black) indicating loss at 2qter. Image courtesy of Applied Imaging.
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Fig.4-3 Schematic overview of the CGH microarray technique.
Tumour and reference DNA are labelled as for standard CGH and hybridised to fragments of DNA 
(instead of metaphase chromosomes) attached to a glass slide, ordered in arrays. Images of the 
fluorescent signals are captured and the green to red signal ratios are measured digitally for each 
target. From Weiss et al (1999).
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Fig.4-4 The basic principle of mapping  
translocation breakpoints by array painting. 
Derivative chromosomes are flow-sorted, PCR- 
amplified, differentially labelled and 
co-hybridised to a chromosome-specific 
microarray. At the breakpoint site a reversal is 
apparent in the predominant fluor.
From Fiegler et al (2003).
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4.4 Primed In Situ Labeding
Assessment of PRINS with commercial kits confirmed the reliability of the Boehringer 
Mannheim system and that results could be obtained without a thermal cycler using this 
repetitive target kit. PRINS with 'in house’ repetitive sequence primers was also 
successful, but no satisfactory results were obtained with primers for unique or very low 
copy sequences.
Two of the modifications assessed possibly offer potential for future PRINS optimisation. 
Pretreatment in Carnoy’s fixative then 2xSSC appeared to increase penetrance and 
therefore signal. Also an alternative, relatively inexpensive, enzyme not previously 
reported in PRINS (Dynazyme) was shown, with low detergent, to give highly efficient 
amplification of repetitive primers D3Z1 and 267, requiring only one FITC detection layer 
to produce satisfactory non-cycling PRINS results.
The primary aim of these studies was to investigate the potential of PRINS for robust 
detection of unique target sequences. Statistical analysis of signal distribution had been 
necessary following chromogenic detection of in situ PGR with porcine unique sequences 
(Troyer et al 1994a,b), and the only report of unique sequence PRINS with fluorescence 
detection, Ginti et al (1993), had described Factor IX signal as barely detectable with 
conventional fluorescence microscopy' and stated that ‘the signal to noise ratio and fading 
did not allow satisfactory photographic recording’. This suggested some amplification of 
signal would be needed, therefore for this study of Factor IX primers both PRINS and (as 
In Troyer et al 1994a,b), cycling PRINS were attempted. As no signal was produced in 
the absence of MgGIg with either Factor IX or control primers, placing the accuracy of the 
description of Ginti’s method in question, PRINS was performed both using Ginti’s 
approach and modifications, including use of MgGla. These tests also failed. Access to 
confocal laser scanning microscopy and signal enhancement for visualisation possibly 
improved the sensitivity of Ginti’s system. Further modifications in the present study may 
have been beneficial, however solution PGR suggested specific amplification with these 
primers might not be consistently reproducible.
PRINS with DAZ and RBM1 primers was then investigated because these genes were 
believed to be present as low copy repeats and DAZ oligonucleotides had a large 
amplification product (1300 base pairs, Vogt et al 1996), which suggested that they could 
be useful as PRINS primers. Though solution PGR with Dynazyme worked well, PRINS 
was again unsuccessful. These sequences have actually had to be treated as ‘unique’ for 
the purposes of recent PRINS investigations (Kadandale et al 2002, see below).
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Cycling invariably introduced damage and generally did not produce more signal than that 
achieved without cycling. In some experiments increased cycle numbers resulted in 
signal loss, suggesting diffusion might have been occuring. Published opinions on this 
effect differ. Though it has been reported that the products of PRINS cycles remain 
associated with their point of origin (Gosden and Hanratty 1993), Koch (1996) found that 
the majority of the extra DNA synthesised apparently did leave the site of synthesis 
producing increased background and less distinct signal, Komminoth (1994) also 
reported problems with diffusion during in situ PGR.
The initial restriction of PRINS to repetitive sequence detection meant it did not achieve 
widespread use. Also, PRINS rapidity offered little advantage as alphoid sequences can 
be detected (for PND or PGD) by FISH with only 2 hours Incubation. One reported 
unique PRINS facility, differentiation of chromosome 13 and 21 alphoid sequences 
(Pellestor et al 1994, 1995b,c), might have significantly increased PRINS usage, 
particularly in PND. However preliminary PRINS investigations for this study found that 
signal with either 13 or 21 primers (though of differing strengths) was present both on 
chromosomes 13 and on chromosomes 21. It was subsequently confirmed that neither 
the 13 or 21 sequence variant is chromosome specific, but represents polymorphisms 
(Nilsson et al 1997, Yang et al 2001), which suggests that Pellestor’s results could have 
depended on the individuals tested.
Among the findings in this study at variance with those of other reports is the optimal slide 
age for PRINS. Ginti et al (1993) stressed the importance of using 10 day-old slides for 
unique target PRINS, though use of such old slides would disadvantage diagnostic 
application. In this study no improvement was seen with unique primers on 10 day-old 
slides, instead, with repetitive primers, it was repeatedly found that 3 day-old slides 
produced optimal results and older slides reduced signal. Other authors (e.g. Gosden 
and Lawson 1994, Koch 1996) recommend the use of freshly prepared slides, certainly no 
older than 1 week. Also, PRINS results did not necessarily agree with published primer 
specificity, the pattern of signal appearance on 267-primed chromosomes regularly 
varying from that reported (Gosden and Hanratty 1993). For example, acrocentric 
chromosomes could display signal, even when signal was not present on both 
chromosomes 9 (as in 267 test 23).
It became clear from these experiments that optimisation of PRINS, even for the 
detection of repetitive target sequences, was not always straightforward - e.g. increasing 
annealing temperature to reduce signal might fail to do this and instead introduce 
speckled background. It is also more difficult to optimise PRINS than PGR as, generally, 
only a few experiments can be run simultaneously because of limited hotblock space.
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These considerations, consensus that single-copy PRINS was, if achievable, never going 
to be a robust approach (Dr J. Gosden, MRC, Edinburgh, personal communication) 
therefore limiting its diagnostic applicability, and practical difficulties arising from changed 
work circumstances led to the conclusion of the PRINS component of this study in 1997. 
Repetitive sequence PRINS continued to be used by some investigators, as in the study 
of sequence organisation on chromosomes and extended chromatin (Therkelsen et al 
1997, Shibasaki and Gosden 1997) and for sex determination in fetal cells in maternal 
blood (Orsetti et al 1998).
In 1999 and 2000 there were reports of PRINS adaptation and optimisation for the 
detection of single copy loci (Paskins et al 1999, Kadandale et al 2000). Pasklns and 
colleagues used cycling PRINS on blood smears following ethanol fixation and microwave 
pretreatment. Due to the low frequency of cells with signal (40-50%) these authors did 
not, however, consider this approach to be applicable in a clinical diagnostic setting.
During their investigations they discerned that the optimum size for primer pair products in 
cycling PRINS is 550bp, a longer product (900bp) dramatically reducing amplification 
efficiency. This may explain the poor cycling results in the present study as D3Z1 and all 
of the low/unique copy primers (except Factor IX) selected for use have larger 
amplification products.
More recently several presentations involving single-copy target PRINS were delivered at 
an international workshop on PRINS (Tharapel et al 2002, Kadandale et al 2002,
Tharapel and Kadandale 2002, Cinti et al 2002). These included investigations of 
chromosomal regions studied in this thesis work, namely the DGA/CFS, RBM1, DAZ and 
dystrophin loci.
Three of these reports came from the same group at the University of Tennessee. Their 
modifications to the standard PRINS protocol included use of 1 day-old slides pretreated 
with 0.02N HCI, use of multiple primers for the same locus, single step annealing and 
protracted (30 minute) extension, use of TaqStart, a monoclonal antibody against Taq 
polymerase which prevents nonspecific amplification and formation of primer-dimers, and, 
as Investigated in this work, TSA. Use of nested primers (for multiple DMD exons) had 
been considered for this study but not attempted due to lack of time.
Cinti et at (2002) also used no cycling, protracted extension and (unlike their 1993 report)
1 day-old slides, but not HCI treatment or TSA, incubating slides submerged in water to 
allow ‘uniform diffusion of warmth’.
These 2002 single target PRINS reports suggested that PRINS might be about to have a 
fundamental impact on medical genetics. However a literature search covering the period 
since their publication, while revealing several reports including a new application of
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PRINS in breakpoint refinement (Nimmakayalu et al 2003), demonstrates no obvious 
burgeoning of PRINS use. This may be because FISH has become established and 
routine in clinical cytogenetics laboratories and the range of commercial FISH probes has 
increased to cover the most frequently requested molecular cytogenetic investigations 
(Satinover and Schwartz 2002). Also unique target PRINS is probably more 
technologically demanding than FISH, the necessity for multiple primer sets and TSA 
makes the technique rather complex, and the ready availability of BAC and PAC probes 
provides a resource for FISH investigation of any region of the genome. PRINS may 
however continue to benefit research, e.g. in the investigation of the genomes of other 
species for which there are no, or only very limited, FISH probes.
214
5. CONCLUSION
Over the last decade molecular cytogenetic methods have greatly advanced cytogenetic 
resolution. We now stand on the brink of the full impact of even more powerful 
techniques aimed at the characterisation of segmental aneusomy, the most exciting of 
which is genomic microarray. This ultra high resolution CGH provides screening for gain 
as well as loss of genetic material, particularly relevant in the light of increased 
recognition of the clinical significance of microduplications which are not always 
detectable by subtelomeric screening and other FISH.
Genomic microarrays can be used for genome-wide screening or to investigate specific 
chromosomes (Buckley et al 2002) or chromosome sites (Yu et al 2003). Disease- 
specific probe sets to rival multiplex PCR may be developed. They have also been used 
to assess subtelomeric loci (Vissers et al 2003), however the significant number of cryptic 
interstitial abnormalities now being reported (Kriek et al 2004, Kirchhoff et al 2004) 
highlights the benefit of genome-wide, rather than targeted, screening of patients with 
idiopathic MR.
Microarray investigations will provide not only detection of microdeletion/duplication but 
also, because the arrays use characterised BACs therefore imbalances are directly linked 
to chromosome bands and genetic markers, instant detailed characterisation of the 
segmental aneusomy. This should greatly assist genotype/phenotype correlation and 
facilitate the detection of genes involved in physical and mental development.
Microarrays can provide a comprehensive screen, are high resolution, amenable to 
automation, rapid and sensitive, however a disadvantage is their current high cost which 
prevents their use on large sample numbers. Alternative, molecular, methods for targeted 
screening have different drawbacks, e.g. the presence of multiple primer pairs in a 
multiplex reaction reduces the robustness of PGR and the reliability of quantification, and 
the use of quantitative fluorescent PCR in a multiplex assay is limited by the spectral 
overlap of the fluorescent dyes used. New molecular techniques which increase the 
number of simultaneously analysable genetic loci include Multiplex Amplifiable Probe 
Hybridisation (MAPH, Armour et al 2000) and Multiplex Ligation-dependent Probe 
Amplification (MLPA, Schouten et al 2002). Both allow simultaneous amplification of a 
collection of target-specific probe sequences following hybridisation to patient DNA.
MLPA Is convenient in being a ‘one-tube’ assay, but probe development is more complex. 
These techniques currently detect copy number changes -  deletions and duplications - at 
around 40 loci in a single reaction and some commercial kits are now available. In
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addition to being less expensive, MAPH and MLPA have higher resolution (~100bp) than 
microarrays (BAC clones are 100-180kb) (Kriek et a! 2004).
Amongst the first MAPH/MLPA probe kits to be developed were sets for subtelomeric 
regions (Sismani et al 2001, Hollox et al 2002, Rooms et al 2004) and DMD exons (White 
et al 2002). The DMD set provides comprehensive quantitative analysis of all 79 
dystrophin exons, though appropriate exon-specific probes can be selected for carrier 
determination (White et al 2003). MLPA is now also available as an alternative to FISH 
for detection of segmental aneusomy in DGA/CF and Rubinstein-Taybi syndromes 
(Roelfsema et al 2005).
It has been suggested (Kriek et al 2004) that array CGH should be used for finding 
regions in the genome which harbour genes involved in particular diseases - microarrays 
have recently been exploited for this purpose by Vissers and colleagues (2004) - then, 
when these areas have been identified, less expensive MAPH/MLPA assays could be 
designed for their targeted diagnostic investigation. However it may be that, as with 
currently recognised recurrent segmental aneusomies, ‘new’ syndrome-associated 
imbalances will be associated with variable phenotypes. Global, rather than targeted, 
investigation will therefore continue to be preferable for many patients.
Additionally, the choice of targeted approach (microarray or MAPH/MLPA) is likely to be 
dependent on whether microarray prices reduce sufficiently, how rapidly the respective 
techniques are optimised for routine diagnostic use, and on the particular expertise in any 
department.
The Interpretation of Genetic Imbalances and the Role of Collaborative Databases 
Segmental aneusomy of uncertain clinical significance is a frequent finding as 
determined, for example, in the FISH subtelomeric screening reported here and 
elsewhere and in microarray studies (Shaw-Smith et al 2004a). The advent of diagnostic 
microarray, MAPH, MLPA and HR-CGH has resulted in the institution of collaborative 
databases (ECARUCA, European Cytogeneticists Association Register of Unbalanced 
Chromosome Aberrations; CAC, Chromosome Anomaly Collection; DECIPHER, 
DatabasE of Chromosomal Imbalance and Phenotype In Humans using EnsembI 
Resources) to help establish the clinical significance of any detected imbalance. 
DECIPHER will allow the user to determine whether a similar deletion or duplication has 
previously been reported by any other contributor to DECIPHER, compare a patient’s 
phenotype with previous records, and visualise the known genes, putative genes and 
ESTs within the deleted/duplicated region. Pooling of data on molecularly-defined
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segmental aneusomies will improve clinical definition of phenotypes and further assist 
genotype/phenotype correlation as well as definition of polymorphic variants.
This systematic analysis of polymorphisms should generate additional benefits, including 
insight into the flexibility of the human genome. It has been suggested that such large 
rearrangements, involving multiple genes, could serve as predisposing factors for 
multifactorial disorders (Vissers et al 2003).
Continuing Role of FISH in Determination of Segmental Aneusomy and Breakpoint 
Refinement
Choice of methodology is often determined by resources and expertise, as exemplified by 
the ongoing use of FISH, rather than quantitative molecular investigations, for DMD 
carrier testing in some departments (Ligon et al 2000).
Also the cost of digital imaging is now less than ten years ago, and developments such as 
automated interphase spot counting (Applied Imaging) and multicolor chromosome 
banding kits for individual chromosomes (Metasystems GmbH, Altlussheim, Germany) 
make FISH an increasingly attractive diagnostic and research tool, especially in 
combination with other molecular cytogenetic techniques.
Even with the introduction of new methodologies, a continuing role for FISH is assured, 
not just in, as currently, targeting well recognised syndromic sites but in mapping clones 
prior to their use in arrays (Shaffer and Bejjani 2004) and in validating the results of CGH 
and microarray (Lundsteen et al 2002, Vissers et al 2003) and MAPH/MLPA (e.g. Hollox 
et al 2002, Rooms et al 2004). Also, FISH screening, unlike microarray or MAPH/MLPA, 
is capable of detecting cryptic rearrangements in balanced carriers.
The potency of FISH has been increased by more straightforward access to large, 
accurately localised probe sequences and to online genome browsers (EnsembI, Birney 
et al 2004; UCSG genome browser, Kent et al 2002; various clone repositories including 
the Human BAC Resource), offering even the diagnostic laboratory the opportunity to 
precisely define breakpoints for more accurate genotype/phenotype correlation. Further 
definition of the cryptic chromosomal aberrations detected in this study was considered, 
but such comprehensive information and probe resources have only recently become 
accessible. Through investigation of the chromosome 8 and 21 rearrangements 
described here, experience in detailed mapping using these resources has been acquired 
and will continue to be utilised in the characterisation of chromosome abnormalities in the 
future.
The use of these new resources for the investigation of cytogenetically visible as well as 
cryptic aberrations is now being reported (Boylan et al 2004, Fantes et al 2004, H a rewood
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et al 2004, Willatt et al 2004, Collinson et al 2004, Novell! et al 2004, Johnson et al 2004a, 
Shaw-Smith et al 2004b), recent investigations in this department providing independent 
evidence for a CHARGE critical region at 8q (Johnson et al 2004b, manuscript in 
preparation).
It is apparent that the combination of molecular cytogenetic and microarray technology 
now available represents a highly effective means for revealing and accurately defining 
the many segmental aneusomies of clinical significance which undoubtedly await 
disclosure, particularly as aspects of these approaches may be amenable to automation 
and high-throughput screening. An associated benefit will be the uncovering of candidate 
genes for targeted mutation screening in appropriately affected individuals without 
segmental aneusomy, and the elucidation of genetic mechanisms involved in the 
aetiology of mental retardation and malformation syndromes.
However, whether diagnostic services can take full advantage of these new technologies 
in the near future will, as ever, be heavily dependent on funding considerations.
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6. ELECTRONIC-DATABASE INFORMATION
BA CPAC  Resources Center, Children’s Hospital O akland Research Institute, O akland, 
CA, http://www.chori.org/bacpac/
B A CP AC  Resources C enter’s hum an BAC Minimal Tiling Set, 
http://bacpac.chori.org/pHum anM inSet.htm
C A C  (Chrom osom e Anom aly Collection), w w w .ngrl.org.uk/W essex/Register 
Confidence interval calculation,
http://hom e.ubalt.edu.ntsbarsh/business-stat/otherapplets/ConflntPro.htm
D E C IP H E R  (D atabasE  of Chrom osom al Im balance and Phenotype in Hum ans using 
Ensem bI Resources), http://w w w .sanger.ac.uk/PostG enom ics/decipher/
E C A R U C A  (European Cytogeneticists Association Register of Unbalanced Chrom osom e  
Aberrations), http://www .ecaruca.net
Ensem bI G enom e Browser, http://www.ensembl.org/Homo__sapiens
G enB ank/N C B I G ene (links to NCBl nucleotide): 
http://www.ncbi.nlm .nih.gov/entrez/query.fcgi?db=gene
Hum an BAC Resource, The S anger Centre, Cam bridge, 
http://w w w .sanger.ac. uk/T  eam s/T  eam 63/C loneR equest
M A P H  probe kit for subtelom eric regions,
w w w .genetix.com /productpages/reagents/G enom ics% 20reagents/genecounter.htm
M ax-P lanck Institute for M olecular Genetics, http://www .m pim g-beriin-dahlem .m pg.de
M LP A  kits for 22q11, subtelom eric regions and D M D  exons, http://www.m rc-holland.com  
M LP A  kit for detection of microdeletions in RTS, http://www.servicexs.com
O M IM , http://www.ncbi.nlm .nih.gov/entrez/query.fcgi?db=O M IM
Percentage of dystrophin deletions including any particular exon, 
http://www.dmd.nl/DMD_deldup__Leiden.html
Roswell Park C ancer Institute hum an BAC library, http://bacpac.m ed.buffalo.edu
S T S  m arkers for 32k rearray clones used in chrom osom e 21 breakpoint mapping, 
http://genom e.ucsc.edu/cgi-bin/hgTracks
219
7. BIBLIOGRAPHY
Abbs S, Yau SC, Clark S, Mathew CG, Bobrow M (1991) A convenient multiplex PCR system for 
the detection of dystrophin gene deletions: a comparative analysis with cDNA hybridization shows 
mistypings by both methods. J Med Genet 28:304-311
Abbott C, West L, Povey 8, Jeremiah S, Murad Z, DiScipio R, Fey G (1989) The gene for human 
complement component C9 mapped to chromosome 5 by polymerase chain reaction. Genomics 
4(4):606-609
Adinolfi M, Sherlock J, Tutschek B, Haider A, Delhanty J, Rodeck C (1995) Detection of foetal cells 
in transcervical samples and prenatal diagnosis of chromosomal abnormalities. Prenat Diagn 
15(10);943-949
Afify A, Bland Kl, Mark HFL (1996) Fluorescent in situ hybridization assessment of chromosome 
copy number in breast cancer. Breast Cancer Res Treat 38:201-208
Aikens RS, Agard DA, Sedat JW (1989) Solid-state imagers for microscopy. Methods Cell Biol 
29:291-313
Alers JC, Rochat J, Krijtenburg P-J, van Dekken H, Raap AK, Rosenberg C (1999) Universal 
Linkage System: An improved method for labeling archival DNA for comparative genomic 
hybridization. Genes Chromosomes and Cancer 25:301-305
Altherr MR, Bengtsson U, Elder FF. Ledbetter DH, Wasmuth JJ, McDonald ME, Gusella JF, 
Greenberg F (1991) Molecular confirmation of Wolf-Hirschhorn syndrome with a subtle 
translocation of chromosome 4. Am J Hum Genet 49(6): 1235-1242
Amati F. Mari A, Digilio MC, Mingarelli R, Marino B, Giannotti A, Novelli G, Dallapiccola B (1995) 
22q11 deletions in isolated and syndromic patients with tetralogy of Fallot. Hum Genet 95:479-482 
Anastasi J, Thangaveiu M. Vardiman JW, Hooberman AL, Bian ML, Larson RA, Le Beau MM 
(1991) Interphase cytogenetic analysis detects minimal residual disease in a case of acute 
lymphoblastic leukemia and resolves the question of origin of relapse after allogeneic bone marrow 
transplantation. Blood 77(5): 1087-1091
Anastasi J, Le Beau MM. Vardiman JW, Fernald AA, Larson RA, Rowley JD (1992) Detection of 
trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells; 
a simple and sensitive method. Blood 79:1796-1801
Armour JAL, Sismani C, Patsalis PC, Cross G (2000) Measurement of locus copy number by 
hybridisation with amplifiable probes. NucI Acids Res 28(2):605-609
Baldini A, Ward DC (1991) In situ hybridization banding of human chromosomes with Alu-PCR
products: a simultaneous karyotype for gene mapping studies. Genomics 9(4):770-774
Baldini A (2003) DiGeorge’s syndrome: A gene at last. Lancet 362(9393): 1342-1343
Bartsch O, Nemeckova M, Kocarek E, Wagner A, Puchmajerova A, Poppe M, Ounap K, Goetz P
(2003) DiGeorge/velocardiofacial syndrome:FISH studies of chromosomes 22q11 and 10p14, and
clinical reports on the proximal 22q11 deletion. Am J Med Genet 117A:1-5
Bauman JG, Weigant J, Borst P, van Duijn P (1980) A new method for fluorescence microscopical
localization of specific DNA sequences by in situ hybridization of fluorochrome-labelled RNA. Exp
Cell Res 128:485-490
Bauman JG, Weigant J, van Duijn P (1981a) Cytochemical hybridization with fluorochrome-labeled 
RNA. I. Development of a method using nucleic acids bound to agarose beads as a model. J 
Histochem Cytochem 29(2):227-237
Bauman JG, Weigant J, van Duijn P (1981b) Cytochemical hybridization with fluorochrome-labeled 
RNA. II. Applications. J Histochem Cytochem 29(2):238-246
Bauman JG, Weigant J, van Duijn P (1981c) Cytochemical hybridisation with fluorochrome-labelled 
RNA. in. Increased sensitivity by the use of anti-fluorescein antibodies. Histochemistry 73(2):181- 
193
Bauman JG, Weigant J, Van Duijn P, Lubsen NH, Sondermeijer PJ, Hennig W, Kubli E (1981d) 
Rapid and high resolution detection of in situ hybridisation to polytene chromosomes using 
fluorochrome-labeled RNA. Chromosoma 84(1); 1-18
Bauman JG. Wiegant J, van Duijn P (1983) The development, using poly(Hg-U) in a model system, 
of a new method to visualize cytochemical hybridization in fluorescence microscopy. J Histochem 
Cytochem 31 (5):571-578
Baumer A, Riegel M, Schinzel A (2004) Non-random asynchronous replication at 22q11.2 favours 
unequal meiotic crossovers leading to the human 22q11.2 deletion. J Med Genet 41 (6):413-420
220
Bedell MA, Jenkins NA, Copeland NG (1996) Good genes In bad neighbourhoods. Nature Genet 
12:229-232
Bell Gl, Karam JH, Rutter WJ (1981) Polymorphic DNA region adjacent to the 5' end of the human 
insulin gene. Proc Natl Acad Sci U S A 78(9):5759-63
Bello MJ, Salagnon N, Rey JA, Guichaoua MR, Berge-Lefranc JL, Jordan BR, Luciani JM (1989) 
Precise in situ localization of NCAM, ETS1 and D11S29 on human meiotic chromosomes.
Cytogenet Cell Genet 52(1-2):7-10
Bennett RR, den Dunnen J, O ’Brien KF. Darras BT, Kunkel LM (2001) Detection of mutations in the 
dystrophin gene via automated DHPLC screening and direct sequencing. BMC Genet 2:17 
Bensimon A, Simon A, Chiffaudel A, Croquette V, Heslot F, Bensimon D (1994) Alignment and 
sensitive detection of DNA by a moving interface. Science 265(5181 ):2096-2098 
Bentz M. Dohner H, Cabot G, Lichter P (1994) Fluorescence in situ hybridization in leukaemia:The 
FISH are spawning. Leukaemia 8(9): 1447-1452
Bentz M, Plesch A, Stilgenbauer S, Dohner H, Lichter P (1998) Minimal sizes of deletions detected 
by comparative genomic hybridization. Genes Chromosomes Cancer 21:172-175 
Berend SA. Spikes AS, Kashork CD, Wu JM, Daw SC, Scam bier PJ, Shaffer LG (2000) Dual-probe 
fluorescence in situ hybridization assay for detecting deletions associated with VCFS/DiGeorge 
syndrome II loci. Am J Med Genet 91(4):313-317
Bhatt B, Burns J, Flannery D, McGee JO’D (1988) Direct visualization of single copy genes on 
banded metaphase chromosomes by nonisotopic in situ hybridization. NucI Acids Res 16(9):3951- 
3961
Biesecker LG (2002) The end of the beginning of chromosome ends. Am J Med Genet 107:263- 
266
Birney E, Andrews TD, Bevan P, Caccamo M, Chen Y, Clarke L, Coates G, Cuff J, Curwen V, Cutts 
T, Down T, Eyras E, Fernandez-Suarez XM, Gane P, Gibbins B, Gilbert J, Hammond M, Hotz HR, 
Iyer V, Jekosch K, Kahari A, Kasprzyk A, Keefe D, Keenan S, Lehvasiaiho H, McVickerG, Melsopp 
C, MeidI P, Mongin E, Pettett R, Potter S, Proctor G, Rae M, Searle S, Slater G, Smedley D, Smith 
J, Spooner W, Stabenau A, Stalker J, Storey R, Ureta-Vidal A, Woodwark KC, Cameron G, Durbin 
R, Cox A, Hubbard T, Clamp M (2004) An overview of EnsembI. Genome Res 14(5):925-928 
Blennow E, Telenius H, Larsson C, Devos D, Bajalica S, Ponder BAJ, Nordenskjold M (1992) 
Complete characterization of a large marker chromosome by reverse and forward chromosome 
painting. Hum Genet 90:371-374
Blonden LAJ, Grootscholten PM, den Dunnen JT, Bakker E, Abbs S, Bobrow M, Boehm C, van 
Broeckhoven C, Baumbach L, Chamberlain J, Caskey CT, Denton M, Felicetti L, Gatluzi G, 
Fischbeck KH, Francke U, Darras B, Gilgenkrantz H, Kaplan J-C, Herrmann FH, Junien C, Boileau 
C, Liechti-Gallati S, Lindlof M, Matsumoto T, NIikawa N, Muller CR, Poncin J, Malcolm S, Robertson 
E, Romeo G, Covone AE, Scheffer H, Schroder E, Schwartz M, Verelten C, Walker A, Worton R, 
Gillard E, van Ommen GJB (1991) 242 breakpoints in the 200-kb deletion-prone P20 region of the 
DMD gene are widely spread. Genomics 10:631-639
Boylan J, Miles K, Willett L, Moore AT, Trump D (2004) Identification of a novel gene implicated in 
cleft lip and palate, learning disability and retinal dystrophy. J Med Genet 41 (SuppI 1):Abstracts of 
the British Human Genetics Conference 2004, 872, 3.36
Boyle AL, Lichter P, Ward DC (1990) Rapid analysis of mouse-hamster hybrid cell lines by in situ 
hybridization. Genomics 7:127-130
Brandriff B, Gordon L, Trask B (1991) A new system for high-resolution DNA sequence mapping 
interphase pronuclei. Genomics 10(1):75-82
Brandt CA, Kierkegaard O, Hindkjaer J, Jensen PK, Pedersen S, Therkelsen AJ (1993) Ring 
chromosome 20 with loss of telomeric sequences detected by multicolour PRINS. Clin Genet 
44(1):26-31
Breen CJ, Barton L, Carey A, Dunlop A, Glancy M, Hall K, Hegarty AM, Khokhar MT, Power M,
Ryan K, Green AJ, Stallings RL (1999) Applications of comparative genomic hybridisation in 
constitutional chromosome studies. J Med Genet 36(7):511-517
Breuning MH, Dauwerse HG, Fugazza G, Saris JJ, Spruit L, Wijnen H, Tommerup N, van der 
Hagen CB, Imaizumi K, Kuroki Y, van den Boogaard M-J, dePater JM, Mariman ECM, Hamel BCJ, 
Himmelbauer H, Frischauf A-M, Stallings RL, Beverstock GC, van Ommen GJB, Hennekam RCN 
(1993) Rubinstein-Taybi syndrome caused by submicroscopic deletions within 16p13.3. Am J Hum 
Genet 52:249-254
Bryce LA. Morrison N, Hoare SF, Muir S, Keith W N (2000) Mapping of the gene for the human 
telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ 
hybridisation. Neoplasia 2:197-201
221
Bryndorf T, Kirchhoff M, Rose H, Maahr J, Gerdes T, Karhu R, Kalllonlemi A, Christensen B, 
Lundsteen C, Philip J (1995) Comparative genomic hybridization in clinical cytogenetics. Am J Hum 
Genet 57:1211-1220
Buckle VJ, Kearney L (1993) Untwirling dirvish. Nature Genetics 5:4-5
Buckle VJ, Kearney L (1994) New methods in cytogenetics. Current Opinion in Genetics and
Development 4:374-382
Buckley PG, Mantripragada KK, Benetklewicz M, Tapia-Paez I, Diaz De Stahl T, Rosenquist M, All 
H, Jarbo C, De Bustos C, Hirvela C, Sinder Wilen B, Fransson I, Thyr C, Johnsson Bl, Bruder CE, 
Menzel U, Hergersberg M, Mandahl N, Blennow E, Wedell A, Beare DM, Collins JE, Dunham I, 
Albertson D, Pinkel D, Bastian BC, Faruqi AF, Lasken RS, Ichlmura K, Collins VP, Dumanski JP 
(2002) A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and 
research applications. Hum Mol Genet 11(25):3221-3229
Bunyan DJ, Robinson DO, Collins AL, Cockwell AE, Bullman HMS, Whittaker PA (1994) Germline 
and somatic mosaicism in a female carrier of Duchenne muscular dystrophy. Hum Genet 93:541- 
544
Bunyan DJ, Crolla JA, Collins AL, Robinson DO (1995) Fluorescence in situ hybridisation studies 
provide evidence for somatic mosaicism in de novo dystrophin gene deletions. Hum Genet 
95(1):43-45
Burke DT, Carle GT, Olsen MV (1987) Cloning of large segments of exogenous DNA into yeast by 
means of artificial chromosome vectors. Science 236:806-812
Burn J, Takao A, Wilson D, Cross I, Momma K, Wadey R, Scambler P, Goodship J (1993) 
Conotruncal anomaly face syndrome is associated with a deletion within chromosome 22q11. J 
Med Genet 30:822-824
Calien DF, Eyre HJ, Yip MY, Freemantle J, Haan EA (1992) Molecular cytogenetic and clinical 
studies of 42 patients with marker chromosomes. Am J Med Genet 43:709-715 
Cacheux V, Tachdjian G, Druart L, Oury JF, Serero S, Blot P, Nessmann C (1994) Evaluation of X, 
Y, 18, and 13/21 alpha satellite DNA probes for interphase cytogenetic analysis of uncultured 
amniocytes by fluorescence in situ hybridization. Prenat Diagn 14:79-86
Calvano S, Memeo E, Piemontese MR, Melchionda S, Biscegtia L, Gasparini P, Zelante L (1997) 
Detection of dystrophin deletion carriers using FISH analysis. Clin Genet 52(1 ):17-22 
Carey AH, Roach S, Williamson R, Dumanski JP. Nordenskjold M, Collins VP, Rouleau G, Blin N, 
Jalbert P, Scambler PJ (1990) Localization of 27 DNA markers to the region of human chromosome 
22q11-pter deleted in patients with the DiGeorge syndrome and duplicated in the der22 syndrome. 
Genomics 7:299-306
Carey AH, Kelly D, Halford S, Wadey R, Wilson D, Goodship J, Burn J, Paul T, Sharkey A. 
Dumanski J, Nordenskjold M, Williamson R, Scambler PJ (1992) Molecular genetic study of the 
frequency of monosomy 22q11 in DiGeorge Syndrome. Am J Hum Genet 51:964-970 
Carlson C, Sirotkin H, Pandita R, Goldberg R, McKie J, Wadey R, Pantanjali SR, Weissman SM, 
Anyane-Yeboa K, Warburton D, Scambler P, Shprintzen R, Kucherlapati R, Morrow BE (1997) 
Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. Am J Hum 
Genet 61:620-629
Carter NP, Ferguson-Smith MA, Perryman MT, Telenius H, Pelmear AH, Leversha MA, Glancy MT, 
Wood SL, Cook K, Dyson HM, Ferguson-Smith ME, Willatt LR (1992) Reverse chromosome 
painting: a method for the rapid analysis of aberrant chromosomes in clinical cytogenetics. J Med 
Genet 29:299-307
Carter N (2002) Can DNA microarrays replace conventional cytogenetics in chromosome 
diagnoses? J Med Genet 39 (Supp11 ):Abstracts of the British Human Genetics Conference, SP44 
Carter NP, Fiegler H, Piper J (2002) Comparative analysis of comparative genomic hybridization 
microarray technologies: report of a workshop sponsored by the Wellcome Trust. Cytometry 
49(2):43-48
Caspersson T, Zech L, Johansson C (1970) Differential binding of alkylating fluorochromes in 
human chromosomes. Exp Cell Res 60(3):315-319
Chen Z, Morgan R, Berger CS, Sandberg AA (1992) Application of fluorescence in situ hybridization 
in haematological disorders. Cancer Genet C^ogenet 63(1):62-69 
Cherif D, Bernard O, Berger R (1989) Detection of single-copy genes by nonisotopic in situ 
hybridization on human chromosomes. Hum Genet 81:358-362
Cherif D, Julier C, Delattre O, Derre J, Lathrop GM, Berger R (1990) Simultaneous localization of 
cosmids and chromosome R-banding by fluorescence microscopy: Application to regional mapping 
of human chromosome 11. Proc Natl Acad Sci USA 87:6639-6643
222
Choo KH, Visse! B, Nagy A, Earle E, Kalitsis P (1991) A  survey of the genomic distribution of alpha 
satellite DNA on all the human chromosomes, and derivation of a new consensus sequence. NucI 
Acids Res 19:1179-1182
Cinti C, Santi S, Maraldi NM (1993) Localization of single copy gene by PRINS technique. NucI 
Acids Res 21 (24):5799-5800
Cinti C, Stuppia L, Maraldi NM (2002) Combined use of PRINS and FISH In the study of the 
dystrophin gene. Am J Med Genet 107:115-118
Clark MS and Wall WJ (1996) Chromosomes. The complex code. Chapman and Hall, London. 
Clarkson B, Pavenski K, Dupuis L, Kennedy S, Meyn S, Nezarati MM, Nie G, Weksberg R, Withers 
S, Quercia N. Teebi AS, Teshlma I (2002) Am J Med Genet 107(4):267-274 
Clemens PR, Fenwick RG, Chamberlain JS, Gibbs RA, de Andrade M, Chakraborty R, Caskey CT 
(1991) Carrier detection and prenatal diagnosis in Duchenne and Becker muscular dystrophy 
families, using dinucleotide repeat polymorphisms. Am J Hum Genet 49(5):951-960 
Cohen D, Chumakov I, Weissenbach J (1993) A first generation physical map of the human 
genome. Nature 366(6456):698-701
Colleaux L, Rio M, Heuertz S, Moindrault S, Turleau C, Ozilou C, Gosset P, Raoult O, Lyon net S, 
Cormier-Daire V, Amiel J, Le Merrer M, Picq M, de Blols M-C, Prieur M, Romana S, Cornelis F, 
Vekemans M, Munnich A (2001) A novel automated strategy for screening cryptic telomeric 
rearrangements in children with idiopathic mental retardation. Eur J Hum Genet 9:319-327 
Collins J, Hohn B (1978) Cosmids: a type of plasmid gene-cloning vector that is packageable in 
vitro in bacteriophage lambda heads. Proc Natl Acad Sci USA 75(9):4242-4246 
Collins C, Kuo WL, Segraves R, Fuscoe J, Pinkel D, Gray JW (1991) Construction and 
characterization of plasmid libraries enriched in sequences from single human chromosomes. 
Genomics 11(4):997-1006
Collinson M, Maloney V, Browne CE (2004) Using the 1 Mb cloneset to change the interpretation of 
conventional cytogenetic abnormalities. J Med Genet 41 (Supp11):Abstracts of the British Human 
Genetics Conference, S I6, SP14
Conley ME, Beckwith JB, Mancer JFK, Tenckhoff L (1979) The spectrum of the DiGeorge 
syndrome. J Pediatr 94(6):883-890
Connor JM, Ferguson-Smith MA (1993) Essential medical genetics. 4*^  ed. Blackwell Science, 
Oxford
Counter CM, Avilion AA, Le Feuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S (1992) 
Telomere shortening associated with chromosome instability is arrested in immortal cells which 
express telomerase activity. EM BO J 11:1921-1929
Crem erT, Lichter P, Borden J, Ward DC, Manuelidis L (1988) Detection of chromosome 
aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome- 
specific library probes. Hum Genet 80:235-246
Crem erT, Popp S, Emmerich P, Lichter P, Cremer C (1990) Rapid metaphase and interphase 
detection of radiation induced chromosome aberrations in human lymphocytes by chromosomal 
suppression in situ hybridization. Cytometry 11:110-118
Dallapiccola B, Pizzuti A, Novelli G (1996) How many breaks do we need to CATCH on 22q11? Am 
J Hum Genet 59:7-11
D'Antoni S, Mattina T, Di Mare P, Federico C, Motta S, Saccone S (2004) Altered replication timing 
of the HIRA/Tuple1 locus in the DiGeorge and Velocardiofacial syndromes. Gene 333:111-119 
Darras BT, Franke U (1988) Normal human genomic restriction-fragment patterns and 
polymorphisms revealed by hybridization with the entire dystrophin cDNA. Am J Hum Genet 43:612- 
619
Dasouki M, Jurecic V, Phillips JAIII, Whitlock JA, Baldini A (1997) DiGeorge anomaly and 
chromosome lOp deletions: One or two loci? Am J Med Genet 73:72-75 
Dauwerse JG, Weigant J, Raap AK, Breuning MH, van Ommen GJB (1992) Multiple colours by 
fluorescence in situ hybridization using ratio-labelled DNA probes create a molecular karyotype. 
Hum Mol Genet 8:593-598
Davies KE (1981) The application of DNA recombinant technology to the analysis of the human 
genome and genetic disease. Hum Genet 58:351-357
Daw SCM, Taylor C, Kraman M, Call K, Mao J, Schuffenhauer S, Meitinger T, Lipson T, Goodship 
J, Scambler P (1996) A common region of lOp deleted in DiGeorge and velocardiofacial 
syndromes. Nature Genet 13:458-460
De la Chapelle A, Herva R, Koivisto M, Aula P (1981) A deletion in chromosome 22 can cause 
DiGeorge syndrome. Hum Genet 57:253-256
223
Delhanty JD, Griffin DK, Handyside AH, Harper J, Atkinson GH, Pieters MH, Winston RM (1993) 
Detection of aneuploidy and chromosomal mosaicism in human embryos during preimplantation 
sex determination by fluorescent in situ hybridisation, (FISH) Hum Mol Genet 2(8): 1183-1185 
Den Dunnen JT, Grootscholten PM, Bakker E, Blonden LAJ, Ginjaar HB, Wapenaar MC, van 
Passen HMB, van Broeckhoven C, Pearson PL, van Ommen GJB (1989) Topography of the 
Duchenne Muscular Dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 
deletions and 13 duplications. Am J Hum Genet 45(6):835-847
de Vries BBA, White SM, Knight SJL, Regan R, Homfray T, Young ID, Super, M, McKeown C, Splitt 
M, Quarrel! OWJ, Trainer AH, Niermeijer MF, Malcolm S, Flint J, Hurst JA, Winter RM (2001)
Clinical studies on submicroscopic subtelomeric rearrangements:a checklist. J Med Genet 38:145- 
150
de Vries BBA, Winter R, Schinzel A, van Ravensv/aaij-Arts (2003) Telomeres: a diagnosis at the 
end of the chromosomes. J Med Genet 40:385-398
DiGeorge AM (1965): Discussions on a new concept of the cellular basis of Immunology. J Pediatr 
67:907
Divane A, Carter NP, Spathas DH, Ferguson-Smith MA (1994) Rapid prenatal diagnosis of 
aneuploidy from uncultured amniotic fluid cells using five-colour fluorescence in situ hybridization. 
Prenat Diagn 14:1061-1069
Drets ME, Shaw MW  (1971) Specific banding patterns of human chromosomes. Proc Natl Acad Sci 
U S A  68(9):2073-2077
Driscoll DA, Spinner NB, Budarf ML, McDonald-McGInn DM, Zackai EH, Goldberg RB, Shprintzen 
RJ, Saal HM, Zonana J, Jones MC, Mascarelto JT, Emanuel BS (1992) Deletions and 
microdeletions of 22q11.2 in velo-cardio-facial syndrome. Am J Med Genet 44:261-268 
Driscoll DA, Salvin J, Sellinger B, Budarf ML, McDonald-McGinn DM, Zackai EH, Emanuel BS 
(1993) Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: 
implications for genetic counselling and prenatal diagnosis. J Med Genet 30:813-817 
du Manoir S. Spelcher MR, Joos 8, Schrock E, Popp S, Dohner H, Kovacs G, Robert-Nlcoud M, 
Lichter P, Cremer T (1993) Detection of complete and partial chromosome gains and losses by 
comparative genomic in situ hybridization. Hum Genet 90:590-610
du Manoir S, Kallioniemi OP, Lichter P, Piper J, Benedetti PA, Carothers AD, Fantes JA, Garcia- 
Sagredo JM, Gerdes T, Giollant M, Hemery B, Isola J, Maahr J, Morrison H, Perry P, Stark M,
Sudar D, Vliet LJ van, Verwoerd N, Vrolijk J (1995) Hardware and software requirements for
quantitative analysis of comparative genomic hybridization. Cytometry 19:4-9
Dunham 1, Lengauer C, Crem erT, Featherstone T  (1992) Rapid generation of chromosome
specific alphoid DNA probes using the polymerase chain reaction. Hum Genet 88:457-462
Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp
M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN,
Beasley O. Bird CP. Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O’Brien KP (1999)
The DNA sequence of human chromosome 22. Nature 402(6761 ):489-495
Dutly F, Schinzel A (1996) Unequal interchromosomal rearrangements may result in elastin gene
deletions causing Williams-Beuren syndrome. Hum Mol Genet 5(12): 1893-1898
Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N, Chaganti RSK, Magenis 
E, Shprintzen RJ, Morrow BE (1999) A common molecular basis for rearrangement disorders on 
chromosome 22q11. Hum Mol Genet 8:1157-1167
Edery P, Attie T, Amiel J, Pelet A, Eng C, Hofstra RM, Martelli H, Bidaud C, Munnich A, Lyonnet S
(1996) Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah- 
Waardenburg syndrome). Nat Genet:442-444
Edmondson DG, Smith MM, Roth SY (1996) Repression domain of the yeast global repressor Tup1 
interacts directly with histones H3 and H4. Genes Dev 10(10): 1247-1259
Emery AEH (1993) Duchenne muscular dystrophy. Second edition. Oxford Monographs on Medical 
Genetics, no.24. Oxford University Press, Oxford
Ensenauer RE, Adeyinka A, Flynn HC, Michels W ,  Lindor NM, Dawson DB, Thoriand EC, Lorentz 
CP, Goldstein JL, McDonald MT, Smith WE. Simon-Fayard E, Alexander AA, Kulharya AS,
Ketterling RP, Clark RD, Jalal SM (2003). Microduplication 22q11.2, an emerging syndrome: 
clinical, cytogenetic, and molecular analysis of thirteen patients. Am J Hum Genet 73:1027-1040 
Evans HJ, Buckland RA, Pardue ML (1974) Location of the genes coding for 18S and 28S 
ribosomal RNA in the human genome. Chromosoma 48:405-426
Ewart AK, Morris CA, Atkinson D, Jin WS, Sternes K, Spallone P, Stock AD, Leppert M, Keating MT 
(1993) Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nature 
Genet 5:11-16
224
Fan YS, Davis LM, Shows TB (1990) Mapping small DNA sequences by fluorescence in situ 
hybridization directly on banded metaphase chromosomes. Proc Natl Acad Sci USA 87:6223-6227 
Fantes J, Boland E, Ramsay J, Donnai D, van Heyningen V, Clayton -Smith J, Fitzpatrick D, Black 
G (2004) Breakpoint mapping in apparently balanced de novo chromosome rearrangements: no 
evidence for significant loss of chromosome material at the breakpoints. J Med Genet 41 (SuppI 
1): Abstracts of the British Human Genetics Conference, S21, SP32
Feinberg AP, Vogelstein B (1983) A technique for radiolabeling DNA restriction endonuclease 
fragments to high specific activity. Anal Biochem 132(1):6-13
Ferguson Smith MA, Aitken DA (1982) The contribution of chromosome aberrations to the precision 
of human gene mapping. Cytogenet Cell Genet 32:24-42
Fiegler H, Gribble SM, Burford DC, Carr P, Prigmore E, Porter KM, Clegg S, Crolla JA, Dennis NR, 
Jacobs P, Carter NP (2003) Array painting; a method for the rapid analysis of aberrant 
chromosomes using DNA microarrrays. J Med Genet 40(9):664-670
Flint J, Wilkie AOM, Buckle VJ, Winter RM, Holland AJ, McDermid HE (1995) The detection of 
subtelomeric chromosomal rearrangements in idiopathic mental retardation. Nature Genet 9:132- 
140
Flint J and Wilkie AO (1996) The genetics of mental retardation. Br Med Bull 52:453-464 
Florijn RJ, Bonden LA, Vrolijk H. Weigant J, Vaandrager JW, Baas F, den Dunnen JT, Tanke HJ, 
van Ommen GJ, Raap AK (1995) High-resolution DNA Fiber-FISH for genomic DNA mapping and 
colour bar-coding of large genes. Hum Mol Genet 4(5):831-836
Ford CE, Jones KW, Polani PE, De Almeida JC, Briggs JH (1959) A sex-chromosome anomaly in a 
case of gonadal dysgenesis (Turner's syndrome). Lancet 1(7075):711-3 
Forozan F, Karhu R, Kononen J, Kallioniemi A, Kallioniemi O-P (1997) Genome screening by 
comparative genomic hybridization. TIG 13(10):405-409
Friedrich U, Caprani M, Niebuhr E, Therkelsen AJ, Jorgensen AL (1996) Extreme variant of the 
short arm of chromosome 15. Hum Genet 97(6):710-713
Francke U, Ochs HD. de Martinville B, Giacalone J, Lindgren V, Disteche C, Pagon RA, Hofker MH,
van Ommen G-JB, Pearson PL, Wedgwood RJ (1985) Minor Xp21 chromosome deletion in a male
associated with expression of Duchenne muscular dystrophy, chronic granulomatous disease,
retinitis pigmentosa and McLeod syndrome. Am J Hum Genet 37:250-267
Francke U (1995) Clinical and Molecular Cytogenetics and Gene Mapping: Principles and
Techniques. Southeast Asian J Trop Med Public Health 26 Supp11:34-43
Fukushima Y, Ohashi H, Wakui K, Nishida T, Nakamura Y, Hoshino K, Ogawa K, Oh-ishi T (1992)
DiGeorge syndrome with del(4)(q21.3q25): Possibility of the fourth chromosomal region responsible
for DiGeorge syndrome. Am J Hum Genet 51:(A80) 306
Fuscoe JC, Collins CC, Pinkel D, Gray JW (1989) An efficient method for selecting unique- 
sequence clones from DNA libraries and its application to fluorescent staining of human 
chromosome 21 using in situ hybridization. Genomics 5(1): 100-109
Gail JG, Pardue ML (1969) Formation and detection of RNA-DNA hybrid molecules in cytological 
preparations. Proc Natl Acad Sci USA 63:378-381
Gandelman KY, Gibson L, Meyn MS, Yang-Feng TL (1992) Molecular definition of the smallest 
region of deletion overlap in the Wolf-Hirschhorn syndrome. Am J Hum Genet 51:571-578 
Garcia-Minaur S, Fantes J, Murray RS, Porteous MEM, Strain L, Burns JE, Stephen J, Warner JP 
(2002) A novel atypical 22q11.2 distal deletion in father and son. J Med Genet 39(10) e62 
Gardner RJM, Sutherland GR (1996) Chromosome abnormalities and genetic counselling, 2"  ^
Edition. Oxford University Press
Garson JA, van den Berghe J, Kemshead JT (1987) Novel non-isotopic in situ hybridization 
technique detects small (1Kb) unique sequences in routinely G-banded human chromosomes: fine 
mapping of N-myc and p-NGF genes. NucI Acids Res 15:4761-4770
Gerhard DS, Kawasaki ES, Bancroft FE, Szabo P (1981) Localisation of a unique gene by direct 
hybridisation in situ. Proc Natl Acad Sci USA 78:3755-3759
Gersh M, Goodart SA, Pasztor LM, Harris DJ, Weiss L, Overhauser J (1995) Evidence for a distinct 
region causing a cat-like cry in patients with 5p deletions. Am J Hum Genet 56:1404-1410 
Ghaffari SR, Boyd E, Tolmie JL, Crow YJ, Trainer AH, Connor JM (1998) A new strategy for cryptic 
telomeric translocation screening in patients with idiopathic mental retardation. J Med Genet 
35:225-233
Giglio S, Broman KW, Matsumoto N, Caivari V, Gimelli G, Neumann T, Ohashi H, Voullaire L, 
Larizza D, Glorda R, Weber JL, Ledbetter DH, Zuffardi O (2001) Olfactory receptor-gene clusters,
225
genomic-inversion polymorphisms, and common chromosome rearrangements. Am J Hum Genet 
68(4):874-883
Giglio S, Caivari V, Gregato G, Gimelli G, Camanini S, Giorda R, Rag usa A, Guerneri S, Selicorni 
A, Stumm M, Tonnies H, Ventura M, Zollino M, Neri G, Barber J, Wieczorek D, Rocchi M, Zuffardi 
O (2002) Heterozygous submicroscopic inversions involving olfactory receptor-gene clusters 
mediate the recurrent t(4;8)(p16;p23) translocation. Am J Hum Genet 71:276-285 
Goldman ASH, Hulten MA (1992) Chromosome in situ suppression hybridisation in human male 
meiosis. J Med Genet 29:98-102
Goidmuntz E, Driscoll D, Budarf ML, Zackai EH, McDonald-McGinn DM, Biegel JA, Emanuel BS 
(1993) Microdeletions of chromosomal region 22q11 in patients with congenital conotruncal cardiac 
defects. J Med Genet 30:807-812
Gong W, Emanuel BS, Collins J, Kim DH, Wang Z, Chen F, Zhang G, Roe B, Budarf ML (1996) A 
transcription map of the DiGeorge and velo-cardio-facial syndrome minimal critical region on 22q11. 
Hum Mol Genet 5(6):789-800
Goodship J, Curtis A, Cross I, Brown J, Emslie J, Wolstenholme J, Bhattacharya S, Burn J (1992) A 
submicroscopic translocation, t(4;10), responsible for recurrent Wolf-Hirschhorn syndrome 
identified by allele loss and fluorescent in situ hybridisation. J Med Genet. 29(7):451-454 
Goodship J, Lynch S, Brown J, Cross I, Milligan D (1994) Comparison of facial features of 
DiGeorge syndrome (dgs) due to deletion 10p13-1 Opter with dgs due to 22q11 deletion. Am J Hum 
Genet 55 (SuppI):A105
Goodship J, Cross I, Scambler P, Burn J (1995) Monozygotic twins with chromosome 22q11 
deletion and discordant phenotype. J Med Genet 32:746-748
Gosden J, Hanratty D, Starling J, Fantes J, Mitchell A, Porteous D (1991) Oligonucleotide primed in 
situ DNA synthesis (PRINS): a method for chromosome mapping, banding and investigation of 
sequence organization. Cytogenet Cell Genet 57:100-104
Gosden J, Hanratty D (1993) PCR in situ, a rapid alternative to in situ hybridization for mapping 
short, low copy number sequences without isotopes. BioTechniques 15(1):78-80 
Gosden J, Lawson D (1994) Rapid chromosome identification by oligonucleotide-primed in situ 
DNA synthesis (PRINS). Hum Mol Genet 3(6):931-936
Gosden J, Lawson D (1995) Instant PRINS: a rapid method for chromosome identification by 
detecting repeated sequences in situ. Cytogenet Cell Genet 68:57-60
Gosden J, Scopes G (1996) Uncultured blood samples can be labeled by PRINS and ready for 
chromosome enumeration analysis 1 H after collection. Biotechniques 21(1);88-91 
Gottlieb S, Emanuel BS, Driscoll DA, Sellinger B, Wang Z, Roe B, Budarf ML (1997) The DiGeorge 
syndrome minimal critical region contains a Gooseco/d-like (GSCL) homeobox gene that is 
expressed early in human development. Am J Hum Genet 60:1194-1201
Gottlieb S, Driscoll DA, Punnett HH, Sellinger B, Emanuel BS, Budarf ML (1998) Characterization of 
lOp deletions suggests two non-overlapping regions contribute to the DiGeorge syndrome 
phenotype. Am J Hum Genet 62:495-498
Greenberg F, Elder FFB, Haffner P, Northrup H, Ledbetter DH (1988) Cytogenetic findings in a 
prospective series of patients with DiGeorge anomaly. Am J Hum Genet 43:605-611 
Gregory SG, Sekhon M, Schein J, Zhao S, Osoegawa K, Scott CE, Evans RS, Burridge PW, Cox 
TV, Fox CA, Hutton RD, Mullenger IR, Phillips KJ, Smith J, Stalker J, Threadgold GJ, Birney E, 
Wylie K. Chinwalla A, Wallis J, Hillier L, Carter J, Gaige T, Jaeger S, Kremitzki C, Layman D, Maas 
J, McGrane R, Mead K, Walker R, Jones S, Smith M, Asano J, Bosdet 1, Chan S, Chittaranjan S, 
Chiu R, Fjell C, Fuhrmann D, Girn N, Gray C, Guin R, Hsiao L, Krzywinski M, Kutsche R, Lee SS, 
Mathewson C, McLeavy C, Messervier S, Ness S, Pandoh P, Prabhu AL, Saeedi P, Smailus D, 
Spence L, Stott J, Taylor S, Terpstra W, Tsai M, Vardy J, Wye N, Yang G, Shatsman S, Ayodeji B, 
Geer K, Tsegaye G, Shvartsbeyn A. Gebregeorgis E, Krol M, Russell D, Overton L, Malek JA, 
Holmes M, Heaney M, Shetty J, Feldblyum T, Nierman WC, Catanese JJ, Hubbard T, Waterston 
RH, Rogers J, de Jong PJ, Fraser CM, Marra M, McPherson JD, Bentley DR (2002) A physical map 
of the mouse genome. Nature 418(6899):743-750.
Griffin DK, Handyside AH, Harper JC, Wilton LJ, Atkinson G, Soussis I, Wells D, Kontogianni E, 
Tarin J, Geber S, Ao A, Winston RML, Delhanty JDA (1994) Clinical experience with 
preimplantation diagnosis of sex by dual fluorescent in situ hybridization. J Assist Reprod Genet 
11(3):132-143
Guan XY. Zhang H, Bittner M, Jiang Y, Meltzer P, Trent J (1996) Chromosome arm painting 
probes. Nature Genet 12:10-11
Gusella JF, Wexler NS, Conneaily PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, 
Wallace M, SakaguchI A, Young A, Shoulson I, Bonilla E, Martin JB (1983) A polymorphic DNA 
marker genetically linked to Huntington’s disease. Nature 306(5940):234-238
226
Guyot B, Bazin A, Sole Y, Julien C, Daffos F, Forestier F (1988) Prenatal diagnosis with biotinylated 
chromosome specific probes. Prenat Diagn 8:485-493
Haaf T and Ward DC (1994) Structural analysis of alpha-satellite DNA and centromere proteins 
using extended chromatin and chromosomes. Hum Mol Genet 3(5):697-709 
Hagg MM, Lunt B, Berry R, Collins J, Manchester D, Bloch C, McGavran L (1992) Detection of a 
cryptic translocation 4p and l i p  common to two unrelated families using fluorescent in situ 
hybridization (FISH) techniques. Am J Hum Genet 51 (A80)
Halford S, Wadey R, Roberts C, Daw SCM, Whiting JA, O’Donnell H, Dunham I, Bentley D, Lindsay 
E, Baldini A, Francis F, Lehrach H, Williamson R, Wilson DI, Goodship J, Cross I, Burn J, Scambler 
PJ (1993a) Isolation of a putative transcriptional regulator from the region of 22q11 deleted in 
DiGeorge syndrome, Shprintzen syndrome and familial congenital heart disease. Hum Mol Genet 
2:2099-2107
Halford S, Lindsay E, Nayudu M, Carey AH, Baldini A, Scambler PJ (1993b) Low-copy-number 
repeat sequences flank the DiGeorge/velo-cardio-facial syndrome loci at 22q11. Hum Mol Genet 
2:191-196
Harewood L, Fantes JA, Fitzpatrick DR (2004) Interphase FISH mapping of chromosomal 
rearrangements on paraffin-embedded archival patient material. J Med Genet 41 (SuppI 
1):Abstracts of the British Human Genetics Conference, S21, SP34
Harper ME, Saunders GF (1981) Localisation of single-copy DNA sequences on G-banded human 
chromosomes by in situ hybridization. Chromosoma 83:431-439
Hassed SJ, Hopcus-Niccum D, Zhang L, Li S, Mulvihill JJ (2004) A new genomic duplication 
syndrome complementary to the velocardiofacial (22q11 deletion) syndrome. Clin Genet 65(5):400- 
404
Hatchwell E (1996) Monozygotic twins with chromosome 22q11 deletion and discordant phenotype. 
J Med Genet 33:261-264
Heiles HBJ, Genersch E, Kessler C, Neumann R, Eggers HJ (1988) In situ hybridization with 
digoxygenin-labeled DNA of human papillomaviruses (HPV 16/18) in HeLa and SiHa cells. 
Biotechniques 6:978-981
Heilstedt HA, Ballif BC, Howard LA, Lewis RA, Stal S, Kashork CD, Bacino CA, Shapira SK, Shaffer 
LG (2003) Physical Map of 1 p36, placement of breakpoints in monosomy 1p36, and clinical 
characterization of the syndrome. Am J Hum Genet 72:1200-1212
Heiskanen M, Karhu R, Hellsten E, Peltonen L, Kallioniemi OP, Paiotie A (1994) High resolution 
mapping using fluorescence in situ hybridization to extended DNA fibers prepared from agarose- 
embedded cells. Biotechniques 17(5):928-929, 932-933
Heiskanen M, Hellsten E, Kallioniemi OP, M akelaTP, Alitalo K, Peltonen L, Paiotie A (1995a)
Visual mapping by fiber-FISH. Genomics 30(1):31-36
Heiskanen M, Saltta B, Paiotie A, Chu ML (1995b) Head to tail organization of the human COL6A1 
and COL6A2 genes by fiber-FISH. Genomics 29(3):801-803
Heiskanen M, Peltonen L, Paiotie A (1996) Visual mapping by high resolution FISH. TIG  
12(10):379-382
Heng HH, Squire J, Tsui LC (1992) High-resolution mapping of mammalian genes by in situ 
hybridization to free chromatin. Proc Natl Acad Sci USA 89(20):9509-9513 
Hertz JM, Tommerup N, Sorensen FB, Henriques UV. Nielsen A, Therkelsen AJ (1995) Partial 
deletion 11q:report of a case with a large terminal deletion 11q21-qter without loss of telomeric 
sequences, and review of the literature. Clin Genet 1995 47(5):231-235
Hindkjaer J, Brandt CA, Koch J, Lund TB, Kolvraa S, Bolund L (1995a) Simultaneous detection of
centromere-specific probes and chromosome painting libraries by a combination of primed in situ
labelling and chromosome painting (PRINS-painting). Chromosome Res 3(1):41-44
Hindkjaer J, Hammoudah SA, Hansen KB, Jensen PD, Koch J, Pedersen B (1995b) Translocation
(1;16) identified by chromosome painting, and Primed In Situ-labeling (PRINS). Report of two cases
and review of the cytogenetic literature. Cancer Genet Cytogenet 79(1): 15-20
Hirschhorn K, Cooper HL, Firschein IL (1965) Deletion of short arms of chromosomes 4-5 in a child
with defects of midline fusion. Humangenetik 1:479-482
Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne 
muscular dystrophy locus. Cell 51 (6):919-928
Holder SE, Winter RM, Kamath S, Scambler PJ (1993) Velocardiofacial syndrome in a mother and 
daughter:variability of the clinical phenotype. J Med Genet 30:825-827 
Hollox EJ, Atia T, Cross G, Parkin T, Armour JAL (2002) High throughput screening of human 
subtelomeric DNA for copy number changes using multiplex amplifiable probe hybridisation 
(MAPH). J Med Genet 39:790-795
227
Holmes SE, Ali Riazi M, Gong W, McDermid HE, Sellinger BT, Hua A, Chen F, Wang Z, Zhang G, 
Roe B, Gonzalez I, McDonald-McGinn DM, Zackai E, Emanuel BS, Budarf ML (1997) Disruption of 
the clathrin heavy chain-like gene (CLTCL) associated with features of DGSA/CFS: a balanced 
(21;22)(p12;q11) translocation. Hum Mol Genet 6(3):357-367
Hopman AHN, Weigant J, Tesser Gl, Van Duijn P (1986a) A nonradioactive in situ hybridization 
method based on mercurated nucleic acid probes and sulphydryl-hapten ligands. NucI Acids Res 
14:6471-6488
Hopman AHN, Weigant J, Raap AK, Landegent JE, van der Ploeg M, van Duijn P (1986b) Bi-colour 
detection of two target DNAs by non-radioactive in situ hybridization. Histochemistry 85:1-4
Innis MA, Gelfand DH, Sninsky JJ and White TJ eds (1990) PCR protocols. A guide to methods and 
applications. Academic Press Inc., San Diego, CA
loannou PA, de Jong PJ (1996) Construction of bacterial artificial chromosome libraries using the 
modified P1 (PAC) system. In: Current Protocols in Human Genetics, Draco poli et al (eds) Wiley, 
New York
ISCN (1995) An International System for Human Cytogenetic Nomenclature (1995) 
Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. 
Ed. Felix Mitelman. Karger
Jalbert P, Sele B, Jalbert H (1980) Reciprocal translocations: Away to predict the mode of 
imbalanced segregation by pachytene-diagram drawing. A study of 151 human translocations. Hum 
Genet 55:209-222
Jhanwar SC, Neel BG, Hayward WS, Chaganti RS (1983) Localization of c-ras oncogene family on
human germ-line chromosomes. Proc Natl Acad Sci USA 80(15):4794-4797
John HA, Birnstiel ML, Jones KW (1969) RNA-DNA hybrids at the cytological level. Nature
223(206):582-587
Johnson DS, Morrison N, Ray K, Tolmie JL, Ryan E (2004a) Mild clinical phenotype associated with 
direct duplication of proximal 8p (46,XX,dup(8)(p11.1p21.1~p21.2)). J Med Genet 41 (Supp11); 
Abstracts of the British Human Genetics Conference, S61, 2.40
Johnson DS, Morrison N, Murday VA, Connor JM, Turner T (2004b) CDH7 is located at the 
breakpoint of a de novo balanced reciprocal translocation in twins with CHARGE association. 
Manuscript in preparation.
Johnson VP, Altherr MR, Blake JM, Keppen LD (1994) FISH detection of Wolf-Hirschhorn 
syndrome: exclusion of D4F26 as critical site. Am J Med Genet 52(1):70-74 
Jones KW, Prosser J, Corneo G, Ginelii E (1973) The chromosomal location of human satellite 
DNA III. Chromosoma 42:445-451
Joos S, Scherthan H, Spelcher MR, Schlegel J, Cremer T, Lichter P (1993) Detection of amplified 
DNA sequences by reverse chromosome painting using genomic tumor DNA as probe. Hum Genet 
90(6):584-589
Joyce CA, Dennis NR, Cooper S, Browne CE (2001) Subtelomeric rearrangements: results from a
study of selected and unselected probands with idiopathic mental retardation and control individuals
by using high-resolution G-banding and FISH. Hum Genet 109(4):440-451
Juyal RC, Greenberg F, Mengden GA, Lupski JR, Trask BJ, van den Engh G, Lindsay EA, Christy
H, Chen K-S, Baldini A, Shaffer LG, Patel PI (1995) Smith-Magenis syndrome deletion; A case with
equivocal cytogenetic findings resolved by fluorescence in situ hybridization. Am J Med Genet
58:286-291
Kadandale JS, Wachtel SS, Tunca Y, Wilroy RS Jr, Martens PR, Tharapel AT (2000) Localization 
of SRY by primed in situ labeling in XX and XY sex reversal. Am J Med Genet 95:71-74 
Kadandale JS, Wachtel SS, Tunca Y, Martens PR, Wilroy RS Jr, Tharapel AT (2002) Deletion of 
RBM and DAZ in azoospermia.evaluation by PRINS. Am J Med Genet 107:105-108 
Kaestner KH, Christy RJ, McLenithan JC, Braiterman LT, Cornelius P, Pekala PH, Lane MD (1989) 
Sequence, tissue distribution, and differential expression of mRNA for a putative insulin-responsive 
glucose transporter in mouse 3T3-L1 adipocytes. Proc Natl Acad Sci USA 86:3150-3154 
Kalkhoven E, Roelfsema JH, Teunissen H, den Boer A, Ariyurek Y, Zantema A, Breuning MH, 
Hennekam RCM, Peters DJM (2003) Loss of CBP acetyltransferase activity by PHD finger 
mutations in Rubinstein-Taybi syndrome. Hum Mol Genet 12(4):441-450
Kallioniemi A, Kallioniemi OP, Waldman FM, Chen LC, Yu LC, Fung YK, Smith HS, Pinkel D, Gray 
JW  (1992a) Detection of retinoblastoma gene copy number in metaphase chromosomes and 
interphase nuclei by fluorescence in situ hybridization. Cytogenet Cell Genet 60:190-193
228
Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1992b) 
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 
258:818-821
Kallioniemi O-P, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D (1994) Optimizing 
Comparative Genomic Hybridization for analysis of DNA sequence copy number changes in solid 
tumors. Genes Chromosomes and Cancer 10:231-243
Kallioniemi A, VisakorpI T, Karhu R, Pinkel D, Kallioniemi O-P (1996) Gene copy number analysis 
by fluorescence in situ hybridization and comparative genomic hybridization. Methods: A companion 
to methods in enzymology 9:113-121
Karhu R, Marketta K, Kuukasjarvi T, Pennanen S, Tirkkonen M, Kallioniemi O (1997) Quality control 
of CGH:Impact of metaphase chromosomes and the dynamic range of hybridization. Cytometry 
28:198-205
Karhu R, Rummukainen J, Lorch T, Isola J (1999) Four-Color CGH:A new method for quality 
control of comparative genomic hybridization. Genes Chromosomes and Cancer 24:112-118 
Kelly D, Goldberg R, Wilson D, Lindsay E, Carey A, Goodship J, Burn J, Cross I, Shprintzen RJ, 
Scambler PJ (1993) Confirmation that the velo-cardio-facial syndrome Is associated with haplo- 
insufficiency of genes at chromosome 22q11. Am J Med Genet 45:308-312 
Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussier D (2002) The 
Human Genome Browser at UCSC. Genome Res 12(6):996-1006
Kievits T, Devilee P, Wiegant J, Wapenaar MC, Cornelisse CJ, van Ommen GJ, Pearson PL (1990) 
Direct nonradioactive in situ hybridization of somatic cell hybrid DNA to human lymphocyte 
chromosomes. Cytometry 11 (1 ): 105-109
Kinouchi A, Mori K, Ando M, Takao A (1976) Facial appearance of patients with conotruncal 
anomalies. Pediatr Jpn 17:84
Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM, Lundsteen C (1998) Detection of 
chromosomal gains and losses in comparative genomic hybridization analysis based on standard 
reference intervals. Cytometry 31:163-173
Kirchhoff M, Rose H, Maahr J, Gerdes T, Bugge M, Tommerup N, Tumer Z, Lespinasse J, Jensen 
PKA, Wirth J, Lundsteen C (2000) High resolution comparative genomic hybridisation analysis 
reveals imbalances in dyschromosomal patients with normal or apparently balanced conventional 
karyotypes. Eur J Hum Genet 8:661-668
Kirchhoff M, Rose H, Lundsteen C (2001) High resolution comparative genomic hybridisation in 
clinical cytogenetics. J Med Genet 38:740-744
Kirchhoff M, Pedersen S, Kjeldsen E, Rose H, Duno M, Kolvraa S, Lundsteen C (2004) Prospective 
study comparing HR-CGH and subtelomeric FISH for investigation of individuals with mental 
retardation and dysmorphic features and an update of a study using only HR-CGH. Am J Med 
Genet 127A: 111-117
Klever M, Grond-Ginsbach C, Scherthan H, Schroeder-Kurth TM (1991) Chromosomal in situ
suppression hybridization after Giemsa banding. Hum Genetics 86:484-486
Klinger K, Landes G, Shook D, Harvey R, Lopez L, Locke P, Lerner T, Osathanondh R, Leverone B,
Houseal T, Pavelka K, Dackowski W  (1992) Rapid detection of chromosome aneuploidies in
uncultured amniocytes by using fluorescence in situ hybridization (FISH). Am J Hum Genet 51:55-
65
Knight SJL, Horsley SW, Regan R, Lawrie NM, Maher EJ, Cardy DLN, Flint J, Kearney L (1997) 
Development and clinical application of an innovative fluorescence in situ hybridization technique 
which detects submicroscopic rearrangements involving telomeres. Eur J Hum Genet 5:1-8 
Knight SJL, Regan R, Nlcod A, Horsley SW, Kearney L, Homfray T, Winter RM, Bolton P, Flint J 
(1999) Subtle chromosomal rearrangements In children with unexplained mental retardation. Lancet 
354:1676-1681
Knight SJL, Flint J (2000a) Perfect endings: a review of subtelomeric probes and their use in clinical 
diagnosis. J Med Genet 37:401-409
Knight SJL, Lese CM, Precht KS, Kuc J, Ning Y, Lucas S, Regan R, Brenan M, Nicod A, Lawrie 
NM, Cardy DLN, Nguyen H, Hudson TJ, Riethman HC, Ledbetter DH, Flint J (2000) An optimised 
set of human telomere clones for studying telomere integrity and architecture. Am J Hum Genet 
67:320-332
Knoll JHM, Sinnett D, Wagstaff J, Glatt K, Schantz Wilcox A, Whiting PM, Wingrove P, Sikela JM, 
Lalande M (1993) FISH ordering of reference markers and of the gene for the a5 subunit of the y- 
aminobutyric acid receptor (GABRA5) within the Angelman and Prader-Willi syndrome 
chromosomal regions. Hum Mol Genet 2(2): 183-189
Koch JE, Kolvraa S, Petersen KB, Gregersen N, Bolund L (1989) Oligonucleotide-priming methods 
for the chromosome-specific labelling of alpha satellite DNA in situ. Chromosoma 98:259-265
229
Koch J, Hindkjaer J, Morgesen J, Kolvraa S, Bolund L (1991) An improved method for 
chromosome-specific labeling of a  satellite DNA in situ using denatured double-stranded DNA 
probes as primers in a primed in situ labeling (PRINS) procedure. Genet Anal Tech AppI 8(6): 171- 
178
Koch J, Morgesen J, Pedersen S, Fischer H, Hindkjaer J, Kolvraa S, Bolund L (1992) Fast one-step 
procedure for the detection of nucleic acids in situ by primer-induced sequence-specific labeling 
with fluorescein-12-dUTP. Cytogenet Cell Genet 60(1): 1-3
Koch J, Fischer H. Askholm H, Hindkjaer J, Pedersen S, Kolvraa S, Bolund L (1993) Identification 
of a supernumerary der(18) chromosome by a rational strategy for the cytogenetic typing of small 
marker chromosomes with chromosome-specific DNA probes. Clin Genet 43(4):200-203 
Koch J (1996) Primed in situ labeling as a fast and sensitive method for the detection of specific 
DNA sequences in chromosomes and nuclei. METHODS: A Companion to Methods in Enzymology 
9:122-128
Komminoth P, Long AA, Ray R, Wolfe HJ (1992) in situ polymerase chain reaction detection of viral 
DNA, single copy genes, and gene rearrangements in cell suspensions and cytospins. DIagn Mol 
Pathol 1(2): 85-97
Komminoth P (1994) In situ gene amplification theory and practice. Hybald Guide to In Situ Ch3 pp 
49-72
Korenberg JR and Rykowski MC (1988) Human genome organization: Alu, Lines and the molecular 
structure of metaphase chromosome bands. Cell 53:391-400
Korenberg JR, Chen XN, Adams MD, Venter JC (1995) Towards a cDNA map of the human 
genome. Genomics 29(2):364-370
Kraus J, Lederer G, Keri C, Seidel H, Rost I, Wirst A, Fauth C, Spelcher MR (2003) A familial 
unbalanced subtelomeric translocation resulting in monosomy 6q27->qter. J Med Genet 40(4);e48 
Kriek M, White SJ, Bouma MC, Dauwerse HG, Hansson KBM, Nijhuis JV, Bakker B, van Ommen 
G-JB, den Dunnen JT, Breuning MH (2004) Genomic imbalances in mental retardation. J Med 
Genet 41 (4):249-255
Kunkel LM, Monaco AP, Middlesworth W , Ochs HD, Latt SA (1985) Specific cloning of DNA 
fragments absent from the DNA of a male patient with an X chromosome deletion. Proc Natl Acad 
Sci USA 82{14):4778-4782
Kurahashi H, Nakayama T. Osugi Y, Tsuda E, Masuno M, Imaizumi K, Kamiya T, Sano T, Okada 
S, Nishisho I (1996) Deletion mapping of 22q11 in CATCH 22 syndrome: identification of a second 
critical region. Am J Hum Genet 58:1377-1381
Kurahashi H, Tsuda E, Kohama R, Nakayama T, Masuno M, Imaizumi K, Kamiya T, Sano T, Okada 
S, Nishisho I (1997) Another critical region for deletion of 22q11: a study of 100 patients. Am J Med 
Genet 72:180-185
Kuwano A, Ledbetter SA, Dobyns WB, Emanuel BS, Ledbetter DH (1991) Detection of deletions 
and cryptic translocations in Miller-Dieker syndrome by in situ hybridization. Am J Hum Genet 
49(4):707-714
Kuwano A, Mutlrangura A, Dittrich B, Suiting K, Horsthemke B, Saitoh S, Niikawa N, Ledbetter SA, 
Greenberg F, Chinault AC, Ledbetter DH (1992) Molecular dissection of the Prader-Willi/Angelman 
syndrome region (15q11-13) by YAC cloning and FISH analysis. Hum Mol Genet 6:417-425
Lamb J, Wilkie AO, Harris PC, Lindenbaum RH, Barton NJ, Reeders ST, Weatherall DJ, Higgs DR 
(1989) Detection of breakpoints in submicroscopic chromosomal translocation, illustrating an 
important mechanism for genetic disease. Lancet 2(8677):819-824
Lammer EJ, Opitz JM (1986) The DiGeorge anomaly as a developmental field defect. Am J Med 
Genet SuppI 2:113-127
Lamour V, Lecluse Y, Desmaze C, Spector M, Bodescot M, Aurias A, Osley MA, Lipinski M (1995)
A human homologue of the S. cerevisiae HIR1 and HIR2 transcriptional repressors cloned from the 
DiGeorge syndrome critical region. Hum Molec Genet 4(5):791-799 
Landegent JE, Jansen de Wai N, Baan RA, Hoeijmakers JHJ, Van der Ploeg M (1984) 2- 
acetylaminofluorene-modified probes for the indirect hybridochemical detection of specific nucleic 
acid sequences. Exp Cell Res 153:61-72
Landegent JE, Jansen in de Wal N, Ploem JS, Van der Ploeg M (1985a) Sensitive detection of 
hybridocytochemical results by means of reflection-contrast microscopy. J Histochem Cytochem 
33:1241-1246
Landegent JE, Jansen in de Wal N, van Ommen GJ, Baas F, de Vijlder JJM, van Duijn P, Van der 
Ploeg M (1985b) Chromosomal localization of a unique gene by non-autoradiographic in situ 
hybridization. Nature 317(6033): 175-177
230
Landegent JE, Jansen in de Wal N, Fisser-Groen YM, Bakker E, van der Ploeg M, Pearson PL 
(1986) Fine mapping of the Huntington disease linked D4S10 locus by non-radioactive in situ 
hybridization. Hum Genet 73:354-357
Landegent JE, Jansen in de Wal N, Dirks RW, Baao F, van der Ploeg M (1987) Use of whole 
cosmid cloned genomic sequences for chromosomal localization by non-radioactive in situ 
hybridization. Hum Genet 77(4):366-370
Langer PR, Waldrop AA, Ward DC (1981) Enzymatic synthesis of biotin-labelled polynucleotides:
novel nucleic acid affinity probes. Proc Natl Acad Sci USA 78:6633-6637
Langer-Safer PR, Levine M, Ward DC (1982) Immunological method for mapping genes on
Drosophila polytene chromosomes. Proc Natl Acad Sci USA 79:4381-4385
Lawrence B, Villnave CA, Singer RH (1988) Sensitive, high-resolution chromatin and chromosome
mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma
line. Cell 52(1):51-61
Lebo RV, Lynch ED, Bird TD, Golbus MS, Barker DF, O ’Connell P, Chance PF (1992) Multicolor in 
situ hybridization and linkage analysis order Charcot-Marie-Tooth Type I (CMTIA) gene-region 
markers. Am J Hum Genet 50:42-55
Lebo RV, Martelli L, Su Y, Li L, Lynch E, Mansfield E, Pua K-H, Watson DF, Chueh J, Hurko O 
(1993) Prenatal diagnosis of Charcot-Marie-Tooth Disease Type 1A by multicolor in situ 
hybridization. Am J Med Genet 47:441-450
Lee C, Gisselsson D, Jin C, Nordgren A, Ferguson DO, Blennow E, Fletcher JA, Morton CC (2001) 
Limitations of chromosome classification by multicolor karyotyping. Am J Hum Genet 68:1043-1047 
Leitch, AR, Schwarzacher T, Jackson D, Leitch IJ ((1994) In situ hybridization: a practical guide. 
Royal Microscopical Society Microscopy Handbooks 27. Bios Scientific Publishers Ltd, Oxford. 
Lejeune J, Turpin R, Gautier M (1959) Le mongolisme, premiere example d’aberration autosomique 
humaine. Ann Genet 1:41-49
Lengauer C, RIethman H, Cremer T (1990) Painting of human chromosomes with probes 
generated from hybrid cell lines by PCR with Alu and LI primers. Hum Genet 86:1-6 
Lengauer C, Spelcher MR, Popp S, Jauch A, Taniwaki M, Nagaraja R, Riethman HC, Donis-Keiler 
H, D’Urso M, Schlessinger D, Crem erT (1993) Chromosomal barcodes produced by multicolor 
fluorescence in situ hybridization with multiple YAC clones and whole chromosome painting probes. 
Hum Mol Genet 2(5):505-512
Leong PK, Thorner P, Yeger H, Ng K, Zhang Z, Squire J (1993) Detection of MYCN gene 
amplification and deletions of chromosome 1 p in neuroblastoma by in situ hybridization using 
routine histologic sections. Lab Invest 69(1 ):43-50
Levy A, Demczuk S, Aurias A, Depetris D, Mattei M-G, Philip N (1995) Interstitial 22q11 
microdeletion excluding the ADU breakpoint in a patient with DiGeorge syndrome. Hum Mol Genet 
4(12):2417-2419
Li M, Budarf ML, Sellinger B, Jaquez M, Matalon R, Bail S, Pagon RA, Rosengren SS, Emanuel BS, 
Driscoll DA (1994) Narrowing the DiGeorge region (DGCR) using DGS-VCFS associated 
translocation breakpoints. Am J Hum Genet 55: AID
Lichter P, Cremer T, Borden J, Manuelidis L, Ward DC (1988) Delineation of individual human 
chromosomes in metaphase and interphase cells by in situ suppression hybridization using 
recombinant DNA libraries. Hum Genet 80:224-234
Lichter P, Tang C-J C, Call K, Hermanson G, Evans GA, Housman D, Ward DC (1990) High- 
resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. Science 
247:64-69
Lichter P, Cremer T (1992) Chromosome analysis by non-isotopic in situ hybridization. In: Human 
Cytogenetics A Practical Approach Vol I Constitutional Analysis, ed. Rooney DE, Czepulkowski BH. 
Second Edition Ch 6 pp157-192. Oxford University Press (New York)
Ligon AH, Kashork CD, Richards CS, Shaffer LG (2000) Identification of female carriers for 
Duchenne and Becker muscular dystrophies using a FISH-based approach. Eur J Hum Genet 
8:293-298
Lindgren V, Rosinsky B, Chin J, Berry-Kravis E (1994) Two patients with overlapping de novo 
duplications of the long arm of chromosome 9, including one case with DiGeorge sequence. Am J 
Med Genet 49:67-73
Lindsay EA, Halford S, Wadey R, Scambler PJ, Baldini A (1993) Molecular cytogenetic 
characterization of the DiGeorge syndrome region using fluorescence in situ hybridization. 
Genomics 17:403-407
Lindsay EA, Goldberg R, Jurecic V, Morrow B, Carlson C, Kucherlapati RS, Shprintzen RJ, Baldini 
A (1995) Velo-cardio-faclal syndrome: frequency and extent of 22q11 deletions. Am J Med Genet 
57:514-522
231
Lipson A, Fagan K, Colley A, Colley P, Sholler G, Issacs D, Oates RK (1996) Velo-carcllo-faclal and 
partial DiGeorge phenotype in a child with interstitial deletion at 10p13 -implications for cytogenetics 
and molecular biology. Am J Med Genet 65:304-308
Llevadot R, Scambler P, Estivill X, Pritchard M (1996) Genomic organization of TUPLE1/HIRA: a 
gene implicated in DiGeorge syndrome. Mamm Genome 7(12):911-914 
Lobdell DH (1959) Congenital absence of the parathyroid glands. Arch Pathol 67:412-418 
Lorain S, Quivy JP, Monier-Gavelle F, Scamps C, Lecluse Y, Almounzi G, Lipinski M (1998) Core 
histones and HIRIP3, a novel histone-binding protein, directly interact with W D repeat protein HIRA. 
Mol Cell Biol 18:5546-5556
Lu Y-J, Wiliamson D, Clark J. Wang R, Tiffin N, Skelton L, Gordon T, Williams R, Allan B, Jackman 
A, Cooper C, Pritchard-Jones K, Shipley J (2001) Comparative expressed sequence hybridization 
to chromosomes for tumor classification and identification of genomic regions of differential gene 
expression. Proc Natl Acad Sci USA 98(16):9197-9202
Lundsteen C, Gerdes T, Rose H, Dunoe M, Kirchhoff M (2002) Screening for submicoscopic 
chromosomal imbalances using high resolution comparative genomic hybridization. J Med Genet 39 
(Supp11 ):Abstracts of the British Human Genetics Conference, SP42
Lupski JR, Wise CA, Kuwano A, Pentao L, Parke JT, Glaze DG, Ledbetter DH, Greenberg F, Patel 
PI (1992) Gene dosage is a mechanism for Charcot-Marie -Tooth disease type 1A. Nature Genet 
1:29-33
Ma K, Inglls JD, Sharkey A, Bickmore WA, Hill RE, Prosser EJ, Speed RM, Thomson EJ, Jobling 
M, Taylor K, Wolfe J, Cooke HJ, Hargreave TB, Chandley AC (1993) A Y chromosome gene family 
with RNA-binding protein homology: candidates for the azoospermia factor AZF controlling human 
spermatogenesis. Cell 75:1287-1295
MacDonald ME, Anderson MA, Gilliam TC, Tranejaerg L, Carpenter NJ, Magenis E, Hayden MR, 
Healey ST, Bonner Tl, Gusella JF (1987) A somatic cell hybrid panel for localizing DNA segments 
near the Huntington's disease gene. Genomics 1(1):29-34
Macoska JA, Micale MA, Sakr WA, Benson PD, Wolman SR (1993) Extensive genetic alterations in 
prostate cancer revealed by dual PCR and FISH analysis. Genes Chromosomes Cancer 8(2):88-97 
Magnaghi P, Roberts C, Lorain S, Lipinski M, Scambler PJ (1998) HIRA, a mammalian homologue 
of Saccharomyces cerevisiae transcriptional co-repressors, interacts with Pax3. Nature Genet 
20:74-77
Malcolm S, Barton P, Murphy C, Ferguson-Smith MA (1981) Chromosomal localization of a single 
copy gene by in situ hybridization: human beta globln genes on the short arm of chromosome 11. 
Ann Hum Genet 45:135-141
Malcolm S, Cowell JK, Young BD (1986) Specialist techniques in research and diagnostic clinical 
cytogenetics. In: Human Cytogenetics: A Practical Approach, ed. Rooney DE, Czepulkowski BH.
IRL Press (Oxford)
Mancini M, Nanni M, Cedrone M, Diverio D, Avvisati G, Riccioni R, De Cuia MR, Fenu S, Alimena G 
(1995) Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at 
diagnosis and in complete remisssion. Br J Haematol 91(4):878-884
Manning JE, Hershey ND, Brooker TR, Pellegrini M, Mitchell HK, Davidson N (1975) A new method 
of in situ hybridization. Chromosoma 53:107-117
Mansfield ES, Robertson JM, Lebo RV, Lucero MY, Mayrand PE, Rappaport E, Parrella T, Sartore 
M, Surrey S, Fortina P (1993) Duchenne/Becker muscular dystrophy carrier detection using 
quantitative PCR and fluorescence-based strategies. Am J Med Genet 48(4):200-208 
Manuelidis L, Langer-Safer PR, Ward DC (1982) High-resolution mapping of satellite DNA using 
biotin-labelled DNA probes. J Cell Biol 95:619-625
Manuelidis L (1985) Individual interphase chromosome domains revealed by in situ hybridization. 
Hum Genet 71:288-293
McBride MW, Russell AJ, Vass K, Forster V, Burridge SM, Morrison N, Boyd E, Ponder BAJ, 
Sutcliffe RG (1995a) New members of the 3|3-hydroxysteroid dehydrogenase gene family.
Molecular and Cellular Probes 9:121-128
McBride MW, Russell AJ, Vass K, Frank-Raue K, Craig NJ, Morrison N, Boyd E, Szpirer C,
Sutcliffe RG (1995b) The human 3p-hydroxysteroid dehydrogenase gene cluster on chromosome 
1p13 contains a presumptive pseudogene; 3P-HSD and CYP17 do not segregate with dominantly 
inherited hirsutism. J Mol Endocrinology 15:167-176
McConkey EH (1993) Human Genetics The Molecular Revolution. Jones and Bartlett Publishers, 
Boston and London
232
McQuade L, Christodoulou J, Budarf M, Sachdev R, Wilson M, Emanuel B, Colley A (1999) Patient 
with a 22q11.2 deletion with no overlap of the minimal DiGeorge syndrome critical region (MDGCR). 
Am J Med Genet 86:27-33
Meltzer PS, Guan X-Y, Burgess A, Trent JM (1992) Rapid generation of region specific probes by
chromosome microdissection and their application. Nature Genet 1:24-28
Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddie SD, Ziaugra L, Beijersbergen
RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA (1997) hEST2, the putative human
telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell
90(4):785-795
Micale MA, Sanford JS, Powell IJ, Sakr WA, Wolman SR (1993) Defining the extent and nature of 
cytogenetic events in prostatic adenocarcinoma: paraffin FISH vs metaphase analysis. Cancer 
Genet Cytogenet 69(1):7-12
Michail J, Matsoukas J, Theodorou S (1957) Pouce bot arque en forte abduction-extension et 
autres symptômes concomitants. Rev Chir Orthop Appar Mot 43:142-146 
Miranda RN, Mark HF, Medeiros LJ (1994) Fluorescent in situ hybridization in routinely processed 
bone marrow aspirate clot and core biopsy sections. Am J Pathol 145(6): 1309-1314 
Mohammed FM (1999) Strategies for mutation detection in sex-chromosome related disorders.
PhD thesis submitted to the University of Glasgow.
Moncrieff CL, Bailey MES, Morrison N, Johnson KJ (1999) Cloning and chromosomal localization of 
human Cdc42-binding protein kinase p. Genomics 57:297-300
Monaco AP, Larin Z (1994) YACs, BACs, PACs and MACs:artificial chromosomes as research 
tools. Trends Biotechnol 12:280-286
Montanaro V, Casamassimi A, D’Urso M, Yoon J-Y, Freije W, Schlessinger D, Muenke M, 
Nussbaum RL, Saccone S, Maugeri S, Santoro AM, Motta S, Della Valle G (1991) In situ 
hybridization to cytogenetic bands of yeast artificial chromosomes covering 50% of human Xq24- 
Xq28 DNA. Am J Hum Genet 48:183-194
Moog U, Engelen JJM, Albrechts JCM, Baars LGM, de Die-Smulders CEM (2000) Familial 
dup(8)(p12p21.1): Mild phenotypic effect and review of partial 8p duplications. Am J Med Genet 
94:306-310
Moorhead PS, Nowell PC, Mellman WJ, Battips DM, Hungerford DA (1960) Chromosome 
preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 20:613-616 
Morimoto H, Monden T, Shimano T, Higashiyama M, Tomita N, Murotani M, Matsuura N, Okuda H, 
Mori T (1987) Use of sulfonated probes for in situ detection of amylase mRNA in formalin-fixed 
paraffin sections of human pancreas and submaxillary gland. Lab Invest 57(6):737-741 
Morin GB (1989) The human telomere terminal transferase enzyme is a ribonucleoprotein that 
synthesizes TTAGGG repeats. Cell 59(3):521-529
Morris A, Boyd E, Dhanjal S, Lowther GW, Aitken DA, Young J, Menzies AL, Imrie SJ, Connor JM 
(1999) Two years’ prospective experience using fluorescence in situ hybridisation on uncultured 
amniotic fluid cells for rapid prenatal diagnosis of common chromosomal aneuploidies. Prenat 
Diagn 19:546-551
Morrison N, Harrap SB, Arriza JL, Boyd E, Connor JM (1990) Regional chromosomal assignment of 
the human mineralocorticoid receptor gene to 4q31.1. Hum Genet 85:130-132 
Morrison N, Goddard JP, Ledbetter DH, Boyd E, Bourn D, Connor JM (1991a) Chromosomal 
assignment of a large tRNA cluster (tRNA^^", tRNA®'", tRNA"- '^, tRNA^'®, tRNA^'^) to 17p13.1. Hum 
Genet 87:226-230
Morrison N, Nickson DA, McBride MW, Mueller UW, Boyd E, Sutcliffe RG (1991b) Regional 
chromosomal assignment of human 3-beta-hydroxy-5-ene steroid dehydrogenase to 1 p i 3.1 by 
non-isotopic in situ hybridization. Hum Genet 87:223-225
Morrison N, Simpson C, Fothergill-Gilmore L, Boyd E, Connor JM (1992) Regional chromosomal 
assignment of the human platelet phosphofructokinase gene to 10p15. Hum Genet 89:105-106 
Morrison N, Duthie SM, Boyd E, Eidne KA, Connor JM (1994a) Assignment of the gene encoding 
the human thyrotropin-releasing hormone receptor to 8q23 by fluorescence in situ hybridization. 
Hum Genet 93:716-718
Morrison N, Seilar RE, Boyd E, Eidne KA, Connor JM (1994b) Assignment of the gene encoding the 
human gonadotropin-releasing hormone receptor to 4q13.2-13.3 by fluorescence in situ 
hybridization. Hum Genet 93:714-715
Morrow B, Goldberg R, Carlson C, Das Gupta R, Sirotkin H, Collins J, Dunham I, O’Donnell H, 
Scambler P, Shprintzen R, Kucherlapati R (1995) Molecular definition of the 22q11 deletions in 
velo-cardio-facial syndrome. Am J Hum Genet 56:1391-1403
233
Munne S, Weier HU (1996) Simultaneous enumeration of chromosomes 13, 18, 21, X  and Y in 
interphase cells for preimplantation genetic diagnosis of aneuploidy. Cytogenet Cell Genet 
75(4):263-270
Murphy DS, McHardy P, Courts J, Mallon EA, George WD, Kaye SB, Brown R, Keith W N (1995) 
Interphase cytogenetic analysis of ert)B2 and topolla co-amplification in invasive breast cancer and 
polysemy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 64:18-26 
Murphy MT, Morrison N, Miles JS, Fraser RH, Spurr NK, Boyd E (1993) Regional chromosomal 
assignment of the Kell blood group locus {KEL) to chromosome 7q33-q35 by fluorescence in situ 
hybridization: evidence for the polypeptide nature of antigenic variation. Hum Genet 91:585-588 
Murray JC, Buetow KH, Weber JL, Ludwigsen S, Scherpbier-Heddema T, Manion F, Quillen J, 
Sheffield VC, Sunden S, Duyk GM, et al (1994) A comprehensive human linkage map with 
centimorgan density. Cooperative Human Linkage Center (CHLC). Science 265(5181 ):2049-2054
Nederlof PM, Robinson D, Abuknesha R, Weigant J, Hopman AH, Tanke HJ, Raap AK (1989) 
Three-color fluorescence in situ hybridization for the simultaneous detection of multiple nucleic acid 
sequences. Cytometry 10(1):20-27
Nederlof PM, van der Flier S, Weigant J, Raap AK, Tanke HJ, Ploem JS, van der Ploeg M (1990) 
Multiple fluorescence in situ hybridization. Cytometry 11(1):126-131 
Nederlof PM, van der Flier S, Vrolijk J, Tanke HJ, Raap AK (1992) Fluorescence ratio 
measurements of double-labeled probes for multiple in situ hybridization by digital imaging 
microscopy. Cytometry 13(8):839-845
Newton CR, Graham GA (1994) PCR. Bios Scientific Publishers Ltd, Oxford 
Nilsson M, Krejci K, Koch J, Kwiatkowski M, Gustavsson P, Landegren U (1997) Padlock probes 
reveal single-nucleotide differences, parent of origin and in situ distribution of centromeric 
sequences in human chromosomes 13 and 21. Nature Genet 16:252-255
Nimmakayalu MA, Gotter AL, Shaikh TH, Emanuel BS (2003) A novel sequence-based approach to 
localize translocation breakpoints identifies the molecular basis of a t(4;22). Hum Mol Genet 
12(21):2817-2825
Ning Y, Roschke A, Smith ACM, Macha M, Precht K, Riethman H, Ledbetter DH, Flint J, Horsley S, 
Regan R, Kearney L, Knight S, Kvaloy K, Brown W RA (National Institutes of Health and Institute of 
Molecular Medicine Collaboration, 1996) A complete set of human telomeric probes and their 
clinical application. Nature Genet 14:86-89
Nishio H, Heiskanen M, Palotie A, Belanger L, Dugaiczyk A (1996) Tandem arrangement of the 
human serum albumin multigene family in the sub-centromeric region of 4q: evolution and 
chromosomal direction of transcription. J Mol Biol 259(1): 113-119
Novelli A, Ceccarini C, Bernardini L, Zuccarello D, Caputo V, Digilio MC, Mingarelli R, Dallapiccola 
B (2004) High frequency of subtelomeric rearrangements in a cohort of 92 patients with severe 
mental retardation and dysmorphism. Clin Genet 66:30-38
O ’Donnell H, McKeown C, Gould C, Morrow B, Scambler P (1997) Detection of an atypical 22q11 
deletion that has no overlap with the DiGeorge syndrome critical region. Am J Hum Genet 
60(6): 1544-1548
Orsetti B, Lefort G, Boulot P, Andreo B, Pellestor F (1998) Fetal cells in maternal blood: the use of 
primed in situ (PRINS) labelling technique for fetal cell detection and sex assessment. Prenat Diagn 
18:1014-1022
Overhauser J, Bengtsson U, McMahon J, Ulm J, Butler MG, Santiago L, Wasmuth JJ (1989) 
Prenatal diagnosis and carrier detection of a cryptic translocation by using DNA markers from the 
short arm of chromosome 5. Am J Hum Genet 45(2):296-303
Para I, Windle B (1993) High resolution visual mapping of stretched DNA by fluorescent 
hybridization. Nature Genet 5:17-21
Paskins L, Brownie J, Bull J (1999) In situ polymerase chain reaction and cycling primed in situ 
amplification: improvements and adaptations. Histochem Cell Biol 111:411-416 
Pellestor F, Girardet A, Andreo B, Charlieu J-P (1994) A polymorphic alpha satellite sequence 
specific for human chromosome 13 detected by oligonucleotide primed in situ labelling (PRINS) 
Hum Genet 94:346-348
Pellestor F, Girardet A, Lefort G, Andreo B, Charlieu JP (1995a) PRINS as a method for rapid 
chromosomal labeling on human spermatozoa. Molec Reprod Dev 40:333-337 
Pellestor F, Girardet A, Lefort G, Andreo B, Charlieu JP (1995b) Rapid in situ detection of 
chromosome 21 by PRINS technique. Am J Med Genet 56:393-397
234
Pellestor F, Girardet A, Lefort G, Andreo B, Charlieu JP (1995c) Use of the primed in situ labelling 
(PRINS) technique for the rapid detection of chromosomes 13,16,18,21, X and Y. Hum Genet 
95:12-17
Pellestor F, Quennesson I, Coignet L, Girardet A, Andreo B, Charlieu JP (1996a) Direct detection of 
disomy in human sperm by the PRINS technique. Hum Genet 97(1):21-25 
Pellestor F, Girardet A, Andreo B, Lefort G, Charlieu JP (1996b) The PRINS technique: potential 
use for rapid preimplantation embryo chromosome screening. Molec Hum Reprod 2:135-138 
Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RCM, Masuno M, Tommerup N, van 
Ommen G-JB, Goodman RH, Peters DJM, Breuning MH (1995) Rubinstein-Taybi syndrome caused 
by mutations in the transcriptional co-activator CBP. Nature 376:348-351 
Petrij F, Dauwerse HG, Blough Rl, Giles RH, van derSmagt JJ, Wallerstein R, Maaswinkel-Mooy 
PD, van Karnebeek CD, van Ommen G-JB, van Haeringen A, Rubinstein JH, Saal HM, Hennekam 
RCM, Peters DJM, Breuning MH (2000) Diagnostic analysis of the Rubinstein-Taybi syndrome: five 
cosmids should be used for microdeletion detection and low number of protein truncating 
mutations. J Med Genet 37:168-176
Pettenati MJ, Hayworth R, Cox K, Rao PN (1994) Prenatal detection of cri du chat syndrome on 
uncultured amniocytes using fluorescence in situ hybridization (FISH). Clin Genet 45:17-20 
Piper J, Rutovitz D, Sudar D, Kallioniemi A, Kallioniemi 0-P , Waldman FM, Gray JW, Pinkel D 
(1995) Computer image analysis of comparative genomic hybridization. C>4ometry 19:10-26 
Pinkel D, Straume T, Gray JW  (1986) Cytogenetic analysis using quantitative, high-sensitivity, 
fluorescence hybridization. Proc Natl Acad Sci USA 83:2934-2938
Pinkel D, Landegent J, Collins C, Fuscoe J, Segraves R, Lucas J, Gray JW  (1988) Fluorescence in 
situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and 
translocation of chromosome 4. Proc Natl Acad Sci USA 85:9138-9142
Precht KS, Lese CM. Spiro RP, Hutteniocher PR, Johnston KM, Baker JC, Christian SL, Kittikamron 
K, Ledbetter DH (1998) Two 22q telomere deletions serendipitously detected by FISH. J Med Genet 
35:939-942
Raap AK, van de Corput MPC, Vervenne RAW, van Gijiswijk RPM, Tanke HJ, Weigant J (1995) 
Ultra-sensitive FISH using peroxidase-mediated deposition of biotin- or fluorochrome tyramides. 
Hum Mol Genet 4(4):529-534
Rappold GA (1993) The pseudoautosomal regions of the human sex chromosomes. Hum Genet 
92(4):315-24
Rauch A, Pfeiffer RA, Leipold G, Singer H, Tigges M, Hofbeck M (1999) A novel 22q11.2 
microdeletion in DiGeorge syndrome. Am J Hum Genet 64:659-667 
Rauch A, Devriendt K, Koch A, Rauch R, Gewillig M, Kraus C, Weyand M, Singer H, Reis A, 
Hofbeck M (2004) Assessment of association between variants and haplotypes of the remaining 
TBX1 gene and manifestations of congenital heart defects in 22q11.2 deletion patients. J Med 
Genet 41 (4):e40
Reid T, Mahler V, Vogt P, Blonden L, van Ommen GJB, Cremer T, Cremer M (1990) Direct carrier 
detection by in situ suppression hybridization with cosmid clones of the Duchenne/Becker muscular 
dystrophy locus. Hum Genet 85:581-586
Reid T, Baldini A, Rand TC, Ward DC (1992) Simultaneous visualization of seven different DNA 
probes by in situ hybridization using combinatorial fluorescence and digital imaging microscopy.
Proc Natl Acad Sci USA 89:1388-1392
Reid E, Morrison N, Barron L, Boyd E. Cooke A, Fielding D, Tolmie JL (1996) Familial Wolf- 
Hirschhorn syndrome resulting from a cryptic translocation: a clinical and molecular study. J Med 
Genet 33:197-202
Reijo R, Lee TY, Salo P, Alagappan R, Brown LG, Rosenberg M, Rozen S, Jaffe T, Straus D, 
Hovatta O (1995) Diverse spermatogenic defects in humans caused by Y chromosome deletions 
encompassing a novel RNA-binding protein gene. Nat Genet 10(4):383-393 
Rio M, Molinari F, Heuertz S, Ozilou C, Gosset P, Raoul O, Cormier-Daire V, Amiel J, Lyonnet S, Le 
Merrer M, Turleau C, de Blots M-C, Prieur M, Romana S, Vekemans M, Munnich A, Colleaux L 
(2002) Automated fluorescent genotyping detects 10% of cryptic subtelomeric rearrangements in 
idiopathic syndromic mental retardation. J Med Genet 39:266-270
Roberts R, Coffey AJ, Bobrow M, Bentley DR (1993) Exon structure of the human dystrophin gene. 
Genomics 16: 536-538
Roberts C, Daw SCM, Halford S, Scambler PJ (1997) Cloning and developmental expression 
analysis of chick Hira (Chira), a candidate gene for DiGeorge syndrome. Hum Mol Genet 6:237-245 
Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, den Dunnen 
JT, van Ommen GJ, Breuning MH, Hennekam RC, Peters DJ (2005) Genetic heterogeneity in
235
Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J 
Hum Genet 76(4):572-580
Romana SP, Tachdjian G, Druart L, Cohen D, Berger R, Cherif D (1993) A simple method for 
prenatal diagnosis of trisomy 21 on uncultured amniocytes. Eur J Hum Genet 1:245-251 
Rooms L, Reyniers E, van Luijk R, Scheers S, Wauters J, Ceulemans B, Van Den Ende J, Van 
Bever Y, Kooy RF (2004) Subtelomeric deletions detected in patients with idiopathic mental 
retardation using multiplex ligation-dependent probe amplification (MLPA). Hum Mutation 23:17-21 
Rosenberg C, Blakemore KJ, Kearns W G. Giraldez RA, Escallon CS, Pearson PL, Stetten G (1992) 
Analysis of reciprocal translocations by chromosome painting: applications and limitations of the 
technique. Am J Hum Genet 50:700-705
Rosenberg C, Florijn RJ, Van de Rijke FM, Blonden LA, Raap TK, Van Ommen GJ, Den Dunnen 
JT (1995) High resolution DNA fiber-fish on yeast artificial chromosomes: direct visualization of 
DNA replication. Nature Genet 10(4):477-479
Rosenberg C, Navajas L, Vagenas DF, Bakker E, Vainzof M, Passos-Bueno MR, Takata Rl, Van 
Ommen GJ, Zatz M, Den Dunnen JT (1998) Clinical diagnosis of heterozygous dystrophin gene 
deletions by fluorescence in situ hybridization. Neuromuscul Disord 8(7):447-452 
Ross MT, Nizetic D, Nguyen C, Knights C, Vatcheva R, Burden N, Douglas C, Zehetner G, Ward 
DC, Baldini A, Lehrach H (1992) Selection of a human chromosome 21 enriched YAC sub-library 
using a chromosome-specific composite probe. Nature Genet 284-290
Rost I, Fiegler H, Fauth C, Carr P, Bettecken T, Kraus J, Meyer C, Enders A, WIrtz A, Meitinger T, 
Carter NP, Speicher MR (2004) Tetrasomy 21pter-q21.2 in a male infant without typical Down's 
syndrome dysmorphic features but moderate mental retardation. J Med Genet 41 (3):e26 
Rothfels KH, Siminovitch L (1958) An air-drying technique for flattening chromosomes in 
mammalian cells grown in vitro. Stain Technol 33(2):73-77
Rubinstein JH, Taybi H (1963) Broad thumbs and toes and facial abnormalities. A possible mental 
retardation syndrome. Am J Dis Child 105:588-608
Ryan AK, Goodship JA, Wilson Dl, Philip N, Levy A, Seidel H, Schuffenhauer S, Oechsler H, 
Belohradsky 8, Prieur M, Aurias A, Raymond FL, Clayton-Smith J, Hatchwell E, McKeown C, 
Beemer FA, Dallapiccola B, Novelli G, Hurst JA, Ignatius J, Green AJ, Winter RM, Brueton L, 
Brondum-Nielsen K, Stewart F, Van Essen T, Patton M, Paterson J, Scambler PJ (1997) Spectrum 
of clinical features associated with interstitial chromosome 22q11 deletions: a European 
collaborative study. J Med Genet 34:798-804
Saccone S, De Sario A, Delia Valle G, Bernard! G (1992) The highest gene concentrations in the 
human genome are in the telomeric bands of metaphase chromosomes. Proc Natl Acad Sci 
89:4913-4917
Sacchi N, Magnani I, Kearney L, Wijsman J, Hagemeijer A, Darfier M (1995) Interphase 
cytogenetics of the t(8;21)(q22;q22) associated with acute myelogenous leukaemia by two-color 
fluorescence in situ hybridization. Cancer Genet Cytogenet 79(2):97-103 
Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N (1985) Enzymatic 
amplification of p-globin genomic sequences and restriction site analysis for the diagnosis of sickle 
cell anaemia. Science 230:1350-1354
Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988) Primer 
directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487- 
491
Saitta SC, McGrath JM, Mensch H, Shaikh TH, Zackai EH, Emanuel BS (1999) A22q11 deletion 
that excludes UFD1L and CDC45L in a patient with conotruncal and craniofacial defects. Am J Hum 
Genet 65:562-566
Satinover DL, Schwartz S (2002) Clinical application of PRINS. Am J Med Genet 107:95-96 
Saxena R, Brown LG, Hawkins T, Alagappan RK, Skaletsky H, Reeve MP, Reijo R, Rozen S, 
Dinulos MB, Disteche CM, Page DC (1996) The DAZ gene cluster on the human Y chromosome 
arose from an autosomal gene that was transposed, repeatedly amplified and pruned. Nat Genet 
14:294-299
Saunders GF, Hsu TC, Getz MJ, Simes EL, Arrighi FE (1972) Locations of a human satellite DNA in 
human chromosomes. Nature New Biol 236:244-246
Scambler PJ, Carey AH, Wyse RKH, Roach S, Dumanski JP, Nordenskjold M, Williamson R (1991) 
Microdeletions within 22q11 associated with sporadic and familial DiGeorge syndrome. Genomics 
10:201-206
Scambler PJ, Kelly D, Lindsay E, Williamson R, Goldberg R, Shprintzen R, Wilson Dl, Goodship JA, 
Cross IE, Burn J (1992) Velo-cardio-facial syndrome associated with chromosome 22 deletions 
encompassing the DiGeorge locus. Lancet 339:1138-1139
236
Schoumans J, Nielsen K. Jeppesen I, Anderlid B-M, Blennow E, Brondum-Nielsen K, Nordenskjold 
M (2004) A comparison of different metaphase CGH methods for the detection of cryptic 
chromosome aberrations of defined size. Eur J Hum Genet 12:447-454 
Schouten JP, McElgunn CJ. Waaijer R, Zwijnenburg D, Diepvens F, Pais G (2002) Relative 
quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.
NucI Acids Res 30(12):e57
Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter 
DH, Bar-Am I, Soenksen D, Garini Y, Reid T (1996) Multicolour spectral karyotyping of human 
chromosomes. Science 273:494-497
Schwartz DC, Gaffran W , Welsh J, Haas R, Goldenberg M Cantor CR (1983) New techniques for 
purifying large DNAs and studying their properties and packaging. Cold Spring Harb Symp Quant 
Biol 47:189-195
Scire G, Dallapiccola B, lannetti P, Bonaiuto F, Galasso C, Mingarelli R, Boscherini B (1994) 
Hypoparathyroidism as the major manifestation in two patients with 22q11 deletions. Am J Med 
Genet 52:478-482
Seabright M (1971) A rapid banding technique for human chromosomes. Lancet 2(7731 ):971-972 
Sedlackova E (1955) Insuficience patrohltanoveho zaveru jako vyvojova porucha. Cas Lek Cesk 
94:1304-1307
Shaffer LG, Bejjani BA (2004) A cytogeneticist’s perspective on genomic microarrays. Hum Reprod 
Update 10(3):221-226
Shaikh TH, Kurahashi H, Saitta SC, O'Hare AM, Hu P, Roe BA. Driscoll DA, McDonald-McGInn 
DM, Zackai EH, Budarf ML, Emanuel BS (2000) Chromosome 22-specific low copy repeats and the 
22q11.2 deletion syndrome:genomic organization and deletion endpoint analysis. Hum Mol Genet 
9(4):489-501
Shapira SK, McCaskill C, Northrup H, Spikes AS, Elder FF, Sutton VR, Korenberg JR, Greenberg 
F, Shaffer LG (1997) Chromosome 1p36 deletions: the clinical phenotype and molecular 
characterization of a common newly delineated syndrome. Am J Hum Genet 61 (3):642-650 
Shaw-Smith C, Redon, R, Rickman L, Rio M, Willatt L, Fiegler H, Firth H, Sanlaville D, Winter R, 
Colleaux L, Bobrow M, Carter NP (2004a) Microarray based comparative genomic hybridisation 
(array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with 
learning disability/mental retardation and dysmorphic features. J Med Genet 41 (4):241-248 
Shaw-Smith C, Willatt L, Firth H, Kalaitzopouios D, Carter NP, Bobrow M (2004b) A submicroscopic 
(400kb) interstitial deletion at 17(q21.3q21.3) in a boy with severe learning difficulties encompasses 
the MAPT gene and is flanked by segmental duplications 40kbp in size. J Med Genet 41 (SuppI 
1 ):Abstracts of the British Human Genetics Conference S16, SP12
Shibasaki Y, Gosden JR (1997) Oligonucleotide PRINS DNA synthesis on extended chromatin 
preparations. Methods Mol Biol 71:45-51
Shimokawa O, Kurosawa K, Ida T, Harada N, Kondoh T, Miyake N, Yoshiura K, Kishino T, Ohta T, 
Niikawa N. Matsumoto N (2004) Molecular characterization of inv dup det(8p): analysis of five 
cases. Am J Med Genet 128A(2): 133-137
Shprintzen RJ, Goldberg RB, Lewin ML, Sidoti EJ, Berkman MD, Argamaso RV, Young D (1978) A  
new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: 
Velo-cardio-facial syndrome. Cleft Palate J 15:56-62
Shprintzen RJ, Goldberg RB, Young D, Wolford L (1981) The velo-cardio-facial syndrome: A clinical 
and genetic analysis. Pediatr 67:167-172
Shroyer KR, Nakane PK (1983) Use of DNP-labeled cDNA for in situ hybridization. J Cell Biol 
97:377a,1422
Sibert JR, Harper PS, Thompson RJ, Newcombe RG (1979) Carrier detection in Duchenne 
muscular dystrophy: evidence from a study of obligatory carriers and mothers of isolated cases. 
Arch Dis Child 54(7):634-537
Singh SM, Murphy B, O'Reilly RG (2002) Monozygotic twins with chromosome 22q11 deletion and 
discordant phenotypes: updates with an epigenetic hypothesis. J Med Genet 39:e71 
Sismani C, Armour JAL, Flint J, GIrgalli C, Regan R, Patsalis PC (2001) Screening for subtelomeric 
chromosome abnormalities in children with idiopathic mental retardation using multiprobe telomeric 
FISH and the new MAPH telomeric assay. Eur J Hum Genet 9:527-532
Siu VM, Li M-D, Teshima IE (1996) De novo interstitial deletion in a child with features of Di George 
syndrome. Am J Hum Genet 59:A133
Slagboom PE, Droog S, Boomsma Dl (1994) Genetic determination of telomere size in humans: a 
twin study of three age groups. Am J Hum Genet 55(5):876-882
237
Solinas-Totdo S, Lampei S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P
(1997) Matrix-based comparative genomic hybridization: biochips to screen for genomic 
imbalances. Genes Chromosomes and Cancer 20:399-407
Spathas DH, Divane A, Maniatis GM, Ferguson-Smith ME, Ferguson-Smith MA (1994) Prenatal 
detection of trisomy 21 in uncultured amniocytes by fluorescence in situ hybridization: a prospective 
study. Prenat Diagn 14(11): 1049-1054
Speei EJM, Lawson D, Hopman AHN, Gosden J (1995) Multi-PRINS: multiple sequential 
oligonucleotide primed in situ DNA synthesis reactions label specific chromosomes and produce 
bands. Hum Genet 95:29-33
Speel EJM, Lawson D, Ramaekers FC, Gosden JR, Hopman AH (1996) Rapid bright-field detection 
of oligonucleotide primed in situ (PRINS)-labeled DNA in chromosome preparations and frozen 
tissue sections. Biotechniques 20(2):226-234
Speicher MR, du Manoir 8, Schrock E, Holtgreve-Grez H, Schoell B, Lengauer C, Cremer T, Reid T  
(1993) Molecular cytogenetic analysis of formalin-fixed, paraffin-embedded solid tumors by 
comparative genomic hybridization after universal DNA-amplification. Hum Mol Genet 11(2): 1907- 
1914
Speicher MR, Gwyn Ballard S, Ward DC (1996) Karyotyping human chromosomes by combinatorial 
multi-fluor FISH. Nature Genet 12:368-375
Sperling K, Rao PN (1974) The phenomenon of premature chromosome condensation: its
relevance to basic and applied research. Humangenetik 23(4):235-258
Stankiewicz P, Shaw CJ, Dapper JD, Wakui K, Shaffer LG, Withers M, Elizondo L, Park S-S,
Lupski JR (2003) Genome architecture catalyzes nonrecurrent chromosomal rearrangements. Am J 
Hum Genet 72:1101-1116
Steele MW, Breg W R Jr (1966) Chromosome analysis of human amniotic-fluid cells. Lancet 
1(7434):383-385
Steele CD, Wapner RJ, Smith JB, Haynes MK, Jackson LG (1996) Prenatal diagnosis using fetal 
cells isolated from maternal peripheral blood: a review. Clin Obstet Gynecol 39(4):801-813
Taylor CP, McGuckin AG, Bown NP, Reid MM, Malcolm AJ, Pearson AD, Sheer D (1994) Rapid 
detection of prognostic genetic factors in neuroblastoma using fluorescence in situ hybridisation on 
tumour imprints and bone marrow smears. United Kingdom Children’s Cancer Study Group. Br J 
Cancer 69(3):445-451
Telenius H, PelmearAH, Tunnacliffe A, Carter NP, Behmel A, Ferguson-Smith MA, Nordenskjold 
M, Pfragner R, Ponder BA (1992) Cytogenetic analysis by chromosome painting using DOP-PCR  
amplified flow-sorted chromosomes. Genes Chromosomes Cancer 4(3):257-263 
Tezenas du Montcel S, Mendizabal H, Ay me S, Levy A, Philip N (1996) Prevalence of 22q11 
microdeletion. J Med Genet 33:719
Tharapel AT, Kadandale JS, Martens PR, Wachtel SS, Wilroy RS Jr (2002) Prader Willi/Angelman 
and DiGeorge/velocardiofacial syndrome deletions: diagnosis by primed in situ labeling (PRINS). 
Am J Med Genet 107:119-122
Tharapel SA, Kadandale JS (2002) Primed in situ labeling (PRINS) for evaluation of gene deletions 
in cancer. Am J Med Genet 107:123-126
Therkelsen AJ, Nielsen A, Kolvraa S (1997) Localisation of the classical DNA satellites on human 
chromosomes as determined by primed in situ labelling (PRINS). Hum Genet 100(3-4):332-326 
Therman E, Susman M (1993) Human chromosomes: structure, behaviour and effects. 3"^  ^ed. 
Springer-Verlag, New York
Tjio JH, Levan A (1956) The chromosome number in man. Hereditas 42:16 
Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suryanarayan K, Homge M, 
Redner A, Gray J, Pinkel D (1990) Detection of bcr-abi fusion in chronic myelogenous leukemia by 
in situ hybridization. Science 250(4980):559-562
Tobias ES, Morrison N, Whiteford ML, Tolmie JL (1999) Towards earlier diagnosis of 22q11 
deletions. Arch Dis Child 81:513-514 Trainer AH, Morrison N, Dunlop A, Wilson N, Tolmie J (1996) 
Chromosome 22q11 microdeletions in tetralogy of Fallot. Arch Dis Child 74(1):62-63 
Tranebjaerg L, Petersen A, Hove K, Rehder H, Mikkelsen M (1984) Clinical and cytogenetic studies 
in a large (4;8) translocation family with pre-and postnatal Wolf syndrome. Ann Genet 27(4):224- 
229
Trask B, Pinkel D, Van Den Engh G (1989) The proximity of DNA sequences in interphase cell 
nuclei is correlated to genomic distance and permits ordering of cosmids spanning 250 Kilo base 
pairs. Genomics 5:710-717
Trask B (1991) Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. 
TIG 7:149-154
238
Trask B, Massa M, Kenwrick S, Gitschier J (1991) Mapping of human chromosome Xq28 by two- 
color fluorescence in situ hybridization of DNA sequences to interphase cell nuclei. Am J Hum 
Genet 48:1-15
Troyer DL, Goad DW, Xie H, Rohrer GA, Alexander LJ, Beattie CW  (1994a) Use of direct in situ 
single-copy (DISC) PCR to physically map five porcine micro satellites. Cytogenet Cell Genet 
67(3): 199-204
Troyer DL, Xie H, Goad DW, Skinner DZ (1994b) Use of a new technique to map the porcine alpha 
interferon gene to chromosome 1. Mamm Genome 5(2): 112-114
van Essen AJ, Schoots CJF, van Lingen RA, Mounts MJE, Tuerlings JHAM, Leegte B (1993) 
Isochromosome 18q in a girl with holoprosencephaly, DiGeorge anomaly, and streak ovaries. Am J 
Med Genet 47:85-88
van Karnebeek CDM, Koevoets C, Sluijter S, Bijisma EK, Smeets DFMC, Redeker EJ, Hennekam 
RCM, Hoovers JMN (2002) Prospective screening for subtelomeric rearrangements in children with 
mental retardation of unknown aetiology: the Amsterdam experience. J Med Genet 39:546-553 
Verma RS, Luke S (1992) Variations in alphoid DNA sequences escape detection of aneuploidy at 
interphase by FISH technique. Genomics 14(1):113-116
Verma RS and Babu A (1995) Ch 3 and 4 in Human Chromosomes, Principles and Techniques, 
Second Edition. McGraw-Hill Inc (New York)
Vernole P (1990) Digoxygenin-labeled probes can detect single-copy genes in human metaphase 
chromosomes. Biotechniques 9(2):200-204
Vincent C, Tchen P, Cohen-Solal M, Kourilsky P (1982) Synthesis of 8-(2-4 dinitrophenyl 2-6 
aminohexyl) amino-adenosine 5’ triphosphate: biological properties and potential uses. NucI Acids 
Res 10(21):6787-6796
Vissers LELM, de Vries BBA, Osoegawa K, Janssen IM, Feuth T, Choy CO, Straatman H, van der 
Vliet W, Huys EHLPG, van Rijk A, Smeets D, van Ravenswaaij-Arts CMA, Knoers NV, van der 
Burgt I, de Jong PJ, Brunner HG, van Kessel AG, Schoenmakers EFPM, Veltman JA (2003) Array- 
based comparative genomic hybridization for the genomewide detection of submicroscopic 
chromosomal abnormalities. Am J Hum Genet 73:1261-1270
Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, De Vries BB, Janssen IM, van der Vliet 
WA, Huys EH, de Jong PJ, Hamel BC, Schoenmakers EF, Brunner HG, Veltman JA, Van Kessel 
AG (2004) Mutations in a new member of the chromodomain gene family cause CHARGE 
syndrome. Nature Genet 36(9):955-957
Vogt PH, Edelmann A, Kirsch S, Henegariu O, Hirschmann P, Kiesewetter F, Kohn FM, Schill WB, 
Farah S, Ramos C, Hartmann M, Hartschuh W , Meschede D, Behre HM, Caste! A, Nieschlag E, 
Weidner W, G rone HJ, Jung A, Engel W , HaidI G (1996) Human Y chromosome azoospermia 
factors (AZF) mapped to different subregions in Yql 1. Hum Mol Genet 5(7):933-943 
Voskova-Goldman A, Peier A, Caskey CT, Richards CS, Shaffer LG (1997) DMD-specific FISH 
probes are diagnostically useful in the detection of female carriers of DMD gene deletions. 
Neurology 48(6): 1633-1638
Wapenaar MC, Kievits T, Hart KA, Abbs S, Blonden LAJ, den Dunnen JT, Grootscholten PM, 
Bakker E, Verellen-Dumoulin Ch, Bobrow, M, van Ommen GJB, Pearson PL (1988) A deletion hot 
spot in the Duchenne muscular dystrophy gene. Genomics 2:101-108 
Ward DC, Boyle A, Haaf T (1996) Fluorescence in situ hybridization techniques. In: Human 
Chromosomes, Principles and Techniques, ed Verma RS, Babu A. Second Edition Ch.6 pp184- 
231. McGraw-Hill Inc (New York)
Watson JD (1972) Origin of concatameric T7 DNA. Nature New Biol 239:197-201 
Weber-Hall S, McManus A, Anderson J, Nojima T, Abe S, Pritchard-Jones K, Shipley J (1996) 
Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar 
rhabdomyosarcoma. Genes Chromosomes Cancer 17:7-13
Weier HU, Wang M, Mullikin JC, Zhu Y, Cheng JF, Greulich KM, Bensimon A, Gray JW (1995) 
Quantitative DNA fiber mapping. Hum Mol Genet 4(10): 1903-1910
Weigant J, Ried T. Nederlof PM, van der Ploeg M, Tanke HJ, Raap A (1991) In situ hybridization 
with fluoresceinated DNA. NucI Acids Res 19(12):3237-3241
Weigant J, Kalle W, Mullenders L, Brookes S, Hoovers JMN, Dauwerse JG, van Ommen GJB, 
Raap AK (1992) High resolution in situ hybridization using DNA halo preparations. Hum Molec 
Genet 1(8):587-591
Weiss MM, Hermsen MAJA, Meijer GA, van Grleken NCT, Baak JPA, Kuipers EJ, van Diest PJ 
(1999) Demystified...: Comparative genomic hybridisation. Mol Pathol 52(5):243-251
239
Wessman M, Popp S, Ruutu T, Volin L, Cremer T, Knuutila S (1993) Detection of residual host cells 
after bone marrow transplantation using non-isotopic in situ hybridization and karyotype analysis. 
Bone Marrow Transplant 11 (4);279-284
Weinberg J, Jauch A, Stanyon R, Cremer T  (1990) Molecular cytotaxonomy of primates by 
chromosomal suppression in situ hybridization. Genomics 8:347-350
Wheater RF, Roberts SH (1987) An improved lymphocyte culture technique: deoxycytidine release 
of a thymidine block and use of a constant humidity chamber for slide making. J Med Genet 24:113- 
115
White S, Kalf M, Liu Q, Villerius M, Engelsma D, Kriek M, Vollebregt E. Bakker B, van Ommen G- 
JB, Breuning MH, den Dunnen JT (2002) Comprehensive detection of genomic duplications and 
deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet 
71:365-374
White SJ, Sterrenburg E, van Ommen G-JB, den Dunnen JT, Breuning MH (2003) An alternative to 
FISH: detecting deletion and duplication carriers within 24 hours. J Med Genet 40(10):e113 
WIeczorek D, Krause M, Majewski F. Albrecht B, Horn D, Riess O, Gillessen-Kaesbach G (2000) 
Effect of the size of the deletion and clinical manifestation in Wolf-Hirschhorn syndrome: analysis of 
13 patients with a de novo deletion. Eur J Hum Genet 8:519-526
Willard HF, Waye JS (1987) Hierarchical order in chromosome-specific human alpha satellite DNA. 
TIG 3(7): 192-198
Willatt L, Shaw-Smith C, Simonic I, Whittaker J, Carter NP, Bobrow M (2004) FISH mapping of 
duplications and deletions detected by micro-array CGH. J Med Genet 41 (Supp11):Abstracts of the 
British Human Genetics Conference, S62, 2.45
Wilming LG, Snoeren CAS, van Rijswijk A, Grosveld F, Meijers C (1997) The murine homologue of 
Hira, a DiGeorge syndrome candidate gene, is expressed in embryonic structures affected in 
human CATCH22 patients. Hum Mol Genet 6:247-258
Wilson Dl, Goodship JA, Burn J, Cross IE, Scambler PJ (1992a) Deletions within chromosome 
22q11 in familial congenital heart disease. Lancet 340:573-575
Wilson Dl, Cross IE, Goodship JA, Brown J, Scambler PJ, Bain HH, Taylor JFN, Walsh K, Bankier 
A, Burn J, Wolstenholme J (1992b) A prospective cytogenetic study of 36 cases of DiGeorge 
syndrome. Am J Hum Genet 51:957-963
Wilson TA, Blethen SL, Vallone A, Alenick S, Nolan P, Katz A, Amorillo TP, Goldmuntz E, Emanuel 
BS, Driscoll DA (1993) DiGeorge anomaly with renal agenesis in infants of mothers with diabetes. 
Am J Med Genet 47:1078-1082
Wolf U, Reinwein H, Porsche R, Schroter R, Baitsch H (1965) Defizienz an den kurzen armen eines 
chromosome nr 4 (1965) Humangenetik 1:397-413
Wright TJ, RIcke DO, Denison K, Abmayr S, Cotter PD, Hirschhorn K, Keinanen M, McDonald- 
McGinn D, Somer M, Spinner N, Yang-Feng T, Zackai E, Altherr MR (1997) A transcript map of the 
newly defined 165 kb Wolf-Hirschhorn syndrome critical region. Hum Mol Genet 6(2):317-324 
Wullich B, Henn W, Groterath E, Ermis A, Fuchs S, ZankI M (1991) Mosaic tetraploidy in a liveborn 
infant with features of the DiGeorge anomaly. Clin Genet 40:353-357
Xiang K, Karam JH, Bell Gl (1987) BamHI RFLP at the insulin-like growth factor II (1GF2) locus on 
chromosome 11. NucI Acids Res 15(18):7655
Xiao Y, Jiang X, Wang R (2003) Screening for DMD/BMD deletion carriers by fluorescence in situ 
hybridization. Genet Test 7(3): 195-201
Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, Minoshima S, Ichida F, Joo K, Kimura M, 
Imamura S, Kamatani N, Momma K, Takao A, Nakazawa M, Shimizu N, Matsuoka R (2003) Role of 
TBX1 in human del22q11.2 syndrome. Lancet 362(9393): 1366-1373
Yamagishi H, Garg V, Matsuoka R, Thomas T, Srivastava D (1999) A molecular pathway revealing 
a genetic basis for human cardiac and craniofacial defects. Science 283(5405): 1158-1161 
Yang J, Schwinger E, Mennicke K (2001) Primed in situ labeling: sensitivity and specificity for 
detection of alpha-satellite DNA in the centromere regions of chromosomes 13 and 21. Cytogenet 
Cell Genet 95(1-2):28-33
Yau SC, Bobrow M, Mathew CG, Abbs SJ (1996) Accurate diagnosis of carriers of deletions and 
duplications in Duchenne/Becker muscular dystrophy by fluorescent dosage analysis. J Med Genet 
33(7):550-558
Yokota H, van den Engh G, Hearst JE, Sachs RK, Trask BJ (1995a) Evidence for the organization 
of chromatin in megabase pair-sized loops arranged along a random walk path in the human G0/G1 
interphase nucleus. J Cell Biol 130(6): 1239-1249
240
Yokota H, van den Engh G, Mostert M, Trask BJ (1995b) Treatment of cells with alkaline borate 
buffer extends the capability of interphase FISH mapping. Genomics 25(2):485-491 
Yong DEJ, Booth P, Baruni J, Massie D, Stephen G, Gouzin D, Dean JCS (1999) Chromosome 
22q11 microdeletion and congenital heart disease - a survey in a paediatric population. Eur J 
Pediatr 158:566-570
Yu W, Ballif BC, Kashork CD, Heilstedt HA, Howard LA, Cai W -W , White LD, Liu W, Beaudet AL, 
Bejjani BA, Shaw CA, Shaffer LG (2003) Development of a comparative genomic hybridization 
microarray and demonstration of its utility with 25 well-characterised 1p36 deletions. Hum Mol 
Genet 12(17):2145-2152
Yunis JJ (1976) High resolution of human chromosomes. Science 191 (4233): 1268-1270
Zhang L, Ge L, Parimoo S, Stenn K, Prouty SM (1999) Human stearoyl-CoA desaturase: alternative 
transcripts generated from a single gene by usage of tandem polyadenylation sites. Biochem J 
340:255-264
Zhang A, Zheng C, Hou M, Lindvall C, Ke-Jun L, Erlandsson F, Bjorkholm M, Gruber A, Blennow E, 
Xu D (2003) Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of 
telomere maintenance in cri du chat syndrome. Am J Hum Genet 72:940-948 
Zheng YL, Ferguson-Smith MA, Warner JP, Ferguson-Smith ME, Sargent CA, Carter NP (1992) 
Analysis of chromosome 21 copy number in uncultured amniocytes by fluorescence in situ 
hybridization using a cosmid contig. Prenat Diagn 12:931-943
Zheng Y, Prouty SM, Harmon A, Sundberg JP, Stenn KS, Parimoo S (2001) Scd3 - a novel gene of 
the stearoyl-CoA desaturase family with restricted expression in skin. Genomics 71:182-191 
Zollino M, Di Stefano C, Zampino G, Mastroiacovo P, Wright TJ, Sorge G, Selicorni A, Tenconi R, 
Zappala A, Battaglia A, Di Rocco M, Palka G, Pallotta R, Altherr MR, Neri G (2000) Genotype- 
phenotype correlations and clinical diagnostic criteria in Wolf-Hirschhorn syndrome. Am J Med 
Genet 94(3):254-261
Zollino M, Lecce R, Fischetto R, Murdolo M, Faravelll F, Selicorni A, Butte C, Memo L, Capovilla G, 
Neri G (2003) Mapping the Wolf-Hirschhorn syndrome phenotype outside the currently accepted 
W HS critical region and defining a new critical region, WHSCR-2. Am J Hum Genet 72(3):590-597 
Zollino M, Lecce R, Selicorni A, Murdolo M, Mancuso I, Marangi G, Zampino G, Garavelli L,
Ferrarini A, Rocchi M, Opitz JM, Neri G (2004) A double cryptic chromosome imbalance is an 
important factor to explain phenotypic variability in Wolf-Hirschhorn syndrome. Eur J Hum Genet 
12(10):797-804
241
8. APPENDICES
8.1 Appendix I - Details of Non commercial Probe Sequences
8.1.1 Chromosomal Localisation of Unique Sequences
Endothelin 3-like Sequence
Endothelln is a vasoconstrictor released by the endothelium. Th ere  is evidence that 
mutation in this gene m ay be one of the causes of W aardenburg-H irshsprung disease  
(Edery et al 1996). The P A C 227  probe supplied for localisation had been isolated from  
the human genom e mapping project (H G M P ) PAG library, using a short endothelin  
sequence probe, by Ms K W arp eha  and D r A  Hughes (The Departm ent of Medical 
Genetics, Opthalm ology and Vision Sciences, Q u een ’s University Belfast). PA C 227 w as  
expected to m ap to the sam e location (20q 13 .2 -q 13 .3 ) as that determ ined, by restriction 
enzym e techniques in combination with som atic cell hybrids and also in situ techniques, 
for endothelin 3 {EDN3  M IM  131242).
Myotonic dystrophy protein kinase-related Cdc42-binding kinase (3 
T h e  p21 G TPases, Rho and Cdc42, regulate m any cellular functions by binding to 
m em bers of a serine/threonine protein kinase subfamily. These  functions include the  
remodelling of the cytoskeleton in cell growth and differentiation. In rat, two of these p21 
G TPase-regu lated  kinases, the myotonic dystrophy protein kinase-related Cdc42-binding  
kinases (a  and p), phosphorylate nonmuscle myosin light chain, a prerequisite for the  
activation of actin-myosin contractility. The sequence supplied for mapping, nam ed  
CDC42BPB  or 82-h2, w as a PAG clone of the human homologue of MRCK/3 isolated by 
our collaborators (M r G Moncrieff and Dr K Johnson, Division of M olecular Genetics, 
Institute of Biomedical and Life Sciences, University of G lasgow) from the RP1 library 
(Roswell Park G ancer Institute, loannou and de Jong 1996).
S equence data on CDC42BPB  w as deposited by our collaborators with the  
EM B L/G enB ank Data Libraries under accession num ber A F 128625 .
Hum an Telom erase R everse Transcriptase
Telom erase is a ribonucleoprotein com plex which maintains chrom osom e length by 
adding D N A  repeats to chrom osom e ends. In its absence, telom eres shorten with every  
cell division until, at a critical length, the cell becom es senescent. Loss of telom eric D NA
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during cell proliferation m ay play a role in ageing and cancer (Counter et al 1992).
H um an telom erase is widely active during developm ent but in adult tissues its activity is 
restricted to m ale germ  cells, activated lymphocytes and stem cells of regenerating  
tissues. It is also detectable at high level in most immortal cell lines and human cancers. 
Telom erase is com posed of an R N A  tem plate subunit, hTR, and a reverse transcriptase  
catalytic subunit hTERT which had, prior to this study, been tentatively m apped to distal 
chrom osom e 5p by P C R  analysis of radiation hybrid panels (M eyerson et al 1997).
O ur collaborator, Dr W N  Keith of the Departm ent of Medical Oncology, University of 
Glasgow, initially provided a P1 clone containing the putative hTERT sequence for F IS H  
mapping. As its localisation to 1 0q 11 .21~ q 11 .22  (with a secondary site at 1Gq22.3) 
suggested that it could not be hTERT, another putative hTERT probe suitable for F IS H  
mapping, 5 1 8 0 1 3 , was obtained by our collaborators through screening the RP11 BAG  
library with the 3454bp  cD N A  insert of hTERT plasmid P G R N 1 45  (Geron Corporation). 
Incorporation of the gene was confirmed by PG R  amplification and sequencing of a 348bp  
prom oter region.
Stearoyl coenzym e A  desaturase 2
Stearoyl coenzym e A  desaturase {SCO) Is part of a m em brane bound complex, catalysing  
the creation of c/s double bonds in acyl-GoA derivatives of saturated fatty acids to 
produce m ono-unsaturated fatty acids which are incorporated in cellular m em branes. At 
the tim e of this mapping investigation rodent studies had identified two scd genes, scd1 
and scd2, with tissue-specific expression patterns. Scd1 acts predominantly in liver and  
adipose tissue w hereas scd2 acts predominantly in the brain (Kaestner et al 1989).
Hum an SCD1 had been com pletely characterised by our collaborators, M s K Dem psey  
and D r J Graft of the Biological Sciences Departm ent, G lasgow  Galedonian University, 
and others (Zhang et al 1999) and the gene localised to chrom osom e 10. To attem pt 
isolation of hum an SCD2 our collaborators identified sequences which w ere SCO-like but 
not 100%  homologous to SCD1 from the G enB ank database. O ne was amplified by PG R  
and identified as exon 4  of the putative SCD2 gene. It was localised to chrom osom e 4  
using PG R amplification of the sequence in a somatic cell hybrid panel. A  LANL (Los 
Alam os National Library) chrom osom e 4  cosmid genom ic library from the UK H G M P  
Resource Gentre was then screened with the sequence to derive cosmid clones. Four 
clones (9, 17, 22 and 30) produced positive hybridisation to the SCD2 sequence, and  
w ere supplied, at 0.18ug/ul, for regional localisation by F ISH .
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8.1.2 DG/VCF Syndrome Microdeletion Testing
All non-com m ercial probe sequences used w ere cosmid-incorporated and generously  
supplied by Professor P Scam bler (M olecular Medicine, Institute of Child Health,
University of London).
Early work involved cosmids sc4.1 (D 2 2S 13 4), which had been selected by Professor 
Scam bler's group using m olecular probe H P 500 , and sc11.1, which detected two loci, 
s c i 1.1a and b, at opposite ends of the commonly deleted 2 -3M b  region (Carey et al 1992, 
Halford et al 1993b). The sc4.1 sequence w as considered, at that time, to be included in 
all deletions. Cosmid s c i 1.1 showed high ISH efficiency and could provide indication of 
reduced deletion size, as the deletion in som e individuals was believed to exclude the  
distal s c i 1.1b locus D 22 S 1 39  (Lindsay et al 1995). On the recom m endation of Professor 
Scam bler the use of cosmid sequence E 0 47 2  (D 22S 933) was later adopted, because it 
was located relatively close to sc4.1 in the D G A /C F S  region and produced stronger 
signals.
Cosmid D 0832  (D 22S 502), cloned from the proximal end of a Y A C  containing sc4.1, was  
primarily obtained for the investigation of a patient (EH ) with particularly strong clinical 
indication of D G A /C F S  but no deletion of sc11.1, sc4.1 or E 0472. It w as the most 
proximal single-copy sequence available to us at the time, so w as also used to confirm  
the absence of deletion in one individual from the series of T O F  patients and to exam ine  
the extent of the deletion in two deleted patients from this group. No m etaphase  
preparations rem ained from the other two deleted patients in this series to allow testing 
with D 0832 , and the probe was not more widely em ployed because of the introduction of 
H 1012.
H I 012  included candidate gene sequence TUPLE 1 and was believed to be the most 
appropriate diagnostic indicator, therefore the use of other 2 2 q 1 1 cosmids w as gradually  
discontinued.
Com m ercial probes which share sequences with H I 012  w ere eventually used for testing. 
These w ere initially sourced from Cytocell (the coverslip-bound Chrom oprobe-D G ) and 
then Vysis (LSI T U P L E  1 (2 2 q 1 1 .2 ,3 T U P L E  1 /D 2 2 S 5 53 /D 22 S 6 09 /D 22 S 9 42 ) with LSI 
A R S A  22q 13 .3  control probe). N 25  probe (LSI D iG eorge N 25 (D 22S 75 ) Region Probe  
with LSI A R S A  22q 13 .3  control probe) w as additionally em ployed for the most recent 
diagnostic testing.
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8.1.3 Detection in a Large Pedigree of a Cryptic Chromosomal Rearrangement 
involving the Wolf-Hirschhorn Syndrome Locus
Plasmid pK082, specific for chrom osom e region 4p16.3 , was a 5 .5kb  EcoRI fragm ent in 
pB R 328 and the gift of D r JF Gusella (Harvard Medical School, Boston, M assachusetts). 
This sequence w as a subclone of phage insert G 8 and a polymorphic D N A  m arker linked 
to the Huntington’s disease defect (G usella et al 1983, M acDonald et al 1987).
T h e  first 11 p i 5 .5  probe used w as phinsSIO, a 0 .8kb sequence from the insulin locus 
cloned in the Bam HI site of pB R 327 (Bell et al 1981). This w as replaced with phins311, 
an 11 p i 5.5-specific, 8 .6kb  pB R 322 clone of the insulin-like growth factor 2 sequence  
(Xiang et al 1987). Plasm ids phins310 and phins311 are available from the Am erican  
Type Culture Collection (A TC C  5 74 00  and 5 9300  respectively).
8.1.4 Microdeletion Testing in Rubinstein-Taybi Syndrome
T h e  RT1 probe is a IG p l 3.3-specific sequence (D l 6 8 2 3 7 ) cloned in cosmid pCpG . It 
w as the generous gift of Drs Breuning and Petrij of the D epartm ent of Hum an Genetics, 
Leiden University.
R T 1 covers only 29kb of the 3 ’ end of the CBP  gene, therefore later studies investigated  
the use of four additional cosmids to cover the entire 146kb CBP  coding sequence.
Listing the most 3 ’ (telomeric) sequence first, these were R T191, R T102, R T 203  and  
R T 166  (Petrij et al 2000). D N A  and bacterial cultures w ere obtained from the Leiden  
G enom e Technology C enter (Hum an and Clinical Genetics, Leiden University Medical 
Center, The Netherlands, h ttp://w w w .LG TC .nl/).
8.1.5 Duchenne and Becker Muscular Dystrophy Carrier Studies
Tw enty nine bacterial stab cultures containing different D M D /B M D  exon-specific cosmids, 
mostly from dystrophin deletion hotspots around exons 7 and 47, w ere obtained from Dr L 
Blonden and Dr JT  den Dunnen (Departm ent of Hum an Genetics, Leiden University) and  
Dr R Mountford and Nicola Robinson (North W es t Regional G enetics Service, St M ary ’s 
Hospital, M anchester). T h e  M anchester cosmids had originally been sourced from the  
Imperial C ancer R esearch Fund Reference Library and screened with exon-specific  
primers for identification.
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8.2 Appendix 11 - Details of Patient Samples
8.2.1 Chromosomal Localisation of Unique Sequences and Breakpoint Mapping
Mapping and Ordering of Chrom osom e 21 -Specific Probes for Breakpoint Definition in a 
C ase of Partial Trisom y 21
T h e  case of partial trisomy 21 investigated in these studies w as detected on chrom osom e  
analysis by the cytogenetic service at the Duncan Guthrie Institute following referral, by 
clinicians at the Southern G eneral Hospital, Glasgow, of a heparinised blood sam ple from  
the affected neonate DP.
Patient LF, aged 28, w as referred with mild M R, seizures and multiple physical 
abnormalities by clinicians of the W e s t of Scotland Clinical Genetics Service. Cytogenetic  
analysis of a heparinised blood sam ple revealed a 46 ,X X ,? d e l(21)(p ) karyotype.
Mapping and Ordering of Chrom osom e 8-Specific Probes for Investigation of a 
Paracentric Duplication of 8p
Patient RM  was referred by Dr K R ay of the Departm ent of Com m unity Health, Hamilton, 
for clinical genetic and cytogenetic exam ination in this departm ent. In addition to mild 
global delay, difficulty sleeping, language and social problems, this three year-old child 
exhibited mild dysmorphic features including relative microcephaly, overturned ear 
helices, a notched incisor, slightly short palpebral fissures, proximally placed thumbs and  
overlapping toes. Toenails showed koilonychia and w ere dystrophic distally.
8.2.2 DG/VCF Syndrome Microdeletion Testing
Patients w ere  referred for testing from hospitals served by the W e s t of Scotland Clinical 
Genetics Service and from three other Scottish regions - G ram pian, Lothian, and 
Dum fries and Galloway. Four of the investigations w ere perform ed on lymphoblastoid cell 
lines. The remaining sam ples w ere  cytogenetic preparations from heparinised blood 
sam ples, two post-m ortem tissue cultures, an amniotic fluid culture and a chorionic villus 
sam ple. Most tests w ere requested by a clinical geneticist or clinical geneticist in 
collaboration with a paediatrician or obstetrician. The tissue sam ples w ere referred by a 
paediatric pathologist. Karyotyping was, or had previously been, performed on all 
samples.
T hree patients appeared to have variant deletions. Patient JF was referred with a patent 
ductus arteriosus, right aortic arch, mild learning difficulties, behavioural problems, and
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facial dysmorphisms including hypertelorism and simple ears. Patient KA had interrupted 
aortic arch, V S D , absent thymus, hypocalcaem ia, nystagmus, feeding problems, long 
slender fingers and abnorm al facies, and patient HG  presented with absent thymus, 
hypocalcaem ia, dysmorphic features, velopharyngeal incom petence and failure to thrive.
8.2.3 Detection In a Large Pedigree of a Cryptic Chromosomal Rearrangement 
Involving the Wolf-Hirschhorn Syndrome Locus
T he proband V  11 (F ig .3 -11 ) presented in infancy with cleft palate, high nasal root, low  
set, posteriorly rotated ears, a w ell-dem arcated philtrum, cupid’s bow mouth, 
microcephaly, failure to thrive and poor feeding. A  V S D , mild pulmonary valve stenosis, 
epilepsy, severe growth retardation (below the 10"  ^centiles for height, weight and head  
circum ference) and intellectual disability w ere  later diagnosed.
Th e  proband’s second cousins once rem oved, a brother iV-8 and sister IV  10 aged 31 
and 25 years respectively, had a sim ilar pattern of abnormalities (severe cognitive  
disability, microcephaly, seizures, cleft palate and postnatal growth retardation). These  
sibs, like the proband, w ere  originally thought to have an underlying diagnosis of Seckel 
syndrome.
M olecular cytogenetic Investigations w ere perform ed on fixed m etaphase preparations  
from lymphoblastoid cell lines (V  I I ,  IV  11, IV -12) or heparinised blood sam ples. These  
sam ples w ere  referred by Dr J Tolm ie of this departm ent. Dr E Thom son of the Kennedy- 
Galton Centre, Northwick Park Hospital, Harrow (111-6, IV-7, IV  16, IV -17) and Dr D  
Fielding of the Countess of C hester Hospital, C hester (IV-8 and IV -10).
8.2.4 Microdeletion Testing in Rubinstein-Taybi Syndrome
Fifteen patients considered to have a possible clinical diagnosis of R T S  on the basis of 
characteristic physical and intellectual disabilities w ere referred by clinical geneticists of 
the W es t of Scotland Clinical Genetics Service. All had a normal karyotype. Three  w ere  
also tested, and shown to be undeleted, with D G A /C FS  probe. Two of these three and  
two others subsequently underwent subtelom ere screening with negative results.
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8.2.5 Duchenne and Becker Muscular Dystrophy Carrier Studies
Patient heparinised blood sam ples, from which cytogenetic preparations w ere m ade, w ere  
referred for F ISH  testing with D M D /B M D  cosmids by clinical geneticists of the W es t of 
Scotland Clinical G enetics Service and other Scottish Clinical Genetics Services in 
G ram pian, Tayside and the South East.
Multiplex P C R  w as used by the m olecular genetics division of this departm ent to screen  
D N A  sam ples from the m ale patients for deletion of D M D /B M D  exons. Creatine kinase 
levels w ere determ ined for the fem ale  patients by the biochemical genetics division.
8.2.6 Testing with Cytocell Multiprobe-T for the Detection of Cryptic Subtelomeric 
Rearrangements in Idiopathic MR
All sam ples w ere received from Scottish Clinical Genetics Services except the blood 
sam ples from m em bers of the family with cryptic t(10;18). These w ere referred by David  
M acG regor and Dr S M oore of the Janew ay Genetics Clinic, St John’s, Newfoundland, 
Canada.
The  physical abnormalities present in 99  of the 100 patients tested included, among  
others, minor facial and distal dysmorphism (e.g. brachy-, clino- or camptodactyly, simian  
crease), reduced growth (most commonly, m easurem ents of -2 S D ) and dysmorphisms  
affecting external genitalia such as undescended testis, inguinal hernia and micropenis. 
The spectrum of abnormalities observed at two years in patient D D  of the t(10 ;18 ) family  
included m oderate to severe developm ental delay, failure to thrive, small head  
circum ference (5^  ^ percentile), V S D , and like his uncles, short stature (5 “^  percentile), 
hypotonia and joint laxity, asthm a, reduced pigment, gastro-oesophageal reflux and 
recurrent aspiration (resulting in pneum onia). Dysmorphic features noted w ere  m alar 
hypoplasia, epicanthus (like SC ), flat nasal bridge with short nose and anteverted nares, 
w ell-developed philtrum, wide down-turned mouth, low-positioned and spatulate thumbs, 
prominent fingertip pads on som e digits and blue eyes with brushfield spots (as in SC ). 
Previous F IS H  testing for D G /V C F  and Sm ith-M agenis syndromes had proved normal.
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